RU2806915C2 - Antibodies that bind tumor tissue for diagnosis and treatment - Google Patents

Abstract

FIELD: biotechnology.

SUBSTANCE: antibody that binds to tumor tissue, where the antibody binds to an extracellular RNA-protein complex, as well as to a method for its production. Also a vector and a cell containing polynucleotides encoding the V_H and V_L regions of this antibody are proposed.

EFFECT: efficient for inducing an immune response and for inhibiting the growth of tumor cells.

31 cl, 64 dwg, 3 tbl, 15 ex

Description

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to US Provisional Application No. 62/806285, filed February 15, 2019; US Provisional Patent Application No. 62/806310, filed February 15, 2019; US Provisional Patent Application No. 62/843298, filed May 3, 2019; US Provisional Patent Application No. 62/843751, filed May 6, 2019; US Provisional Patent Application No. 62/852830, filed May 24, 2019; U.S. Provisional Patent Application 62/927501, filed Oct. 29, 2019, each of which is incorporated by reference in its entirety for all purposes.

FIELD OF ANTI-CANCER THERAPEUTIC AGENTS

[0002] Therapeutic antibodies for the treatment of various types of cancer have had a tremendous impact on remission and survival of patients. However, there is still a need for alternative oncology therapeutic agents, for example, for the treatment of patients who respond poorly to therapy and/or become resistant to therapy.

SUMMARY OF THE INVENTION

[0003] In one aspect, provided herein is an isolated antibody that binds to tumor tissues, wherein the antibody binds to an extracellular RNA-protein complex containing polyadenylated RNA. In some embodiments, the extracellular RNA-protein complex further comprises rRNA. In some embodiments, the extracellular RNA-protein complex comprises mRNA. In some embodiments, the extracellular RNA-protein complex comprises one or more polyadenylated RNA binding proteins. In some embodiments, the extracellular RNA-protein complex further comprises a ribosomal protein. In some embodiments, the extracellular RNA-protein complex comprises an mRNA binding protein. In some embodiments, the extracellular RNA-protein complex comprises a poly(A)+ binding protein. In some embodiments, the extracellular RNA-protein complex comprises a member of the polyadenylate binding protein family. In some embodiments, the extracellular RNA-protein complex comprises a member of the cytoplasmic polyadenylate binding protein (PABPC) family. In some embodiments, the PABPC family member is PABPC 1 (PABPC1), PABPC 3 (PABPC3), or PABPC 4 (PABPC4). In some embodiments, the PABPC family member is PABPC1. In some embodiments, the extracellular RNA-protein complex contains MOV10. In some embodiments, the extracellular RNA-protein complex includes a biomolecular condensate. In some embodiments, the biomolecular condensate is stress-induced. In some embodiments, the biomolecular condensate is induced by hypoxia and/or a chemotherapeutic drug. In some embodiments, the antibody induces cellular signaling by binding to an FcγR. In some embodiments, the antibody comprises an Fc region that binds FcγRIIa. In some embodiments, the antibody has an EC of _50,500 nM or lower in an FcγRIIa interaction assay. In some embodiments, the FcγRIIa interaction assay uses EMT6 tumor cells passaged in vivo .

[0004] In a further aspect, provided herein is an antibody that binds to an extracellular RNA-protein complex, wherein said antibody comprises:

(a) a heavy chain variable region containing:

(i) HCDR1 any of SEQ ID NO: 1-8 or 169-362, or a variant thereof in which 1, 2, 3, 4 or 5 amino acids are substituted relative to the specified sequence;

(ii) HCDR2 any of SEQ ID NO:9-19 or 363-556, or a variant thereof in which 1, 2, 3, 4 or 5 amino acids are substituted relative to the specified sequence; And

(iii) HCDR3 any of SEQ ID NO: 20-47, 557-750 or 1727, or a variant thereof, in which 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids are substituted relative to the specified sequence ;

(b) a light chain variable region comprising:

(i) LCDR1 any of SEQ ID NO:48-58 or 751-944, or a variant thereof, in which 1, 2, 3, 4 or 5 amino acids are substituted relative to the specified sequence;

(ii) LCDR2 any of SEQ ID NO:59-67 or 945-1138 or a variant thereof in which 1, 2, or 3 amino acids are substituted relative to the specified sequence; And

(iii) LCDR3 any of SEQ ID NO:68-76 or 1139-1332, or a variant thereof, in which 1, 2, 3, 4 or 5 amino acids are substituted relative to the specified sequence. In some embodiments, at least 1 or 2 of the substitutions are conservative substitutions; at least 50% of the substitutions are conservative substitutions; or all substitutions are conservative.

[0005] In some embodiments, the substitutions in each of the CDRs provide HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3 comprising an amino acid sequence that corresponds to the following formula:

(a) sequence HCDR1 G(F/Y)X ₃ X ₄ (A/S)X ₆ A(W/Y)X ₉ (S/T) (SEQ ID NO:1734), where X ₃ represents D, T or V; X ₄ represents A, F, or Y; X ₆ represents A, H, K, M, N or R; and X ₉ represents F, M, or Y;

(b) sequence HCDR2 (F/R)I(K/Q)(A/S)X ₅ X ₆ X ₇ (A/G)X ₉ X ₁₀ T(D/E)(A/S)(P/ S)(K/Q) (SEQ ID NO:1735), where X ₅ represents A, N, T, or V; X ₆ represents D, H, Q, S or T; X7 represents D, E, or N; X ₉ represents E, G, H, K or Q; and X ₁₀ is A, I, Q or T; And

(c) sequence HCDR3 (I/T)(S/T)X ₃ (F/Y)X ₅ CX ₇ (G/S)X ₉ X ₁₀ CX ₁₂ X ₁₃ X ₁₄ (D/E)X ₁₆ SX ₁₈ X ₁₉ X ₂₀ X 21 X ₂₂ X ₂₃ X _{24 X 25 (} F/Y) (F/Y)X ₂₈ X ₂₉ (D/N)X ₃₁ (SEQ ID NO:1736) where X ₃ represents A, P, S, or T; X ₅ represents A, C, or S; X ₇ represents H, L, Q, or R; X ₉ represents A, G, K, or N; X ₁₀ represents A, N, Q, R, or S; X ₁₂ represents A, L, or P; X ₁₃ represents A, N, or S; X ₁₄ represents H, Q, R, or S; X ₁₆ represents N, Q, or T; X ₁₈ represents F, M, or Y; X ₁₉ represents C, S, or V; X ₂₀ represents A, G, or N; X ₂₁ represents A, G, or N; X ₂₂ represents Q, S, or Y; X ₂₃ represents D, F, N, S, or Y; X ₂₄ represents A, K, N, P, Q, or S; X ₂₅ represents D, K, Q, R, or S; X ₂₈ represents F, L, W, or Y; X ₂₉ represents F, M, or V; and X ₃₁ represents I, P, or V;

(d) sequence LCDR1 X ₁ G(A/S)X ₄ (S/T)(D/N)I(G/Q)(H/S)X ₁₀ X ₁₁ (T/V)X ₁₃ (SEQ ID NO:1737), where X ₁ represents H, S, or T; X ₄ represents E, K, P, or S; X ₁₀ represents A, H, N, S, or T; X ₁₁ represents A, D, S, T, or Y; and X ₁₃ is A, L, S, T or Y;

(e) sequence LCDR2 X ₁ (D/N)X ₃ X ₄ (Q/R)(A/P)X ₇ (SEQ ID NO:1738), where X ₁ represents A, H, K, M, N , or R; X ₃ represents N, S, or T; X ₄ represents A, L, Q, or Y; and X ₇ represents L, Q, S, or Y; And

(f) sequence LCDR3 (A/S)(S/T)(F/W)(D/N)X ₅ X ₆ X ₇ X ₈ (I/V)X ₁₀ (I/V) (SEQ ID NO: 1739), where X ₅ represents D, E, or N; X ₆ represents A, D, Q, or S; X ₇ represents L, N, or S; X ₈ represents L, N, S, or T; and X ₁₀ is H, K, Q, R, or W.

[0006] In some embodiments, the antibody comprises a _VH region that contains HCDR1 comprising the sequence of any of SEQ ID NOs:1-8 or 169-362, HCDR2 comprising the sequence of any of SEQ ID NOs:9-19 or 363-556 , HCDR3, comprising the sequence of any of SEQ ID NO:20-47, or 557-750, or 1727; LCDR1, including the sequence of any of SEQ ID NO:48-58 or 751-944, LCDR2, including the sequence of any of SEQ ID NO:59-67 or 945-1138, and LCDR3, including the sequence of any of SEQ ID NO:68-76 or 1139-1332, in which 1 or 2 amino acids are substituted in at least one of HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3.

[0007] In some embodiments, the antibody comprises a _VH region comprising the HCDR1, HCDR2 and HCDR3 _VH regions of any of SEQ ID NO:77-122 or 1333-1526 or 1725; or a V _L region containing LCDR1, LCDR2, LCDR3 any of SEQ ID NO:123-168 or 1527-1720, or 1726.

[0008] In some embodiments, the antibody comprises a V _H region comprising the HCDR1, HCDR2 and HCDR3 antibodies specified in the V _H region of any of SEQ ID NO: 77-122 and 1333-1526 or 1725; and a V _L region containing LCDR1, LCDR2 and LCDR3 of the corresponding light chain of any of SEQ ID NOs: 123-168, or 1527-1720, or 1726. In some embodiments, substitutions in each of the CDRs provide HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, LCDR3, comprising an amino acid sequence that corresponds to the following formula:

(a) the sequence HCDR1 G(F/Y)X ₃ X ₄ (A/S)X ₆ A(W/Y)(F/M)(S/T), where X ₃ represents D, T or V; X ₄ represents A, F, or Y; and X ₆ represents A, H, K, M, or N;

(b) HCDR2 sequence RIK(A/S)X ₅ X ₆ (D/N)(A/G)X ₉ X ₁₀ (D/E)(A/S)(P/S)(K/Q), where X ₅ represents A, N, T, or V; X ₆ represents D, H, Q, S or T; X ₉ represents E, G, H, K or Q; and X ₁₀ is A, I, Q, or T;

(c) sequence HCDR3 (I/T)(S/T)X ₃ (F/Y)CCX ₇ (G/S)X ₉ X ₁₀ CX ₁₂ (N/S)X ₁₄ (D/E)TS(F /Y)CX ₂₀ (G/N)X ₂₂ X ₂₃ X ₂₄ ,X ₂₅ (F/Y)YX ₂₈ X ₂₉ (D/N)X ₃₁ where X ₃ represents A, P, or S; X ₇ represents H, L, Q, or R; X ₉ represents A, G, K, or N; X ₁₀ represents A, N, Q, R, or S; X ₁₂ represents A, L, or P; X ₁₄ represents H, Q, R, or S; X ₂₀ represents A, G, or N; X ₂₂ represents Q, S, or Y; X ₂₃ represents D, F, N, or Y; X ₂₄ represents A, K, N, P, or Q; X ₂₅ represents D, Q, R, or S; X ₂₈ represents F, L, W, or Y; X ₂₉ represents F, M, or V; and X ₃₁ represents I, P, or V;

(d) sequence LCDR1 (S/T)G(A/S)X ₄ (S/T)(D/N)IG(H/S)X ₁₀ X ₁₁ (T/V)X ₁₃ , where X ₄ represents is K, P, or S; X ₁₀ is A, N, S, or T; X ₁₁ represents A, S, T, or Y; and X ₁₃ is A, S, T or Y;

(e) the sequence LCDR2 X ₁ (D/N)X ₃ X ₄ (Q/R)(A/P)X ₇ where X ₁ represents A, H, K, M, N, or R; X ₃ represents N, S, or T; X ₄ represents A, L, Q, or Y, and X ₇ represents L, Q, S, or Y; And

(f) sequence LCDR3 (A/S)(S/T)W(D/N)X ₅ X ₆ X ₇ X ₈ (I/V)X ₁₀ (I/V), where X ₅ represents D, E , or N, X ₆ represents A, D, Q, or S, X ₇ represents L, N, or S; X8 represents L, N, S, or T; and X ₁₀ is H, K, Q, or R.

[0009] In some embodiments, the antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 antibodies, designated AIP-192482, AIP-171142, AIP-165430, AIP-189526, AIP-122563, AIP-158623, AIP- 155066, AIP-166120, AIP-133645, AIP-187893, AIP-142079, AIP-160470, AIP-102396, AIP-150055, AIP-167084, AIP-185304, AIP-134770, AIP-141887, AIP-1 96203, AIP-128195, AIP-116579, AIP-192329, AIP-197809, AIP-142489, AIP-167726, AIP-199834, AIP-143179, AIP-195587, AIP-153462, AIP-115363, AIP-151090, AIP - 168083, AIP-161082, AIP-114196, AIP-189338, AIP-183190, AIP-110143, AIP-147176, AIP-134312, AIP-128243, AIP-156172, AIP-147389, AIP-124314, AIP-1 85291, AIP-135247, AIP-113513, AIP-102299, AIP-179097, AIP-109343, AIP-119622, AIP-191735, AIP-157078, AIP-153475, AIP-133650, AIP-190915, AIP-167400, AIP - 109729, AIP-151709, AIP-136628, AIP-101601, AIP-146871, AIP-170053, AIP-199483, AIP-162041, AIP-180675, AIP-183133, AIP-191470, AIP-151167, AIP-1 06633, AIP-102624, AIP-109484, AIP-126080, AIP-161571, AIP-163039, AIP-101235, AIP-182061, AIP-181246, AIP-192216, AIP-171912, AIP-172872, AIP-167833, AIP - 190051, AIP-145518, AIP-167533, AIP-112580, AIP-143155, AIP-119664, AIP-190526, AIP-114403, AIP-156760, AIP-103803, AIP-195588, AIP-145722, AIP-1 78251, AIP-116142, AIP-183350, AIP-127108, AIP-128147, AIP-109510, AIP-104086, AIP-143132, AIP-170105, AIP-169636, AIP-152243, AIP-138776, AIP-103817, AIP - 130491, AIP-188155, AIP-167246, AIP-106139, AIP-198351, AIP-159326, AIP-192275, AIP-190761, AIP-166832, AIP-148062, AIP-129145, AIP-111240, AIP-1 53888, AIP-130915, AIP-109048, AIP-170569, AIP-154873, AIP-159037, AIP-186826, AIP-156514, AIP-157122, AIP-173276, AIP-150485, AIP-166847, AIP-124013, AIP - 126285, AIP-168605, AIP-190274, AIP-136060, AIP-180422, AIP-166722, AIP-127782, AIP-189473, AIP-192571, AIP-112328, AIP-125258, AIP-150199, AIP-1 25062, AIP-177193, AIP-115388, AIP-107759, AIP-170221, AIP-143369, AIP-189475, AIP-102833, AIP-157045, AIP-175775, AIP-154181, AIP-125984, AIP-160829, AIP - 184744, AIP-128136, AIP-181273, AIP-153125, or AIP-131972 in Table 1A or Table 2A, or a variant thereof, wherein at least one, two, three, four, five, or all six of the CDRs contain 1 or 2 amino acid substitutions compared to the corresponding CDR sequence shown in Table 1B or Table 2B.

[0010] In some embodiments, the antibody comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 antibodies, designated AIP-192482, AIP-171142, AIP-165430, AIP-189526, AIP-122563, AIP-158623, AIP- 155066, AIP-166120, AIP-133645, AIP-187893, AIP-142079, AIP-160470, AIP-102396, AIP-150055, AIP-167084, AIP-185304, AIP-134770, AIP-141887, AIP-1 96203, AIP-128195, AIP-116579, AIP-192329, AIP-197809, AIP-142489, AIP-167726, AIP-199834, AIP-143179, AIP-195587, AIP-153462, AIP-115363, AIP-151090, AIP - 168083, AIP-161082, AIP-114196, AIP-189338, AIP-183190, AIP-110143, AIP-147176, AIP-134312, AIP-128243, AIP-156172, AIP-147389, AIP-124314, AIP-1 85291, AIP-135247, AIP-113513, AIP-102299, AIP-179097, AIP-109343, AIP-119622, AIP-191735, AIP-157078, AIP-153475, AIP-133650, AIP-190915, AIP-167400, AIP - 109729, AIP-151709, AIP-136628, AIP-101601, AIP-146871, AIP-170053, AIP-199483, AIP-162041, AIP-180675, AIP-183133, AIP-191470, AIP-151167, AIP-1 06633, AIP-102624, AIP-109484, AIP-126080, AIP-161571, AIP-163039, AIP-101235, AIP-182061, AIP-181246, AIP-192216, AIP-171912, AIP-172872, AIP-167833, AIP - 190051, AIP-145518, AIP-167533, AIP-112580, AIP-143155, AIP-119664, AIP-190526, AIP-114403, AIP-156760, AIP-103803, AIP-195588, AIP-145722, AIP-1 78251, AIP-116142, AIP-183350, AIP-127108, AIP-128147, AIP-109510, AIP-104086, AIP-143132, AIP-170105, AIP-169636, AIP-152243, AIP-138776, AIP-103817, AIP - 130491, AIP-188155, AIP-167246, AIP-106139, AIP-198351, AIP-159326, AIP-192275, AIP-190761, AIP-166832, AIP-148062, AIP-129145, AIP-111240, AIP-1 53888, AIP-130915, AIP-109048, AIP-170569, AIP-154873, AIP-159037, AIP-186826, AIP-156514, AIP-157122, AIP-173276, AIP-150485, AIP-166847, AIP-124013, AIP - 126285, AIP-168605, AIP-190274, AIP-136060, AIP-180422, AIP-166722, AIP-127782, AIP-189473, AIP-192571, AIP-112328, AIP-125258, AIP-150199, AIP-1 25062, AIP-177193, AIP-115388, AIP-107759, AIP-170221, AIP-143369, AIP-189475, AIP-102833, AIP-157045, AIP-175775, AIP-154181, AIP-125984, AIP-160829, AIP - 184744, AIP-128136, AIP-181273, AIP-153125, or AIP-131972 in Table 1B or Table 2B.

[0011] In a further aspect, provided herein is an antibody that binds to an extracellular RNA-protein complex, wherein said antibody comprises:

(a) a heavy chain variable region containing:

(i) HCDR1 having the sequence GF(T/V)(F/Y)(S/A)X ₆ AWM(S/T) (SEQ ID NO:1728), where X ₆ represents K, A, or M ;

(ii) HCDR2 having the sequence RIK(S/A)X ₅ X ₆ (D/E)(G/A)X ₉ X ₁₀ T(D/E)YAA(P/S)VKG (SEQ ID NO:1729 ), where X ₅ represents V, N, A, or T; X ₆ represents T, Q, S, D, or H; X ₉ represents E, H, K, or G; and X ₁₀ represents T, Q, or I;

(iii) HCDR3 having the sequence

(I/T)(S/T)SFCC(H/R)(G/S)X ₉ X ₁₀ CPSX ₁₄ (D/E)TS(F/Y)CX ₂₀ (G/N)X ₂₂ X ₂₃ X ₂₄ X ₂₅ (F/Y)Y(F/Y)(M/V)(D/N)X ₃₁ (SEQ ID NO:1730), where X ₉ represents A, G, K, or N; X ₁₀ represents N, Q, R, or S; X ₁₄ represents H, R, or S; X ₂₀ represents A, G, or N; X ₂₂ represents Q, S, or Y; X ₂₃ represents D, F, N, or Y; X ₂₄ represents A, K, N, P, or S; X ₂₅ represents D, Q, R, or S; X ₁₉ represents D or N; and X ₃₁ represents I, P, or V;

(b) a light chain variable region comprising:

(i) LCDR1 having the sequence SG(S/A)X ₄ (S/T)(N/D)IGSSX ₁₁ VX ₁₃ (SEQ ID NO:1731), where X ₄ represents S, P, or K; X ₁₁ represents S, Y, or T; and X ₁₃ represents S, Y, or T;

(ii) LCDR2 having the sequence (K/M)(N/D)X ₃ X ₄ R(P/A)X ₇ (SEQ ID NO:1732), where X ₃ represents S, N or T; X ₄ represents L, Q, or A; X ₅ represents P or A; X ₇ represents Q, S, Y, or L; And

(iii) LCDR3 having the sequence (S/A)(T/S)W(D/N)X ₅ X ₆ (L/N)X ₈ (V/I)R(V/I) (SEQ ID NO: 1733), where X ₅ represents E, D or N; X ₆ represents S, A, or Q; and X ₈ is N, S, or T. In some embodiments, in the HCDR1 sequence, position 3 is T; position 4 represents F; position 5 represents S; position 6 represents K; and/or position 10 is S. In some embodiments, the HCDR1 sequence includes the sequence GFTFSKAWMS (SEQ ID NO:1). In some embodiments, HCDR1 comprises the sequence of any one of GFTFSAAWMS (SEQ ID NO:4), GFVFSKAWMS (SEQ ID NO:7), GFTFAKAWMS (SEQ ID NO:6), GFTYSKAWMS (SEQ ID NO:5), GFTFSMAWMS (SEQ ID NO: :3), GFTYSAAWMS (SEQ ID NO:2), or GFTFSKAWMT (SEQ ID NO:8). In some embodiments, in the HCDR2 sequence, position 4 is S; position 5 represents V; position 6 represents T; position 7 represents D; position 8 represents G; position 9 represents E; position 10 represents T; position 12 represents D; and/or position 16 is P. In some embodiments, HCDR2 includes the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9). In some embodiments, HCDR2 includes the sequence RIKSVTDGEQTDYAAPVKG (SEQ ID NO:18), RIKAADDGKQTDYAAPVKG (SEQ ID NO:19), RIKSVTDGETTEYAASVKG (SEQ ID NO:9), RIKAVHDGETTDYAAPVKG (SEQ ID NO:10), RIKSNTDAETTDYAAPVKG (SEQ ID NO:11) ), RIKSVQDGETTDYAAPVKG (SEQ ID NO:12), RIKSVTDGHTTDYAAPVKG (SEQ ID NO:13), RIKSVTDGGITDYAAPVKG (SEQ ID NO:14), RIKSTSDGETTDYAAPVKG (SEQ ID NO:15), RIKSTSDGGITDYAAPVKG (SEQ ID NO:16), or RIKSVTEGETTDYAA PVKG ( SEQ ID NO:17). In some embodiments, in the HCDR3 sequence, position 1 is T; position 2 represents S; position 7 represents R; position 8 represents G; position 9 represents G; position 10 represents S; position 14 represents H; position 15 represents D; position 18 represents Y; position 20 represents G; and/or position 21 is G. In some embodiments, HCDR3 includes the sequence TSSFCCRGGSCPSHDTSYCGGYYKSYYYMDV (SEQ ID NO:33), TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21), or TSSFCCRGGSCPSHDTSYCGGQYKSFYYMDV (SEQ ID NO:28). In some embodiments, HCDR3 includes the sequence:

TSSFCCRGGSCPSSDTSYCGGQYKSYYFMDV (SEQ ID NO:32), ISSFCCRGGSCPSRDTSYCGGQYKSYYFMDV (SEQ ID NO:30), ISSFCCRGNSCPSSDTSYCNGQYKSYYFMDV (SEQ ID NO:29), ISSFCCRGNSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:27), ISSFCCHSNNCPSSDTSYCNG YYKQYYFMDV (SEQ ID NO:26), ISSFCCRGKQCPSSDTSYCGGQFKSYYFMDV (SEQ ID NO :25), ISSFCCRGKQCPSSDTSYCNGYYADYYFMDV (SEQ ID NO:24), TSSFCCRGNQCPSSDTSYCGGQYPSYYYMDP (SEQ ID NO:23), TTSFCCRGASCPSSDTSYCAGSYKSYYFVNI (SEQ ID NO:22), TSSFCCRSGSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:20), TSS FCCRGGSCPSHDTSYCGGQDSRYYYMDV (SEQ ID NO:42), TSSFCCRGGSCPSHDTSFCGGSYKSYYYMDV (SEQ ID NO:41), TSSFCCRGGSCPSHDTSFCGGQYKSYYYMDV (SEQ ID NO:37), TSSFCCRGGSCPSHDTSFCGGQDSRYYYMDV (SEQ ID NO:40), TTSFCCRGGSCPSHDTSFCGGQYKSYYYMDV (SEQ ID NO:39), TSSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:34), TTS FCCRGGRCPSRDTSFCGGQYNSYYYMDV (SEQ ID NO: 38), TSSFCCRGGSCPSHDTSFCGGQYNRYYYMDV (SEQ ID NO:36) and TTSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:35). In some embodiments, in the LCDR1 sequence, position 3 is S; position 4 represents S; position 5 represents S; position 6 represents N; position 11 represents S; and/or position 13 is S. In some embodiments, LCDR1 includes the sequence SGSSSNIGSSSVS (SEQ ID NO:48). In some embodiments, LCDR1 includes the sequence SGSKSNIGSSYVS (SEQ ID NO:50), SGSSSNIGSSSVY (SEQ ID NO:56), SGSKSNIGSSSVY (SEQ ID NO:55), SGSSTNIGSSSSVS (SEQ ID NO:54), SGASSNIGSSSVS (SEQ ID NO:52 ), SGSSTNIGSSTVS (SEQ ID NO:53), SGSKSNIGSSSVS (SEQ ID NO:51), or SGSSTNIGSSSVT (SEQ ID NO:49). In some embodiments, in the LCDR2 sequence, position 1 is K; position 2 represents N; position 3 represents N; position 4 represents Q; position 6 represents P; and/or position 7 is S. In some embodiments, the LCDR2 sequence includes the sequence KNNQRPS (SEQ ID NO:59). In some embodiments, LCDR2 includes the sequence KNNQRPY (SEQ ID NO:66), KDNQRPS (SEQ ID NO:62), KNTQRPS (SEQ ID NO:65), KNNARPY (SEQ ID NO:64), KNTQRAS (SEQ ID NO:63 ), MNNQRPY (SEQ ID NO:61), or KDNQRPL (SEQ ID NO:60). In some embodiments, in the LCDR3 sequence, position 1 is S; position 2 represents T; position 4 represents D; position 5 represents D; position 6 represents S; position 7 represents L; position 8 represents S; position 9 represents V; and/or position 11 is V. In some embodiments, the LCDR3 sequence includes the sequence STWDDSLSVRV (SEQ ID NO:68). In some embodiments, the LCDR3 sequence includes the sequence STWDDALSVRV (SEQ ID NO:72), SSWDDSNSVRI (SEQ ID NO:71), ATWDDQLSVRV (SEQ ID NO:69), ATWDDSLTVRI (SEQ ID NO:76), ATWDNSLSIRV (SEQ ID NO: 70), or STWDESLSVRV (SEQ ID NO:73).

[0012] In some embodiments, HCDR1 has the sequence GFTFSKAWMS (SEQ ID NO:1), GFTFSAAWMS (SEQ ID NO:4), or GFTFSKAWMT (SEQ ID NO:8); HCDR2 has the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) or RIKSTSDGETTDYAAPVKG (SEQ ID NO:15); HCDR3 has the sequence TSSFCCRGGSCPSSDTSYCGGQYKSYYFMDV (SEQ ID NO:32), TSSFCCRSGSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:20), TSSFCCRGNQCPSSDTSYCGGQYPSYYYMDP (SEQ ID NO:23), ISSFCCRGGSCPSRDTSYCGGQYKSYYFMDV (SEQ ID NO:30), IS SFCCRGNSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:27), TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV ( SEQ ID NO:21), or TSSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:34);

LCDR1 has the sequence SGSSSNIGSSSVY (SEQ ID NO:56), SGSSSNIGSSSVS (SEQ ID NO:48), SGSSTNIGSSSVS (SEQ ID NO:54) or SGSKSNIGSSSVS (SEQ ID NO:51);

LCDR2 has the sequence KNNQRPS (SEQ ID NO:59) or KDNQRPS (SEQ ID NO:62); And

LCDR3 has the sequence STWDDALSVRV (SEQ ID NO:72), STWDDSLSVRV (SEQ ID NO:68), SSWDDSNSVRI (SEQ ID NO:71) or ATWDNSLSIRV (SEQ ID NO:70)

[0013] In some embodiments, the heavy chain variable region has a sequence having at least 90% sequence identity to any of EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSSDTSYCGGQYKSYYFMDVWGKGTTV TVSS (SEQ ID NO:92) SKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGNQCPSSDTSYCGGQYPSYYYMDPWGKGTTVTVSS (SEQ ID NO:80 ), EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSTSDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGGSCPSRDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:90), EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEW VGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGNSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:86), EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTED TAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:94), and EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSVLYLQMSSLKTEDTAVYFCTSSFCCRGGSCPSHDTSFCGGQDKRYYYMDVWGK GTTVTVSS (SEQ ID NO:95). In some embodiments, which may be combined with the foregoing, the light chain variable region has a sequence having at least 90% identity to the sequence of any of QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSSGTSASLAISGLRSEDEADYYCSTWDDALSVRVFGGGTKLTVL (SEQ ID NO:138), QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTDWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140), QSVLTQPPSASGTPGQRVTISCSGSSTNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTS ASLAISGLRSEDEADYYCSSWDDSNSVRIFGGGTKLTVL (SEQ ID NO:136), QSVLTQPPSASGTPGQRVTISCSGSKSNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDNSLSIRVFGGGTKLTVL (SEQ ID NO:132), and QSVLTQAPSASETPGQRVIISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRP SGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:141).

[0014] In some embodiments, the antibody comprises HCDR1 having the sequence GFTFSKAWMS (SEQ ID NO:1); HCDR2 having the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 having the sequence TSSFCCRGGSCPSSDTSYCGGQYKSYYFMDV (SEQ ID NO:32); LCDR1 having the sequence SGSSSNIGSSSVY (SEQ ID NO:56); LCDR2 having the sequence KNNQRPS (SEQ ID NO:59); and LCDR3 having the sequence STWDDALSVRV (SEQ ID NO:72). In some embodiments, the heavy chain variable region has a sequence having at least 90% identity with the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSSDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO: 92); and the light chain variable region has a sequence having at least 90% identity with the sequence QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDALSVRVFGGGTKLTVL (SEQ ID NO:138). In some embodiments, the heavy chain variable region comprises the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSSDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:92); and the light chain variable region contains the sequence QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSSVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDALSVRVFGGGTKLTVL (SEQ ID NO:138).

[0015] In some embodiments, HCDR1 has the sequence GFTFSKAWMS (SEQ ID NO:1); HCDR2 has RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 has the sequence TSSFCCRSGSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:20); LCDR1 has the sequence SGSSSNIGSSSVS (SEQ ID NO:48); LCDR2 has the sequence KNNQRPS (SEQ ID NO:59); and LCDR3 has the sequence STWDDSLSVRV (SEQ ID NO:68). In some embodiments, the heavy chain variable region has a sequence having at least 90% identity with the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRSGSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO :77); and the light chain variable region has a sequence having at least 90% identity with the sequence QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140).

[0016] In some embodiments, the heavy chain variable region comprises the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRSGSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:77); and the light chain variable region contains the sequence QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140)

[0017] In some embodiments, HCDR1 has the sequence GFTFSKAWMS (SEQ ID NO:1); HCDR2 has the sequence RIKSVTTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 has the sequence TSSFCCRGNQCPSSDTSYCGGQYPSYYYMDP (SEQ ID NO:23); LCDR1 has the sequence SGSSSNIGSSSVS (SEQ ID NO:48); LCDR2 has the sequence KNNQRPS (SEQ ID NO:59); and LCDR3 has the sequence STWDDSLSVRV (SEQ ID NO:68).

[0018] In some embodiments, the heavy chain variable region has a sequence having at least 90% identity with the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGNQCPSSDTSYCGGQYPSYYYMDPWGKGTTV TVSS (SEQ ID NO:80); and the light chain variable region has a sequence having at least 90% identity with the sequence QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140).

[0019] In some embodiments, the heavy chain variable region comprises the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGNQCPSSDTSYCGGQYPSYYYMDPWGKGTTVTVSS (SEQ ID NO:80); and the light chain variable region contains the sequence QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140).

[0020] In some embodiments, HCDR1 has the sequence GFTFSAAWMS (SEQ ID NO:4); HCDR2 has the sequence RIKSTSDGETTDYAAPVKG (SEQ ID NO:15); HCDR3 has the sequence ISSFCCRGGSCPSRDTSYCGGQYKSYYFMDV (SEQ ID NO:30); LCDR1 has the sequence SGSSTNIGSSSSVS (SEQ ID NO:54); LCDR2 has the sequence KDNQRPS (SEQ ID NO:62); and LCDR3 has the sequence SSWDDSNSVRI (SEQ ID NO:71).

[0021] In some embodiments, the heavy chain variable region has a sequence having at least 90% identity with the sequence EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSTSDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGGSCPSRDTSYCGGQYKSYYFMDVWGKGTTVTVSS ( SEQ ID NO:90); and the light chain variable region has a sequence having at least 90% identity with the sequence QSVLTQPPSASGTPGQRVTISCSGSSTNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSNSVRIFGGGTKLTVL (SEQ ID NO:136).

[0022] In some embodiments, the heavy chain variable region comprises the sequence EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSSTSDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGGSCPSRDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:90); and the light chain variable region contains the sequence QSVLTQPPSASGTPGQRVTISCSGSSTNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSNSVRIFGGGTKLTVL (SEQ ID NO:136).

[0023] In some embodiments, the antibody has the sequence HCDR1 GFTFSAAWMS (SEQ ID NO:4); HCDR2 sequence RIKSVTTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 sequence ISSFCCRGNSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:27); LCDR1 sequence SGSKSNIGSSSVS (SEQ ID NO:51); LCDR2 sequence KDNQRPS (SEQ ID NO:62); and LCDR3 sequence ATWDNSLSIRV (SEQ ID NO:70).

[0024] In some embodiments, the heavy chain variable region has a sequence having at least 90% identity with the sequence EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGNSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:86); and the light chain variable region has a sequence having at least 90% identity with the sequence QSVLTQPPSASGTPGQRVTISCSGSKSNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDNSLSIRVFGGGTKLTVL (SEQ ID NO:132).

[0025] In some embodiments, the heavy chain variable region comprises the sequence EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGNSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:86); and the light chain variable region contains the sequence QSVLTQPPSASGTPGQRVTISCSGSKSNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDNSLSIRVFGGGTKLTVL (SEQ ID NO:132).

[0026] In some embodiments, the antibody comprises the HCDR1 sequence GFTFSKAWMT (SEQ ID NO:8); HCDR2 sequence RIKSVTTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 sequence TSSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:34); LCDR1 sequence SGSSSNIGSSSVS (SEQ ID NO:48); LCDR2 sequence KNNQRPS (SEQ ID NO:59); and LCDR3 sequence STWDDSLSVRV (SEQ ID NO:68).

[0027] In some embodiments, the heavy chain variable region has a sequence having at least 90% identity with the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSVLYLQMSSLKTEDTAVYFCTSSFCCRGGSCPSHDTSFCGGQDKRYYYMDVWGKGTTVTVSS (SEQ ID NO:95); and the light chain variable region has a sequence having at least 90% identity with the sequence QSVLTQAPSASETPGQRVIISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTDWDDSLSVRVFGGGTKLTVL (SEQ ID NO:141).

[0028] In some embodiments, the heavy chain variable region comprises the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSVLYLQMSSLKTEDTAVYFCTSSFCCRGGSCPSHDTSFCGGQDKRYYYMDVWGKGTTVTVSS (SEQ ID NO:95); and the light chain variable region has a sequence comprising the sequence QSVLTQAPSASETPGQRVIISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:141).

[0029] In some embodiments, the antibody comprises a heavy chain variable region comprising: HCDR1 comprising the sequence GFTFSKAWMT (SEQ ID NO:8) or GFTFSKAWMS (SEQ ID NO:1), or a variant HCDR1 in which 1 or 2 amino acids are substituted relative to sequences; HCDR2 comprising the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9), or a variant HCDR2 in which 1 or 2 amino acids are substituted relative to the sequence; and HCDR3 comprising the sequence TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21), or a variant HCDR3 in which 1, 2 or 3 amino acids are substituted relative to the sequence; a light chain variable region comprising: LCDR1 comprising the sequence SGSSDNIGSSSVS (SEQ ID NO:48), or a variant LCDR1 in which 1 or 2 amino acids are substituted relative to the sequence; LCDR2 comprising the sequence KNNQRPS (SEQ ID NO:59), or a variant LCDR2 in which 1 or 2 amino acids are substituted relative to the sequence; and LCDR3 comprising the sequence STWDDSLSVRV (SEQ ID NO:68), or a variant LCDR3 in which 1 or 2 amino acids are substituted relative to the sequence.

[0030] In some embodiments, the antibody comprises: a heavy chain variable region containing FR1 that contains a substitution at 1, 2 or 3 positions relative to the corresponding FR1 sequence of the VH region of any of SEQ ID NO: 77-122 or 1333-1526 or 1725, FR2 that contains a substitution at 1, 2 or 3 positions relative to the corresponding FR2 sequence of the VH region of any of SEQ ID NO: 77-122 or 1333-1526 or 1725, FR3 that contains a substitution at 1, 2 or 3 positions relative to the corresponding FR3 sequence VH region any of SEQ ID NO:77-122, 1333-1526 or 1725; and/or FR4 that contains a substitution at 1 or 2 positions relative to the corresponding FR4 sequence of the VH region of any of SEQ ID NO:77-122, 1333-1526 or 1725; and a light chain variable region containing FR1 that contains a substitution at 1, 2 or 3 positions relative to the corresponding FR1 sequence of the VL region of any of SEQ ID NO:123-168 or 1527-1720 or 1726, FR2 that contains a substitution at 1, 2 or 3 positions relative to the corresponding VL region FR2 sequence of any of SEQ ID NO:123-168 or 1527-1720 or 1726, FR3, which contains a substitution at 1, 2 or 3 positions relative to the corresponding VL region FR3 sequence of any of SEQ ID NO:123 -168, or 1527-1720, or 1726; and/or FR4, which contains a substitution at 1 or 2 positions relative to the corresponding FR4 sequence of the VL region of any of SEQ ID NO: 123-168, or 1527-1720, or 1726.

[0031] In some embodiments, the antibody contains a _VH having at least 95% identity with any of SEQ ID NO:77-122 or 13333-1526 or 1725; and a corresponding V _L having at least 95% identity with any of SEQ ID NO: 123-168, 1527-1720 or 1726.

[0032] In some embodiments, the antibody comprises a heavy chain constant region sequence of SEQ ID NO:1721 and a light chain constant region sequence of SEQ ID NO:1722.

[0033] In a further aspect, provided herein is an antibody that binds to an extracellular RNA-protein complex, wherein the antibody comprises: a heavy chain variable region comprising: HCDR1 comprising the sequence GFTFSKAWMS (SEQ ID NO:1), or a variant HCDR1, in in which 1 amino acid is substituted relative to the sequence; HCDR2 comprising the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9), or a variant HCDR2 in which 1 amino acid is substituted relative to the sequence; and HCDR3 comprising the sequence TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21), or a variant HCDR3 in which 1, 2 or 3 amino acids are substituted relative to the sequence; and a light chain variable region comprising: LCDR1 including the sequence SGSSSNIGSSSVS (SEQ ID NO:48), or a variant LCDR1 in which 1 amino acid is substituted relative to the sequence; LCDR2 comprising the sequence KNNQRPS (SEQ ID NO:59), or a variant LCDR2 in which 1 amino acid is substituted relative to the sequence; and LCDR3 comprising the sequence STWDDSLSVRV (SEQ ID NO:68), or a variant LCDR3 in which 1 amino acid is substituted relative to the sequence.

[0034] In some embodiments, the antibody comprises HCDR1 comprising the sequence GFTFSKAWMS (SEQ ID NO:1), HCDR2 comprising the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9), HCDR3 comprising the sequence TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21) LCDR1 comprising the sequence SGSSSNIGSSSVS (SEQ ID NO:48), LCDR2 including the sequence KNNQRPS (SEQ ID NO:59), and LCDR3 including the sequence STWDDSLSVRV (SEQ ID NO:68). In some embodiments, V _H includes an amino acid sequence having at least 95% identity with EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:94); and V _L includes an amino acid sequence having 95% identity with QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTDWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140). In some embodiments, V _H includes the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:94); and V _L includes the sequence QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140). In some embodiments, the antibody comprises a heavy chain constant region sequence of SEQ ID NO:1721 and a light chain constant region sequence of SEQ ID NO:1722. In some embodiments, the heavy chain includes the sequence of SEQ ID NO:1723 and the light chain includes the sequence of SEQ ID NO:1724.

[0035] In a further aspect, this document provides a method of inducing an immune response, the method comprising administering to a subject any of the antibodies described in the preceding paragraphs of this section. In some embodiments, the immune response includes an ADCP response. In some embodiments, the antibody is administered intravenously.

[0036] In a further aspect, provided herein is a method of treating a cancer patient having a tumor that contains an extracellular RNA-protein complex, wherein the method comprises administering to the patient any of the antibodies described in the preceding paragraphs. In some embodiments, the antibody is an antibody as described in any of paragraphs [0011] - [0034] above. In some embodiments, the cancer is lung cancer, breast cancer, colorectal cancer, esophageal cancer, stomach cancer, kidney cancer, ovarian cancer, melanoma, uterine cancer, liver cancer, bladder cancer, or testicular cancer. In some embodiments, the cancer is non-small cell lung cancer, triple negative breast cancer, colorectal cancer, ovarian cancer, or melanoma. In some embodiments, the antibody is administered intravenously. In some embodiments, the method further includes administering chemotherapy and/or radiation therapy. In some embodiments, the method further includes administering an agent that targets an immunological checkpoint antigen. In some embodiments, the agent is a monoclonal antibody. In some embodiments, the monoclonal antibody blocks the binding of a PD-1 ligand to PD-1. In some embodiments, the monoclonal antibody is an anti-PD-1 antibody.

[0037] In a further aspect, provided herein is a method for identifying a patient who has a tumor containing an extracellular RNA-protein complex, where the method includes contacting a tumor sample from the patient with an antibody as described in the preceding paragraphs.

[0038] In yet another aspect, provided herein is an expression vector comprising a polynucleotide encoding the V _H region of an antibody as set forth in the preceding paragraphs. Additionally provided herein is an expression vector containing a polynucleotide encoding the V _L region of an antibody, as indicated in the preceding paragraphs. In some embodiments, the expression vector contains a polynucleotide encoding the V _H region and V _L region of the antibody. In some embodiments, the expression vector provided herein contains a polynucleotide encoding the CDR3 V _H or V _L of an antibody specified in any of the preceding paragraphs. Also provided herein are host cells that contain an expression vector as described in this paragraph. In some embodiments, the host cell is a CHO cell, such as a CHO K-1 cell.

[0039] Further provided herein is a method for producing an antibody, comprising culturing a host cell as described in the previous paragraph under conditions in which a heavy chain-encoding polynucleotide and a light chain-encoding polynucleotide are expressed.

[0040] In a further aspect, provided herein is a method for identifying an antibody having antitumor activity, wherein the method comprises mutagenizing a polynucleotide encoding the CDR3 V _H or V _L of either antibody as described in the preceding paragraphs, expressing the antibody comprising the mutagenized CDR3 V _H or V _L ; and selecting an antibody that inhibits tumor growth or reduces tumor size, tumor invasion and/or metastasis in vivo .

[0041] In a further aspect, this document provides the use of any of the antibodies described in the previous paragraphs in a method for inducing an immune response in vivo. Further provided herein is the use of any of the antibodies described in the preceding paragraphs in a method for treating cancer. In some embodiments, cancer is treated in a subject having a tumor containing an extracellular RNA-protein complex. In some embodiments, the cancer is lung cancer, breast cancer, colorectal cancer, esophageal cancer, stomach cancer, kidney cancer, ovarian cancer, melanoma, uterine cancer, liver cancer, bladder cancer, or testicular cancer. In some embodiments, the cancer is non-small cell lung cancer, triple negative breast cancer, colorectal cancer, ovarian cancer, or melanoma. In some embodiments, the antibody is administered intravenously. In some embodiments, the method further includes administering chemotherapy and/or radiation therapy. In some embodiments, the method further includes an agent that targets an immunological checkpoint antigen. In some embodiments, the agent is a monoclonal antibody. In some embodiments, the monoclonal antibody blocks the binding of a PD-1 ligand to PD-1. In some embodiments, the monoclonal antibody is an anti-PD-1 antibody.

[0042] In a further aspect, provided herein is a polypeptide comprising the sequence V _H EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:94); and sequence V _L QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140). Additionally provided herein is a polypeptide comprising the heavy chain region sequence of SEQ ID NO:1723 and the light chain region sequence of SEQ ID NO:1724.

[0043] In a further aspect, provided herein is an antitumor antibody comprising a heavy chain variable region ( _VH ) and a light chain variable region ( _VL ), wherein: (a) the _VH region contains a CDR1 sequence including GFTFSKAWMS (SEQ ID NO :1), or a variant thereof containing 1, 2 or 3 substitutions, a CDR2 sequence comprising RIKSVTDGETTDYAAPVKG (SEQ ID NO:9), RIKSVTEGETTDYAAPVKG (SEQ ID NO:17) or RIKSTSDGGITDYAAPVKG (SEQ ID NO:16), or a variant of the sequence CDR2 having 1, 2, 3, 4 or 5 amino acid substitutions; and a CDR3 sequence including T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)(Y/D)(K/N/S)(R/ S)YYYMDV, as numbered with reference to any of SEQ ID NO:77-122; and (b) the V _L region contains a CDR1 sequence comprising SGSSSNIGSSSVS (SEQ ID NO:48), or a variant thereof containing 1, 2, 3 or 4 amino acid substitutions, a CDR2 comprising KNNQRPS (SEQ ID NO:59), or a variant containing 1 or 2 amino acid substitutions, and a CDR3 sequence including STWD(D/E)DSLSVRV, as numbered with reference to any of SEQ ID NO:77-122. In some embodiments, the V _H region comprises a variant CDR1 sequence GFTFSKAWM(S/T) and/or a CDR2 sequence RIKS(V/T)(T/S)(D/E)G(E/G)(I/T)TDYAAPVKG . In some embodiments, the _VH CDR3 sequence includes:

T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)YKSYYYMDV, T(S/T)SFCCRGG(R/S)CPS(H/R) DTS(Y/F)CGG(Q/S)DSRYYYMDV, T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)YNRYYYMDV, T(S/ T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)YNSYYYMDV, or T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y /F)CGG(Q/S)DKRYYYMDV.

In some embodiments, the V _H region comprises a variant CDR1 sequence GFTFSKAWMT (SEQ ID NO:8), a CDR2 sequence RIKSVT(D/E)GETTDYAAPVKG, and a CDR3 sequence T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S )(Y/D)(K/N/S)(R/S)YYYMDV, for example,

T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)YKSYYYMDV, T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)DSRYYYMDV, T(S/T)SFCCRGGSCPSHDTS(Y/ F)CGG(Q/S)YNRYYYMDV, or T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)DKRYYYMDV. In some embodiments, V _H comprises a CDR3 sequence

TSSFCCRGGSCPSHDTSFCGGQYKSYYYMDV (SEQ ID NO:37),

TTSFCCRGGSCPSHDTSFCGGQYKSYYYMDV (SEQ ID NO:39),

TSSFCCRGGSCPSHDTSFCGGQDSRYYYMDV (SEQ ID NO:40),

TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21),

TSSFCCRGGSCPSHDTSFCGGSYKSYYYMDV (SEQ ID NO:41),

TSSFCCRGGSCPSHDTSYCGGQDSRYYYMDV (SEQ ID NO:42),

TSSFCCRGGSCPSHDTSFCGGQYNRYYYMDV (SEQ ID NO:36),

TSSFCCRGGRCPSRDTSFCGGQYNSYYYMDV (SEQ ID NO:1740),

TSSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:34), or

TTSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:35). In some embodiments, the antitumor antibody comprises CDR1, CDR2 and/or CDR3 V _H as set forth in Table 1B. In some embodiments, the antitumor antibody comprises a V _L region comprising the CDR1 sequence SGSSSNIGSSSVS (SEQ ID NO:48) or a variant thereof containing 1, 2, 3 or 4 amino acid substitutions; the CDR2 sequence KNNQRPS (SEQ ID NO:59) or a variant thereof having 1, 2 or 3 substitutions, and the CDR3 sequence STWD(D/E)SLSVRV. In some embodiments, the CDR1 sequence is SGSSSNIGSSSVS (SEQ ID NO:48) and/or the CDR2 sequence is KNNQRPS (SEQ ID NO:59).

[0044] Further provided herein is an antitumor antibody comprising a V _H region and a V _L region, wherein: (a) the V _H region contains a CDR1 sequence having at least 80% identity with the CDR1 sequence shown in Table 1B , at least 80% identity with the CDR2 sequence shown in Table 1B; and at least 80% identity with the CDR3 sequence shown in Table 1B; and (b) the V _L region contains: (i) a CDR1 sequence having at least 80% identity with the CDR1 sequence shown in Table 1B, a CDR2 sequence having at least 80% identity with the CDR2 sequence shown in Table 1B, and a CDR3 sequence having at least 80% identity with the CDR3 sequence specified in 1B. In some embodiments, the antibody comprises a V _H containing FR1 having at least 90% identity with the amino acid sequence from position 1-25 of any of SEQ ID NO: 77-122, where FR2 has at least 90% identity with the amino acid sequence from positions 36-49 of any of SEQ ID NO:77-122, FR3 has at least 90% identity with the amino acid sequence of positions 69-98 of any of SEQ ID NO:77-122; and/or FR4 has at least 90% identity with the amino acid sequence from positions 130-140, as defined by reference to any of SEQ ID NO:77-122. In some embodiments, the antitumor antibody comprises a V _L comprising FR1 having at least 90% identity to the amino acid sequence of positions 1-22 of one of SEQ ID NOs: 123-168, wherein FR2 has at least 90% identity to the amino acid sequence from positions 36-50 of any of SEQ ID NO:123-168, FR3 has at least 90% identity with the amino acid sequence from positions 58-89 of any of SEQ ID NO:123-168; and/or FR4 has at least 90% identity with the amino acid sequence from positions 101-110, as defined by reference to any of SEQ ID NO: 123-168. In some embodiments, the antibody comprises a V _H region having at least 70% identity with any of SEQ ID NO:77-122; and/or V _L having at least 70% identity with any of SEQ ID NO:123-168. In some embodiments, the V _H region has at least 80% identity with any of SEQ ID NO:77-122; and/or the V _L region has at least 80% identity with any of SEQ ID NO:123-168. In some embodiments, the V _H region has at least 90% identity with any of SEQ ID NO:77-122; and/or the V _L region has at least 90% identity with any of SEQ ID NO:123-168. In additional embodiments, the V _H region has at least 95% identity with any of SEQ ID NO:77-122; and/or the V _L region has at least 95% identity with any of SEQ ID NO:123-168.

[0045] In some embodiments, an antitumor antibody, or an antibody that can be used to evaluate a tumor sample that has an extracellular RNA-protein complex, comprises:

a V _H region containing the amino acid sequence of SEQ ID NO:101, and a V _L region containing the amino acid sequence of SEQ ID NO:147;

a V _H region containing the amino acid sequence of SEQ ID NO:102, and a V _L region containing the amino acid sequence of SEQ ID NO:148;

a V _H region containing the amino acid sequence of SEQ ID NO:203, and a V _L region containing the amino acid sequence of SEQ ID NO:149;

a V _H region containing the amino acid sequence of SEQ ID NO:104, and a V _L region containing the amino acid sequence of SEQ ID NO:150;

a V _H region containing the amino acid sequence of SEQ ID NO:105, and a V _L region containing the amino acid sequence of SEQ ID NO:151;

a V _H region containing the amino acid sequence of SEQ ID NO:106, and a V _L region containing the amino acid sequence of SEQ ID NO:152;

a V _H region containing the amino acid sequence of SEQ ID NO:107, and a V _L region containing the amino acid sequence of SEQ ID NO:153;

a V _H region containing the amino acid sequence of SEQ ID NO:94, and a V _L region containing the amino acid sequence of SEQ ID NO:140;

a V _H region containing the amino acid sequence of SEQ ID NO:1335, and a V _L region containing the amino acid sequence of SEQ ID NO:1529;

a V _H region containing the amino acid sequence of SEQ ID NO:108, and a V _L region containing the amino acid sequence of SEQ ID NO:154;

a V _H region containing the amino acid sequence of SEQ ID NO:97, and a V _L region containing the amino acid sequence of SEQ ID NO:143;

a V _H region containing the amino acid sequence of SEQ ID NO:98, and a V _L region containing the amino acid sequence of SEQ ID NO:144;

a V _H region containing the amino acid sequence of SEQ ID NO:109, and a V _L region containing the amino acid sequence of SEQ ID NO:155;

a V _H region containing the amino acid sequence of SEQ ID NO:110, and a V _L region containing the amino acid sequence of SEQ ID NO:156;

a V _H region containing the amino acid sequence of SEQ ID NO:1136, and a V _L region containing the amino acid sequence of SEQ ID NO:1530;

a V _H region containing the amino acid sequence of SEQ ID NO:99, and a V _L region containing the amino acid sequence of SEQ ID NO:145;

a V _H region containing the amino acid sequence of SEQ ID NO:95, and a V _L region containing the amino acid sequence of SEQ ID NO:141;

a V _H region containing the amino acid sequence of SEQ ID NO:100, and a V _L region containing the amino acid sequence of SEQ ID NO:146;

a V _H region containing the amino acid sequence of SEQ ID NO:96, and a V _L region containing the amino acid sequence of SEQ ID NO:142;

a V _H region containing the amino acid sequence of SEQ ID NO:1333, and a V _L region containing the amino acid sequence of SEQ ID NO:1527; or

a V _H region containing the amino acid sequence of SEQ ID NO:1334, and a V _L region containing the amino acid sequence of SEQ ID NO:1528.

[0046] In some embodiments, an antibody as described herein, for example, an antitumor antibody having a V _H and the corresponding V _L listed in Table 1A, contains an IgG1 heavy chain constant region having at least 90% identity with SEQ ID NO:1721 and a lambda light chain constant region having at least 90% identity with SEQ ID NO:1722. In some embodiments, the IgG1 heavy chain constant region comprises the sequence SEQ ID NO:1721 and the lambda light chain constant region comprises the sequence SEQ ID NO:1722.

[0047] In a further aspect, provided herein is an expression vector comprising a polynucleotide encoding the V _H region and/or the V _L region of an antibody, as described herein, for example, in the previous two paragraphs. In addition, this document provides an expression vector containing a polynucleotide encoding the CDR3 V _H or V _L of an antitumor antibody, as described herein, for example, in the previous two paragraphs. The invention further provides a host cell containing an expression vector of the present invention, for example, as described herein; or a host cell that contains a polynucleotide that encodes the V _H region and/or the V _L region of an antitumor antibody, as described herein, for example, in the previous two paragraphs.

[0048] In a further aspect, provided herein is a method for identifying an antibody having antitumor or tumor binding activity, wherein the method comprises mutagenizing a polynucleotide encoding a CDR3 V _H or V _L as listed in Table 1B or 2B, expressing the antibody comprising the mutagenized CDR3 _VH or _VL ; and selecting an antibody that inhibits tumor growth, reduces tumor size, reduces tumor invasion and/or metastasis in vivo .

[0049] In a further aspect, provided herein is a method of treating cancer, the method comprising administering an antibody of the present invention to a patient who has cancer, such as lung cancer, breast cancer, colorectal cancer, esophageal cancer, stomach cancer, kidney cancer, ovarian cancer, melanoma, uterine cancer, liver cancer, bladder cancer or testicular cancer. In some embodiments, the patient is also administered a chemotherapeutic agent and/or radiation therapy, for example, prior to administration of an antitumor antibody. In some embodiments, the patient is further administered a therapeutic agent that targets an immunocheckpoint antigen, e.g., the therapeutic agent is a checkpoint inhibitor, such as a monoclonal antibody, that targets the PD-1/PD-L1 immunocheckpoint antigen, such as an antibody anti-PD-1 or anti-PD-L1 antibody.

[0050] In a further aspect, provided herein is an antitumor antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises a heavy chain variable region (V _H ), which contains a CDR1 comprising GFTFSKAWMS (SEQ ID NO:1), a CDR2 comprising RIKSVTDGETTDYAAPVKG (SEQ ID NO:9), and CDR3 comprising TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21); and the light chain comprises a light chain variable region (V _L ) that contains CDR1 including SGSSSNIGSSSVS (SEQ ID NO:48), CDR2 including (SEQ ID NO:59), and CDR3 including STWDDSLSVRV (SEQ ID NO:68) ; and further wherein the antibody comprises an IgG1 heavy chain constant region having at least 90% identity with SEQ ID NO:1721, and a lambda light chain constant region having at least 90% identity with SEQ ID NO:1722. In some embodiments, the IgG1 heavy chain constant region comprises the sequence SEQ ID NO:1721 and the lambda light chain constant region comprises the sequence SEQ ID NO:1722. In some embodiments, the antitumor antibody comprises a V _H region having the sequence of SEQ ID NO:94 and a V _L region having the sequence of SEQ ID NO:140. In some embodiments, an antitumor antibody described herein comprises the heavy chain amino acid sequence of SEQ ID NO:1723 and the light chain amino acid sequence of SEQ ID NO:1724.

[0051] In yet another aspect, provided herein is a pharmaceutical composition comprising an antitumor antibody as described herein, for example, in the previous paragraph, and a physiologically acceptable carrier. In some embodiments, the pharmaceutical composition contains 20 mM histidine buffer, 8% (w/v) sucrose, 0.02% (w/v) polysorbate 80 at pH 5.5. In some embodiments, the antibody is stored at a concentration of 20 mg/ml.

[0052] In yet another aspect, provided herein is a method of treating cancer that includes administering the pharmaceutical composition of the previous paragraph above to a patient who has cancer. In some embodiments, the patient has lung cancer, breast cancer, colorectal cancer, esophageal cancer, stomach cancer, kidney cancer, ovarian cancer, melanoma, uterine cancer, liver cancer, bladder cancer, or testicular cancer. In specific embodiments, the patient has non-small cell lung cancer, colorectal cancer, breast cancer, ovarian cancer, or melanoma. In certain embodiments, the melanoma is acral melanoma. In some embodiments, the pharmaceutical composition is administered intravenously. In specific embodiments, the pharmaceutical composition is administered intravenously at a dose ranging from 0.1 mg/kg to 100 mg/kg (eg, 0.3 mg/kg to 30 mg/kg). In some embodiments, the pharmaceutical composition is administered once every three weeks. In some embodiments, the method may further include the use of chemotherapy and/or radiation therapy. In some embodiments, administration of an agent targeting an immunological checkpoint antigen may be used. In certain embodiments, the agent that targets an immune checkpoint antigen may be a monoclonal antibody, for example, a monoclonal antibody that blocks the binding of a PD-1 ligand to PD-1. In certain embodiments, the monoclonal antibody is an anti-PD-1 antibody.

[0053] In yet another aspect, provided herein is a polynucleotide comprising a nucleic acid sequence encoding the heavy chain of an antitumor antibody described herein. In yet another aspect, provided herein is an expression vector comprising a polynucleotide. In another aspect, the invention also provides a host cell that contains a polynucleotide. In another aspect, the invention also provides a host cell that contains an expression vector.

[0054] In yet another aspect, the invention provides a polynucleotide comprising a nucleic acid sequence encoding a light chain of an antitumor antibody described herein. In yet another aspect, the invention also provides an expression vector comprising a polynucleotide. In another aspect, the invention also provides a host cell that contains a polynucleotide. In another aspect, the invention also provides a host cell that contains an expression vector.

[0055] In yet another aspect, the invention also provides an expression vector comprising a polynucleotide that contains a nucleic acid sequence encoding the heavy chain of an antitumor antibody described herein and a polynucleotide that contains a nucleic acid sequence encoding the light chain of an antitumor antibody described herein in this document. In another aspect, the invention also provides a host cell that contains an expression vector.

[0056] In another aspect, the invention also provides a host cell that contains two polynucleotides, one polynucleotide containing a polynucleotide containing a nucleic acid sequence encoding the heavy chain of an antitumor antibody described herein, and another polynucleotide containing a nucleic acid sequence encoding the light chain of an antitumor antibody described herein.

[0057] In another aspect, the invention also provides a host cell that contains two expression vectors, one expression vector containing a polynucleotide containing a nucleic acid sequence encoding the heavy chain of an antitumor antibody described herein, and another expression vector containing the polynucleotide containing a nucleic acid sequence encoding the light chain of an antitumor antibody described herein.

[0058] In some embodiments, the host cell described herein is a CHO cell, for example, a CHO-K1 cell.

[0059] In yet another aspect, the invention relates to a method for producing an antibody described herein. The method involves culturing a host cell as described herein under conditions in which a polynucleotide encoding a heavy chain and a polynucleotide encoding a light chain are expressed.

[0060] In another aspect, the invention relates to a method for producing an antibody described herein. The method includes culturing a host cell that has a polynucleotide containing a nucleic acid sequence encoding the heavy chain of an antitumor antibody described herein, and a host cell that has a polynucleotide containing a nucleic acid sequence encoding the light chain of an antitumor antibody described herein. document, together under conditions in which the polynucleotide encoding the heavy chain and the polynucleotide encoding the light chain are expressed in their respective host cells.

[0061] In yet another aspect, the invention relates to a method for producing an antibody described herein. The method includes culturing a host cell that has an expression vector that contains a polynucleotide containing a nucleic acid sequence encoding the heavy chain of an antitumor antibody described herein, and another host cell that has an expression vector that contains a polynucleotide containing the nucleic acid . a sequence encoding the light chain of an antitumor antibody described herein together under conditions in which the polynucleotide encoding the heavy chain and the polynucleotide encoding the light chain are expressed in the respective host cells.

[0062] In any of the methods for producing an antibody described herein, in some embodiments, the host cell is a CHO cell, for example, a CHO-K1 cell. In some embodiments, the method further includes purifying the antibody.

BRIEF DESCRIPTION OF GRAPHIC MATERIALS

[0063] In FIG. Figure 1 shows tumor growth data from a pooled antibody screen (4 antibodies, each obtained from a lung cancer patient) and a promising antibody identified in the screen in combination with an anti-PD-1 antibody. Panel A, PBS control; Panel B, anti-PD1 antibody only; Panel C, anti-PD1 pool plus antibodies; Panel E, combination of anti-PD1 antibody and AIP-192482 (promising antibody).

[0064] In FIG. 2A and 2B provide data demonstrating the effects of administration of a promising antibody and its variants on tumor growth in the EMT6 mouse tumor model.

[0065] In FIG. 3A and 3B provide data demonstrating the effects of administration of the original candidate antibody and its variants on survival in the EMT6 mouse tumor model.

[0066] In FIG. 4A and 4B provide tumor volume data as normalized area above the curve (NAAC) for the promising antibody and variants in the EMT6 mouse tumor model.

[0067] In FIG. 5A-5D show data demonstrating the effects of administration of the promising antibody and its variants on tumor growth in the EMT6 mouse tumor model.

[0068] In FIG. 6A and 6B show survival data in the EMT6 tumor model comparing the promising antibody and control variants.

[0069] In FIG. 7A-7B show NAAC data obtained for the original promising antibody and variants tested in the EMT6 mouse tumor model.

[0070] In FIG. Figure 8 summarizes the study design for testing individual options as monotherapy and in combination with an anti-PD-1 antibody in the EMT-6 mouse tumor model.

[0071] In FIG. 9 shows monotherapy survival data for the original antibody candidate and the two variants tested in the study summarized in FIG. 8.

[0072] In FIG. 10 presents tumor growth data with monotherapy for the original promising antibody and the two variants tested in the study summarized in FIG. 8.

[0073] In FIG. 11 presents the probability of survival with monotherapy for the original promising antibody and the two variants tested in the study summarized in FIG. 8.

[0074] In FIG. 12 presents tumor volume data with monotherapy for the original promising antibody and the two variants tested in the study summarized in FIG. 8.

[0075] In FIG. 13 presents tumor growth data with combination therapy for the original promising antibody and two variants tested in combination with an anti-PD1 antibody in the study summarized in FIG. 8.

[0076] In FIG. 14 presents the probability of survival with combination therapy for the original promising antibody and two variants tested in combination with an anti-PD1 antibody in the study summarized in FIG. 8.

[0077] In FIG. 15 provides tumor volume data from combination therapy for the original promising antibody and two variants tested in combination with an anti-PD1 antibody in the study summarized in FIG. 8.

[0078] In FIG. Figure 16 shows tumor growth data for the original promising antibody and two variants in the CT26 mouse model.

[0079] In FIG. Figure 17 presents the survival probability data for the original promising antibody and two variants tested in the CT26 mouse model.

[0080] In FIG. Figure 18 shows tumor volume data for the original promising antibody and two variants tested in the CT26 mouse model.

[0081] In FIG. 19 presents immunohistochemical binding data demonstrating binding of variant antibodies AIP-157397 and AIP-165430 to tumor and tumor-adjacent tissue (TAT).

[0082] In FIG. 20 presents immunohistochemical binding data demonstrating binding of the AIP-106042 variant to tumor tissue.

[0083] In FIG. 21 provides immunohistochemical binding data demonstrating binding of the AIP-100196 variant to tumor tissue.

[0084] In FIG. 22 shows immunohistochemical binding data demonstrating binding of the promising candidate and variants, including antibodies AIP-192482, AIP-160470, AIP-133645, AIP-158623, AIP-155066, AIP-136538, AIP-166120, AIP-187893, AIP-142079 , AIP-184490, and AIP-104188, to estrogen receptor-positive breast tumor tissue and TAT.

[0085] In FIG. 23A-23C show immunohistochemical data demonstrating binding of the original antibody candidate (FIG. 23A), variant AIP-133645 (FIG. 23B), and variant AIP-160470 (FIG. 23C) to tumor tissue arising from human lung A549 cells, pancreatic cells BXPC3 human glands, Colo-205 human colon cancer cells or PC3 human prostate cancer cells; and tumors arising from mouse colon, breast, lung, or kidney cancer cell lines.

[0086] In FIG. 24 presents immunohistochemical data demonstrating immune cell infiltration into tumors following treatment with an anti-PD-1 antibody, the original promising antibody, or a combination of the two antibodies.

[0087] In FIG. 25 shows a schematic diagram of an ex vivo binding assay to determine correlation with in vivo antitumor activity.

[0088] In FIG. 26 presents data demonstrating binding of variants to EMT6 cells ex vivo in correlation with in vivo data.

[0089] In FIG. 27 presents data demonstrating that binding of variants to EMT6 cells ex vivo correlates with in vivo outcome. C=anti-EGFR control antibody

[0090] In FIG. 28 shows the results of SDS-PAGE analysis of protein immunoprecipitated with AIP-192482.

[0091] In FIG. 29 presents the results of the analysis of immunoprecipitates of the AIP-192482-target complex treated with RNase or DNase.

[0092] In FIG. 30 shows the results of an SDS-PAGE immunoprecipitation assay using unlabeled A549 cell lysate incubated with M-280 beads conjugated to AIP-192482 and then cross-linked.

[0093] In FIG. 31 shows gel filtration purification of the AIP-192482-antigen complex with and without RNase treatment and analysis of column fractions by SDS-PAGE.

[0094] In FIG. 32A-D show the results of immunofluorescence imaging experiments showing significant overlap between the signal of AIP-192482 and the signal for G3BP, a marker of stress granules. The results also demonstrate that although a subset of these G3BP-positive structures, i.e., very small dots, are not positive for AIP-192482 immunoreactivity, larger aggregates that are more heterogeneous in structure share reactivity.

[0095] In FIG. 33A-D show the results of a confocal imaging experiment performed on EMT6 tumor tissue. A spherical object (indicated by a dashed rectangle) approximately 4 μm in diameter was highlighted by fluorescent staining, indicating that it had reacted on its surface with AIP-160470 and had CD9 reactivity in its lumen. CD9 is a tetraspanin that has been reported to be a marker of extracellular vesicles. In FIG. 33B-D are high magnification images of certain areas within the image of FIG. 33A, taken in each case from one plane of the three-dimensional reconstruction. The 3D confocal imaging reconstruction results demonstrate that the reactivity of AIP-160470 is clearly extracellular in nature, confirming the findings from the flow cytometry data shown in FIG. 35.

[0096] In FIG. 34 shows the results of confocal imaging experiments performed on human breast carcinoma tissue. The images show a mass of CD9-positive vesicles, approximately 1 μm in diameter, included in the signal from AIP-160470 (indicated by white arrows). In FIG. 34B-D are high magnification images of certain areas within the image of FIG. 34A, taken in each case from one plane of the three-dimensional reconstruction. Three-dimensional confocal imaging reconstruction results demonstrate that the CD9-positive vesicle mass is external to neighboring cells.

[0097] In FIG. 35A and 35B show flow cytometry analysis of EMT6 cells stained with AIP-192482 and AIP-160470 following treatment with the chemotherapy agent doxorubicin (“DOX”) for 16 hours in vitro . The geometric mean fluorescence corresponding to antibody binding to EMT6 cells detected by flow cytometry was plotted against the DOX concentrations used to treat EMT6 cells. The results demonstrate that DOX induced surface reactivity over time for AIP-192482 and AIP-160470 in EMT6 cells. These data are in addition to the data in Fig. 33, which demonstrates growth of EMT6 cells in vivo , also induces such surface reactivity.

[0098] In FIG. 36 shows surface reactivity induced by doxorubicin (“DOX”) and cisplatin (“CDDP”) in EMT6 cells.

[0099] FIG. 37A and 37B. Numbering by Kabat, Chothia, and IMGT for AIP-160470.

[0100] FIG. 38A and 38B. In FIG. 38A and 38B provide data demonstrating that RNA is preferentially immunoprecipitated by AIP-192482. Immunoprecipitations were performed from A549 lysates and bound RNA was extracted with TRIzol and then purified using the Zymo Quick-RNA Miniprep kit. After purification, RNA was quantified using Qubit and analyzed on an Agilent Bioanalyzer 2100 using the RNA 6000 Pico assay. The RNA was then processed for sequencing using the NEBNext Ultra II RNA Library Prep Kit for Illumina and sequenced on an Illumina MiSeq instrument with a V3 600 cycle sequencing kit (2x300 PE). Reads were quality filtered using AfterQC, then mapped to the hg19 human genome using TopHat and mapped reads quantified using featureCounts.

[0101] In FIG. 39 shows the activity of the variants in an in vitro FcR interaction assay.

[0102] In FIG. 40 lists the options selected for Round 1 of the in vivo study.

[0103] In FIG. 41 lists the options selected for Round 2 of the in vivo study.

[0104] In FIG. 42 shows the design of an in vivo activity study.

[0105] In FIG. Figure 43 presents data demonstrating tumor volume by cohort at round 2 randomization.

[0106] In FIG. Figure 44 shows the antitumor effects of the options in round 2, ranked by median survival.

[0107] In FIG. Figure 45 shows the antibodies that showed the most effective responses in round 2, ranked by NAAC effect size.

[0108] In FIG. Figure 46 shows the antibodies that showed the most effective responses in round 2, ranked by NGRM effect size.

[0109] In FIG. Figure 47 shows the antibodies that produced the most complete responses in round 2.

[0110] In FIG. 48 shows the antibodies that showed the most consistent responses in round 2

[0111] In FIG. 49 provides a summary of the in vivo activity of a subset of variant antibodies having antitumor effects that are presented in FIG. 49.

[0112] In FIG. 50A and 50B show the relationship between in vitro Fc-gamma receptor assay results and in vivo activity.

[0113] In FIG. 51 shows a schematic representation of the ATRC-101 sequence variants generated during the discovery and pharmacological evaluation of ATRC-101. The numbers represent AIP numbers indicating Fv variants: 192482=AIP-192482, 133645=AIP-133645, 160470=AIP-160470. Fc=crystallizable fragment; Fv=variable fragment; hIgG1=human immunoglobulin G, subclass 1; IRC™=Immune Repertoire Capture ^® ; mIgG1=mouse immunoglobulin G, subclass 1; mIgG2a=mouse immunoglobulin G subclass 2a, mIgG3=mouse immunoglobulin G subclass 3; N297A=asparagine to alanine modification at position 297. ATRC-101 is a fully human immunoglobulin G subclass 1 (IgG1)/lambda antibody that contains the V _H and V _L regions of AIP-160470.

[0114] In FIG. 52 shows the results of expression analysis for ATRC-101 binding for colorectal cancer, triple negative breast cancer and melanoma using immunofluorescence. Binding of chimeric antibody AIP-160470-mIgG2a to formalin-fixed, paraffin-embedded tumor and tumor-adjacent tissue from CRC, TNBC, and melanoma. Binding was assessed using 10 μg/ml Alexa Fluor 647 mIgG2a-conjugated AIP-160470 using standard immunofluorescence methodology and compared with an Alexa Fluor 647-conjugated mIgG2a monoclonal antibody isotype control. The fabrics were counter-dyed with Hoechst. Signals detected by AIP-160470-mIgG2a or isotype are shown in red/magenta and nuclei are labeled in blue. H&E staining from a section of tissue adjacent to the tumor is shown. The red line on H&E stain indicates 50 µm. Adenocarcinoma = adenocarcinoma; CRC=colorectal cancer; H&E=hematoxylin and eosin; mcg=microgram; mIgG2a=mouse immunoglobulin G, subclass 2a; TNBC=triple negative breast cancer

[0115] In FIG. 53 shows the effect of nuclease pretreatment on the binding of the chimeric antibody AIP-160470-mIgG2a to ER+ human breast carcinoma tissues. Fresh frozen tissue sections were pretreated with the indicated concentrations of RNase A, RNase H, or DNase I. Sections were washed, fixed in paraformaldehyde, and blocked before staining with 20 μg/ml Alexa Fluor 647-conjugated AIP-160470-mIgG2a and mIgG2a to E-cadherin or Alexa-conjugated Fluor 647 mIgG2a and rabbit IgG isotype control antibodies. Microslides were incubated with Alexa Fluor 488-conjugated secondary anti-rabbit antibody. Sections were washed and counterstained with Hoechst. AIP-160470-mIgG2a is shown in red/magenta, E-cadherin is shown in green, and yellow indicates co-localization of AIP-160470-mIgG2a and E-cadherin. Nuclei are marked in blue. Images were acquired using an automated microslide scanner, Axio Scan (Zeiss). H&E staining from a section of tissue adjacent to the tumor is shown. The white line on the black inset indicates 50 µm. DNase=deoxyribonuclease; E-Cad=E-cadherin; ER+=estrogen receptor positive; H&E=hematoxylin and eosin; mcg=microgram; mIgG2a=mouse immunoglobulin G, subclass 2a; ml=milliliter; NSCLC=non-small cell lung cancer; RNase=ribonuclease; Unit=unit(s).

[0116] In FIG. 54A and 54B show the distribution of immunoreactivity of the chimeric antibody AIP-160470-mIgG2a and human PABPC-1 in normal tissues and human carcinoma by immunofluorescence. Images demonstrate the distribution of chimeric antibody AIP-160470-mIgG2a immunoreactivity in human small intestinal adenocarcinoma (FIG. 39A) and representative normal tissues of brain, cerebellum, heart, lung, liver, kidney, pancreas, stomach and spleen from two FFPE TMAs. (FDA808J-1 and FDA808J-2; Fig. 39B). Sections were stained using 1.25 μg/ml chimeric antibody AIP-160470-mIgG2a conjugated to Alexa Fluor 647. Sections of adjacent tumor tissue were incubated with rabbit polyclonal anti-PABPC-1 antibody detected using anti-rabbit secondary antibody conjugated to Alexa Fluor 647 or H&E dye. FFPE=formalin-fixed and paraffin-embedded; H&E=hematoxylin and eosin; mcg=microgram; mIgG2a=mouse immunoglobulin G, subclass 2a; ml=milliliter; PABPC-1=cytoplasmic polyadenylate binding protein 1; RabIgG=rabbit immunoglobulin G; TMA=tissue microarray.

[0117] In FIG. 55A and 55B show dose-dependent inhibition of tumor growth by ATRC-101 and the chimeric antibody AIP-160470-mIgG2a in the syngeneic EMT6-BALB/c mouse tumor model. BALB/c mice were inoculated with 1 x 106 EMT6 tumor cells and given intraperitoneal doses of the chimeric antibody MFC-042 (AIP-160470-mIgG2a; Fig. 41A) or ATRC-101 (Fig. 41B) twice weekly, with group AOR from 112 to 113 mm3 and 108 mm3, respectively. The mean and standard error of the mean for each experimental group (15 animals/group) are shown. i.p. = intraperitoneal; kg=kilogram; mg=milligram; MVR=mean tumor volume.

[0118] In FIG. 56 shows the influence of Fc effector function on the antitumor efficacy of chimeric variants of the parent antibody AIP-192482 in the syngeneic mouse tumor model EMT6-BALB/c. BALB/c mice were inoculated with 1x10 ⁶ EMT6 tumor cells and randomized to treatment groups 6 days later. 7 days after EMT6 inoculation, with a group mean tumor volume of 94.5 mm ³ , mice were intraperitoneally injected twice weekly with 10 mg/kg of the chimeric variants AIP-192482-mIgG2a, AIP-192482-mIgG1, AIP-192482-mIgG3, or AIP-192482 -mIgG2a-N297A of the parent antibody AIP-192482 or vehicle (phosphate-buffered saline). Tumor volumes of individual animals from each treatment group (20 animals per group) are shown. For treatment groups with PR, the ratio of mice with PR to the total number of animals in the group is shown. CR=complete tumor regression; i.p. = intraperitoneal; kg=kilogram; mg=milligram; mIgG1=mouse immunoglobulin G, subclass 1; mIgG2a=mouse immunoglobulin G, subclass 2a; mIgG3=mouse immunoglobulin G, subclass 3; N297A=modification by replacing asparagine with alanine at position 297; mm=millimetre.

[0119] In FIG. 57 shows the antitumor efficacy of the chimeric parent antibody AIP-192482 and sequence optimized variants in the syngeneic EMT6-BALBc mouse tumor model, study EFF-016. In the EFF-016 study, BALB/c mice were inoculated with 1 x 10 ⁶ EMT6 tumor cells and randomized to treatment groups (20 animals per group) after 6 days. 7 days after EMT6 inoculation (mean tumor volume in the group 156 mm ³ ), mice were intraperitoneally injected twice a week with the indicated doses of the chimeric parent antibody AIP-192482-mIgG2a, the sequence-optimized chimeric variant AIP-133645-mIgG2a, and the chimeric antibody AIP-160470- mIgG2a, or carrier (DPBS). Tumor volumes in individual mice in each treatment group up to day 53 are shown. DPBS=Dulbecco's phosphate buffered saline; i.p. = intraperitoneal; mIgG2a=mouse immunoglobulin G, subclass 2a; mm=millimetre.

[0120] In FIG. 58A and 58B show the antitumor efficacy of the chimeric parent antibody AIP-192482-mIgG2a and sequence optimized variants in the syngeneic EMT6-BALBc mouse tumor model, study EFF-020. In the EFF-020 study, BALB/c mice were inoculated with 1x10 ⁶ EMT6 tumor cells and randomized to treatment groups (20 animals per group) after 6 days, when the average tumor volume per group was approximately 10 ⁴ mm ³ . Mice were intraperitoneally administered twice weekly with a dose equal to 5 mg/kg or 10 mg/kg of the chimeric parent antibody AIP-192482-mIgG2a, 2.5 mg/kg or 5 mg/kg of the chimeric antibody AIP-160470-mIgG2a, or vehicle (DPBS). , starting from day 7, a total of 7 doses. Mice were also intraperitoneally injected with 10 mg/kg anti-mouse PD-1 monoclonal antibody or vehicle (DPBS) twice weekly starting on day 7 for a total of 4 doses. In the monotherapy groups, vehicle was administered according to the dosing schedule of the missing study drug. In FIG. 44A shows tumor volumes of individual mice in the AIP-192482-mIgG2a treatment and control groups up to day 35. In FIG. 44B shows tumor volumes of individual mice in the AIP-160470-mIgG2a treatment and control groups up to day 35. CR=complete tumor regression; DPBS=Dulbecco's phosphate buffered saline; i.p. = intraperitoneal; kg=kilogram; mg=milligram; mIgG2a=mouse immunoglobulin G, subclass 2a; mm=millimetre; PD-1=programmed death receptor 1.

[0121] In FIG. 59A and 59B show the antitumor efficacy of the chimeric parent antibody AIP-192482-mIgG2a in the syngeneic CT26-BALBc mouse model, study EFF-039. In the EFF-039 study, BALB/c mice were inoculated with ^1x106 CT26 tumor cells and randomized to treatment groups 6 days later. 7 days after CT26 inoculation (mean tumor volume in the group approximately 145 mm ³ ), mice were intraperitoneally injected three times a week with 20 mg/kg of the chimeric parent antibody AIP-192482-mIgG2a (40 animals) or vehicle (DPBS; 20 animals). In FIG. 45A shows tumor volumes in individual mice in each treatment group up to day 35. In FIG. 45B shows tumor volumes for treatment groups dosed with AIP-192482-mIgG2a up to day 97. The number of PRs up to 97 days is indicated. DPBS=Dulbecco's phosphate buffered saline; i.p. = intraperitoneal; kg=kilogram; mg=milligram; mIgG2a=mouse immunoglobulin G, subclass 2a; mm=millimetre

[0122] In FIG. 60 shows the antitumor efficacy of the AIP-192482-mIgG2a antibody alone or in combination with PD-1 blockade in a syngeneic mouse tumor model E0771 - C57BL/6, study EFF-006. In the EFF-006 study, C57BL/6 mice were inoculated with 1 x 10 ⁶ E0771 tumor cells and randomized to treatment groups of 20 animals per group after 8 days, when the average tumor volume per group was approximately 104 mm3. Nine days after E0771 inoculation, mice were intraperitoneally administered twice weekly until day 30 with 20 mg/kg of the chimeric parent antibody AIP-192482-mIgG2a or vehicle (DPBS). In addition, mice were intraperitoneally dosed with 2.5 mg/kg anti-mouse PD-1 monoclonal antibody or vehicle (DPBS) twice weekly starting on day 9. In the monotherapy groups, vehicle was administered according to the dosing schedule of the missing study drug. Tumor volumes in individual mice in each treatment group up to day 35 are shown. The number of CRs in each treatment group is indicated.

CR=complete tumor regression; DPBS=Dulbecco's phosphate buffered saline; i.p. = intraperitoneal; kg=kilogram; mg=milligram; mIgG2a=mouse immunoglobulin G, subclass 2a; mm=millimeter; PD-1=programmed death receptor 1.

[0123] In FIG. 61 shows assessment of T cell requirement for antitumor efficacy in the syngeneic EMT6-BALBc mouse tumor model, study TMD04. In the TMD04 study, BALB/c mice were inoculated with 1 x 10 ⁶ EMT6 cells and intraperitoneally injected with DPBS or anti-mouse Cd8α antibody, clone 2.43 (BioXCell) three times a week starting on day 6. The chimeric parent antibody AIP-192482-mIgG2a or vehicle (DPBS) was administered intraperitoneally at a dose of 10 mg/kg twice weekly starting on day 7 (10 animals per group). Individual tumor volumes up to day 27 are shown. DPBS=phosphate buffered saline; i.p. = intraperitoneal; mIgG2a=mouse immunoglobulin G, subclass 2a

[0124] In FIG. 62A and 62B show in vivo assessment of CD8+ T cells and M1 macrophage polarization in EMT6 tumors following treatment with the chimeric parent antibody AIP-192482-mIgG2a. BALB/c mice with established EMT6 tumors were dosed with vehicle (DPBS) or 20 mg/kg of the chimeric parent antibody AIP-192482-mIgG2a on days 7, 10, 14 as part of the EFF-004 antitumor study. EMT6 tumors were collected from representative mice on day 15 of the study. Samples were sectioned and stained with anti-CD8 or anti-iNOS antibodies using tyramide signal amplification immunofluorescence methodology. In FIG. 48A shows representative tumor sections from animals treated with DPBS or AIP-192482-mIgG2a stained for CD8+ T cells or iNOS+ macrophages (green). The inset shows H&E staining from a section of tissue adjacent to the tumor. White lines on a black background indicate 50 µm. In FIG. 48B shows the ratio of CD8+ (5 animals) to iNOS+ cells (10 animals) after administration of DPBS or AIP-192482-mIgG2a. Significance was assessed using an unpaired t test with *=p <0.05; **=p <0.01. DPBS=Dulbecco's phosphate buffered saline; i.p. = intraperitoneal; H&E=hematoxylin and eosin; iNOS=inducible nitric oxide synthase; mIgG2a=mouse immunoglobulin G, subclass 2a; PBS=phosphate buffered saline

[0125] In FIG. 63 shows serum concentrations in cynomolgus monkeys following intravenous administration of a single dose of ATRC-101 (study ATRC-101.PK.18.01). Male and female cynomolgus monkeys were given a single intravenous bolus injection of 1 mg/kg, 10 mg/kg, or 30 mg/kg ATRC-101. Blood samples were collected at 5 minutes and 1, 4, 8, 12, 24, 48, 96, 168, 240, 336, 504, and 672 hours after dosing. Serum concentrations of ATRC-101 measured by ELISA are shown. ELISA = enzyme-linked immunosorbent assay.

[0126] In FIG. 64 shows serum concentrations in cynomolgus monkeys following repeated dosing of ATRC-101 (study ATRC-101.TX.18.01.). Male and female cynomolgus macaques were administered 10 mg/kg, 30 mg/kg, or 100 mg/kg ATRC-101 by intravenous infusion once a week for a total of 4 doses. Blood samples were collected 15 minutes and 1, 4, 8, 12, 24, 48, 96, and 168 hours after the first and last dose and ATRC-101. Serum concentrations of ATRC-101 measured by ELISA are shown.

DETAILED DESCRIPTION OF THE INVENTION

Terminology

[0127] As used herein, the singular forms include references to the plural forms unless the context clearly indicates otherwise. Thus, for example, reference to “antibody” does not necessarily include a combination of two or more such molecules and the like.

[0128] The term "about" as used herein refers to a typical error range for the corresponding value well known to one skilled in the art, for example, ±20%, ±10%, or ±5% are within the expected limit of the given value.

[0129] As used herein, the term “antibody” means an isolated or recombinant binding agent that contains the necessary variable region sequences to specifically bind an antigenic epitope. Therefore, as used herein, the term “antibody” is any form of antibody of any class or subclass, or fragment thereof, that exhibits a desired biological activity, such as binding to a specific target antigen. Thus, it is used in the broadest sense and specifically covers monoclonal antibodies (including full-length monoclonal antibodies), human antibodies, chimeric antibodies, nanobodies, diabodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, including but not limited to: scFv, Fab, etc. provided they exhibit the desired biological activity.

[0130] “Antibody fragments” are a portion of an intact antibody, such as the antigen binding region or variable region of an intact antibody. Examples of antibody fragments include Fab, Fab', F(ab') ₂ and Fv fragments; diabodies; linear antibodies (eg, Zapata et al., Protein Eng. 8(10): 1057-1062 (1995)); single chain antibody molecules (eg scFv); and polyspecific antibodies formed from antibody fragments. Cleavage of antibodies with papain produces two identical antigen-binding fragments, called "Fab fragments", each of which has one antigen-binding site, and a residual "Fc fragment", a designation reflecting the ability to readily crystallize. Treatment with pepsin produces an F(ab') ₂ fragment that has two antigen binding sites and is still capable of antigen cross-linking.

[0131] As used herein, the term “tumor-binding antibody” refers to an antibody that binds tumor tissue. In one embodiment, the tumor-binding antibody binds tumor tissue through a binding interaction with an extracellular RNA-protein complex. "Extracellular RNA-protein complex" refers to a complex that is found outside tumor cells. The complex does not need to be integrated into the outer surface of the cells, but in some embodiments, it may be associated with the exterior of the tumor cells as a conglomerate or aggregate of RNA and protein molecules interacting with the cell membrane or otherwise present outside the tumor cells. Although the extracellular RNA-protein complex is found outside tumor cells, it may additionally be present inside the cell. The “tumor binding antibody” of the present invention exhibits preferential binding to tumor tissue compared to tumor adjacent tissue (TAT), eg, a specific signal above noise with increased reactivity exhibited in the tumor compared to adjacent tissue. In some embodiments, the tumor-binding antibody is an “antitumor antibody” that reduces tumor growth rate, tumor size, invasion, and/or metastasis through direct or indirect effects on tumor cells.

[0132] As used herein, "V region" refers to the antibody variable region domain comprising framework 1, CDR1, framework 2, CDR2, and framework 3 segments, including CDR3 and framework 4. The heavy chain V region, _VH , is is a consequence of rearrangement of the V gene (HV), D gene (HD) and J gene (HJ) in the so-called V(D)J recombination during B cell differentiation. The light chain V region, V _L , is a consequence of rearrangement of the V gene (LV) and J gene (LJ).

[0133] The term “complementarity determining region (CDR),” as used herein, refers to the three hypervariable regions (HVRs) on each chain that interrupt the four “framework” regions defined by the light and heavy chain variable regions. CDRs are primarily responsible for binding to the epitope of an antigen. The CDRs of each chain are designated CDR1, CDR2 and CDR3, numbered sequentially starting from the N-terminus, and are also identified by the chain on which the particular CDR is located. Thus, for example, CDR3 V _H (HCDR3) is located in the variable domain of the heavy chain of the antibody in which it is located, while CDR3 V _L (LCDR3) is CDR3 from the variable domain of the light chain of the antibody in which it is located. The term "CDR" is used interchangeably with "HVR" in this application in relation to CDR sequences.

[0134] The amino acid sequences of CDRs and framework regions can be determined using various definitions well known in the art, for example, Kabat, Chothia, the international ImMunoGeneTics database (IMGT), and AbM (see, for example, Chothia & Lesk, 1987, Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196, 901-917; Chothia C. et al., 1989, Conformations of immunoglobulin hypervariable regions. Nature 342, 877-883; Chothia C. et al. ., 1992, structural repertoire of the human VH segments J. Mol. Biol. 227, 799-817; Al-Lazikani et al., J. Mol. Biol 1997, 273(4)). Antibody active site definitions are also described below: Ruiz et al., IMGT, the international ImMunoGeneTics database. Nucleic Acids Res., 28, 219-221 (2000); and Lefranc, M.-P. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. Jan 1;29(1):207-9 (2001); MacCallum et al, Antibody-antigen interactions: Contact analysis and binding site topography, J. Mol. Biol., 262(5), 732-745 (1996); and Martin et al, Proc. Natl Acad. Sci. USA, 86, 9268-9272 (1989); Martin, et al, Methods Enzymol., 203, 121-153, (1991); Pedersen et al, Immunomethods, 1, 126, (1992); and Rees et al, In Sternberg M.J.E. (ed.), Protein Structure Prediction. Oxford University Press, Oxford, 141-172 1996). References to CDRs identified by Kabat numbering are based, for example, on Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institute of Health, Bethesda, MD (1991)). The Chothia CDR is determined as defined by Chothia (see, eg, Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).

[0135] "Fc region" refers to the constant region of an antibody, excluding the first immunoglobulin domain of the constant region. Thus, for example, for human immunoglobulins, Fc refers to the last two immunoglobulin constant region domains IgA, IgD and IgG and the last three immunoglobulin constant region domains IgE and IgM, as well as the flexible hinge N-terminus of these domains. In the case of IgA and IgM, the Fc may contain a J chain. For IgG, the Fc contains the immunoglobulin domains Cγ2 and Cγ3 and the hinge between Cγ1 and Cγ. It will be appreciated in the art that the boundaries of the Fc region may vary, however, the human IgG heavy chain Fc region is generally defined as containing residues C226 or P230 at its carboxyl terminus, using EU numbering as in Kabat et al . (1991, NIH Publication 91-3242, National Technical Information Service, Springfield, Va.). The term "Fc region" may refer to this region alone or to this region in the context of an antibody or antibody fragment. "Fc region" includes naturally occurring allelic variants of the Fc region, as well as modified Fc regions, for example, that are modified to modulate effector function or other properties, such as pharmacokinetics, stability or production properties of the antibody. Fc regions also include variants that do not exhibit changes in biological function. For example, one or more amino acids can be deleted from the N-terminus or C-terminus of the Fc region of an immunoglobulin without significant loss of biological function. Such options may be selected in accordance with general rules known in the art to have minimal impact on activity (see, eg, Bowie, et al. , Science 247:306-1310, 1990). For example, for IgG4 antibodies, a simple amino acid substitution (S228P according to Kabat numbering; designated IgG4Pro) can be introduced to eliminate the heterogeneity observed in the recombinant IgG4 antibody (see, for example, Angal, et al ., Mol Immunol 30:105-108, 1993).

[0136] "EC ₅₀ ", as used herein, in the context of an Fc receptor interaction assay, refers to the half-maximal effective concentration, which is the concentration of antibody that elicits a response (the signal generated in the interaction assay) midway between baseline and maximum after a certain time of exposure. Fc receptor interaction assays are further described herein in the “Variant Binding Activity” section. In some embodiments, the "EC50 fold" is determined by dividing the EC50 of the reference antibody by the _EC50 of the test antibody.

[0137] The term “equilibrium dissociation constant,” abbreviated as (K _D ), refers to the dissociation rate constant (k _d , time ⁻¹ ) divided by the association rate constant ( _ka , time ⁻¹ M ⁻¹ ). Equilibrium dissociation constants can be measured by any method. Thus, in some embodiments, the antibodies of the present invention have a K _D of less than about 50 nM, typically less than about 25 nM or less than 10 nM, such as less than about 5 nM, or about 1 nM, and often less than about 10 nM , as determined by surface plasmon resonance analysis using a biosensor system such as the Biacore ^® system, which is performed at 37 °C. In some embodiments, an antibody of the present invention has a K _D of less than 5x10 ^-5 M, less than 10 ^-5 M, less than 5x10 ^-6 M, less than 10 ^-6 M, less than 5x10 ^-7 M, less than 10 ^{- 7} M, less than 5×10 ^-8 M, less than 10 ^-8 M, less than 5×10 ^-9 M, less than 10 ^-9 M, less than 5 x10 -10 M, less than ^{10 -10 M} , less than 5×10 ^-11 M, less than 10 ^-11 M, less than 5×10 ^-12 M, less than 10 ^-12 M, less than 5×10 ^-13 M, less than 10 ^-13 M, less than 5×10 ^-14 M, less than 10 ^-14 M, less than 5×10 ^-15 M, or less than 10 ^-15 M or lower, as measured for a divalent antibody. In the context of the present invention, "improved" K _D refers to lower K _D . In some embodiments, an antibody of the present invention has a K _D of less than 5x10 ^-5 M, less than 10 ^-5 M, less than 5x10 ^-6 M, less than 10 ^-6 M, less than 5x10 ^-7 M, less than 10 ^{- 7} M, less than 5×10 ^-8 M, less than 10 ^-8 M, less than 5×10 ^-9 M, less than 10 ^-9 M, less than 5 x10 -10 M, less than ^{10 -10 M} , less than 5×10 ^-11 M, less than 10 ^-11 M, less than 5×10 ^-12 M, less than 10 ^-12 M, less than 5×10 ^-13 M, less than 10 ^-13 M, less than 5×10 ^-14 M, less than 10 ^-14 M, less than 5×10 ^-15 M, or less than 10 ^-15 M or less, as measured for a monovalent antibody, such as a monovalent Fab. In some embodiments, the antitumor antibody of the present invention has a K _D of less than 100 pM, for example, or less than 75 pM, for example, in the range of 1 to 100 pM, as determined by surface plasmon resonance analysis using a biosensor system, for example, the Biacore ^® system , which was performed at 37 °C. In some embodiments, the antitumor antibody of the present invention has a K _D greater than 100 pM, for example, in the range of 100-1000 pM or 500-1000 pM, as determined by surface plasmon resonance analysis using a biosensor system, such as the ^Biacore® system, which is performed at 37 °C.

[0138] As used herein, the term “monivalent molecule” refers to a molecule that has a single antigen binding site, such as a Fab or scFv.

[0139] As used herein, the term “divalent molecule” refers to a molecule that has two antigen binding sites. In some embodiments, the divalent molecule of the present invention is a divalent antibody or a divalent fragment thereof. In some embodiments, the divalent molecule of the present invention is a divalent antibody. In some embodiments, the divalent molecule of the present invention is an IgG. Typically, monoclonal antibodies have a divalent basic structure. IgG and IgE have only one divalent unit, whereas IgA and IgM are composed of several divalent units (2 and 5, respectively) and therefore have higher valences. This bivalency increases the avidity of antibodies to antigens.

[0140] As used herein, the terms “monovalent binding” or “monovalently binds to” refer to the binding of a single antigen binding site to its antigen.

[0141] As used herein, the terms “divalent binding” or “divalently binds to” refer to the binding of both antigen binding sites of a divalent molecule to its antigen. In some embodiments, both antigen binding sites of a divalent molecule have the same antigen specificity.

[0142] As used herein, the term “valency” refers to the number of different binding sites of an antibody to an antigen. A monovalent antibody contains a single antigen binding site. A bivalent antibody contains two binding sites for the same antigen.

[0143] The term "avidity" as used herein in the context of antibody-antigen binding refers to the combined binding strength of multiple antibody binding sites. Thus, "bivalent avidity" refers to the combined strength of the two binding sites.

[0144] The terms “identical” or percentage “identity” in the context of two or more polypeptide sequences refer to two or more sequences or subsequences that are the same or have a certain percentage of amino acid residues the same (e.g., at least 70%, at least 75%, at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher) identical in a given area, for example, the length of two sequences when compared and aligned for maximum fit in a comparison window or a given region. Alignment to determine percent amino acid sequence identity can be performed in a variety of ways, including using publicly available computer software such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR). Examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402 (1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990). Thus, for the purposes of this invention, BLAST 2.0 can be used with default parameters to determine percent sequence identity.

[0145] The terms “corresponding to,” “defined by reference to,” or “numbered by reference to,” when used in the context of identifying a given amino acid residue in a polypeptide sequence, refer to the position of the residue of the specified reference sequence when the specified amino acid sequence is maximally aligned and compared with the reference sequence. Thus, for example, an amino acid residue in a V _H region polypeptide “matches” an amino acid in the V _H region of SEQ ID NO:1 when the residue matches the amino acid in SEQ ID NO:1 in an optimal alignment with SEQ ID NO:1. A polypeptide that is aligned to a reference sequence need not be the same length as the reference sequence.

[0146] A “conservative” substitution as used herein refers to an amino acid substitution that preserves the charge, polarity, hydropathy (hydrophobic, neutral, or hydrophilic), and/or chain size of the side group. Exemplary sets of amino acids that may be substituted for each other include (i) the positively charged amino acids Lys and Arg; and His at pH about 6; (ii) negatively charged amino acids Glu and Asp; (iii) aromatic amino acids Phe, Tyr and Trp; (iv) amino acids with the nitrogen ring His and Trp; (v) aliphatic hydrophobic amino acids Ala, Val, Leu and Ile; (vi) hydrophobic sulfur-containing amino acids Met and Cys, which are not as hydrophobic as Val, Leu and Ile; (vii) small polar uncharged amino acids Ser, Thr, Asp and Asn; (viii) small hydrophobic or neutral amino acids Gly, Ala and Pro; (ix) amide-containing amino acids Asn and Gln; and (xi) amino acids with beta-branched side chains Thr, Val and Ile. The reference to amino acid charge in this paragraph refers to charge at pH 6-7.

[0147] The terms “nucleic acid” and “polynucleotide” are used interchangeably and as used herein refer to both sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the foregoing. In specific embodiments, nucleotide refers to a ribonucleotide, deoxynucleotide, or a modified form of any type of nucleotide, and combinations thereof. The terms also include, but are not limited to, single-stranded and double-stranded forms of DNA. In addition, a polynucleotide, such as cDNA or mRNA, may include both naturally occurring and modified nucleotides linked together by naturally occurring and/or non-naturally occurring nucleotide linkages. Nucleic acid molecules may be chemically or biochemically modified, or may contain non-natural or derivatized nucleotide bases, as will be readily understood by those skilled in the art. Such modifications include, for example, tags, methylation, replacement of one or more naturally occurring nucleotides with an analogue, internucleotide modifications such as uncharged linkers (e.g. methylphosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkers (e.g. phosphorothioates , phosphorodithioates, etc.), pendants (e.g. polypeptides), intercalators (e.g. acridine, psoralen, etc.), chelators, alkylators and modified linkers (e.g. alpha-anomeric nucleic acids, etc. ). The above term is also intended to include any topological conformation, including single-stranded, double-stranded, partially duplex, triplex, hairpin, round and closed conformations. A reference to a nucleic acid sequence includes its complementary strand unless otherwise indicated. Thus, it should be understood that reference to a nucleic acid molecule having a particular sequence includes its complementary strand with its complementary sequence. The term also includes codon optimized nucleic acids that encode the same polypeptide sequence.

[0148] The term “vector” as used herein refers to a nucleic acid molecule capable of causing the replication of another nucleic acid linked to it. The term includes a vector as a self-replicating nucleic acid structure, as well as a vector incorporated into the genome of the host cell into which it has been introduced. As used herein, the term “vector” refers to a recombinant construct in which a nucleic acid sequence of interest is inserted into a vector. Certain vectors are capable of directing the expression of the nucleic acids to which they are operably linked. Such vectors are referred to herein as “expression vectors.”

[0149] As used herein, the term “substitution” means the replacement of one or more amino acids or nucleotides with other amino acids or nucleotides, respectively.

[0150] An “isolated” nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that typically contain the nucleic acid molecule, but the nucleic acid molecule is present off a chromosome or at a chromosomal location that is different from its natural chromosomal location.

[0151] “Isolated nucleic acid encoding an antibody or fragment thereof” refers to one or more nucleic acid molecules encoding antibody heavy or light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors , and such nucleic acid molecule(s) present at one or more locations in the host cell.

[0152] The terms “host cell,” “host cell line,” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Thus, the host cell is a recombinant host cell and includes the primary transformed cell and the progeny derived from it, regardless of the number of passages.

[0153] A "variant" polypeptide as used herein is a polypeptide that generally differs from one or more polypeptide sequences specifically disclosed herein by one or more substitutions, deletions, additions and/or insertions.

[0154] The term “cancer cell” or “tumor cell” as used herein refers to a neoplastic cell. This term includes both benign and malignant tumor cells. Neoplastic transformation is associated with phenotypic changes in the tumor cell compared to the cell type from which it originated. Changes may include loss of contact inhibition, morphological changes, and unregulated cell growth.

[0155] “Inhibiting tumor growth” and “inhibiting cancer growth” as used herein are used interchangeably and refer to slowing the growth and/or reducing the number of cancer cells in a patient who has cancer. “Inhibiting cancer growth” thus includes killing cancer cells as well as reducing tumor growth rate, tumor size, invasion and/or metastasis by directly or indirectly affecting tumor cells.

[0156] As used herein, the term “therapeutic agent” refers to an agent that, when administered to a patient having a disease, in a therapeutically effective dose, will cure or at least partially relieve the symptoms of the disease and complications associated with the disease.

Antibodies that bind to tumors

[0157] In one aspect, provided herein are antibodies that bind to tumor tissue through a binding interaction with an extracellular RNA-protein complex. The extracellular RNA-protein complex is further described below in the section entitled “Target Binding Antibody.”

[0158] The heavy and light chain variable region sequences of exemplary tumor-binding antibodies of the present invention are presented in Tables 1A and 2A.

[0159] Residue positions in the heavy chain variable regions are indicated herein by reference to any of the V _H region sequences (SEQ ID NOs: 77-122, 1333-1526 and 1725) in Tables 1A and 2A, each of which consists of 140 amino acids in length.

[0160] Residue positions in the light chain variable regions are indicated herein by reference to any of the 110 amino acid V _L region sequences (SEQ ID NOs: 123-168, 1527-1720 and 1726) shown in Tables 1A and 2A.

[0161] Position 140, as numbered relative to the _VH region sequences presented in Tables 1A and 2A, and position 110 of the _VL region sequences presented in Tables 1A and 2A, are considered the last amino acids of the _VH and _VL regions, respectively, according to the system EU numbering. In human IgG format (e.g., IgG1, IgG2, IgG3, or IgG4), the subsequent residue is called a "junction codon" and is initially encoded by joining the last 3' base of the variable region gene (HJ or LJ) to the first two 5' bases of the constant region gene ( heavy or light chain) and exhibits amino acid variation due to variation in the terminal 3' bases of HJ and LJ. The human heavy chain compound codon may initially be Ala, Ser, Pro or Thr and is typically Ala. The human kappa chain junction codon may initially be Arg or Gly, and is typically Arg. The human lambda chain junction codon may initially be Gly, Ser, Arg, or Cys and is typically Ser or Gly.

[0162] The CDRs shown in Table 1B and Table 2B are defined by IMGT and Kabat. The heavy chain CDRs include amino acid residues from amino acid residues 26-35 (HCDR1), 50-68 (HCDR2) and 99-129 (HCDR3). The light chain CDRs include amino acid residues from amino acid residues 23-35 (LCDR1), 51-57 (LCDR2), and 90-100 (LCDR3). Residue numbering corresponds to positions in the V _H and V _L sequences in Tables 1A and 2A. The CDR V _H listed in Table 1B and Table 2B are defined as follows: HCDR1 are determined by combining Kabat and IMGT; HCDR2 determined by Kabat; and HCDR3 are determined by IMGT. The CDR V _L listed in Table 1B and Table 2B are determined by Kabat. As is known in the art, the numbering and placement of CDRs may vary depending on the numbering system used. It will be understood that disclosure of a heavy chain variable region sequence and/or a light chain variable region sequence includes disclosure of associated CDRs, regardless of the numbering system used.

[0163] Using AIP-160470 as a reference sequence, FIG. 37 shows the numbering of residues in the V _H and V _L sequences of AIP-160470 using the IMGT, Kabat and Chothia numbering systems.

The CDRs defined using the IMGT numbering system are as follows:

HCDR1: 27-38 (excluding provisions 31-34)

HCDR2: 56-65

HCDR3: 105-117 (including 18 insertions between 111 and 112)

LCDR1: 27-38 (excluding provisions 31-34)

LCDR2: 56-65 (excluding provisions 58-64) and

LCDR3: 105-117 (excluding provisions 111-112).

Accordingly, the corresponding IMGT CDRs for AIP-160470:

HCDR1: GFTFSKAW

HCDR2: IKSVTDGETT

HCDR3: TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV

LCDR1: SSNIGSSS

LCDR2: KNN

LCDR3: STWDDSLSVRV.

[0164] The CDRs defined using the Kabat numbering system are as follows:

HCDR1: 31-35

HCDR2: 50-65 (including insertions 52a, 52b, and 52c)

HCDR3: 95-102 (including 100a-100u insertions)

LCDR1: 24-34 (including insertions 27a and 27b)

LCDR2: 50-56

LCDR3: 89-97 (including insertions 95a and 95b).

Accordingly, the corresponding KABAT CDRs for AIP-160470:

HCDR1: KAWMS

HCDR2: RIKSVTDGETTDYAAPVKG

HCDR3: SFCCRGGSCPSHDTSYCGGQYKSYYYMDV

LCDR1: SGSSSNIGSSSVS

LCDR2: KNNQRPS

LCDR3: STWDDSLSVRV

[0165] CDRs defined using the Chothia numbering system:

HCDR1: 26-32;

HCDR2: 52-56 (including insertions 52a, 52b, and 52c)

HCDR3: 95-102 (including 100a-100u insertions)

LCDR1: 24-34 (including insertions 30a and 30b)

LCDR2: 50-56

LCDR3: 89-97 (including insertions 95a and 95b.

Accordingly, the corresponding Chothia CDRs for AIP-160470 are:

HCDR1: GFTFSKA

HCDR2: KSVTDGET

HCDR3: SFCCRGGSCPSHDTSYCGGQYKSYYYMDV

LCDR1: SGSSSNIGSSSVS

LCDR2: KNNQRPS

LCDR3: STWDDSLSVRV

Region V _H

[0166] In some embodiments, a tumor-binding antibody of the present invention that binds to an extracellular RNA-protein complex, for example, that has activity in an FcγRIIa interaction assay, has one, two, or three CDR V _H sequences, as shown in the table 1A or Table 2A. In some embodiments, the tumor-binding antibody has at least one mutation and no more than 10, 20, 30, 40, or 50 mutations in the _VH amino acid sequences relative to the _VH sequence specified in any of SEQ ID NO:77-122 or 1333 -1526 or 1725. In some embodiments, the V _H amino acid sequence may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid insertions or deletions relative to the V _H sequence specified in any of SEQ ID NO :77-122 or 1333-1526 or 1725. In some embodiments, the amino acid sequence of V _H may contain a deletion or insertion, for example, 1, 2, 3, 4 or 5 amino acid deletions or insertions relative to the CDR sequence specified in table 1B or table 2B. In some embodiments, the V _H amino acid sequence may contain a deletion or insertion of 1 or 2 amino acids relative to the CDR sequence shown in Table 1B or Table 2B. In some embodiments, the V _H region contains a CDR1 having 1 or 2 substitutions relative to the CDR1 sequence of any of SEQ ID NO: 1-8 or 169-362. In some embodiments, HCDR1 has 3 or 4 substitutions relative to the CDR1 sequence of any of SEQ ID NO: 1-8 or 169-362. In some embodiments, the V _H region contains a CDR2 that has 1, 2, 3, or 4 substitutions relative to the CDR2 sequence of any of SEQ ID NO: 9-19 or 363-556. In some embodiments, the V _H region has 5, 6, 7, or 8 substitutions relative to the CDR2 sequence of any of SEQ ID NO: 9-19 or 363-556. In some embodiments, the V _H region contains a CDR3 that has 1, 2, 3, or 4 substitutions relative to the CDR3 sequence of any of SEQ ID NO: 20-47, or 557-750, or 1727. In some embodiments, the V _H region has 5 , 6, 7, or 8 substitutions relative to the CDR3 sequence of any of SEQ ID NO: 20-47, or 557-750, or 1727. In some embodiments, the V _H region has 9, 10, 11, 12, 13, or 14 substitutions relative to CDR3 any of SEQ ID NOs: 20-47, or 557-750, or 1727. In some embodiments, a tumor-binding antibody of the present invention comprises CDR1, CDR2, and CDR3, each of which has at least 80% identity with CDR1, CDR2 and CDR3, as shown in Table 1B or 2B. In some embodiments, a tumor-binding antibody of the present invention comprises CDR1, CDR2, and CDR3, each of which has at least 90% identity with CDR1, CDR2, and CDR3, as shown in Table 1B or Table 2B. In some embodiments, the antitumor antibody of the present invention comprises CDR1, CDR2, and CDR3, as shown in Table 1B or Table 2B. In some embodiments, the tumor binding antibody of the present invention comprises HCDR1, HCDR2 and HCDR3 antibodies, designated AIP-158623, AIP-155066, AIP-136538, AIP-166120, AIP-133645, AIP-187893, AIP-142079, AIP -160470, AIP-104188, AIP-157397, AIP-165430, AIP-189526, AIP-192482, AIP-122563, or AIP-171142 in Table 1.

[0167] In some embodiments, the V _H region of a tumor-binding antibody of the present invention has a solvent contact area for each CDR side chain in square Angstroms as defined in this paragraph based on the Fab crystal structure of the exemplary antibody. The classification as closed, intermediate or open is based on the following limits: less than about 10 Ang ² , about 10-50 Ang ² or more than about 50 Ang ² , respectively. Positions are determined by reference to any of the V _H region sequences presented in Table 1A or Table 2A. Thus, in some embodiments, an antitumor antibody of the invention comprises a CDR1 in which positions 26, 27, 28, 29, 30, and 31 are open; position 32 is closed; position 33 is open; and positions 34 and 35 are intermediate. In some embodiments, an antitumor antibody of the invention comprises a CDR2 in which position 50 is intermediate; position 51 is open; position 53 is closed; positions 54, 55, 56, 57, 58, 59 and 60 are open; position 61 is intermediate; and positions 62, 63, 64, 65, 66, 67 and 68 are open. In some embodiments, an antitumor antibody of the invention contains a CDR3 in which position 99 is open; position 100 is closed; position 101 is intermediate; positions 102, 103 and 104 are closed; provisions 105, 106, 107 and 108 are open; positions 109 and 110 are closed; position 111 is intermediate; provisions 112 and 113 are open; position 114 is intermediate; provisions 115 and 116 are open; position 117 is intermediate; position 118 is open; position 119 is intermediate; position 120 is open; position 121 is intermediate; provisions 122 and 123 are open; position 124 is intermediate; and provisions 125, 126, 127, 128 and 129 are open. In some embodiments, a residue that is classified as “closed” includes a substitution relative to a CDR specified in the CDR of Table 1B or Table 2B that is a conservative substitution that maintains the charge and approximate size to maintain the conformation of the antibody. In some embodiments, a residue classified as “open” is replaced, for example, by a conservative substitution or a residue that provides improved binding to cancer cells compared to the original sequence, as shown in Table 1A or Table 2A.

[0168] In some embodiments, the HCDR3 of a tumor binding antibody as described herein has at least 60% identity, at least 70% identity, at least 80% identity, at least 85% identity, at least 90% identity or at least 95% identity to any of the HCDR3 sequences shown in Table 1B or Table 2B. In some embodiments, at least two, three, or all four cysteine residues in the HCDR3 sequence as described herein are conserved in the variant. In additional embodiments, HCDR3 is at least 27, 28, 29, or 30 amino acids in length. In typical embodiments, HCDR3 is 31 amino acids in length.

[0169] In some embodiments, the FR1 region of the _VH region of a tumor binding antibody as described herein has at least 80% or at least 90% identity with the FR1 sequence from positions 1-25 of the _VH region of any of SEQ ID NO:77-122 or 1333-1526, or 1725. In some embodiments, the FR1 region has at least 95% identity with the FR1 sequence from positions 1-25 of the V _H region of any of SEQ ID NO:77-122, 1333- 1526 or 1725. In some embodiments, FR1 comprises the amino acid sequence from positions 1-25 of the V _H region of any of SEQ ID NOs: 77-122, 1333-1526, or 1725.

[0170] In some embodiments, the FR2 region of the _VH region of a tumor binding antibody as described herein has at least 80% or at least 90% identity with the FR2 sequence from positions 36-49 of the _VH region of any of SEQ ID NO:77-122 or 1333-1526, or 1725. In some embodiments, the FR2 region has at least 95% identity with the FR2 sequence from positions 36-49 of the V _H region of any of SEQ ID NO:77-122, 1333 -1526 or 1725. In some embodiments, FR2 comprises the amino acid sequence from positions 36-49 of the _VH region of any of SEQ ID NOs: 77-122, 1333-1526, or 1725.

[0171] In some embodiments, the FR3 region of the _VH region of a tumor-binding antibody of the invention has at least 80% or at least 90% identity with the FR3 sequence from positions 69-98 of the _VH region of any of SEQ ID NO:77- _B In some embodiments, FR3 comprises the amino acid sequence from positions 69-98 of the V _H region of any of SEQ ID NO: 77-122, 1333-1526, or 1725.

[0172] In some embodiments, the FR4 region and the V _H region comprise the amino acid sequence from positions 130-140 of the V _H region of any of SEQ ID NO: 77-122, 1333-1526, or 1725. In some embodiments, the FR4 region contains a substitution in one or two of positions 130-140 relative to the corresponding V _H region sequence of any of SEQ ID NO:77-122, 1333-1526 or 1725.

[0173] In some embodiments, a tumor-binding antibody of the invention comprises the heavy chain CDR1 sequence GFTFSKAWM(S/T). In some embodiments, CDR1 includes GFTFSKAWMS (SEQ ID NO:1). In alternative embodiments, CDR1 includes GFTFSKAWMT (SEQ ID NO:8). In some embodiments, 1, 2, or 3 amino acids are substituted relative to the sequence GFTFSKAWMS (SEQ ID NO:1) or GFTFSKAWMT (SEQ ID NO:8). For example, in some embodiments, CDR1 contains an N at position 30, an N at position 31; and/or Y at position 33. In some embodiments, CDR1 has at least 60% identity, or at least 70% identity, at least 80% identity, or at least 90% identity with the sequence GFTFSKAWMS (SEQ ID NO:1 ) or GFTFSKAWMT (SEQ ID NO:8).

[0174] In some embodiments, the tumor-binding antibody of the invention comprises the heavy chain HCDR2 sequence RIKS(V/T)(T/S)(D/E)G(E/G)(I/T)T(D/E )YAAPVKG. In some embodiments, HCDR2 includes RIKS(V/T)(T/S)(D/E)G(E/G)(I/T)TDYAAPVKG. In some embodiments, HCDR2 includes RIKSVTDGETTDYAAPVKG (SEQ ID NO:9). In some embodiments, HCDR2 includes RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). In some embodiments, HCDR2 includes RIKSTSDGGITDYAAPVKG (SEQ ID NO:16). In some embodiments, 1, 2, 3, 4, 5, 6, 7, or 8 amino acids are replaced relative to the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); or 1, 2, 3, 4, 5, 6, 7 or 8 amino acids are replaced relative to the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). For example, in some embodiments, HCDR2 contains a substituted sequence having one or more of the following positions: position 51 is V; position 54 represents K or T; position 55 represents S; position 56 represents S; position 58 represents G; position 59 represents I; position 60 represents K; or position 61 is E. In some embodiments, 1, 2, 3, 4, 5, 6, 7, or 8 amino acids are replaced relative to the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). For example, in some embodiments, HCDR2 contains a substituted sequence in which position 51 is V; position 54 represents V, K or T; position 55 represents T, position 58 represents E; position 59 represents T; position 60 represents K; and/or position 61 is E. In some embodiments, if HCDR2 contains a sequence in which position 56 is S, HCDR1 contains a W at position 33. In some embodiments, HCDR2 has at least 60% identity or at least 70% identity with the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); or at least 60% identity or at least 70% identity with the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). In some embodiments, the CDR2 sequence has at least 80% identity or at least 90% identity with the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:9) or RIKSVTEGETTDYAAPVKG (SEQ ID NO:17).

[0175] In some embodiments, the tumor-binding antibody comprises the sequence CDR3 V _H T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)(Y/D )(K/N/S)(S/R)YYYMDV. In some embodiments, HCDR3 includes any of the HCDR3 sequences shown in Table 1B or Table 2B. In some embodiments, HCDR3 includes the sequence shown in Table 1B or Table 2B in which 1, 2, 3, 4, 5, 6, 7, 8, or 9 amino acids are replaced relative to the CDR3 sequence. For example, in some embodiments, HCDR3 comprises V at position 99, T at position 100, R at position 108, D at position 111, R at position 112, Y at position 116, and/or S at position 120. In some embodiments, CDR3 V _H includes the sequence T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)YKSYYYMDV, T(S/T)SFCCRGG(R/S)CPS( H/R)DTS(Y/F)CGG(Q/S)DSRYYYMDV, T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)YNRYYYMDV, T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)YNSYYYMDV, or T(S/T)SFCCRGG(R/S)CPS(H/R )DTS(Y/F)CGG(Q/S)DKRYYYMDV. In some embodiments, CDR3 V _H includes the sequence T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)YKSYYYMDV, T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)DSRYYYMDV, T (S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)YNRYYYMDV, or T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)DKRYYYMDV.

[0176] In some embodiments, a tumor-binding antibody of the invention comprises the heavy chain CDR1 sequence GFTFSKAWM(S/T). In some embodiments, HCDR1 includes GFTFSKAWMS (SEQ ID NO:1). In alternative embodiments, HCDR1 includes GFTFSKAWMT (SEQ ID NO:8). In some embodiments, 1, 2, or 3 amino acids are substituted relative to the sequence GFTFSKAWMS (SEQ ID NO:1) or GFTFSKAWMT (SEQ ID NO:8). For example, in some embodiments, HCDR1 contains an N at position 30, an N at position 31; and/or Y at position 33. In some embodiments, HCDR1 has at least 60% identity, or at least 70% identity, at least 80% identity, or at least 90% identity with the sequence GFTFSKAWMS (SEQ ID NO:1 ) or GFTFSKAWMT (SEQ ID NO:8).

[0177] In some embodiments, the tumor-binding antibody of the invention comprises the heavy chain CDR2 sequence RIKS(V/T)(T/S)(D/E)G(E/G)(I/T)T(D/E )YAAPVKG. In some embodiments, HCDR2 includes RIKS(V/T)(T/S)(D/E)G(E/G)(I/T)TDYAAPVKG. In some embodiments, HCDR2 includes RIKSVTDGETTDYAAPVKG (SEQ ID NO:9). In some embodiments, HCDR2 includes RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). In some embodiments, CDR2 includes RIKSTSDGGITDYAAPVKG (SEQ ID NO:16). In some embodiments, 1, 2, 3, 4, 5, 6, 7, or 8 amino acids are replaced relative to the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); or 1, 2, 3, 4, 5, 6, 7 or 8 amino acids are replaced relative to the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). For example, in some embodiments, HCDR2 contains a substituted sequence having one or more of the following positions: position 51 is V; position 54 represents K or T; position 55 represents S; position 56 represents S; position 58 represents G; position 59 represents I; position 60 represents K; or position 61 is E. In some embodiments, 1, 2, 3, 4, 5, 6, 7, or 8 amino acids are replaced relative to the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). For example, in some embodiments, HCDR2 contains a substituted sequence in which position 51 is V; position 54 represents V, K or T; position 55 represents T, position 58 represents E; position 59 represents T; position 60 represents K; and/or position 61 is E. In some embodiments, if HCDR2 contains a sequence in which position 56 is S, HCDR1 contains a W at position 33. In some embodiments, HCDR2 has at least 60% identity or at least 70% identity with the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); or at least 60% identity or at least 70% identity with the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). In some embodiments, the CDR2 sequence has at least 80% identity or at least 90% identity with the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:9) or RIKSVTEGETTDYAAPVKG (SEQ ID NO:17).

[0178] In some embodiments, the antitumor antibody comprises the sequence CDR3 V _H T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)(Y/D)( K/N/S)(S/R)YYYMDV. In some embodiments, CDR3 includes any one of the CDR3 sequences shown in Table 1 or Table 2. In some embodiments, CDR3 includes a CDR3 sequence as shown in Table 1 or Table 2, where 1, 2, 3, 4, 5 6. 7, 8 or 9 amino acids are substituted relative to the CDR3 sequence. For example, in some embodiments, CDR3 comprises V at position 99, T at position 100, R at position 108, D at position 111, R at position 112, Y at position 116, and/or S at position 120. In some embodiments, CDR3 V _H includes the sequence T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)YKSYYYMDV, T(S/T)SFCCRGG(R/S)CPS( H/R)DTS(Y/F)CGG(Q/S)DSRYYYMDV, T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)YNRYYYMDV, T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)YNSYYYMDV, or T(S/T)SFCCRGG(R/S)CPS(H/R )DTS(Y/F)CGG(Q/S)DKRYYYMDV. In some embodiments, CDR3 V _H includes the sequence T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)YKSYYYMDV, T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)DSRYYYMDV, T (S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)YNRYYYMDV, or T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)DKRYYYMDV.

Region V _L

[0179] In some embodiments, a tumor-binding antibody of the present invention that binds to an extracellular RNA-protein complex, for example, that has activity in an FcγRIIa interaction assay, has one, two, or three V _L CDR sequences, as shown in the table 1A or Table 2A. In some embodiments, the tumor-binding antibody has at least one mutation and no more than 10, 20, 30, 40, or 50 mutations in the V _L amino acid sequences relative to the V _L sequence of any of SEQ ID NOs: 123-168 or 1527- 1720 or 1726. In some embodiments, the V _L amino acid sequence may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid insertions or deletions relative to the V _L sequence of any of SEQ ID NO: 123-168 or 1527-1720 or 1726. In some embodiments, the V _L amino acid sequence may contain a deletion or insertion, such as a deletion or insertion of 1, 2, 3, 4, 5, 6, or 7 amino acids, relative to the CDR sequence shown in Table 1. In some embodiments, the V _L amino acid sequence may contain a deletion or insertion of 1 or 2 amino acids relative to the CDR sequence shown in Table 1B or Table 2B. In some embodiments, the V _L region contains a CDR1 having 1 or 2 substitutions relative to the CDR1 sequence of any of SEQ ID NO:48-58 or 751-944. In some embodiments, CDR1 has 3, 4, or 5 substitutions relative to the CDR1 sequence of any of SEQ ID NO:48-58 or 751-944. In some embodiments, the V _L region contains a CDR2 that has 1 or 2; or 1, 2, or 3; substitutions relative to the CDR2 sequence of any of SEQ ID NO:59-67 or 945-1138. In some embodiments, the V _L region contains a CDR3 having 1, 2, or 3; or 1, 2, 3 or 4; substitutions relative to the CDR3 sequence of any of SEQ ID NO:68-76 or 1139-1332. In some embodiments, the antitumor antibody of the present invention contains CDR1, CDR2, and CDR3, each of which has at least 70% identity with CDR1, CDR2, and CDR3, as shown in Table 1 or Table 2. In some embodiments, the antitumor antibody of the present the invention contains CDR1, CDR2 and CDR3, each of which has at least 80% identity with CDR1, CDR2 and CDR3, as shown in Table 1B or Table 2B. In some embodiments, the antitumor antibody of the present invention comprises CDR1, CDR2, and CDR3, as shown in Table 1B or Table 2B.

[0180] In some embodiments, the tumor binding antibody of the present invention comprises CDR1, CDR2 and CDR3 antibodies designated as AIP-158623, AIP-155066, AIP-136538, AIP-166120, AIP-133645, AIP-187893, AIP- 142079, AIP-160470, AIP-104188, AIP-157397, AIP-165430, AIP-189526, AIP-192482, AIP-122563, or AIP-171142 in Table 1A.

[0181] In some embodiments, the V _L region of a tumor-binding antibody of the present invention has a solvent contact area for each CDR side chain in square Angstroms as defined in this paragraph, which is based on the Fab crystal structure of the exemplary antibody. The classification as closed, intermediate or open is based on the following limits: less than about 10 Ang ² , about 10-50 Ang ² or more than about 50 Ang ² , respectively. Positions are defined by reference to any of the V _L region sequences presented in Table 1A. Thus, in some embodiments, the V _L of the invention contains a CDR1 in which position 23 is open; position 24 is intermediate; positions 25 and 26 are open; positions 27 and 28 are intermediate; positions 29, 30 and 31 are open; positions 32, 33 and 34 are intermediate; and position 35 is open. In some embodiments, the V _L of an antitumor antibody of the invention contains a CDR2 in which positions 51, 52, 53, 54, 55, 56, and 57 are open. In some embodiments, the V _L of an antitumor antibody of the invention contains a CDR3 in which position 90 is open ; position 91 is closed, position 92 is open; position 93 is closed, positions 94, 95, 96 and 97 are open; position 99 is intermediate; and position 100 is open. In some embodiments, a residue that is classified as “closed” includes a substitution relative to a CDR in Table 1B or Table 2B that is a conservative substitution that maintains the charge and approximate size to maintain the conformation of the antibody. In some embodiments, a residue classified as “open” is replaced, for example, by a conservative substitution or a residue that provides improved binding to cancer cells compared to the sequence as shown in Table 1A or Table 2.

[0182] In some embodiments, the tumor-binding antibody of the invention comprises the light chain CDR1 sequence SGSSSNIGSSSVS (SEQ ID NO:48). In some embodiments, 1, 2, 3, 4, or 5 amino acids are replaced relative to the sequence SGSSSNIGSSSVS (SEQ ID NO:48). For example, in some embodiments, position 28 is Y or H. In some embodiments, position 30 is E. In some embodiments, position 32 is N. In some embodiments, position 33 is Y or F. In some embodiments, position 33 is Y or F. position 35 is D or E. In some embodiments, CDR1 has at least 60% identity, at least 70% identity, at least 80% identity, or at least 90% identity to the sequence SGSSSNIGSSSVS (SEQ ID NO:48 ).

[0183] In some embodiments, a tumor-binding antibody of the invention comprises a light chain CDR2 sequence (K/R)(N/D)(N/D)QRPS. In some embodiments, CDR2 comprises a CDR2 sequence as shown in Table 1 or Table 2. In some embodiments, CDR2 comprises a CDR2 KNNQRPS sequence (SEQ ID NO:59). In some embodiments, 1, 2, or 3 amino acids are substituted relative to the sequence KNNQRPS (SEQ ID NO:59). For example, in some embodiments, position 51 is R, position 52 is D, and/or position 53 is D. In some embodiments, the CDR2 sequence has at least 60% or at least 70% identity with the sequence KNNQRPS (SEQ ID NO:59).

[0184] In some embodiments, the tumor-binding antibody of the present invention comprises the sequence V _L CDR3.STWD(D/E)SLSV(R/W)V. In some embodiments, the CDR3 sequence includes STWD(D/E)SLSVRV. In some embodiments, CDR3 includes a CDR3 sequence as shown in Table 1 or Table 2. In some embodiments, the CDR3 sequence includes STWDDSLSVRV (SEQ ID NO:68) or STWDESLSVRV (SEQ ID NO:73). In some embodiments, 1, 2, or 3 amino acids are substituted relative to the sequence STWDDSLSVRV (SEQ ID NO:68) or STWDESLSVRV (SEQ ID NO:73). For example, in some embodiments, position 90 is A, position 91 is I, and/or position 97 is G.

[0185] In some embodiments, the FR1 region of the V _L region of a tumor-binding antibody of the invention has at least 80% or at least 90% identity with the FR1 sequence from positions 1-22 of the V _L region sequence of Table 1. In some embodiments implementation, the FR1 region has at least 95% identity with the FR1 sequence from positions 1-22 of the V _L region sequence of Table 1. In some embodiments, FR1 includes the amino acid sequence from positions 1-22 of the V _L region sequence of Table 1.

[0186] In some embodiments, the FR2 region of the V _L region of a tumor-binding antibody of the invention has at least 80% or at least 90% identity with the FR2 sequence from positions 36-50 of the V _L region sequence of Table 1. In some embodiments implementation, the FR2 region has at least 95% identity with the FR2 sequence from positions 36-50 of the V _L region sequence of Table 1. In some embodiments, FR2 includes the amino acid sequence from positions 36-50 of the V _L region sequence of Table 1.

[0187] In some embodiments, the FR3 region of the V _L region of a tumor-binding antibody of the invention has at least 80% or at least 90% identity with the FR3 sequence from positions 58-89 of the V _L region sequence of Table 1. In some embodiments implementation, the FR3 region has at least 90% identity or at least 95% identity with the FR3 sequence from positions 58-89 of the V _L region sequence of Table 1. In some embodiments, FR3 includes the amino acid sequence from positions 58-89 of the V _L region sequence from table 1.

[0188] In some embodiments, the FR4 region and the V _H region comprise the amino acid sequence from positions 101-110 of the V _L region sequence from Table 1. In some embodiments, the FR4 region contains a substitution at one or two positions from 101-110 relative to the corresponding region sequence V _L from table 1.

[0189] In some embodiments, the tumor-binding antibody of the present invention comprises the CDR1, CDR2, and/or CDR3 region V _L as described in the previous paragraphs of this section. In some embodiments, one or two V _L CDR sequences comprise a CDR sequence as shown in Table 1. In some embodiments, an antitumor antibody of the present invention comprises the V _L CDR1, CDR2, and/or CDR3 regions as described in the previous paragraphs in this section , and has at least 70% identity, at least 75% identity, at least 80% identity, or at least 85% identity, at least 90% identity, or at least 95% identity with any one of the V sequences _L as shown in Table 1. In some embodiments, the antitumor antibody comprises CDR1, CDR2, and CDR3 as shown in Table 1 and has at least 70% identity, at least 75% identity, at least 80% identity, or at least 85% identity, at least 90% identity, or at least 95% identity to any of the V _L sequences as shown in Table 1.

[0190] In some embodiments, the tumor binding antibody comprises LCDR1, LCDR2 and LCDR3 antibodies, designated AIP-158623, AIP-155066, AIP-136538, AIP-166120, AIP-133645, AIP-187893, AIP-142079, AIP -160470, AIP-104188, AIP-157397, AIP-165430, AIP-189526, AIP-192482, AIP-122563 or AIP-171142, and has at least 80% or at least 90% identity to the corresponding V _L sequence, given in Table 1, or contains the V _L sequence of the corresponding VL sequence in Table 1.

Exemplary Antibodies

[0191] In some embodiments, provided herein is an antibody that binds to a tumor through a binding interaction with an extracellular RNA-protein complex, wherein the antibody comprises the heavy and light chain CDRs set forth in Table 1 or Table 2. In some embodiments, the antibody contains HCDR1 any of SEQ ID NO:1-8 or 169-362, or a variant thereof in which 1, 2, 3, 4 or 5 amino acids are substituted relative to the sequence, HCDR2 any of SEQ ID NO:9-19 or 363- 556, or a variant thereof, in which 1, 2, 3, 4 or 5 amino acids are substituted relative to the sequence; HCDR3 is any of SEQ ID NO:20-47, or 557-750, or 1727, or a variant thereof, in which 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids are substituted relative to the sequence; LCDR1 any of SEQ ID NO:48-58 or 751-944, or a variant thereof in which 1, 2, 3, 4 or 5 amino acids are substituted relative to the sequence; LCDR2 any of SEQ ID NO:59-67 or 945-1138, or a variant thereof in which 1, 2 or 3 amino acids are substituted relative to the sequence; and LCDR3 any of SEQ ID NO:68-76 or 1139-1332, or a variant thereof in which 1, 2, 3, 4 or 5 amino acids are substituted relative to the sequence. In some embodiments, at least 1 or 2 of the substitutions are conservative substitutions. In some embodiments, at least 50%, or at least 60%, at least 70%, at least 80%, or at least 90% of the substitutions relative to the specified CDR sequence in Table 1 or Table 2 are conservative substitutions.

[0192] In some embodiments, the antibody comprises HCDR1 of any of SEQ ID NO:1-8 or 169-362, or a variant thereof in which 1 or 2 amino acids are substituted relative to the sequence, HCDR2 of any of SEQ ID NO:9-19 or 363 -556, or a variant thereof, in which 1 or 2 amino acids are substituted relative to the sequence; HCDR3 any of SEQ ID NO:20-47 or 557-750 or 1727, or a variant thereof in which 1, 2 or 3; or in which 1 or 2; amino acids are substituted relative to the sequence; LCDR1 any of SEQ ID NO:48-58 or 751-944, or a variant thereof in which 1 or 2 amino acids are substituted relative to the sequence; LCDR2 any of SEQ ID NO:59-67 or 945-1138, or a variant thereof in which 1 or 2 amino acids are substituted relative to the sequence; and LCDR3 any of SEQ ID NO:68-76 or 1139-1332, or a variant thereof in which 1 or 2 amino acids are substituted relative to the sequence. In some embodiments, at least 1 or 2 of the substitutions are conservative substitutions.

[0193] In some embodiments, provided herein is an antibody that binds to a tumor through a binding interaction with an extracellular RNA-protein complex, wherein the antibody comprises six CDRs of an antibody set forth in Table 1A or Table 2A; or an antibody variant in which at least one CDR, at least two CDRs, at least three CDRs, at least four CDRs, at least five CDRs, or all six CDRs have 1-2 amino acid substitutions compared to the corresponding CDRs antibodies shown in Table 1A or 2A.

[0194] In some embodiments, provided herein is a tumor-binding antibody that binds to an extracellular RNA-protein complex, wherein the antibody comprises a CDR according to the following formula. For each CDR, the "X" residue is numbered by its position in the CDR, for example, X3 is in the third position of the CDR.

(a) sequence HCDR1 G(F/Y)X ₃ X ₄ (A/S)X ₆ A(W/Y)X ₉ (S/T) (SEQ ID NO:1734), where X ₃ represents D, T or V; X ₄ represents A, F, or Y; X ₆ represents A, H, K, M, N or R; and X ₉ represents F, M, or Y;

(b) sequence HCDR2 (F/R)I(K/Q)(A/S)X ₅ X ₆ X ₇ (A/G)X ₉ X ₁₀ T(D/E)(A/S)(P/ S)(K/Q) (SEQ ID NO:1735), where X5 represents A, N, T, or V; X6 represents D, H, Q, S or T; X7 represents D, E, or N; X9 represents E, G, H, K or Q; and X10 is A, I, Q or T;

(c) sequence HCDR3 (I/T)(S/T)X ₃ (F/Y)X ₅ CX ₇ (G/S)X ₉ X ₁₀ CX ₁₂ X ₁₃ X ₁₄ (D/E)X ₁₆ SX ₁₈ X ₁₉ X ₂₀ X 21 X ₂₂ X ₂₃ X _{24 X 25 (} F/Y) (F/Y)X ₂₈ X ₂₉ (D/N)X ₃₁ (SEQ ID NO:1736) where X ₃ represents A, P, S, or T; X ₅ represents A, C, or S; X ₇ represents H, L, Q, or R; X ₉ represents A, G, K, or N; X ₁₀ represents A, N, Q, R, or S; X ₁₂ represents A, L, or P; X ₁₃ represents A, N, or S; X ₁₄ represents H, Q, R, or S; X ₁₆ represents N, Q, or T; X ₁₈ represents F, M, or Y; X ₁₉ represents C, S, or V; X ₂₀ represents A, G, or N; X ₂₁ represents A, G, or N; X ₂₂ represents Q, S, or Y; X ₂₃ represents D, F, N, S, or Y; X ₂₄ represents A, K, N, P, Q, or S; X ₂₅ represents D, K, Q, R, or S; X ₂₈ represents F, L, W, or Y; X ₂₉ represents F, M, or V; and X ₃₁ represents I, P, or V;

(d) sequence LCDR1 X ₁ G(A/S)X ₄ (S/T)(D/N)I(G/Q)(H/S)X ₁₀ X ₁₁ (T/V)X ₁₃ (SEQ ID NO:1737), where X ₁ represents H, S, or T; X ₄ represents E, K, P, or S; X ₁₀ represents A, H, N, S, or T; X ₁₁ represents A, D, S, T, or Y; and X ₁₃ is A, L, S, T or Y;

(e) sequence LCDR2 X ₁ (D/N)X ₃ X ₄ (Q/R)(A/P)X ₇ (SEQ ID NO:1738), where X ₁ represents A, H, K, M, N , or R; X ₃ represents N, S, or T; X ₄ represents A, L, Q, or Y; and X ₇ represents L, Q, S, or Y; And

(f) sequence LCDR3 (A/S)(S/T)(F/W)(D/N)X ₅ X ₆ X ₇ X ₈ (I/V)X ₁₀ (I/V) (SEQ ID NO: 1739), where X ₅ represents D, E, or N; X ₆ represents A, D, Q, or S; X ₇ represents L, N, or S; X ₈ represents L, N, S, or T; and X ₁₀ is H, K, Q, R, or W. In some embodiments, each antibody heavy or light chain CDR differs from the corresponding heavy or light chain CDR in Table 1A or Table 2A by no more than two amino acids or more than one amino acid.

[0195] In some embodiments, provided herein is an antibody that binds to a tumor through a binding interaction with an extracellular RNA-protein complex, wherein the antibody comprises six CDRs of the antibody shown in Table 1A or Table 2A, or a variant thereof, in which at least one, two, three, four, five or all six CDRs contain 1 or 2 amino acid substitutions relative to the corresponding CDR sequence in Table 1B or Table 2B. In some embodiments, provided herein is an antibody that binds to a tumor through a binding interaction with an extracellular RNA-protein complex, wherein the antibody comprises the six antibody CDRs set forth in Table 1A or Table 2A, or a variant thereof, in which at least one, two, three, four, five or all six CDRs contain 1 or 2 amino acid substitutions relative to the corresponding CDR sequence in Table 1B or Table 2B. In some embodiments, the antibody contains six CDRs of the antibody, designated AIP-192482, AIP-171142, AIP-165430, AIP-189526, AIP-122563, AIP-158623, AIP-155066, AIP-166120, AIP-133645, AIP- 187893, AIP-142079, AIP-160470, AIP-102396, AIP-150055, AIP-167084, AIP-185304, AIP-134770, AIP-141887, AIP-196203, AIP-128195, AIP-116579, AIP-1 92329, AIP-197809, AIP-142489, AIP-167726, AIP-199834, AIP-143179, AIP-195587, AIP-153462, AIP-115363, AIP-151090, AIP-168083, AIP-161082, AIP-114196, AIP - 189338, AIP-183190, AIP-110143, AIP-147176, AIP-134312, AIP-128243, AIP-156172, AIP-147389, AIP-124314, AIP-185291, AIP-135247, AIP-113513, AIP-1 02299, AIP-179097, AIP-109343, AIP-119622, AIP-191735, AIP-157078, AIP-153475, AIP-133650, AIP-190915, AIP-167400, AIP-109729, AIP-151709, AIP-136628, AIP - 101601, AIP-146871, AIP-170053, AIP-199483, AIP-162041, AIP-180675, AIP-183133, AIP-191470, AIP-151167, AIP-106633, AIP-102624, AIP-109484, AIP-1 26080, AIP-161571, AIP-163039, AIP-101235, AIP-182061, AIP-181246, AIP-192216, AIP-171912, AIP-172872, AIP-167833, AIP-190051, AIP-145518, AIP-167533, AIP - 112580, AIP-143155, AIP-119664, AIP-190526, AIP-114403, AIP-156760, AIP-103803, AIP-195588, AIP-145722, AIP-178251, AIP-116142, AIP-183350, AIP-1 27108, AIP-128147, AIP-109510, AIP-104086, AIP-143132, AIP-170105, AIP-169636, AIP-152243, AIP-138776, AIP-103817, AIP-130491, AIP-188155, AIP-167246, AIP - 106139, AIP-198351, AIP-159326, AIP-192275, AIP-190761, AIP-166832, AIP-148062, AIP-129145, AIP-111240, AIP-153888, AIP-130915, AIP-109048, AIP-1 70569, AIP-154873, AIP-159037, AIP-186826, AIP-156514, AIP-157122, AIP-173276, AIP-150485, AIP-166847, AIP-124013, AIP-126285, AIP-168605, AIP-190274, AIP - 136060, AIP-180422, AIP-166722, AIP-127782, AIP-189473, AIP-192571, AIP-112328, AIP-125258, AIP-150199, AIP-125062, AIP-177193, AIP-115388, AIP-1 07759, AIP-170221, AIP-143369, AIP-189475, AIP-102833, AIP-157045, AIP-175775, AIP-154181, AIP-125984, AIP-160829, AIP-184744, AIP-128136, AIP-181273, AIP - 153125, or AIP-131972, or a variant thereof, wherein at least one, two, three, four, five, or all six CDRs contain 1 or 2 amino acid substitutions relative to the corresponding CDR sequence in Table 2B.

[0196] In some embodiments, provided herein is a tumor-binding antibody that binds to an extracellular RNA-protein complex, wherein the antibody comprises a CDR according to the following formula. For each CDR, the "X" residue is numbered by its position in the CDR, for example, X3 is in the third position of the CDR.

(a) the sequence HCDR1 G(F/Y)X ₃ X ₄ (A/S)X ₆ A(W/Y)(F/M)(S/T), where X ₃ represents D, T or V; X ₄ represents A, F, or Y; and X ₆ represents A, H, K, M, or N;

(b) HCDR2 sequence RIK(A/S)X ₅ X ₆ (D/N)(A/G)X ₉ X ₁₀ (D/E)(A/S)(P/S)(K/Q), where X ₅ represents A, N, T, or V; X ₆ represents D, H, Q, S or T; X ₉ represents E, G, H, K or Q; and X ₁₀ is A, I, Q, or T;

(c) sequence HCDR3 (I/T)(S/T)X ₃ (F/Y)CCX ₇ (G/S)X ₉ X ₁₀ CX ₁₂ (N/S)X ₁₄ (D/E)TS(F /Y)CX ₂₀ (G/N)X ₂₂ X ₂₃ X ₂₄ ,X ₂₅ (F/Y)YX ₂₈ X ₂₉ (D/N)X ₃₁ where X ₃ represents A, P, or S; X ₇ represents H, L, Q, or R; X ₉ represents A, G, K, or N; X ₁₀ represents A, N, Q, R, or S; X ₁₂ represents A, L, or P; X ₁₄ represents H, Q, R, or S; X ₂₀ represents A, G, or N; X ₂₂ represents Q, S, or Y; X ₂₃ represents D, F, N, or Y; X ₂₄ represents A, K, N, P, or Q; X ₂₅ represents D, Q, R, or S; X ₂₈ represents F, L, W, or Y; X ₂₉ represents F, M, or V; and X ₃₁ represents I, P, or V;

(d) sequence LCDR1 (S/T)G(A/S)X ₄ (S/T)(D/N)IG(H/S)X ₁₀ X ₁₁ (T/V)X ₁₃ , where X ₄ represents is K, P, or S; X ₁₀ is A, N, S, or T; X ₁₁ represents A, S, T, or Y; and X ₁₃ is A, S, T or Y;

(e) the sequence LCDR2 X ₁ (D/N)X ₃ X ₄ (Q/R)(A/P)X ₇ where X ₁ represents A, H, K, M, N, or R; X ₃ represents N, S, or T; X ₄ represents A, L, Q, or Y, and X ₇ represents L, Q, S, or Y; And

(f) sequence LCDR3 (A/S)(S/T)W(D/N)X ₅ X ₆ X ₇ X ₈ (I/V)X ₁₀ (I/V), where X ₅ represents D, E , or N, X ₆ represents A, D, Q, or S, X ₇ represents L, N, or S; X8 represents L, N, S, or T; and X ₁₀ is H, K, Q, or R.

[0197] In some embodiments, provided herein are tumor-binding antibodies comprising a V _H having at least 70% identity, at least 75% identity, at least 80% identity, or at least 85% identity, to at least 90% identity or at least 95% identity to the amino acid sequence of the V _H region of any of SEQ ID NOs: 77-122, 1333-1526, or 1725. In some embodiments, provided herein are antitumor antibodies comprising a V _L having at least 70% identity, at least 75% identity, at least 80% identity or at least 85% identity, at least 90% identity or at least 95% identity to the amino acid sequence of region V _L of any of SEQ ID NO:123-168, 1527-1720 or 1726.

[0198] In some embodiments, the tumor-binding antibody comprises a _VH comprising the amino acid sequence of one of SEQ ID NO:77-122 or 1333-1526; or V _L containing the amino acid sequence of any of SEQ ID NO: 123-168 or 1527-1720.

[0199] In some embodiments, a tumor-binding antibody of the present invention comprises the V _H and V _L of any of the antibodies designated by an AIP number (“AIP antibody”) in Table 1A or Table 2A. In some embodiments, the tumor-binding antibody is an antibody variant wherein V _H has at least 85% identity or at least 90% identity; or at least 95% identity; and V _L has at least 85% identity or at least 90% identity; or at least 95% identity with the V _H sequence of the AIP antibody as shown in Table 1A or Table 2A, and V _L has at least 85% identity or at least 90% identity; or at least 95% identity with the V _L sequence of the AIP antibody, as shown in Table 1A or Table 2A. In some embodiments, the variant antibody has no more than ten mutations, or no more than nine mutations, no more than eight mutations, or no more than seven mutations in total in the heavy and light chain CDR sequences relative to the AIP antibody CDR sequence. In some embodiments, the antibody has a total of six, five, four, three, two, or one mutation in the heavy and light chain CDR sequences relative to the AIP antibody CDR sequence. In some embodiments, all mutations are substitutions relative to the AIP antibody sequence, as shown in Table 1.

[0200] In some embodiments, the tumor binding antibody of the invention has an antibody CDR designated as AIP-158623, AIP-155066, AIP-136538, AIP-166120, AIP-133645, AIP-187893, AIP-142079, AIP-160470 , AIP-104188, AIP-157397, AIP-165430, AIP-189526, AIP-192482, AIP-122563, or AIP-171142. In some embodiments, the antibody further has at least 80% or at least 90% identity with the corresponding _VH and _VL sequences shown in Table 1.

Antibodies that exhibit antitumor activity

[0201] In one aspect, provided herein are antibodies that exhibit tumor inhibitory effects, including reducing growth rate, tumor size, tumor invasion, and/or metastasis. Such antibodies exhibit antitumor effects in vivo , for example, when administered to subjects who have a tumor that has an extracellular RNA-protein complex. In some embodiments, the V _H region or V _L region of such an antibody has at least two, three, four, five, or six or more modifications, such as substitutions, relative to exemplary antibody sequences as described herein. In some embodiments, the antitumor antibody includes the antibody listed in Table 1A (AIP designation: AIP-101235, AIP-127782, AIP-189473, AIP-192571, AIP-125258, AIP-150199, AIP-115388, AIP-143369, AIP -157045, AIP-175775, AIP-154181, AIP-125984, AIP-160829, AIP-184744, AIP-128136, AIP-181273, AIP-153125, AIP-160470, AIP-192482, AIP-171142, AIP-1 57397 , AIP-165430, AIP-189526, AIP-122563, AIP-158623, AIP-155066, AIP-136538, AIP-166120, AIP-133645, AIP-187893, AIP-142079, AIP-104188, AIP-106042, AIP -100196, AIP-180675, AIP-170105, AIP-126080, AIP-161571, AIP-181246, AIP-192216, AIP-168605, AIP-172872, AIP-190051, AIP-167533, AIP-112580, AIP-1 36060 ), or a variant thereof, as described herein. In some embodiments, the antitumor antibody comprises six antibody CDRs as shown in Table 1B (AIP designation: AIP-101235, AIP-127782, AIP-189473, AIP-192571, AIP-125258, AIP-150199, AIP-115388, AIP- 143369, AIP-157045, AIP-175775, AIP-154181, AIP-125984, AIP-160829, AIP-184744, AIP-128136, AIP-181273, AIP-153125, AIP-160470, AIP-192482, AIP-1 71142, AIP-157397, AIP-165430, AIP-189526, AIP-122563, AIP-158623, AIP-155066, AIP-136538, AIP-166120, AIP-133645, AIP-187893, AIP-142079, AIP-104188, AIP - 106042, AIP-100196, AIP-180675, AIP-170105, AIP-126080, AIP-161571, AIP-181246, AIP-192216, AIP-168605, AIP-172872, AIP-190051, AIP-167533, AIP-1 12580, AIP-136060), or a variant thereof, as described herein.

Region V _H

[0202] In some embodiments, the antitumor antibody of the present invention has one, two, or three V _H CDR sequences, as shown in Table 1. In some embodiments, the antitumor antibody has at least one mutation and no more than 10, 20, 30 , 40 or 50 mutations in the V _H amino acid sequence relative to the V _H sequence of any of SEQ ID NO: 77-122. In some embodiments, the V _H amino acid sequence may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid insertions or deletions relative to the V _H sequence of any of SEQ ID NO: 77-122. In some embodiments, the V _H amino acid sequence may contain a deletion or insertion, for example, 1, 2, 3, 4 or 5 amino acid deletions or insertions, relative to the V _H CDR region sequence of any of SEQ ID NO: 77-122. In some embodiments, the _VH amino acid sequence may comprise a deletion or insertion of 1 or 2 amino acids relative to the _VH CDR region sequence of any of SEQ ID NO:77-122. In some embodiments, the V _H region contains HCDR1 having 1 or 2 substitutions relative to the HCDR1 sequence of any of SEQ ID NO: 1-8. In some embodiments, HCDR1 has 3 or 4 substitutions relative to the HCDR1 sequence of any of SEQ ID NO: 1-8. In some embodiments, the V _H region contains HCDR2 that has 1, 2, 3, or 4 substitutions relative to the HCDR2 sequence of any of SEQ ID NO:9-19. In some embodiments, the V _H region has 5, 6, 7, or 8 substitutions relative to the HCDR2 sequence of any of SEQ ID NO:9-19. In some embodiments, the V _H region contains HCDR3 that has 1, 2, 3, or 4 substitutions relative to the HCDR3 sequence of any of SEQ ID NO:20-47. In some embodiments, the V _H region has 5, 6, 7, or 8 substitutions relative to the HCDR3 sequence of any of SEQ ID NO:20-47. In some embodiments, the V _H region has 9, 10, 11, 12, 13, or 14 substitutions relative to the HCDR3 sequence of any of SEQ ID NO:20-47. In some embodiments, an antitumor antibody of the present invention comprises _VH CDR1, CDR2, and CDR3, each of which has at least 80% identity with the corresponding VH CDR1, CDR2, and _CDR3 of any of SEQ ID NO:77-122. In some embodiments, the antitumor antibody of the present invention contains CDR1, CDR2 and CDR3, each of which has at least 90% identity with the corresponding CDR1, CDR2 and CDR3 of the _VH region of any of SEQ ID NO:77-122. In some embodiments, the antitumor antibody of the present invention comprises the _VH CDR1, CDR2, and CDR3 regions of any of SEQ ID NO:77-122. In some embodiments, the tumor binding antibody of the present invention comprises CDR1, CDR2, and CDR3 antibodies, designated AIP-158623, AIP-155066, AIP-136538, AIP-166120, AIP-133645, AIP-187893, AIP-142079, AIP -160470, AIP-104188, AIP-157397, AIP-165430, AIP-189526, AIP-192482, AIP-122563, or AIP-171142 in Table 1A.

[0203] In some embodiments, the V _H region of an antitumor antibody of the present invention has a solvent contact area for each CDR side chain in square Angstroms as defined in this paragraph based on the Fab crystal structure of the exemplary antibody. The classification as closed, intermediate or open is based on the following limits: less than about 10 Ang ² , about 10-50 Ang ² or more than about 50 Ang ² , respectively. The positions are defined by reference to any one of the V _H region sequences of SEQ ID NO:77-122 of Table 1A. Thus, in some embodiments, an antitumor antibody of the invention comprises a CDR1 in which positions 26, 27, 28, 29, 30, and 31 are open; position 32 is closed; position 33 is open; and positions 34 and 35 are intermediate. In some embodiments, an antitumor antibody of the invention comprises a CDR2 in which position 50 is intermediate; position 51 is open; position 53 is closed; positions 54, 55, 56, 57, 58, 59 and 60 are open; position 61 is intermediate; and positions 62, 63, 64, 65, 66, 67 and 68 are open. In some embodiments, an antitumor antibody of the invention contains a CDR3 in which position 99 is open; position 100 is closed; position 101 is intermediate; positions 102, 103 and 104 are closed; provisions 105, 106, 107 and 108 are open; positions 109 and 110 are closed; position 111 is intermediate; provisions 112 and 113 are open; position 114 is intermediate; provisions 115 and 116 are open; position 117 is intermediate; position 118 is open; position 119 is intermediate; position 120 is open; position 121 is intermediate; provisions 122 and 123 are open; position 124 is intermediate; and provisions 125, 126, 127, 128 and 129 are open. In some embodiments, a residue that is classified as “closed” includes a substitution relative to the CDR region V _H of any of SEQ ID NO: 77-122, that is, a conservative substitution that maintains the charge and approximate size to maintain the conformation of the antibody. In some embodiments, a residue classified as “open” is replaced, for example, with a conservative substitution or a residue that provides improved binding to cancer cells compared to the parent antibody from Table 1A.

[0204] In some embodiments, the HCDR3 of an antitumor antibody as described herein has at least 60% identity, at least 70% identity, at least 80% identity, at least 85%, at least 90% identity identity or at least 95% identity with any of the HCDR3 sequences of SEQ ID NO:20-47. In some embodiments, at least two, three, or all four cysteine residues in the HCDR3 sequence as described herein are conserved in the variant. In additional embodiments, HCDR3 is at least 27, 28, 29, or 30 amino acids in length. In typical embodiments, HCDR3 is 31 amino acids in length.

[0205] In some embodiments, the FR1 region of the _VH region of an antitumor antibody as described herein has at least 80% or at least 90% identity with the FR1 sequence at positions 1-25 of the _VH region of any of the SEQ IDs NO:77-122. In some embodiments, the FR1 region has at least 95% identity with the FR1 sequence from positions 1-25 of the _VH region of any of SEQ ID NO:77-122. In some embodiments, FR1 comprises the amino acid sequence from positions 1-25 of the V _H region of any of SEQ ID NO: 77-122.

[0206] In some embodiments, the FR2 region of the _VH region of an antitumor antibody as described herein has at least 80% or at least 90% identity with the FR2 sequence from positions 36-49 of the _VH region of any of SEQ ID NO :77-122. In some embodiments, the FR2 region has at least 95% identity with the FR2 sequence from positions 36-49 of the _VH region of any of SEQ ID NO:77-122. In some embodiments, FR2 comprises the amino acid sequence from positions 36-49 of the _VH region of any of SEQ ID NO:77-122.

[0207] In some embodiments, the FR3 region of the _VH region of an antitumor antibody of the invention has at least 80% or at least 90% identity with the FR3 sequence at positions 69-98 of the _VH region of any of SEQ ID NO:77-122. In some embodiments, the FR3 region has at least 95% identity with the FR3 sequence from positions 69-98 of the _VH region of any of SEQ ID NO:77-122. In some embodiments, FR3 comprises the amino acid sequence from positions 69-98 of the _VH region of any of SEQ ID NO:77-122.

[0208] In some embodiments, the FR4 region and the V _H region comprise the amino acid sequence from positions 130-140 of the V _H region of any of SEQ ID NO: 77-122. In some embodiments, the FR4 region contains a substitution at one or two of positions 130-140 relative to the corresponding V _H region sequence of any of SEQ ID NO:77-122.

[0209] In some embodiments, an antitumor antibody of the invention comprises a heavy chain CDR1 sequence GFTFSKAWM(S/T). In some embodiments, CDR1 includes GFTFSKAWMS (SEQ ID NO:1). In alternative embodiments, CDR1 includes GFTFSKAWMT (SEQ ID NO:8). In some embodiments, 1, 2, or 3 amino acids are substituted relative to the sequence GFTFSKAWMS (SEQ ID NO:1) or GFTFSKAWMT (SEQ ID NO:8). For example, in some embodiments, CDR1 contains an N at position 30, an N at position 31; and/or Y at position 33. In some embodiments, CDR1 has at least 60% identity, or at least 70% identity, at least 80% identity, or at least 90% identity with the sequence GFTFSKAWMS (SEQ ID NO:1 ) or GFTFSKAWMT (SEQ ID NO:8).

[0210] In some embodiments, an antitumor antibody of the invention comprises a heavy chain CDR2 sequence RIKS(V/T)(T/S)(D/E)G(E/G)(I/T)T(D/E)YAAPVKG . In some embodiments, CDR2 includes RIKS(V/T)(T/S)(D/E)G(E/G)(I/T)TDYAAPVKG. In some embodiments, CDR2 includes RIKSVTDGETTDYAAPVKG (SEQ ID NO:9). In some embodiments, CDR2 includes RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). In some embodiments, CDR2 includes RIKSTSDGGITDYAAPVKG (SEQ ID NO:16). In some embodiments, 1, 2, 3, 4, 5, 6, 7, or 8 amino acids are replaced relative to the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); or 1, 2, 3, 4, 5, 6, 7 or 8 amino acids are replaced relative to the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). For example, in some embodiments, CDR2 contains a substituted sequence having one or more of the following positions: position 51 is V; position 54 represents K or T; position 55 represents S; position 56 represents S; position 58 represents G; position 59 represents I; position 60 represents K; or position 61 is E. In some embodiments, 1, 2, 3, 4, 5, 6, 7, or 8 amino acids are replaced relative to the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). For example, in some embodiments, CDR2 contains a substituted sequence in which position 51 is V; position 54 represents V, K or T; position 55 represents T, position 58 represents E; position 59 represents T; position 60 represents K; and/or position 61 is E. In some embodiments, if CDR2 contains a sequence in which position 56 is S, CDR1 contains W at position 33. In some embodiments, CDR2 has at least 60% identity or at least 70% identity with the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); or at least 60% identity or at least 70% identity with the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). In some embodiments, the CDR2 sequence has at least 80% identity or at least 90% identity with the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:9) or RIKSVTEGETTDYAAPVKG (SEQ ID NO:17).

[0211] In some embodiments, the antitumor antibody comprises the sequence CDR3 V _H T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)(Y/D)( K/N/S)(S/R)YYYMDV. In some embodiments, CDR3 comprises any one of the CDR3 sequences shown in Table 2. In some embodiments, CDR3 comprises a CDR3 sequence as shown in Table 2, in which 1, 2, 3, 4, 5, 6, 7, 8. or 9 amino acids are substituted relative to the CDR3 sequence shown in Table 2. For example, in some embodiments, CDR3 contains V at position 99, T at position 100, R at position 108, D at position 111, R at position 112, Y at position 116 and/or S at position 120. In some embodiments, CDR3 V _H includes the sequence T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)YKSYYYMDV, T (S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)DSRYYYMDV, T(S/T)SFCCRGG(R/S)CPS(H/R)DTS (Y/F)CGG(Q/S)YNRYYYMDV, T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)YNSYYYMDV, or T(S/ T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)DKRYYYMDV. In some embodiments, CDR3 V _H includes the sequence T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)YKSYYYMDV, T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)DSRYYYMDV, T (S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)YNRYYYMDV, or T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)DKRYYYMDV.

[0212] In some embodiments, an antitumor antibody of the invention comprises the heavy chain CDR1 sequence GFTFSKAWM(S/T). In some embodiments, CDR1 includes GFTFSKAWMS (SEQ ID NO:1). In alternative embodiments, CDR1 includes GFTFSKAWMT (SEQ ID NO:8). In some embodiments, 1, 2, or 3 amino acids are substituted relative to the sequence GFTFSKAWMS (SEQ ID NO:1) or GFTFSKAWMT (SEQ ID NO:8). For example, in some embodiments, CDR1 contains an N at position 30, an N at position 31; and/or Y at position 33. In some embodiments, CDR1 has at least 60% identity, or at least 70% identity, at least 80% identity, or at least 90% identity with the sequence GFTFSKAWMS (SEQ ID NO:1 ) or GFTFSKAWMT (SEQ ID NO:8).

[0213] In some embodiments, an antitumor antibody of the invention comprises a heavy chain CDR2 sequence RIKS(V/T)(T/S)(D/E)G(E/G)(I/T)T(D/E)YAAPVKG . In some embodiments, CDR2 includes RIKS(V/T)(T/S)(D/E)G(E/G)(I/T)TDYAAPVKG. In some embodiments, CDR2 includes RIKSVTDGETTDYAAPVKG (SEQ ID NO:9). In some embodiments, CDR2 includes RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). In some embodiments, CDR2 includes RIKSTSDGGITDYAAPVKG (SEQ ID NO:16). In some embodiments, 1, 2, 3, 4, 5, 6, 7, or 8 amino acids are replaced relative to the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); or 1, 2, 3, 4, 5, 6, 7 or 8 amino acids are replaced relative to the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). For example, in some embodiments, CDR2 contains a substituted sequence having one or more of the following positions: position 51 is V; position 54 represents K or T; position 55 represents S; position 56 represents S; position 58 represents G; position 59 represents I; position 60 represents K; or position 61 is E. In some embodiments, 1, 2, 3, 4, 5, 6, 7, or 8 amino acids are replaced relative to the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). For example, in some embodiments, CDR2 contains a substituted sequence in which position 51 is V; position 54 represents V, K or T; position 55 represents T, position 58 represents E; position 59 represents T; position 60 represents K; and/or position 61 is E. In some embodiments, if CDR2 contains a sequence in which position 56 is S, CDR1 contains W at position 33. In some embodiments, CDR2 has at least 60% identity or at least 70% identity with the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); or at least 60% identity or at least 70% identity with the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:17). In some embodiments, the CDR2 sequence has at least 80% identity or at least 90% identity with the sequence RIKSVTEGETTDYAAPVKG (SEQ ID NO:9) or RIKSVTEGETTDYAAPVKG (SEQ ID NO:17).

[0214] In some embodiments, the antitumor antibody comprises the sequence CDR3 V _H T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)(Y/D)( K/N/S)(S/R)YYYMDV. In some embodiments, CDR3 comprises any one of the CDR3 sequences shown in Table 2. In some embodiments, CDR3 comprises a CDR3 sequence as shown in Table 2, in which 1, 2, 3, 4, 5, 6, 7, 8. or 9 amino acids are substituted relative to the CDR3 sequence shown in Table 2. For example, in some embodiments, CDR3 contains V at position 99, T at position 100, R at position 108, D at position 111, R at position 112, Y at position 116 and/or S at position 120. In some embodiments, CDR3 V _H includes the sequence T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)YKSYYYMDV, T (S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)DSRYYYMDV, T(S/T)SFCCRGG(R/S)CPS(H/R)DTS (Y/F)CGG(Q/S)YNRYYYMDV, T(S/T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)YNSYYYMDV, or T(S/ T)SFCCRGG(R/S)CPS(H/R)DTS(Y/F)CGG(Q/S)DKRYYYMDV. In some embodiments, CDR3 V _H includes the sequence T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)YKSYYYMDV, T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)DSRYYYMDV, T (S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)YNRYYYMDV, or T(S/T)SFCCRGGSCPSHDTS(Y/F)CGG(Q/S)DKRYYYMDV.

Region V _L

[0215] In some embodiments, the antitumor antibody of the present invention has one, two, or three V _L CDR sequences of any of SEQ ID NO: 123-168, as shown in Table 1A. In some embodiments, the antitumor antibody has at least one mutation and no more than 10, 20, 30, 40, or 50 mutations in the V _L amino acid sequences relative to the V _L sequence of any of SEQ ID NO: 123-168. In some embodiments, the V _L amino acid sequence may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid insertions or deletions relative to the V _L sequence of any of SEQ ID NO: 123-168. In some embodiments, the V _L amino acid sequence may contain a deletion or insertion, for example, 1, 2, 3, 4, 5, 6, or 7 amino acid deletions or insertions, relative to the V _L CDR region sequence of any of SEQ ID NO: 123-168 . In some embodiments, the V _L amino acid sequence may comprise a deletion or insertion of 1 or 2 amino acids relative to the V _L CDR region sequence of any of SEQ ID NO: 123-168. In some embodiments, the V _L region contains LCDR1 having 1 or 2 substitutions relative to the LCDR1 sequence of any of SEQ ID NO:48-58. In some embodiments, LCDR1 has 3, 4, or 5 substitutions relative to the CDR1 sequence of any of SEQ ID NO:48-58. In some embodiments, the V _L region contains a CDR2 that has 1 or 2; or 1, 2 or 3; substitutions relative to the LCDR2 sequence of any of SEQ ID NO:59-67. In some embodiments, the V _L region contains a CDR3 having 1, 2, or 3; or 1, 2, 3 or 4; substitutions relative to the LCDR3 sequence of any of SEQ ID NO:68-76. In some embodiments, the antitumor antibody of the present invention contains CDR1, CDR2 and CDR3, each of which has at least 70% identity with CDR1, CDR2 and CDR3 with the corresponding CDRs of the V _L region of any of SEQ ID NO: 123-168. In some embodiments, the antitumor antibody of the present invention contains CDR1, CDR2 and CDR3, each of which has at least 80% identity with the corresponding CDR1, CDR2 and CDR3 of the V _L region of any of SEQ ID NO: 123-168. In some embodiments, the antitumor antibody of the present invention comprises the _VL region CDR1, CDR2, and CDR3 of any of SEQ ID NOs: 123-168. In some embodiments, the antitumor antibody of the present invention comprises CDR1, CDR2, and CDR3 antibodies, designated AIP-158623, AIP-155066, AIP-136538, AIP-166120, AIP-133645, AIP-187893, AIP-142079, AIP-160470 , AIP-104188, AIP-157397, AIP-165430, AIP-189526, AIP-192482, AIP-122563, or AIP-171142 in Table 1A.

[0216] In some embodiments, the V _L region of an antitumor antibody of the present invention has a solvent contact area for each CDR side chain in square Angstroms as defined in this paragraph, which is based on the Fab crystal structure of the exemplary antibody. The classification as closed, intermediate or open is based on the following limits: less than about 10 Ang ² , about 10-50 Ang ² or more than about 50 Ang ² , respectively. Positions are defined by reference to any of the sequences of the region V _L SEQ ID NO:123-168 presented in table 1A. Thus, in some embodiments, the V _L region of an antitumor antibody of the invention contains a CDR1 in which position 23 is open; position 24 is intermediate; positions 25 and 26 are open; positions 27 and 28 are intermediate; positions 29, 30 and 31 are open; positions 32, 33 and 34 are intermediate; and position 35 is open. In some embodiments, the V _L of an antitumor antibody of the invention contains a CDR2 in which positions 51, 52, 53, 54, 55, 56, and 57 are open. In some embodiments, the V _L of an antitumor antibody of the invention contains a CDR3 in which position 90 is open ; position 91 is closed, position 92 is open; position 93 is closed, positions 94, 95, 96 and 97 are open; position 99 is intermediate; and position 100 is open. In some embodiments, a residue that is classified as “closed” includes a substitution relative to the CDR region V _L of any of SEQ ID NO: 123-168, that is, a conservative substitution that maintains charge and approximate size to maintain the conformation of the antibody. In some embodiments, a residue classified as “open” is replaced, for example, with a conservative substitution or a residue that provides improved binding to cancer cells compared to the parent antibody from Table 1A.

[0217] In some embodiments, an antitumor antibody of the invention comprises the light chain CDR1 sequence SGSSSNIGSSSVS (SEQ ID NO:48). In some embodiments, 1, 2, 3, 4, or 5 amino acids are replaced relative to the sequence SGSSSNIGSSSVS (SEQ ID NO:48). For example, in some embodiments, position 28 is Y or H. In some embodiments, position 30 is E. In some embodiments, position 32 is N. In some embodiments, position 33 is Y or F. In some embodiments, position 33 is Y or F. position 35 is D or E. In some embodiments, CDR1 has at least 60% identity, at least 70% identity, at least 80% identity, or at least 90% identity to the sequence SGSSSNIGSSSVS (SEQ ID NO:48 ).

[0218] In some embodiments, an antitumor antibody of the invention comprises a light chain CDR2 sequence (K/R)(N/D)(N/D)QRPS. In some embodiments, CDR2 comprises a CDR2 sequence as shown in Table 1B. In some embodiments, CDR2 includes the CDR2 sequence KNNQRPS (SEQ ID NO:59). In some embodiments, 1, 2, or 3 amino acids are substituted relative to the sequence KNNQRPS (SEQ ID NO:59). For example, in some embodiments, position 51 is R, position 52 is D, and/or position 53 is D. In some embodiments, the CDR2 sequence has at least 60% or at least 70% identity with the sequence KNNQRPS (SEQ ID NO:59).

[0219] In some embodiments, an antitumor antibody of the invention comprises the CDR3 sequence V _L STWD(D/E)SLSV(R/W)V. In some embodiments, the CDR3 sequence includes STWD(D/E)SLSVRV. In some embodiments, CDR3 comprises a CDR3 sequence as shown in Table 1. In some embodiments, the CDR3 sequence includes STWDDSLSVRV (SEQ ID NO:68) or STWDESLSVRV (SEQ ID NO:73). In some embodiments, 1, 2, or 3 amino acids are substituted relative to the sequence STWDDSLSVRV (SEQ ID NO:68) or STWDESLSVRV (SEQ ID NO:73). For example, in some embodiments, position 90 is A, position 91 is I, and/or position 97 is G.

[0220] In some embodiments, the FR1 region of the V _L region of an antitumor antibody of the invention has at least 80% or at least 90% identity with the FR1 sequence from positions 1-22 of the V _L region sequence of any of SEQ ID NO: 123-168 . In some embodiments, the FR1 region has at least 95% identity with the FR1 sequence from positions 1-22 of the _VL region sequence of any of SEQ ID NO:123-168. In some embodiments, FR1 comprises the amino acid sequence from positions 1-22 of the _VL region sequence of any of SEQ ID NO:123-168.

[0221] In some embodiments, the FR2 region of the V _L region of an antitumor antibody of the invention has at least 80% or at least 90% identity with the FR2 sequence from positions 36-50 of the V _L region sequence of any of SEQ ID NO: 123-168 . In some embodiments, the FR2 region has at least 95% identity with the FR2 sequence from positions 36-50 of the _VL region sequence of any of SEQ ID NOs:123-168. In some embodiments, FR2 comprises the amino acid sequence from positions 36-50 of the V _L region sequence of any of SEQ ID NO: 123-168.

[0222] In some embodiments, the FR3 region of the V _L region of an antitumor antibody of the invention has at least 80% or at least 90% identity with the FR3 sequence from positions 58-89 of the V _L region sequence of any of SEQ ID NO: 123-168 . In some embodiments, the FR3 region has at least 90% identity or at least 95% identity with the FR3 sequence from positions 58-89 of the _VL region sequence of any of SEQ ID NO:123-168. In some embodiments, FR3 comprises the amino acid sequence from positions 58-89 of the V _L region sequence of any of SEQ ID NO: 123-168.

[0223] In some embodiments, the FR4 region and the V _H region comprise the amino acid sequence from positions 101-110 of the V _L region sequence of any of SEQ ID NO: 123-168. In some embodiments, the FR4 region contains a substitution at one or two positions from 101-110 relative to the corresponding V _L region sequence of the V _L region sequence of any of SEQ ID NO: 123-168.

[0224] In some embodiments, the antitumor antibody of the present invention comprises the CDR1, CDR2, and/or CDR3 region V _L as described in the previous paragraphs of this section. In some embodiments, one or two V _L CDR sequences comprise a CDR sequence as shown in the V _L region sequence of any of SEQ ID NO: 123-168. In some embodiments, an antitumor antibody of the present invention contains the CDR1, CDR2 and/or CDR3 regions of V _L as described in the previous paragraphs of this section, and has at least 70% identity, at least 75% identity, at least 80% identity identity or at least 85% identity, at least 90% identity or at least 95% identity with any of the sequences V _L SEQ ID NO: 123-168. In some embodiments, the antitumor antibody comprises the CDR1, CDR2, and CDR3 sequences of the V _L region of any of SEQ ID NOs: 123-168 and has at least 70% identity, at least 75% identity, at least 80% identity, or at least at least 85% identity, at least 90% identity, or at least 95% identity to the corresponding V _L region sequence as shown in Table 1A. In some embodiments, the antitumor antibody comprises CDR1, CDR2, and CDR3 of the antibody, designated AIP-158623, AIP-155066, AIP-136538, AIP-166120, AIP-133645, AIP-187893, AIP-142079, AIP-160470, AIP- 104188, AIP-157397, AIP-165430, AIP-189526, AIP-192482, AIP-122563, or AIP-171142 in Table 1, and has at least 80% or at least 90% identity with the corresponding V _L sequence given in Table 1A.

Exemplary Antibodies

[0225] In some embodiments, provided herein is an antitumor antibody that binds to tumor tissue through a binding interaction with an extracellular RNA-protein complex, wherein the antibody comprises CDRs of the heavy and light chains of the antibody from Table 1, designated AIP: AIP- 101235, AIP-127782, AIP-189473, AIP-192571, AIP-125258, AIP-150199, AIP-115388, AIP-143369, AIP-157045, AIP-175775, AIP-154181, AIP-125984, AIP-1 60829, AIP-184744, AIP-128136, AIP-181273, AIP-153125, AIP-160470, AIP-192482, AIP-171142, AIP-157397, AIP-165430, AIP-189526, AIP-122563, AIP-158623, AIP - 155066, AIP-136538, AIP-166120, AIP-133645, AIP-187893, AIP-142079, AIP-104188, AIP-106042, AIP-100196, AIP-180675, AIP-170105, AIP-126080, AIP-1 61571, AIP-181246, AIP-192216, AIP-168605, AIP-172872, AIP-190051, AIP-167533, AIP-112580, AIP-136060, or a variant thereof as described herein. In some embodiments, the antibody comprises HCDR1 of any one of SEQ ID NO:1-8, or a variant thereof in which 1, 2, 3, 4 or 5 amino acids are substituted relative to the sequence, HCDR2 of any one of SEQ ID NO:9-19, or a variant thereof in which 1, 2, 3, 4 or 5 amino acids are substituted relative to the sequence; HCDR3 is any of SEQ ID NO:20-47, or a variant thereof, in which 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids are substituted relative to the sequence; LCDR1 is any of SEQ ID NO:48-58, or a variant thereof, in which 1, 2, 3, 4 or 5 amino acids are substituted relative to the sequence; LCDR2 any of SEQ ID NO:59-67, or a variant thereof, in which 1, 2 or 3 amino acids are substituted relative to the sequence; and LCDR3 is any of SEQ ID NO:68-76, or a variant thereof, in which 1, 2, 3, 4 or 5 amino acids are substituted relative to the sequence. In some embodiments, at least 1 or 2 of the substitutions are conservative substitutions. In some embodiments, at least 50%, or at least 60%, at least 70%, at least 80%, or at least 90% of the substitutions relative to the reference CDR sequence are conservative substitutions.

[0226] In some embodiments, the antibody comprises HCDR1 of any of SEQ ID NO:1-8, or a variant thereof, in which 1 or 2 amino acids are substituted relative to the sequence, HCDR2 of any of SEQ ID NO:9-19, or a variant thereof, in in which 1 or 2 amino acids are substituted relative to the sequence; HCDR3 any of SEQ ID NO:20-47, or a variant thereof, in which 1, 2 or 3; or in which 1 or 2; amino acids are substituted relative to the sequence; LCDR1 any of SEQ ID NO:48-58, or a variant thereof, in which 1 or 2 amino acids are substituted relative to the sequence; LCDR2 any of SEQ ID NO:59-67', or a variant thereof, in which 1 or 2 amino acids are substituted relative to the sequence; and LCDR3 any of SEQ ID NO:68-76, or a variant thereof, in which 1 or 2 amino acids are substituted relative to the sequence. In some embodiments, at least 1 or 2 of the substitutions are conservative substitutions.

[0227] In some embodiments, provided herein is an antibody that binds to tumor tissue through a binding interaction with an extracellular RNA-protein complex, wherein the antibody comprises: (a) a heavy chain variable region comprising: (i) HCDR1 having the sequence GF(T/V)(F/Y)(S/A)X ₆ AWM(S/T) (SEQ ID NO:1728), where X ₆ represents K, A, or M; (ii) HCDR2 having the sequence RIK(S/A)X ₅ X ₆ (D/E)(G/A)X ₉ X ₁₀ T(D/E)YAA(P/S)VKG (SEQ ID NO:1729 ), where X ₅ represents V, N, A, or T; X ₆ represents T, Q, S, D, or H; X ₉ represents E, H, K, or G; and X ₁₀ represents T, Q, or I; and (iii) HCDR3 having the sequence (I/T)(S/T)SFCC(H/R)(G/S)X ₉ X ₁₀ CPSX ₁₄ (D/E)TS(F/Y)CX ₂₀ (G /N)X ₂₂ X ₂₃ X ₂₄ X ₂₅ (F/Y)Y(F/Y)(M/V)(D/N)X ₃₁ (SEQ ID NO:1730) where X ₉ represents A, G, K, or N; X ₁₀ represents N, Q, R, or S; X ₁₄ represents H, R, or S; X ₂₀ represents A, G, or N; X ₂₂ represents Q, S, or Y; X ₂₃ represents D, F, N, or Y; X ₂₄ represents A, K, N, P, or S; X ₂₅ represents D, Q, R, or S; X ₃₁ represents I, P, or V; and (b) a light chain variable region containing: (i) CDR L1 having the sequence SG(S/A)X ₄ (S/T)(D/N)IGSSX ₁₁ VX ₁₃ (SEQ ID NO:1731), where X ₄ represents S, P, or K; X ₁₁ represents S, Y, or T; and X ₁₃ represents S, Y, or T; (ii) a CDR L2 having the sequence (K/M)(D/N)X ₃ X ₄ R(A/P)X ₇ (SEQ ID NO:1732), where X ₃ represents S, N or T; X ₄ represents L, Q, or A; and X ₇ represents Q, S, Y, or L; and (iii) an L3 CDR having the sequence (A/S)(S/T)W(D/N)X ₅ X ₆ (L/N)X ₈ (I/V)R(I/V) (SEQ ID NO:1733), where X ₅ represents E, D or N; X ₆ represents S, A, or Q; and X ₈ is N, S or T.

[0228] In some embodiments, in the HCDR1 sequence of an antibody, position 3 of HCDR1 is T; position 4 represents F; position 5 represents S; position 6 represents K; and/or position 10 is S. In certain embodiments, the HCDR1 antibody has the sequence GFTFSKAWMS (SEQ ID NO:1). In other embodiments, the HCDR1 antibody has the sequence of any of GFTFSAAWMS (SEQ ID NO:4), GFVFSKAWMS (SEQ ID NO:7), GFTFAKAWMS (SEQ ID NO:6), GFTYSKAWMS (SEQ ID NO:5), GFTFSMAWMS (SEQ ID NO:3), GFTYSAAWMS (SEQ ID NO:2), and GFTFSKAWMT (SEQ ID NO:8).

[0229] In some embodiments, in the HCDR2 sequence of an antibody, position 4 of HCDR2 is S; position 5 represents V; position 6 represents T; position 7 represents D; position 8 represents G; position 9 represents E; position 10 represents T; position 12 represents D; and/or position 16 is P. In certain embodiments, the HCDR2 antibody has the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9). In other embodiments, the HCDR2 antibody has the sequence of any of RIKSVTDGEQTDYAAPVKG (SEQ ID NO:18), RIKAADDGKQTDYAAPVKG (SEQ ID NO:19), RIKSVTDGETTEYAASVKG (SEQ ID NO:9), RIKAVHDGETTDYAAPVKG (SEQ ID NO:10), RIKSNTDAETTDYAAPVKG (SEQ ID NO:11), RIKSVQDGETTDYAAPVKG (SEQ ID NO:12), RIKSVTDGHTTDYAAPVKG (SEQ ID NO:13). RIKSVTSDGGITDYAAPVKG (SEQ ID NO:14), RIKSSTSDGETTDYAAPVKG (SEQ ID NO:15), RIKSSTSDGGITDYAAPVKG (SEQ ID NO:16), and/or RIKSVTEGETTDYAAPVKG (SEQ ID NO:17).

[0230] In some embodiments, in the HCDR3 sequence of an antibody, position 1 of HCDR3 is T; position 2 represents S; position 7 represents R; position 8 represents G; position 9 represents G; position 10 represents S; position 14 represents H; position 15 represents D; position 18 represents Y; position 20 represents G; and/or position 21 is G. In particular embodiments, the HCDR3 antibody has the sequence of any of TSSFCCRGGSCPSHDTSYCGGYYKSYYYMDV (SEQ ID NO:33), TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21), and TSSFCCRGGSCPSHDTSYCGGQYKSFYYMDV (SEQ ID NO:28). In other embodiments, the HCDR3 antibody has the sequence of any of TSSFCCRGGSCPSSDTSYCGGQYKSYYFMDV (SEQ ID NO:32), ISSFCCRGGSCPSRDTSYCGGQYKSYYFMDV (SEQ ID NO:30), ISSFCCRGNSCPSSDTSYCNGQYKSYYFMDV (SEQ ID NO:29), ISSFCCRGNSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO: :27), ISSFCCHSNNCPSSDTSYCNGYYKQYYFMDV (SEQ ID NO:26), ISSFCCRGKQCPSSDTSYCGGQFKSYYFMDV (SEQ ID NO:25), ISSFCCRGKQCPSSDTSYCNGYYADYYFMDV (SEQ ID NO:24), TSSFCCRGNQCPSSDTSYCGGQYPSYYYMDP (SEQ ID NO:23), TTSFCCRGASCPSSDTSYCAGSYKSYYFVNI (SEQ ID NO:22), TSSF CCRSGSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:20), TSSFCCRGGSCPSHDTSYCGGQDSRYYYMDV (SEQ ID NO:42), TSSFCCRGGSCPSHDTSFCGGSYKSYYYMDV (SEQ ID NO:41), TSSFCCRGGSCPSHDTSFCGGQYKSYYYMDV (SEQ ID NO:37), TSSFCCRGGSCPSHDTSFCGGQDSRYYYMDV (SEQ ID NO:40), TTSFCCRGGSCPSHDTSFCGGQ YKSYYYMDV (SEQ ID NO:39), TSSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO :34), TTSFCCRGGRCPSRDTSFCGGQYNSYYYMDV (SEQ ID NO:38), TSSFCCRGGSCPSHDTSFCGGQYNRYYYMDV (SEQ ID NO:36), and TTSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:35).

[0231] In some embodiments, in the LCDR1 sequence of an antibody, position 3 is S; position 4 represents S; position 5 represents S; position 6 represents N; position 11 represents S; and/or position 13 is S. In certain embodiments, the LCDR1 of the antibody has the sequence SGSSSNIGSSSVS (SEQ ID NO:48). In other embodiments, LCDR1 has the sequence of any of SGSKSNIGSSYVS (SEQ ID NO:50), SGSSSNIGSSSVY (SEQ ID NO:56), SGSKSNIGSSSVY (SEQ ID NO:55), SGSSTNIGSSSSVS (SEQ ID NO:54), SGASSNIGSSSVS (SEQ ID NO :52), SGSSTNIGSSTVS (SEQ ID NO:53), SGSKSNIGSSSVS (SEQ ID NO:51), and SGSSTNIGSSSVT (SEQ ID NO:49).

[0232] In some embodiments, in the LCDR2 sequence of an antibody, position 1 is K; position 2 represents N; position 3 represents N; position 4 represents Q; position 6 represents P; and/or position 7 is S. In certain embodiments, LCDR2 has the sequence KNNQRPS (SEQ ID NO:59). In other embodiments, LCDR2 has the sequence of any of KNNQRPY (SEQ ID NO:66), KDNQRPS (SEQ ID NO:62), KNTQRPS (SEQ ID NO:65), KNNARPY (SEQ ID NO:64), KNTQRAS (SEQ ID NO :63), MNNQRPY (SEQ ID NO:61), and KDNQRPL (SEQ ID NO:60).

[0233] In some embodiments, in the LCDR3 antibody sequence, position 1 of LCDR3 is S; position 2 represents T; position 4 represents D; position 5 represents D; position 6 represents S; position 7 represents L; position 8 represents S; position 9 represents V; and/or position 11 is V. In certain embodiments, the LCDR3 of the antibody has the sequence STWDDSLSVRV (SEQ ID NO:68). In other embodiments, LCDR3 has the sequence of any of STWDDALSVRV (SEQ ID NO:72), SSWDDSNSVRI (SEQ ID NO:71), ATWDDQLSVRV (SEQ ID NO:69), ATWDDSLTVRI (SEQ ID NO:76), ATWDNSLSIRV (SEQ ID NO :70), and STWDESLSVRV (SEQ ID NO:73).

[0234] In the antibodies described herein, HCDR1 may have the sequence of any of GFTFSKAWMS (SEQ ID NO:1), GFTFSAAWMS (SEQ ID NO:4), and GFTFSKAWMT (SEQ ID NO:8); HCDR2 may have the sequence of any of RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) and RIKSTSDGETTDYAAPVKG (SEQ ID NO:15); HCDR3 may have the sequence of any of TSSFCCRGGSCPSSDTSYCGGQYKSYYFMDV (SEQ ID NO:32), TSSFCCRSGSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:20), TSSFCCRGNQCPSSDTSYCGGQYPSYYYMDP (SEQ ID NO:23), ISSFCCRGGSCPSRDTSYCGGQYKSYYFMDV (SEQ ID NO:3 0), ISSFCCRGNSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:27) , TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21), and TSSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:34); LCDR1 may have the sequence of any of SGSSSNIGSSSVY (SEQ ID NO:56), SGSSSNIGSSSVS (SEQ ID NO:48), SGSSTNIGSSSVS (SEQ ID NO:54), and SGSKSNIGSSSVS (SEQ ID NO:51); LCDR2 may have the sequence of any of KNNQRPS (SEQ ID NO:59) and KDNQRPS (SEQ ID NO:62); LCDR3 may have the sequence of any of STWDDALSVRV (SEQ ID NO:72), STWDDSLSVRV (SEQ ID NO:68), SSWDDSNSVRI (SEQ ID NO:71), and ATWDNSLSIRV (SEQ ID NO:70).

[0235] In some embodiments, the heavy chain variable region of antibodies described herein may have a sequence that is at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity with any of EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSSDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:92), EVQLVESGGA LVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRSGSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:77), EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSV TDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGNQCPSSDTSYCGGQYPSYYYMDPWGKGTTVTVSS (SEQ ID NO:80), EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSTSDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYC ISSFCCRGGSCPSRDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:90), EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGNSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:86), EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGL EWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:94), and EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSVLYLQMSSL KTEDTAVYFCTSSFCCRGGSCPSHDTSFCGGQDKRYYYMDVWGKGTTVTVSS (SEQ ID NO:95).

[0236] In some embodiments, the light chain variable region of antibodies described herein may have a sequence that is at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) sequence identity with any of QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDALSVRVFGGGTKLTVL (SEQ ID NO:138), QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSW YQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140), QSVLTQPPSASGTPGQRVTISCSGSSTNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSNSVRIFGGGTK LTVL (SEQ ID NO:136), QSVLTQPPSASGTPGQRVTISCSGSKSNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDNSLSIRVFGGGTKLTVL (SEQ ID NO:132), and QSVLTQAPSASETPGQRVIISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:141).

[0237] In some embodiments, an antibody described herein may comprise HCDR1 having the sequence GFTFSKAWMS (SEQ ID NO:1); HCDR2 having the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 having the sequence TSSFCCRGGSCPSSDTSYCGGQYKSYYFMDV (SEQ ID NO:32); LCDR1 having the sequence SGSSSNIGSSSVY (SEQ ID NO:56); LCDR2 having the sequence KNNQRPS (SEQ ID NO:59); and LCDR3 having the sequence STWDDALSVRV (SEQ ID NO:72). In some embodiments, the antibody heavy chain variable region has a sequence comprising at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100 %) identity with the sequence EVQLVESGGALVKPGGSLRLSCAASGFTFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSSDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:92); and the antibody light chain variable region has a sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with sequence QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSSVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWWDDALSVRVFGGGTKLTVL (SEQ ID NO:138).

[0238] In certain embodiments, an antibody described herein may have an HCDR1 having the sequence GFTFSKAWMS (SEQ ID NO:1); HCDR2 having the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 having the sequence TSSFCCRSGSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:20); LCDR1 having the sequence SGSSSNIGSSSVS (SEQ ID NO:48); LCDR2 having the sequence KNNQRPS (SEQ ID NO:59); and LCDR3 having the sequence STWDDSLSVRV (SEQ ID NO:68). In some embodiments, the antibody heavy chain variable region has a sequence comprising at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100 %) identity with the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRSGSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:77); and the antibody light chain variable region has a sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with sequence QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140).

[0239] In certain embodiments, an antibody described herein may have an HCDR1 having the sequence GFTFSKAWMS (SEQ ID NO:1); HCDR2 having the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 having the sequence TSSFCCRGNQCPSSDTSYCGGQYPSYYYMDP (SEQ ID NO:23); LCDR1 having the sequence SGSSSNIGSSSVS (SEQ ID NO:48); LCDR2 having the sequence KNNQRPS (SEQ ID NO:59); and LCDR3 having the sequence STWDDSLSVRV (SEQ ID NO:68). In some embodiments, the antibody heavy chain variable region has a sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100 %) identity with the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGNQCPSSDTSYCGGQYPSYYYMDPWGKGTTVTVSS (SEQ ID NO:80); and the antibody light chain variable region has a sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with the sequence QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140).

[0240] In certain embodiments, an antibody described herein may have an HCDR1 having the sequence GFTFSAAWMS (SEQ ID NO:4); HCDR2 having the sequence RIKSTSDGETTDYAAPVKG (SEQ ID NO:15); HCDR3 having the sequence ISSFCCRGGSCPSRDTSYCGGQYKSYYFMDV (SEQ ID NO:30); LCDR1 having the sequence SGSSTNIGSSSSVS (SEQ ID NO:54); LCDR2 having the sequence KDNQRPS (SEQ ID NO:62); and LCDR3 having the sequence SSWDDSNSVRI (SEQ ID NO:71). In some embodiments, the antibody heavy chain variable region has a sequence comprising at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100 %) identity with the sequence EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSSTSDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGGSCPSRDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:90); and the antibody light chain variable region has a sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with sequence QSVLTQPPSASGTPGQRVTISCSGSSTNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSNSVRIFGGGTKLTVL (SEQ ID NO:136).

[0241] In certain embodiments, an antibody described herein may have an HCDR1 having the sequence GFTFSAAWMS (SEQ ID NO:4); HCDR2 having the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 having the sequence ISSFCCRGNSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:27); LCDR1 having the sequence SGSKSNIGSSSVS (SEQ ID NO:51); LCDR2 having the sequence KDNQRPS (SEQ ID NO:62); LCDR3 having the sequence ATWDNSLSIRV (SEQ ID NO:70). In some embodiments, the antibody heavy chain variable region has a sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100 %) identity with the sequence EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGNSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:86); and the antibody light chain variable region has a sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with the sequence QSVLTQPPSASGTPGQRVTISCSGSKSNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDNSLSIRVFGGGTKLTVL (SEQ ID NO:132).

[0242] In certain embodiments, an antibody described herein may have an HCDR1 having the sequence GFTFSKAWMS (SEQ ID NO:1); HCDR2 having the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 having the sequence TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21); LCDR1 having the sequence SGSSSNIGSSSVS (SEQ ID NO:48); LCDR2 having the sequence KNNQRPS (SEQ ID NO:59); and LCDR3 having the sequence STWDDSLSVRV (SEQ ID NO:68). In some embodiments, the antibody heavy chain variable region has a sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100 %) identity with the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:94); and the antibody light chain variable region has a sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with the sequence QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140).

[0243] In certain embodiments, an antibody described herein may have HCDR1 having the sequence GFTFSKAWMT (SEQ ID NO:8); HCDR2 having the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 having the sequence TSSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:34); LCDR1 having the sequence SGSSSNIGSSSVS (SEQ ID NO:48); LCDR2 having the sequence KNNQRPS (SEQ ID NO:59); and LCDR3 having the sequence STWDDSLSVRV (SEQ ID NO:68). In some embodiments, the antibody heavy chain variable region has a sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100 %) identity with the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSVLYLQMSSLKTEDTAVYFCTSSFCCRGGSCPSHDTSFCGGQDKRYYYMDVWGKGTTVTVSS (SEQ ID NO:95); and the antibody light chain variable region has a sequence having at least 90% (e.g., 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identity with the sequence QSVLTQAPSASETPGQRVIISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWWDDSLSVRVFGGGTKLTVL (SEQ ID NO:141).

[0244] In one aspect, provided herein is an antibody comprising the _VH and _VL regions as described herein, for example, an antibody having the _VH and _VL regions as set forth in Table 1, or a variant thereof that further contains the human IgG1 constant region and/or the human lambda chain constant region. In some embodiments, the antibody comprises a heavy chain sequence ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO:1721), or a variant thereof having at least 9 0% identity with SEQ ID NO:1721. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO:1721 in which 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids are mutated, for example, to modulate FcR binding, effector function, glycosylation, and /or stability. In some embodiments, the antibody comprises the light chain sequence GQPKAAPSVTLFPPSSEELQANKATLVCLVSDFYPGAVTVAWKADGSPVKVGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCRVTHEGSTVEKTVAPAECS (SEQ ID NO:1722). In some embodiments, the antibody contains a sequence having at least 90% identity, or at least 95% identity or more, to SEQ ID NO:1722.

[0245] In some embodiments, the V _H region of an antibody of the present invention has a CDR1 containing GFTFSKAWMS (SEQ ID NO:1), a CDR2 containing RIKSVTDGETTDYAAPVKG (SEQ ID NO:9), and a CDR3 containing TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21 ); and region V _L containing CDR1 containing SGSSSNIGSSSVS (SEQ ID NO:48), CDR2 containing KNNQRPS (SEQ ID NO:59), and CDR3 containing STWDDSLSVRV (SEQ ID NO:68). In some embodiments, such an antibody comprises a human IgG1 constant region and/or a human lambda chain constant region. In some embodiments, the V _H region contains the amino acid sequence of SEQ ID NO:94, and the V _L region contains the amino acid sequence of SEQ ID NO:140. In some embodiments, the antibody comprises a heavy chain sequence ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO:1721), or a variant thereof having at least 9 0% identity with SEQ ID NO:1721. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO:1721 in which 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids are mutated, for example, to modulate FcR binding, effector function, glycosylation, and /or stability. In some embodiments, the antibody comprises the light chain sequence GQPKAAPSVTLFPPSSEELQANKATLVCLVSDFYPGAVTVAWKADGSPVKVGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCRVTHEGSTVEKTVAPAECS (SEQ ID NO:1722). In some embodiments, the antibody contains a sequence having at least 90% identity, or at least 95% identity or more, to SEQ ID NO:1722. In some embodiments, an antibody of the present invention comprises a heavy chain sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDY FPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA KGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO:1723) and light chain sequence QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVP DRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLVSDFYPGAVTVAWKADGSPVKVGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCRVTHEGSTVEKTVAPAECS (SEQ ID NO:1724).

[0246] In one aspect, provided herein is an antibody comprising the _VH and _VL regions as described herein, for example, an antibody having the _VH and _VL regions as set forth in Table 1A, or a variant thereof that further contains the human IgG1 constant region and/or the human lambda chain constant region. In some embodiments, the antibody comprises a heavy chain sequence ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO:1721), or a variant thereof having at least 9 0% identity with SEQ ID NO:1721. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO:1721 in which 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids are mutated, for example, to modulate FcR binding, effector function, glycosylation, and /or stability. In some embodiments, the antibody comprises the light chain sequence GQPKAAPSVTLFPPSSEELQANKATLVCLVSDFYPGAVTVAWKADGSPVKVGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCRVTHEGSTVEKTVAPAECS (SEQ ID NO:1722). In some embodiments, the antibody contains a sequence having at least 90% identity, or at least 95% identity or more, to SEQ ID NO:1722.

[0247] In some embodiments, the V _H region of an antibody of the present invention has a CDR1 containing GFTFSKAWMS (SEQ ID NO:1), a CDR2 containing RIKSVTDGETTDYAAPVKG (SEQ ID NO:9), and a CDR3 containing TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21 ); and region V _L containing CDR1 containing SGSSSNIGSSSVS (SEQ ID NO:48), CDR2 containing KNNQRPS (SEQ ID NO:59), and CDR3 containing STWDDSLSVRV (SEQ ID NO:68). In some embodiments, such an antibody comprises a human IgG1 constant region and/or a human lambda chain constant region. In some embodiments, the V _H region contains the amino acid sequence of SEQ ID NO:8, and the V _L region contains the amino acid sequence of SEQ ID NO:29. In some embodiments, the antibody comprises a heavy chain sequence ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKP REEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG (SEQ ID NO:1721), or a variant thereof having at least 9 0% identity with SEQ ID NO:43. In some embodiments, the antibody comprises the amino acid sequence of SEQ ID NO:43 in which 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids are mutated, for example, to modulate FcR binding, effector function, glycosylation, and /or stability. In some embodiments, the antibody comprises the light chain sequence GQPKAAPSVTLFPPSSEELQANKATLVCLVSDFYPGAVTVAWKADGSPVKVGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCRVTHEGSTVEKTVAPAECS (SEQ ID NO:1722). In some embodiments, the antibody contains a sequence having at least 90% identity, or at least 95% identity or more, to SEQ ID NO:1722.

Variant binding activity

Activity

[0248] An antibody variant that is useful for binding to tumor tissue through a binding interaction with an extracellular RNA-protein complex and/or for inducing an immune response, including an antitumor immune response, can be identified using various assays. In a preferred embodiment, the binding target of tumor binding antibodies as described herein is present extracellularly in tumor cells when grown in vivo , but is not present extracellularly in tumor cells grown under standard in vitro culture conditions. Therefore, binding assays to evaluate the activity of variants are performed on tumor tissues or tumor cells ex vivo , for example, on tumor cells that have been grown as tumor grafts in syngeneic (immune system-similar) mice in vivo , then collected and processed for 24- 48 hours. Binding can be assessed by any number of methods, including flow cytometry. However, in the present application, a tumor-binding antibody, if presented in a format that includes an Fc region that binds to FcγRIIa, also has the ability to interact with FcγRIIa. In one assay, variant binding activity is assessed in an Fc receptor interaction assay. For the purpose of variant testing, Fc receptor "interaction" occurs when the variant antibody binds to both the target tumor cell through its Fv region and the FcγR present on the immune cell through the Fc region of the antibody so as to transduce a signal. If the Fc region remains constant among variants that differ in their Fv regions, then the assay allows the tumor binding activity of such variants to be assessed in the context of potential signal transduction through a particular Fc region binding a particular Fc receptor. In some embodiments, binding of the Fc region of an antibody may result in clustering and/or internalization of the FcR, resulting in the generation of a luminescence signal in cells harboring the NFAT-RE-luciferase reporter construct.

[0249] In a preferred assay, the binding activity of the antibody variant is assessed using ex vivo tumor cells as described above in the FcγRIIa interaction assay. In certain embodiments, binding of an antibody to both its target and the FcγR results in the generation of a signal. In such an assay, EC ₅₀ values are determined, and in some embodiments, delta activity values are also determined, as described below. In an exemplary assay, variants can be tested using the Promega FcγRIIa-H reporter assay. Other assays are also available, for example BPS Bioscience offers a similar assay using the CD32a reporter cell line. Alternative assays involve the use of a CD16a reporter cell line and are available from either Promega or Invivogen.

[0250] The following assay is preferably used to measure the binding activity of antibodies that specifically bind to a tumor expressed target and activate FcγRIIa. This FcγRIIa-H ADCP assay, available from Promega, uses Jurkat cells stably expressing human FcγRIIa-H (H131 high affinity variant) and NFAT-induced luciferase. Upon interaction of FcγRs in Jurkat effector cells with the Fc region of a test antibody binding to a target cell, intracellular signals are generated in Jurkat cells that lead to NFAT-RE-mediated luciferase activity that can be quantified. The analysis used to analyze the options is detailed in the Detailed Methodology section below. The analysis can be performed as described in more detail below.

[0251] Binding activity is assessed by determining EC ₅₀ values and, in some embodiments, additionally determining delta activity, i.e., the difference in specific activity between the lower and upper plateau of the activation curve, expressed as the percentage of activity of the selected antibody having a known in vitro activity (see also Example 8). In typical embodiments, EC ₅₀ values are compared to a reference antibody. For purposes of this invention, an antibody comprising the V _H and V _L regions of AIP-160470 and the Fc region of mouse IgG2a, when tested ex vivo using a mouse tumor model, is used as the reference antibody and is included in the assay to evaluate the activity of the variants relative to the reference antibody. The EC ₅₀ is calculated by dividing the EC ₅₀ of the reference antibody by the EC ₅₀ of the test antibody. Based on the obtained values, the antibodies were divided into groups and rated from 0 to 4 as follows: 0=(> 500 nM); 1=<0.5; 2=0.5 to 2; 3=2 to 4; 4 => 4.

[0252] The protocol for each stage is presented below.

Inoculation and growth of EMT6 tumors in Balb/c mice in vivo

1. Suspend EMT6 cells in Waymouth medium without FBS to achieve a concentration of 5 x 10 ⁶ cells/ml

a. 1 T225 cell culture flask will yield approximately 18-24×10 ⁶ viable cells

2. Keep cells on ice until the end of the procedure.

3. Anesthetize 8-week-old female BALB/c mice using isoflurane inhalation.

Using a 1 ml syringe with a 25G needle, subcutaneously inject 200 µl of cell suspension (1 x 10 ⁶ cells total) into the shaved left flank of the mouse, ensuring that cells are not lost due to backflow into the syringe or leakage from the injection site during injection .

5. After inoculation, check cell number and viability

a. Should be in the 10% window

6. Monitor tumor growth with calipers

Collect EMT6 tumors and prepare ex vivo cell bank

1. Collect tumors as soon as they reach 500-800 mm ³ when measured with a caliper

2. Remove all surrounding skin and muscle

3. Transfer tumors to RPMI on ice containing 1/500 dilution of primocin (100 μg/ml) 4. (Tumors can be pooled and volumes increased proportionally)

5. Prepare a mixture for breaking down tumors (for 1 tumor)

A. 3.3 ml HBSS with Ca ²⁺ Mg ²⁺

b. 33 µl collagenase A (final concentration: 0.2 mg/ml)

c. 33 µl dispase II (final concentration: 0.8 mg/ml)

d. 17 µl DNase (final concentration: 0.02 mg/ml)

e. 6.6 µl primocin

f. Mix and filter through a 0.22 micron cellulose acetate filter for sterilization

6. Remove tumors from RPMI. Cut tumors into small pieces and add 1 ml of tumor digestion mixture 7. Incubate in either a capped flow cytometry tube, 15 or 50 ml screw cap tube at 37°C, rotating continuously

within 15 minutes

8. Allow the cells to settle for 30 seconds

9. Carefully remove the supernatant with a 1 ml pipette and add to 3 ml of pure FBS on ice containing

Primocin at a concentration of 100 μg/ml

10. Add another 1 ml of splitting mixture and repeat 2 times, 3 times in total

11. (you can cut off the top of the 1 ml pipette tip and use it for mechanical dissociation between

stages of cleavage)

12. After the last digestion, the cell suspension should pass through the 1 ml micropipette tip

13. Filter the collected cells in FBS through a 100 micron cell filter into a new 50 ml tube

14. Centrifuge, 300xg, 4 °C, 10 min.

15. Discard the supernatant and resuspend the cells in 1 ml of neat FBS (with 100 µg/ml primocine)

16. Count and adjust cell count to ^6x106 cells/mL using FBS (with 100 µg/mL primocine)

a. Due to debris, cell counts using the Countess II or hemocytometer may be inaccurate i. Staining of nucleated cells Draq5 1:1000 (initial concentration 5 mM) and

Counting on a flow cytometer in the APC channel is recommended

ii. Addition of DAPI at a ratio of 1:1000 allows gating of a population of nucleated cells over living cells

(Violet laser required)

1. Prepare a staining solution by adding 1 µL Draq5 (5 mM stock solution) and 1 µL

DAPI in 1 ml PBS

2. Add 40 µl of staining solution to a 96-well round bottom plate. 3. Add 10 µl of cell suspension and mix well

4. Incubate for 5 minutes at room temperature in the dark

5. Analyze the sample using flow cytometry

a. First gate Draq5 positive cells (APC channel)

b. Identify DAPI negative cells (channel BV421) within

Draq5 positive population

6.If the flow cytometer can measure the number of events/µL, you can calculate the number

cells directly (Cytflex can do this)

7. If the flow cytometer cannot measure events/µL (like most BD instruments),

you will need to add counting balls to determine the number of squares

b. Viability should be above 75%

17. Resuspend cells at a concentration of 4x10 ⁶ cells/ml with FBS (with primocine at a concentration of 100 μg/ml)

18. Add an equal amount of FBS containing 20% DMSO and 100 µg/ml primocin

19. Mix well by pipetting

20. Add 1 ml (2x10 ⁶ cells) cell suspension to cryovials and freeze at -80°C

a. Expected number of cells ~10×10 ⁶ cells/tumor

21. Transfer to long-term storage in liquid nitrogen the next day

a. Take 1 sample vial and thaw according to Ex Vivo Cell Thawing protocol b. Control cell counting

Using ex vivo EMT6 cells to analyze interactions

Ex vivo cell thawing

1. Thaw the bottle in a water bath at 37°C

2. Transfer the contents of the vial into a 50 ml conical tube

3. Add 19 ml RPMI + 2% FBS to the cells drop by drop, mixing the suspension

4. Centrifuge, 300xg, 4°C, 5 min.

5. Resuspend in 1 ml PBS+2% FBS+2 mM EDTA

6. Centrifuge, 300xg, 4°C, 5 min.

7. Resuspend in 2 ml assay buffer (RPMI1640+4% low IgG serum)

8. Resuspend in 1 ml assay buffer.

9. Count and adjust cell count to 0.5 x 10 ⁶ cells/ml in assay buffer

a. Perform cell counts as described in section C; 16a

FcγRIIa Interaction Assay (Promega, Kit #G9991)

1. Prepare serial dilutions of antibodies in assay buffer at 1.5-fold excess.

A. Total analysis volume 75 µl

b. Initial concentration 10 ^-6 M

c. logarithmic dilutions on a 6-point dose-response curve in triplicate

2. Add 25 µl of antibody dilution to a white 96-well flat bottom plate.

A. use only the inner 60 wells

b. Fill unused wells with 75 µl assay buffer

3. Add 25 µl ex vivo cells to each well containing the antibody dilution

a. Gently tap the plate to mix the cells with the antibody

4. Incubate for 15 minutes at 37°C, 5% CO ₂ .

5. Thaw a vial of FcγRIIa-H effector cells (0.62 ml) (Promega, kit 3G991) in a water bath at 37 °C

a. Remove the bottle from 37°C as soon as it is thawed

6. Transfer the contents of the vial to a conical tube containing 5.3 ml of assay buffer

7. Mix by inverting the test tube 4-5 times

8. Count and adjust the number of cells to 0.5×10 ⁶ cells/ml

a. Cell counting can be done using a conventional cytometer or hemocytometer 9. Add 25 µl of FcγRIIa-H effector cells to the opsonized target cells.

a. E:T ratio 1:1

10. Gently shake the plates to mix the contents (total volume 75 µl)

11. Incubate 5 hours at 37 °C, 5% CO ₂

12. After 5 hours, prepare Bio-Glo Luciferase Solution by adding a whole vial of Bio-Glo™

Bio-Glo Luciferase Assay Substrate Assay Buffer (10 mL total per kit).

13. Remove the plate from the incubator

14. Add 75 µl of Bio-Glo™ mixture to each reaction well

15. Incubate at room temperature in the dark for 15 minutes

16. Measure luminescence using a suitable tablet reader

17. Plot curves and calculate EC ₅₀ values

Reagents and buffers

Complete environment for EMT6 (Normal Growth Media, NGM)

Waymouth MB 752/1 + 2 mM L-glutamine + 15% fetal bovine serum (FBS) + 1% penicillin-streptomycin

Analysis buffer

RPMI1640+4% low IgG fetal bovine serum (FBS)

Collagenase A (Sigma-Aldrich, No. 10103586001)

1. Add HBSS with Ca ²⁺ Mg ²⁺ to obtain a stock solution with a concentration of 50 mg/ml

2. Invert the test tube several times

3. Incubate for 5 minutes at room temperature

4. Add to a 1.5 ml snap cap tube

5. Store at -20°C for up to a month

6. Avoid repeating freeze/thaw cycles

Dispase II (Sigma-Aldrich, No. D4693-1G)

1. Dilute 1 g dispase II in 10 ml water, molecular biology grade, with 10 mM

Sodium acetate (pH 7.5) and 5 mM calcium acetate

2. Invert the test tube several times

3. Incubate 60 minutes at room temperature

4. Add to a 1.5 ml snap cap tube

5. Store at 4°C for up to a month

DNase (Sigma-Aldrich, no. 4536282001)

1. Add HBSS with Ca ²⁺ Mg ²⁺ to obtain a stock solution with a concentration of 2 mg/ml

2. Invert the test tube several times

3. Incubate for 5 minutes at room temperature

4. Add to a 1.5 ml snap cap tube

5. Store at -20°C for up to 7 days

6. Avoid repeating freeze/thaw cycles

[0253] The antibody can also be tested for antitumor function in vivo using an in vivo assay as described in the EXAMPLES section. An antibody variant described herein typically has at least 50%, or at least 60%, or 70% or more of the antitumor activity of a reference antibody, as shown in Table 1, when evaluated under the same assay conditions for measuring antitumor activity. activity in vivo . In some embodiments, the antitumor antibody exhibits improved activity, i.e. activity is more than 100% compared to the reference antibody.

Target binding antibody

[0254] In one aspect, this document provides an antitumor antibody that binds to tumor tissue. In some embodiments, the antibody of the present invention targets an extracellular RNA-protein complex that contains mRNA and further contains an mRNA binding protein. In typical embodiments, the tumor-binding antibody binds through a binding interaction to an extracellular RNA-protein complex. In some embodiments, the RNA-protein complex comprises polyadenylated RNA. In some embodiments, the RNA-protein complex comprises mRNA. Such a complex may also contain other types of RNA, such as ribosomal RNA and/or microRNA and/or long non-coding RNA. In some embodiments, the RNA-protein complex comprises polyadenylated RNA and/or pre-mRNA. In some embodiments, the antibody binds directly to an RNA-binding protein present in the RNA-protein complex. In other embodiments, the antibody may bind a protein that interacts with an RNA-binding protein. In other embodiments, the binding of the antibody to the protein is dependent on RNA. In some embodiments, the antibody can simultaneously bind RNA and protein. In some embodiments, the antibody may bind to RNA. In other embodiments, binding of an antibody to RNA may depend on one or more RNA binding proteins associated with the RNA, or depend on multiple RNA binding proteins in a protein complex.

[0255] In some embodiments, an antitumor antibody provided herein binds to an extracellular RNA-protein complex that contains one, two, three, or more proteins listed in Table 3. In some embodiments, the extracellular RNA-protein complex includes a member family of polyadenylate binding proteins, as further described below. In some embodiments, the extracellular RNA-protein complex contains a member of the polyadenylate binding protein family and additional proteins, such as one or more proteins listed in Table 3. In some embodiments, the antibody binds to a protein listed in Table 3. In some embodiments, the protein is is an RNA binding protein, such as a member of the polyadenylate binding protein family, as further described below. In some embodiments, a tumor-binding antibody provided herein binds to an extracellular RNA-protein complex that includes one or more proteins selected from the following:

ABCF1, ACIN1, ACLY, ADAR, AGO1, AGO2, AGO3, AHNAK, ATP2A2, ATXN2, BAG2, BOP1, BUB3, CAD, CASC3, CDC5L, CELF1, CLTA, CNBP, COPA, CRNKL1, DARS, DDX17, DDX18, DDX21, DDX5, DDX54, DDX6, DHX15, DHX30, DHX36, DHX57, DHX9, DICER1, DKC1, DNTTIP2, EDC4, EEF1D, EEF2, EFTUD2, EIF2AK2, EIF2S1, EIF3D, EIF3E, EIF3I, EIF4A3, EIF4G1, EIF6 ,ELAVL1,EPRS, FAM120A, FBL, FMR1, FTSJ3, FUBP3, FUS, FXR1, FXR2, GAR1, GEMIN4, GNL3, GRSF1, GTPBP4, HEATR1, HIST1H1B, HIST1H1C, HIST1H3A, HNRNPA0, HNRNPA1, HNRNPA2B1, HNRNPA3, HNRNPAB, HNRNPC, HNRNPD, HNRNPDL, HNRNPF, HNRNPH1, HNRNPH3, HNRNPK, HNRNPL, HNRNPM, HNRNPR, HNRNPUL1, HNRNPUL2, IGF2BP1, IGF2BP2, IGF2BP3, ILF2, ILF3, KARS, KHDRBS1, L1RE1, LARP1, MAGOHB, MAK16, MAP1B, MATR3, MBNL1, MOV10 MRTO4 MVP, MYBBP1A, MYO1B, NAT10, NCL, NHP2, NIFK, NKRF, NOL11, NOL6, NOP2, NOP56, NOP58, PABPC1, PABPC4, PCBP2, PDCD11, PES1, PGD, PLEC, PPP1CB, PRKDC, PRKRA, PRPF19, PRPF4B, PRPF8, PRRC2C, PTBP1, PTBP3, PUM1, PURA, PURB, PWP1, PWP2, RAB14, RAB2A, RACK1, RALY, RAN, RBM14, RBM34, RBM4, RBM45, RBM8A, RBMX, RCC2, RPL10A, RPL11, RPL12, RPL13A, RPL14, RPL15, RPL17, RPL18, RPL18A, RPL19, RPL21, RPL22, RPL23, RPL23A, RPL24, RPL26, RPL27, RPL29, RPL3, RPL30, RPL32, RPL34, RPL35A, RPL36, RPL4, RPL5, RPL6, RPL7, RPL7A , RPL8, RPLP0, RPLP1, RPLP2, RPS11, RPS13, RPS17, RPS23, RPS24, RPS26, RPS27A, RPS3, RPS3A, RPS5, RPS6, RPS8, RPS9, RPSA, RRBP1, RRP1, RRP9, RRS1, RSL1D1, RTCB, RUVBL2, RYDEN, SART3, SF3B3, SKIV2L2, SLC3A2, SND1, SNRNP200, SNRNP70, SNRPB, SNRPD1, SNRPD2, SNRPD3, SON, SRP68, SRP72, SRPK1, SRPK2, SRRM2, SRSF1, SRSF10, SRSF2, SRSF3, SRSF6, SRSF7 ,SRSF9, SSB, STAU1, STAU2, STRAP, SYNCRIP, TARBP2, TARDBP, TCOF1, TCP1, THOC2, THOC6, TNRC6A, TOP1, TRA2A, TRA2B, TRIM25, TRIM56, TTN, U2AF2, UGDH, UPF1, UTP15, UTP18, UTP4, UTP6, WDR12, WDR36, WDR43, WDR46, WDR74, WDR75, XAB2, XRCC5, XRN2, YBX1, YBX3, YTHDC2, ZC3H7A, ZC3HAV1, ZCCHC3 and ZNF326.

[0256] In some embodiments, the polyadenylate binding protein family member is polyadenylate binding protein 1, also referred to as poly(A) binding protein 1 (PABP-1), and an RNA, e.g., poly(A)-containing RNA. PABP-1 binds to the 3' poly(A) tail of mRNA and is highly conserved among eukaryotic organisms. PABP-1 is encoded by the cytoplasmic poly(A) binding protein 1 (PABPC1) gene (see, for example, the human PABPC1 gene sequence available in RefSeq from NCBI under accession number NM_002568.4). For purposes of the present invention, "PABPC1" is used interchangeably with "PABP-1" in relation to the polypeptide. Sequence information for the human PABPC1 polypeptide is available under UniProtKB accession number P11940. Two isoforms obtained by alternative splicing have been described. Isoform 1 is considered the canonical sequence and is 636 amino acids long (see, for example, available in RefSeq from NCBI under accession number NP_002559.2). Isoform 2 differs from the canonical sequence by the absence of amino acids 447-553. As used herein, the term “human PABPC1 polypeptide” includes any PABPC1 polypeptide encoded by the human PABPC1 gene, which is located on human chromosome 8q22.2-q23.

[0257] In some embodiments, provided herein is an antibody that targets a complex that contains RNA, PABPC1, and/or additional RNA-binding proteins to elicit an immune response and/or an antitumor response. Illustrative examples of additional RNA-binding proteins that may be contained in such complexes include members of the PABP family, such as PABP-4 (also called PABPC4). In some embodiments, the complex may contain one or more proteins selected from the group consisting of the proteins listed in Table 3. In some embodiments, one or more proteins are RNA-binding proteins.

[0258] In some embodiments, the complex that contains RNA and PABPC1, or RNA and PABPC1 and/or additional RNA-binding proteins, is a component of a ribonucleoprotein (RNP)-RNA condensate, which is a large disordered configuration of denatured RNPs that form nonspecific association with each other and the RNA to form a large clump that phase separates to form distinct droplets (see, e.g., Hyman et al., Annu Rev. Cell Dev. Biol. 30:39-58, 2014). Thus, in some embodiments, an antibody that targets the PABPC1-containing complex is administered to a patient having a tumor that contains ribonucleoprotein (RNP)-RNA condensate droplets that contain the target RNA-PABPC1 complex.

[0259] In some embodiments, the complex comprising RNA and PABPC1, or RNA and PABPC1, and/or additional RNA-binding proteins is a component of the biomolecular condensate. Biomolecular condensates are two- and three-dimensional compartments that concentrate specific collections of different molecules without an encapsulating membrane (Ditlev et al., J. Mol. Biol. 430: 4666-4684, 2018; Mullard, Nature Reviews 18:325, 2019). Thus, in some embodiments, an antibody that targets a complex containing PABPC1 is administered to a patient having a tumor that contains a biomolecular condensate containing the target RNA-PABPC1 complex.

[0260] In some embodiments, the complex comprising RNA and PABPC1, or RNA and PABPC1, and/or additional RNA-binding proteins is a component of a stress granule or otherwise forms a complex with a stress granule. As used herein, the term “stress granule” refers to a non-membrane-associated assembly or granule typically formed in the cytoplasm that enlarges following stress. In some cases, stress granules form when cells shut down general protein synthesis in response to stress, for example by inhibiting translation and releasing mRNA from disassembled polysomes into discrete cytoplasmic foci. Stress granules may contain matrix ribonucleoproteins (mRNPs), including mRNA, small 40S ribosomal subunits, mRNA-associated translation inhibition complexes, and RNA-binding proteins. These stress granule proteins can determine the fate of specific transcripts that move in and out of stress granules, as well as modulate various signaling cascades in stressed cells. PABPC1 is one of the proteins that have been identified in stress granules (Aulas et al. , J. of Cell Science , 130: 927-937, 2017). Thus, in some embodiments, an antibody that targets the PABPC1-containing complex is administered to a patient having a tumor that contains stress granules containing the target RNA-PABPC1 complex.

[0261] In some embodiments, the droplet of ribonucleoprotein (RNP)-RNA condensate, stress granule, and/or biomolecular condensate containing the target RNA-PABPC1 complex contains one or more proteins selected from Table 3. In some embodiments, the stress granules contain one or more stress granule proteins selected from proteins in groups 1, 2, 3, or 4 in Table 3.

[0262] In some embodiments, the ribonucleoprotein (RNP)-RNA condensate droplet, stress granule, and/or biomolecular condensate containing the target RNA-PABPC1 complex further comprises one or more oncofetal proteins. Non-limiting examples of oncofetal proteins include IGF2BP1 and IGF2BP3.

[0263] In some embodiments, the ribonucleoprotein (RNP)-RNA condensate droplet, stress granule, and/or biomolecular condensate containing the target RNA-PABPC1 complex further comprises a cancer antigen, such as testicular cancer antigen. One exemplary testicular cancer antigen is IGF2BP2.

[0264] In some embodiments, a complex that contains RNA and PABPC1, or RNA and PABPC1, and/or additional RNA-binding proteins is found outside cells, such as a ribonucleoprotein (RNP)-RNA condensate droplet, bead, and/or biomolecular condensate (as described above), containing or associated with the target RNA-PABPC1 complex, is found outside the cell. Thus, in some embodiments, an antibody that targets a complex containing PABPC1 is administered to a patient having a tumor that has an extracellular complex containing the target RNA-PABPC1 complex. In some embodiments, the patient is a mammal, such as a human.

[0265] In a further aspect, provided herein is an antibody, for example, having antitumor activity, that targets an RNA-protein complex that contains poly(A+) binding protein (PABP) closely associated with PABPC1. Such RNA-binding proteins are described, for example, in Eliseeva et al., Biochemistry 78:1377-1391, 2013. These include six human poly(A+)-binding proteins, which can be grouped as follows: cytoplasmic (PABPC3, PABPC4, PABPC4L (and PABPC1)), embryonic (ePABP, also called PABPC1L), nuclear (PABPN1), and the X chromosome-encoded protein PABPC5. The gene encoding ePABP (also called PABPC1L) is located on human chromosome 20. The PABPC1L protein has approximately 98% homology with PABPC1. The gene encoding PABPC3 is localized at 13q12-q13. The PABC3 protein (631 amino acids) has approximately 100% homology with the PABPC1 protein (636 amino acids). The gene encoding PABPC4 (three isoforms are known) is located at 1p34.2. All three isoforms of PABPC4 share approximately 99% homology with PABPC1. The gene encoding PABC4L is located on 4q28.3. The PABC4L protein has approximately 63% homology with PABPC1. The gene encoding PABPN1 is located on 14q11.2. The PABPN1 protein has approximately 30% homology with PABPC1. The gene encoding PABPC5 is located in Xq21.3. The PABPC5 protein has approximately 61% homology with PABPC1. The domain structure of these proteins includes one or more RNA recognition motifs. Cytoplasmic PABPs have four such domains, usually in the N-terminal region. The C-terminal region of PABPC1, PABPC1L, PABPC3, and PABC4 contains a coiled-coil domain consisting of five α-helices. The nuclear protein PABPN1 has only one RNA recognition motif.

RNA-PABPC4 complexes

[0266] In some embodiments, provided herein is an antibody that targets a complex that contains RNA and PABPC4 to induce an antitumor response. In some embodiments, the complex contains additional RNA-binding proteins. In some embodiments, the complex is a component of a ribonucleoprotein (RNP)-RNA condensate. Thus, in some embodiments, an antibody that targets a PABPC4-containing complex is administered to a patient having a tumor that contains ribonucleoprotein (RNP)-RNA condensate droplets that contain the target RNA-PABPC4 complex.

[0267] In some embodiments, the complex containing RNA and PABPC4, which may further contain additional RNA-binding proteins, is a component of the biomolecular condensate. Thus, in some embodiments, an antibody that targets a complex containing PABPC4 is administered to a patient having a tumor that contains a biomolecular condensate that contains the target RNA-PABPC4 complex.

[0268] In some embodiments, the complex containing RNA and PABPC4, which may further contain additional RNA-binding proteins, is a component of a stress granule or otherwise forms a complex with a stress granule. Thus, in some embodiments, an antibody that targets a complex containing PABPC4 is administered to a patient having a tumor that contains stress granules containing the target RNA-PABPC4 complex.

[0269] In some embodiments, the droplet of ribonucleoprotein (RNP)-RNA condensate, stress granule, and/or biomolecular condensate containing the target RNA-PABPC4 complex contains one or more proteins selected from Table 5. In some embodiments, the stress granules contain one or more stress granule proteins selected from proteins in groups 1, 2, 3, or 4 in Table 5.

[0270] In some embodiments, the ribonucleoprotein (RNP)-RNA condensate droplet, stress granule, and/or biomolecular condensate containing the target RNA-PABPC4 complex further comprises one or more oncofetal proteins. Non-limiting examples of oncofetal proteins include IGF2BP1 and IGF2BP3.

[0271] In some embodiments, the droplet of ribonucleoprotein (RNP)-RNA condensate, stress bead, and/or biomolecular condensate containing the target RNA-PABPC4 complex further comprises a cancer antigen, such as testicular cancer antigen. One exemplary testicular cancer antigen is IGF2BP2.

[0272] In some embodiments, a complex that contains RNA and PABPC4, which may further contain additional RNA-binding proteins, is found outside cells, such as a droplet of ribonucleoprotein (RNP)-RNA condensate, bead, and/or biomolecular condensate (as described above ), containing or associated with the target RNA-PABPC4 complex, is found outside the cells. Thus, in some embodiments, an antibody that targets a complex containing PABPC4 is administered to a patient having a tumor that has an extracellular complex containing the target RNA-PABPC4 complex. In some embodiments, the patient is a mammal, such as a human.

RNA-PABPC3 complexes

[0273] In some embodiments, provided herein is an antibody that targets a complex that contains RNA and PABPC3 to induce an antitumor response. In some embodiments, the complex contains additional RNA-binding proteins. In some embodiments, the complex is a component of a ribonucleoprotein (RNP)-RNA condensate. Thus, in some embodiments, an antibody that targets a PABPC3-containing complex is administered to a patient having a tumor that contains ribonucleoprotein (RNP)-RNA condensate droplets that contain the target RNA-PABPC3 complex.

[0274] In some embodiments, the complex containing RNA and PABPC3, which may further contain additional RNA-binding proteins, is a component of the biomolecular condensate. Thus, in some embodiments, an antibody that targets a complex containing PABPC3 is administered to a patient having a tumor that contains a biomolecular condensate containing the target RNA-PABPC3 complex.

[0275] In some embodiments, the complex containing RNA and PABPC3, which may further contain additional RNA-binding proteins, is a component of a stress granule or otherwise forms a complex with a stress granule. Thus, in some embodiments, an antibody that targets a complex containing PABPC3 is administered to a patient having a tumor that contains stress granules containing the target RNA-PABPC3 complex.

[0276] In some embodiments, the droplet of ribonucleoprotein (RNP)-RNA condensate, stress granule, and/or biomolecular condensate containing the target RNA-PABPC3 complex contains one or more proteins selected from Table 5. In some embodiments, the stress granules contain one or more stress granule proteins selected from proteins in groups 1, 2, 3, or 4 in Table 5.

[0277] In some embodiments, the ribonucleoprotein (RNP)-RNA condensate droplet, stress granule, and/or biomolecular condensate containing the target RNA-PABPC3 complex further comprises one or more oncofetal proteins. Non-limiting examples of oncofetal proteins include IGF2BP1 and IGF2BP3.

[0278] In some embodiments, the ribonucleoprotein (RNP)-RNA condensate droplet, stress granule, and/or biomolecular condensate containing the target RNA-PABPC3 complex further comprises a cancer antigen, such as testicular cancer antigen. One exemplary testicular cancer antigen is IGF2BP2.

[0279] In some embodiments, a complex that contains RNA and PABPC3, which may further contain additional RNA-binding proteins, is found outside cells, such as a ribonucleoprotein (RNP)-RNA condensate droplet, bead, and/or biomolecular condensate (as described above ), containing or associated with the target RNA-PABPC3 complex, is found outside the cells. Thus, in some embodiments, an antibody that targets a complex containing PABPC3 is administered to a patient having a tumor that has an extracellular complex containing the target RNA-PABPC3 complex. In some embodiments, the patient is a mammal, such as a human.

RNA-PABPC4L complexes

[0280] In some embodiments, provided herein is an antibody that targets a complex that contains RNA and PABPC4L to induce an antitumor response. In some embodiments, the complex contains additional RNA-binding proteins. In some embodiments, the complex is a component of a ribonucleoprotein (RNP)-RNA condensate. Thus, in some embodiments, an antibody that targets the PABPC4L-containing complex is administered to a patient having a tumor that contains ribonucleoprotein (RNP)-RNA condensate droplets that contain the target RNA-PABPC4L complex.

[0281] In some embodiments, the complex containing RNA and PABPC4L, which may further contain additional RNA-binding proteins, is a component of the biomolecular condensate. Thus, in some embodiments, an antibody that targets a complex containing PABPC4L is administered to a patient having a tumor that contains a biomolecular condensate containing the target RNA-PABPC4L complex.

[0282] In some embodiments, the complex containing RNA and PABPC4L, which may further contain additional RNA-binding proteins, is a component of a stress granule or otherwise forms a complex with a stress granule. Thus, in some embodiments, an antibody that targets the PABPC4L-containing complex is administered to a patient having a tumor that contains stress granules that contain the target RNA-PABPC4L complex.

[0283] In some embodiments, the droplet of ribonucleoprotein (RNP)-RNA condensate, stress granule, and/or biomolecular condensate containing the target RNA-PABPC4L complex contains one or more proteins selected from Table 5. In some embodiments, the stress granules contain one or more stress granule proteins selected from proteins in groups 1, 2, 3, or 4 in Table 5.

[0284] In some embodiments, the ribonucleoprotein (RNP)-RNA condensate droplet, stress granule, and/or biomolecular condensate containing the target RNA-PABPC4L complex further comprises one or more oncofetal proteins. Non-limiting examples of oncofetal proteins include IGF2BP1 and IGF2BP3.

[0285] In some embodiments, the ribonucleoprotein (RNP)-RNA condensate droplet, stress granule, and/or biomolecular condensate containing the target RNA-PABPC4L complex further comprises a cancer antigen, such as testicular cancer antigen. One exemplary testicular cancer antigen is IGF2BP2.

[0286] In some embodiments, a complex that contains RNA and PABPC4L, which may further contain additional RNA-binding proteins, is found outside cells, such as a ribonucleoprotein (RNP)-RNA condensate droplet, bead, and/or biomolecular condensate (as described above ), containing or associated with the target RNA-PABPC4L complex, is found outside the cells. Thus, in some embodiments, an antibody that targets a complex containing PABPC4L is administered to a patient having a tumor that has an extracellular complex containing the target RNA-PABPC4L complex. In some embodiments, the patient is a mammal, such as a human.

RNA-ePABP complexes

[0287] In some embodiments, provided herein is an antibody that targets a complex that contains RNA and ePABP to induce an antitumor response. In some embodiments, the complex contains additional RNA-binding proteins. In some embodiments, the complex is a component of a ribonucleoprotein (RNP)-RNA condensate. Thus, in some embodiments, an antibody that targets the ePABP-containing complex is administered to a patient having a tumor that contains ribonucleoprotein (RNP)-RNA condensate droplets that contain the target RNA-ePABP complex.

[0288] In some embodiments, the complex containing RNA and ePABP, which may further contain additional RNA-binding proteins, is a component of the biomolecular condensate. Thus, in some embodiments, an antibody that targets a complex containing ePABP is administered to a patient having a tumor that contains a biomolecular condensate containing the target RNA-ePABP complex.

[0289] In some embodiments, the complex comprising RNA and ePABP, which may further contain additional RNA-binding proteins, is a component of a stress granule or is otherwise complexed with a stress granule. Thus, in some embodiments, an antibody that targets a complex containing ePABP is administered to a patient having a tumor that contains a biomolecular condensate containing the target RNA-ePABP complex.

[0290] In some embodiments, the droplet of ribonucleoprotein (RNP)-RNA condensate, stress granule, and/or biomolecular condensate containing the target RNA-ePABP complex contains one or more proteins selected from Table 5. In some embodiments, the stress granules contain one or more stress granule proteins selected from proteins in groups 1, 2, 3, or 4 in Table 5.

[0291] In some embodiments, the ribonucleoprotein (RNP)-RNA condensate droplet, stress granule, and/or biomolecular condensate containing the target RNA-ePABP complex further comprises one or more oncofetal proteins. Non-limiting examples of oncofetal proteins include IGF2BP1 and IGF2BP3.

[0292] In some embodiments, the ribonucleoprotein (RNP)-RNA condensate droplet, stress granule, and/or biomolecular condensate containing the target RNA-ePABP complex further comprises a cancer antigen, such as testicular cancer antigen. One exemplary testicular cancer antigen is IGF2BP2.

[0293] In some embodiments, a complex that contains RNA and ePABP, which may further contain additional RNA-binding proteins, is found outside cells, such as a ribonucleoprotein (RNP)-RNA condensate droplet, bead, and/or biomolecular condensate (as described above ), containing or associated with the target RNA-ePABP complex, is found outside the cells. Thus, in some embodiments, an antibody that targets a complex containing ePABP is administered to a patient having a tumor that has an extracellular complex containing the target RNA-ePABP complex. In some embodiments, the patient is a mammal, such as a human.

RNA-PABPN1 complexes

[0294] In some embodiments, provided herein is an antibody that targets a complex that contains RNA and PABPN1 to induce an antitumor response. In some embodiments, the complex contains additional RNA-binding proteins. In some embodiments, the complex is a component of a ribonucleoprotein (RNP)-RNA condensate. Thus, in some embodiments, an antibody that targets the PABPN1-containing complex is administered to a patient having a tumor that contains ribonucleoprotein (RNP)-RNA condensate droplets that contain the target RNA-PABPN1 complex.

[0295] In some embodiments, the complex containing RNA and PABPN1, which may further contain additional RNA-binding proteins, is a component of the biomolecular condensate. Thus, in some embodiments, an antibody that targets a complex containing PABPN1 is administered to a patient having a tumor that contains a biomolecular condensate containing the target RNA-PABPN1 complex.

[0296] In some embodiments, the complex containing RNA and PABPN1, which may further contain additional RNA-binding proteins, is a component of a stress granule or otherwise forms a complex with a stress granule. Thus, in some embodiments, an antibody that targets the PABPN1-containing complex is administered to a patient having a tumor that contains stress granules that contain the target RNA-PABPN1 complex.

[0297] In some embodiments, the droplet of ribonucleoprotein (RNP)-RNA condensate, stress granule, and/or biomolecular condensate containing the target RNA-PABPN1 complex contains one or more proteins selected from Table 5. In some embodiments, the stress granules contain one or more stress granule proteins selected from proteins in groups 1, 2, 3, or 4 in Table 5.

[0298] In some embodiments, the ribonucleoprotein (RNP)-RNA condensate droplet, stress granule, and/or biomolecular condensate containing the target RNA-PABPN1 complex further comprises one or more oncofetal proteins. Non-limiting examples of oncofetal proteins include IGF2BP1 and IGF2BP3.

[0299] In some embodiments, the ribonucleoprotein (RNP)-RNA condensate droplet, stress granule, and/or biomolecular condensate containing the target RNA-PABPN1 complex further comprises a cancer antigen, such as testicular cancer antigen. One exemplary testicular cancer antigen is IGF2BP2.

[0300] In some embodiments, a complex that contains RNA and PABPN1, which may further contain additional RNA-binding proteins, is found outside cells, such as a ribonucleoprotein (RNP)-RNA condensate droplet, bead, and/or biomolecular condensate (as described above ), containing or associated with the target RNA-PABPN1 complex, is found outside the cells. Thus, in some embodiments, an antibody that targets a complex containing PABPN1 is administered to a patient having a tumor that has an extracellular complex containing the target RNA-ePABP complex. In some embodiments, the patient is a mammal, such as a human.

RNA-PABPC5 complexes

[0301] In some embodiments, provided herein is an antibody that targets a complex that contains RNA and PABPC5 to induce an antitumor response. In some embodiments, the complex contains additional RNA-binding proteins. In some embodiments, the complex is a component of a ribonucleoprotein (RNP)-RNA condensate. Thus, in some embodiments, an antibody that targets a PABPC5-containing complex is administered to a patient having a tumor that contains ribonucleoprotein (RNP)-RNA condensate droplets that contain the target RNA-PABPC5 complex.

[0302] In some embodiments, the complex containing RNA and PABPC5, which may further contain additional RNA-binding proteins, is a component of the biomolecular condensate. Thus, in some embodiments, an antibody that targets a complex containing PABPC5 is administered to a patient having a tumor that contains a biomolecular condensate containing the target RNA-PABPC5 complex.

[0303] In some embodiments, the complex containing RNA and PABPC5, which may further contain additional RNA-binding proteins, is a component of a stress granule or otherwise forms a complex with a stress granule. Thus, in some embodiments, an antibody that targets a complex containing PABPC5 is administered to a patient having a tumor that contains stress granules that contain the target RNA-PABPC5 complex.

[0304] In some embodiments, the droplet of ribonucleoprotein (RNP)-RNA condensate, stress granule, and/or biomolecular condensate containing the target RNA-PABPC5 complex contains one or more proteins selected from Table 5. In some embodiments, the stress granules contain one or more stress granule proteins selected from proteins in groups 1, 2, 3, or 4 in Table 5.

[0305] In some embodiments, the ribonucleoprotein (RNP)-RNA condensate droplet, stress granule, and/or biomolecular condensate containing the target RNA-PABPC5 complex further comprises one or more oncofetal proteins. Non-limiting examples of oncofetal proteins include IGF2BP1 and IGF2BP3.

[0306] In some embodiments, the ribonucleoprotein (RNP)-RNA condensate droplet, stress granule, and/or biomolecular condensate containing the target RNA-PABPC5 complex further comprises a cancer antigen, such as testicular cancer antigen. One exemplary testicular cancer antigen is IGF2BP2.

[0307] In some embodiments, a complex that contains RNA and PABPC5, which may further contain additional RNA-binding proteins, is found outside cells, such as a droplet of ribonucleoprotein (RNP)-RNA condensate, bead, and/or biomolecular condensate (as described above ), containing or associated with the target RNA-PABPC5 complex, is found outside the cells. Thus, in some embodiments, an antibody that targets a complex containing PABPC5 is administered to a patient having a tumor that has an extracellular complex containing the target RNA-PABPC5 complex. In some embodiments, the patient is a mammal, such as a human.

RNA-PABP vaccines

[0308] In some embodiments, a complex comprising RNA and one or more RNA-binding proteins, such as PABP, such as one or more of PABC1, PABPC3, PABPC4, PABC4L, ePABP, PABPN1, and/or PABPC5, is administered as an anticancer component vaccines. In some embodiments, such a complex is administered in conjunction with an immunomodulatory agent, such as an adjuvant. Examples of immunomodulatory agents include, but are not limited to, cytokines, growth factors, lymphotoxins, tumor necrosis factor (TNF), hematopoietic factors, interleukins (eg, interleukin-1 (IL-1), IL-2, IL-3, IL-1 6, IL-10, IL-12, IL-15, IL-15/IL-15Rα, e.g., sushi domain complex, IL-18 and IL-21), colony-stimulating factors (e.g., granulocyte colony-stimulating factor (G- CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), interferons (eg, interferon-α, -β, or -γ), erythropoietin and thrombopoietin, or a combination thereof. In some embodiments, the complex may be co-administered with an adjuvant, such as an agonist Toll-like receptor (TLR), C-type lectin receptor (CLR) agonist, retinoic acid inducible gene product-like receptor (RLR) agonists, saponin, polysaccharide such as chitin, chitosan, β-glucan, ISCOM, QS -21, stimulator of interferon genes (STING) agonist or other immune stimulating agent.

Antibody formats

[0309] In a further aspect of the invention, an antitumor antibody according to the invention may be an antibody fragment, for example, an Fv, Fab, Fab', scFv, diabody or F(ab') ₂ fragment. In another embodiment, the antibody is a substantially full-length antibody, such as an IgG antibody or other class or isotype of antibodies as defined herein. For a review of some antibody fragments, see Hudson et al. Nat. Med. 9: 129-134 (2003). Antibody fragments can be produced by various methods, including, but not limited to, proteolytic cleavage of the intact antibody, as well as production using recombinant host cells.

[0310] In some embodiments, the antitumor antibody of the present invention that is administered to a patient is an IgG of the IgG1 subclass. In some embodiments, such an antibody has a lambda light chain constant region.

[0311] In some embodiments, the antitumor antibody of the present invention is in a monovalent format. In some embodiments, the antitumor antibody is in fragment format, such as an Fv, Fab, Fab', scFv, diabody, or F(ab') _{2 fragment} .

[0312] In some embodiments, an antibody of the present invention contains an Fc region that performs an effector function, such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and/or complement-dependent cytotoxicity (CDC). In some embodiments, the Fc region may be an Fc region designed to alter one or more functional properties of the antibody, such as serum half-life, complement fixation, Fc receptor binding, and/or ADCC. Accordingly, the Fc region may contain additional mutations to increase or decrease effector functions, that is, the ability to induce certain biological functions upon binding to an Fc receptor expressed on an immune cell. Immune cells include, but are not limited to, monocytes, macrophages, neutrophils, dendritic cells, eosinophils, mast cells, platelets, B cells, large granular lymphocytes, Langerhans cells, natural killer (NK) cells, and cytotoxic T cells.

[0313] Examples of antibody effector functions include, but are not limited to, C1q and CDC binding, Fc receptor binding (eg, FcγR binding); ADCC, antibody-dependent cell-mediated phagocytosis (ADCP), reduction in cell surface receptors (eg, B-cell receptor) and B-cell activation. Effector functions may vary depending on the class of antibodies. For example, native human IgG1 and IgG3 antibodies can induce ADCC and CDC activities upon binding to a suitable Fc receptor present on a cell of the immune system; and native human IgG1, IgG2, IgG3 and IgG4 can induce ADCP functions upon binding to the appropriate Fc receptor present on the immune cell.

[0314] In some embodiments, the Fc region described herein may include additional modifications that modulate effector function. Examples of Fc region amino acid mutations that modulate effector function include, but are not limited to, one or more substitutions at positions 228, 233, 234, 235, 236, 237, 238, 239, 243, 265, 269, 270, 297, 298 , 318, 326, 327, 329, 330, 331, 332, 333 and 334 (EU numbering scheme) Fc areas.

[0315] Exemplary substitutions that reduce effector functions include the following: position 329 may have a mutation in which the proline is replaced by glycine or arginine or an amino acid residue large enough to disrupt the Fc/Fcγ receptor interaction interface that is formed between the Fc proline 329 and tryptophan residues Trp 87 and Trp 110 FcγRIII. Additional exemplary substitutions that reduce effector functions include S228P, E233P, L235E, N297A, N297D, and P331S. Multiple substitutions may also be present, for example, L234A and L235A of the human IgG1 Fc region; L234A, L235A and P329G regions of human IgG1 Fc; S228P and L235E Fc regions of human IgG4; L234A and G237A human IgG1 Fc regions; L234A, L235A and G237A human IgG1 Fc regions; V234A and G237A human IgG2 Fc regions; L235A, G237A and E318A human IgG4 Fc regions; and S228P and L236E Fc regions of IgG4, to reduce effector functions. Examples of substitutions that increase effector functions include, for example, E333A, K326W/E333S, S239D/I332E/G236A, S239D/A330L/I332E, F243L, G236A, and S298A/E333A/K334A. A description of amino acid mutations in the Fc region that can increase or decrease effector functions can be found, for example, in Wang et al., Protein Cell. 9(1): 63-73, 2018; Saunders, Front Immunol. Jun 7, eCollection, 2019; Kellner et al., Transfus Med Hemother. 44(5): 327-336, 2017; and Lo et al., J Biol Chem. 292(9):3900-3908, 2017.

[0316] In some embodiments, the Fc region may have one or more amino acid substitutions that modulate ADCC, for example, substitutions at positions 298, 333 and/or 334, in accordance with the EU numbering scheme. In particular, S298A, E333A and K334A can be introduced into the Fc region to increase the affinity of the Fc region for FcγRIIIa and decrease the affinity of the Fc region for FcγRIIa and FcγRIIb.

[0317] The Fc region may also contain additional mutations to increase serum half-life. By enhancing binding to the neonatal Fc receptor (FcRn), such mutations in the Fc region may improve the pharmacokinetics of the antibody. Examples of substitutions in the Fc region that increase the serum half-life of the antibody include, for example, M252Y/S254T/T256E, T250Q/M428L, N434A, N434H, T307A/E380A/N434A, M428L/N434S, M252Y/M428L, D259I/V308F, N434S, V308W, V308Y, and V308F. A description of amino acid mutations in the Fc region that can increase the half-life of the antibody in serum can be found, for example, in: Dumet et al., MAbs. 26:1-10, 2019; Booth et al., MAbs. 10(7):1098-1110, 2018; and Dall'Acqua et al., J Biol Chem. 281(33):23514-24, 2006.

[0318] Additionally, in some embodiments, an antibody of the invention may be chemically modified (e.g., one or more chemical moieties may be attached to the antibody) or modified, such as produced in cell lines and/or cell culture conditions to alter its glycosylation (eg, hypofucosylation, afucosylation, or enhanced sialylation) to change one or more functional properties of the antibody. For example, the antibody may be associated with one of a variety of polymers, such as polyethylene glycol. In some embodiments, the antibody may contain mutations to facilitate binding to a chemical moiety and/or to alter residues that are subject to post-translational modifications, such as glycosylation.

[0319] In some embodiments, the antitumor antibody of the present invention is used in a bispecific or multispecific format, such as a trispecific format. For example, in some embodiments, the antibody may be included in a bispecific or polyspecific antibody that contains an additional binding domain that binds to the same or a different antigen.

[0320] Exemplary antigens that may be targeted by an additional binding domain in a bispecific or multispecific antibody that contains a heavy and/or light chain variable domain of the present invention include, but are not limited to, antigens on T cells to enhance T recruitment -cells and/or T-cell activation. Illustrative examples of such an antigen include, but are not limited to, CD3, CD2, CD4, CD5, CD6, CD8, CD28, CD40L, CD44, IL-15Rα, CD122, CD132, or CD25. In some embodiments, the antigen is CD3. In some embodiments, the antigen is in a T cell activation pathway, such as 4-1BB/CD137, CD137L, OX40, OX40L, GITRL, GITR, CD27, CD70, CD28, ICOS, HVEM, or LIGHT antigen.

[0321] In some embodiments, a bispecific or polyspecific antibody comprising a heavy and/or light chain variable region of the present invention further comprises a binding domain that binds a checkpoint antigen, PD1, PDL1, CTLA-4, ICOS, PDL2, IDO1 , IDO2, B7-H3, B7-H4, BTLA, HVEM, TIM3, GAL9, GITR, HAVCR2, LAG3, KIR, LAIR1, LIGHT, MARCO, OX-40, SLAM, , 2B4, CD2, CD27, CD28, CD30, CD40, CD70, CD80, CD86, CD137, CD160, CD39, VISTA, TIGIT, CGEN-15049, 2B4, CHK 1, CHK2, A2aR, or a B-7 family ligand or its receptor.

[0322] In some embodiments, a bispecific or polyspecific antibody comprising a heavy and/or light chain variable region of the present invention further comprises a binding domain targeting a tumor-associated antigen. Exemplary tumor associated antigens include, but are not limited to, EpCAM, HER2/neu, HER3/neu, G250, CEA, MAGE, proteoglycans, VEGF, VEGFREGFR, ErbB2, ErbB3, MET, IGF-1R, PSA, PSMA, EphA2, EphA3, EphA4, folate-binding protein αVβ3-integrin, integrin α5βl HLA, HLA-DR, ASC, CD1, CD2, CD4, CD6, CD7, CD8, CD1 1, CD1 3, CD14, CD19, CD20, CD21, CD22, CD23, CD24, CD30, CD33, CD37, CD40, CD41, CD47, CD52, c-erb-2, CALLA, MHCII, CD44v3, CD44v6, p97, ganglioside GM1, GM2, GM3, GD1 a, GD1 b, GD2, GD3 , GT1 b, GT3, GQ1, NY-ESO-1, NFX2, SSX2, SSX4 Trp2, gp100, tyrosinase, Muc-1, telomerase, survivin, SLAMF7 EphG250, p53, CA125 MUC, Wue antigen, Lewis-Y antigen, HSP -27, HSP-70, HSP-72, HSP-90, Pgp, PMEL17, MCSP, and cell surface targets GC182, GT468, or GT512.

[0323] In some embodiments, the heavy and light chain variable regions of an antitumor antibody of the present invention may be included in a chimeric antigen receptor construct to create a CAR-containing immune cell, such as a T cell or NK cell. For example, in some embodiments, the first generation CAR connects the single chain variable region of an antibody to the intracellular signaling domain of the CD3 T cell receptor Cd3-zeta (ζ) via hinge and transmembrane domains. In some embodiments, the CAR may contain costimulatory domains, for example, a second or third generation CAR may include an additional one or two costimulatory domains, such as 4-1BB, CD28, or OX-40). In additional embodiments, a CAR-containing cell, e.g., a CAR-T cell, can be further engineered with an inducible expression component, such as a cytokine, e.g., IL-12 or IL-15, to enhance CAR-T cell activation, and also activation of innate immune cells.

Obtaining antibodies

[0324] The antitumor antibodies disclosed herein are typically produced using vectors and recombinant methodology well known in the art (see, for example, Sambrook & Russell, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; Ausubel, Current Protocols in Molecular Biology). Reagents, cloning vectors, and genetic manipulation kits are available from commercial suppliers. Accordingly, in a further aspect of the invention, provided herein are isolated nucleic acids encoding the V _H and/or V _L region or fragment thereof of any of the antitumor antibodies described herein; vectors containing such nucleic acids and host cells into which the nucleic acids are introduced, which are used for replication of nucleic acids encoding antibodies and/or for expression of antibodies. Such nucleic acids may encode an amino acid sequence containing V _L and/or an amino acid sequence containing V _H of an antitumor antibody (eg, the light and/or heavy chain of an antibody). In some embodiments, the host cell comprises (1) a vector comprising a polynucleotide encoding a V _L amino acid sequence and a polynucleotide encoding a V _H amino acid sequence, or (2) a first vector comprising a polynucleotide encoding a V _L amino acid sequence and a second vector , containing a polynucleotide encoding the amino acid sequence _VH .

[0325] In a further aspect, the invention provides a method for producing an antitumor antibody as described herein. In some embodiments, the method includes culturing the host cell, as described in the previous paragraph, under conditions suitable for expression of the antibody. In some embodiments, the antibody is subsequently isolated from the host cell (or host cell culture medium).

[0326] Suitable vectors containing polynucleotides encoding antibodies of the present invention, or fragments thereof, include cloning vectors and expression vectors. Although the cloning vector chosen may vary depending on the host cell intended for use, useful cloning vectors generally have the ability to self-replicate, may have a single target for a particular restriction endonuclease, and/or may carry genes for a marker that can be used in the selection of clones containing the vector. Examples include plasmids and bacterial viruses, eg pUC18, pUC19, Bluescript (eg pBS SK+) and its derivatives, mpl8, mpl9, pBR322, pMB9, ColE1 plasmids, pCR1, RP4, phage DNA and shuttle vectors. These and many other cloning vectors are available from commercial suppliers.

[0327] Expression vectors are typically replicable polynucleotide constructs that contain a nucleic acid of the invention. The expression vector can replicate in host cells either as episomes or as an integral part of chromosomal DNA. Suitable expression vectors include plasmids and viral vectors, including, but not limited to, adenoviruses, adeno-associated viruses, retroviruses and any other vector.

[0328] Suitable host cells for expression of an antitumor antibody as described herein include both prokaryotic and eukaryotic cells. For example, antitumor antibodies can be produced in bacteria, particularly when glycosylation and Fc effector function are not required. Once expressed, the antibody can be isolated from the bacterial biomass into a soluble fraction and can then be further purified. Alternatively, the host cell may be a eukaryotic host cell, including eukaryotic microorganisms such as filamentous fungi or yeast, including fungal and yeast strains whose glycosylation pathways have been "humanized", resulting in the formation of an antibody with a partially or fully human glycosylation profile, vertebrate, invertebrate and plant cells. Examples of invertebrate cells include insect cells. Numerous strains of baculoviruses have been identified that can be used in combination with insect cells. Plant cell cultures can also be used as host cells.

[0329] In some embodiments, vertebrate host cells are used to produce an antitumor antibody according to the present invention. For example, mammalian cell lines such as the monkey kidney CV1 line transformed with SV40 (COS-7); human embryonic kidney line (293 or 293 cells, as described, for example, in Graham et al., J. Gen Virol . 36:59,1977; baby hamster kidney (BHK) cells); mouse Sertoli cells (TM4 cells, as described for example, in Mather, Biol Reprod 23:243-251, 1980, monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); cervical carcinoma cells (HELA); canine kidney cells (MDCK cells Buffalo rat liver (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor cells (MMT 060562); TRI cells as described, for example, in Mather et al ., Annals NY Acad. Sci. 383:44-68, 1982; MRC 5 cells and FS4 cells can be used to express antitumor antibodies. Other suitable mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR-CHO cells (Urlaub et al., Proc. Natl. Acad. Sci. USA 77:4216, 1980); and myeloma cell lines such as Y0, NS0 and Sp2/0. Host cells of the present invention also include, but are not limited to, isolated cells, cells cells cultured in vitro and cells cultured ex vivo . For a review of some mammalian host cell lines suitable for antibody production, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKC Lo, ed., Humana Press, Totowa, NJ), pp. 255-268, 2003.

[0330] In some embodiments, the antibody of the present invention is produced by a CHO cell line, such as the CHO-K1 cell line. One or more expression plasmids that encode heavy and light chain sequences can be introduced. For example, in one embodiment, an expression plasmid encoding a heavy chain, e.g., SEQ ID NO:1723, and an expression plasmid encoding a light chain, e.g., SEQ ID NO:1724, are transfected into host cells as linearized plasmids in a ratio of 1: 1 in the CHO-K1 host cell line using reagents such as Freestyle Max reagent. Fluorescence-activated cell sorting (FACS) combined with single-cell imaging can be used as a cloning method to obtain a producer cell line.

[0331] A host cell transfected with an expression vector encoding an antitumor antibody of the present invention, or a fragment thereof, can be cultured under appropriate conditions to allow expression of the polypeptide. Polypeptides can be secreted and isolated from a mixture of cells and media containing said polypeptides. Alternatively, the polypeptide may be retained in the cytoplasm or membrane fraction, and the cells are collected, lysed, and the polypeptide isolated using the desired method.

[0332] In some embodiments, the antitumor antibody of the present invention can be produced by in vitro synthesis (see, for example, Sutro Biopharma biochemical protein synthesis platform).

[0333] In some embodiments, provided herein is a method for creating variants of an antitumor antibody described herein. Thus, for example, a construct encoding a CDR3 _VH variant as described herein can be modified, and the _VH region encoded by the modified construct can be tested for binding activity to EMT-6 cells and/or antitumor activity in vivo as exemplified by a V _H region as described herein, which is connected to a V _L region or a variant region as described herein. Similarly, the construct encoding the CDR3 V _L variant as described herein can be modified, and the V _L region encoded by the modified construct can be tested for binding to EMT-6 cells or other tumor cells and/or potency in vivo antitumor activity. Such an analysis can also be performed with other CDRs or framework regions, after which the antibody having the desired activity can be selected.

Antitumor antibody conjugates/costimulatory agents

[0334] In a further aspect, the antitumor antibody of the present invention can be conjugated or linked to therapeutic and/or visualization/detectable moieties. For example, an antitumor antibody may be conjugated to a detectable marker, a cytotoxic agent, an immunomodulatory agent, an imaging agent, a therapeutic agent, or an oligonucleotide. Methods for conjugating or binding antibodies to a desired molecule are well known in the art. The moiety may be linked to the antibody via covalent or non-covalent bonds.

[0335] In some embodiments, the antibody is conjugated to a cytotoxic moiety or other moiety that inhibits cell proliferation. In some embodiments, the antibody is conjugated to a cytotoxic agent, including, but not limited to, ricin A chain, doxorubicin, daunorubicin, maytansinoid, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroanthracinedione, methotrexate , actinomycin, diphtheria toxin, Pseudomonas exotoxin A, Pseudomonas exotoxin 40, abrin, abrin A-chain, modeccin A-chain, alpha-sarcin, gelonin, mitogellin, restrictocin, cobra venom factor, ribonuclease, engineered Shiga toxin, phenomycin, enomycin, chickencin, crotin, calicheamicin, Saponaria officinalis inhibitor, glucocorticoid, auristatin, auromycin, yttrium, bismuth, combrestatin, duocarmycins, dolastatin, cc1065 or cisplatin. In some embodiments, the antibody may be associated with an agent such as an enzyme inhibitor, a proliferation inhibitor, a lytic agent, DNA or RNA synthesis inhibitors, a membrane permeability modifier, a DNA metabolite, a dichloroethyl sulfide derivative, a protein production inhibitor, a ribosome inhibitor, or an apoptosis inducer. In some embodiments, the antibody is conjugated to a drug, such as a topoisomerase inhibitor, e.g., topoisomerase I inhibitor.

[0336] In some embodiments, an antitumor antibody of the invention is attached to a molecule that facilitates transport of the antibody across a biological membrane, for example, by enhancing membrane penetration, facilitating protein translocation across membranes. Thus, for example, an antibody may be coupled to a cell penetrating agent, such as a cell penetrating peptide. Examples of cell penetrating peptides include TAT, penetratin, polyarginine molecules, Kunitz domain-derived peptides such as angiopep-2, SynB, buforin, transportan, amphiphatic peptides and others. In some embodiments, the antibody may be conjugated to a cationic molecule, such as a polyamine. In some embodiments, the antibody may be conjugated to an agent that facilitates transport across the blood-brain barrier, such as transcytosis. Thus, for example, the antibody may be conjugated to an agent that binds to endothelial cell receptors that are internalized, for example, transferrin receptor, insulin receptor, insulin-like growth factor receptor, or low-density lipoprotein receptor, and the like. In some embodiments, the antibody may be conjugated to a toxin that facilitates penetration of the antibody into the cytoplasm, such as Shiga toxin.

[0337] In some embodiments, the antitumor antibody is conjugated or co-administered with an immunomodulatory polypeptide agent, such as an adjuvant. Examples of immunomodulatory agents include, but are not limited to, cytokines, growth factors, lymphotoxins, tumor necrosis factor (TNF), hematopoietic factors, interleukins (eg, interleukin-1 (IL-1), IL-2, IL-3, IL- 6, IL-10, IL-12, IL-15, IL-15/IL-15Rα, e.g., sushi domain complex, IL-18 and IL-21), colony-stimulating factors (e.g., granulocyte colony-stimulating factor (G- CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF), interferons (eg, interferon-α, -β, or -γ), erythropoietin and thrombopoietin, or a combination thereof. In some embodiments, the antibody is associated with or co-administered with an adjuvant, such as Toll-like receptor (TLR) agonist, C-type lectin receptor (CLR) agonist, retinoic acid inducible gene product-like receptor (RLR) agonists, saponin, polysaccharide such as chitin, chitosan, β-glucan, ISCOM, QS-21, stimulator of interferon genes (STING) agonist, or other immune stimulating agent.

[0338] In some embodiments, the antibody may be associated with a radionuclide, iron-related compound, dye, fluorescent agent, or imaging agent. In some embodiments, the antibody may be associated with agents such as, but not limited to, metals; metal chelators; lanthanides; lanthanide chelators; radiometals; radiometal chelators; nuclei emitting positrons; microbubbles (for ultrasound); liposomes; molecules microencapsulated in liposomes or nanospheres; monocrystalline iron oxide nanoparticles; contrast agents for magnetic resonance imaging; light-absorbing, reflecting and/or scattering agents; colloidal particles; fluorophores, such as near-infrared fluorophores.

Methods for inducing an immune response

[0339] In a further aspect, provided herein are methods of inducing an immune response by administering a tumor-binding antibody, as described herein, to a subject who has a tumor that contains an extracellular RNA-protein complex to which the tumor-binding antibody binds. In some embodiments, the tumor-binding antibody is an antibody listed in Table 1 or Table 2, or a variant thereof, as described above.

[0340] The immune response induced by administration of an antibody as described herein can be either an innate or an adaptive immune response. In some embodiments, the antibody directly activates an immune response, for example, by binding the antibody to a target tumor cell and interacting with an Fc receptor on the effector cell such that the effector cell is activated. In some embodiments, the antibody directly activates an immune response by inducing immune responses that are initiated by binding of the antibody to a target cell and an effector cell, followed by the induction of subsequent immune responses. In some embodiments, the antibody activates monocytes, myeloid cells, and/or NK cells, such as macrophages, neutrophils, dendritic cells, mast cells, basophils, eosinophils, and/or NK cells. In some embodiments, the antibody activates T lymphocytes and/or B cells.

Cancer treatment

[0341] In a further aspect, a tumor-binding antibody as provided herein, for example, the antibody listed in Table 1, or a variant thereof, as described above, can be used as a therapeutic agent to treat cancer. In some aspects, the invention further provides methods for identifying subjects that are candidates for treatment with an antitumor antibody having antitumor effects. Thus, in one embodiment, the invention provides a method for identifying a patient who has tumor cells that bind to an antitumor antibody of the present invention. In some embodiments, the tumor sample is taken from a primary tumor. In alternative embodiments, the tumor sample is a metastatic lesion. The binding of an antibody to tumor cells through a binding interaction with the extracellular RNA-protein complex can be measured using any assay such as immunohistochemistry or flow cytometry. In some embodiments, binding of the antibody to at least 0.2%, 0.5%, or 1%, or at least 5% or 10%, or at least 20%, 30%, or 50% of the tumor cells in the sample may be used as a selection criterion to determine which patient should be treated with an antitumor antibody as described herein. In other embodiments, analysis of blood components, such as circulating exosomes and/or extracellular RNA-protein complex, is used to identify a patient whose tumor cells form an extracellular RNA-protein complex.

[0342] Any number of malignancies can be treated with the antitumor antibody of the present invention. In some embodiments, the cancer is a carcinoma or sarcoma. In some embodiments, the cancer is a hematologic malignancy. In some embodiments, the cancer is breast cancer, prostate cancer, testicular cancer, renal cell cancer, bladder cancer, ovarian cancer, cervical cancer, endometrial cancer, lung cancer, colorectal cancer, anal cancer, pancreatic cancer , stomach cancer, esophageal cancer, hepatocellular cancer, head and neck cancer, brain cancer such as glioblastoma, melanoma or sarcoma of bone or soft tissue. In one embodiment, the cancer is acral melanoma. In some embodiments, the cancer is acute lymphoblastic leukemia, acute myeloid leukemia, adrenocortical carcinoma, astrocytoma, basal cell carcinoma, bile duct cancer, bone tumor, brainstem glioma, cerebellar astrocytoma, cerebral astrocytoma, ependymoma, medulloportectocytoma, optic pathway glioma, and hypothalamic glioma , bronchial adenomas, Burkitt's lymphoma, central nervous system lymphoma, cerebellar astrocytoma, chondrosarcoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, chronic myeloproliferative diseases, colon cancer, cutaneous T-cell lymphoma, desmoplastic small cell tumor, endometrial cancer, ependymoma, epithelial hemangio endothelioma (EHE), esophageal cancer, Ewing's sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, extrahepatic bile duct cancer, eye cancer, intraocular melanoma, retinoblastoma, gallbladder cancer, gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (GIST), germ cell tumor, gestational trophoblastic tumor, gastric cancer, hairy cell leukemia, hepatocellular carcinoma, Hodgkin's lymphoma, laryngeal cancer, hypothalamic and optic pathway glioma, childhood melanoma, intraocular melanoma, islet cell carcinoma, Kaposi's sarcoma, kidney cancer, laryngeal cancer, leukemias, lip cancer and oral cavity, liposarcoma, liver cancer, non-small cell lung cancer, small cell lung cancer, lymphomas, macroglobulinemia, male breast cancer, malignant fibrous histiocytoma of bone, medulloblastoma, Merkel cell cancer, mesothelioma, metastatic squamous cell carcinoma of the neck, oral cancer, multiple endocrine neoplasia, multiple myeloma, granuloma fungoides, myelodysplastic syndromes, myeloid leukemia, myeloid leukemia, acute myeloproliferative diseases in adults, chronic, myxoma, cancer of the nasal cavity and paranasal sinuses, nasopharyngeal carcinoma, neuroblastoma, non-Hodgkin's lymphoma, oligodendroglioma, oral cancer, cancer oropharynx, osteosarcoma, epithelial ovarian cancer, ovarian embryonal cell tumor, borderline ovarian tumor, paranasal sinus and nasal cavity cancer, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pineal astrocytoma, pineal germinoma, pineoblastoma, supratentorial primitive neuroectodermal tumor, pituitary adenoma, plasma cell neoplasia, pleuropulmonary blastoma, primary central nervous system lymphoma, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Ewing's sarcoma, Kaposi's sarcoma, soft tissue sarcoma, uterine sarcoma, syndrome Sézary, non-melanoma skin cancer, melanoma, small bowel cancer, squamous cell carcinoma, squamous cell carcinoma of the neck, stomach cancer, T-cell lymphoma of the skin, throat cancer, thymoma, thyroid cancer, transitional cell carcinoma of the pelvis and ureter, gestational trophoblastic tumor, cancer urethra, uterine cancer, vaginal cancer, vulvar cancer, Waldenström's macroglobulinemia, or Wilms' tumor.

[0343] In some embodiments, the cancer is lung cancer, such as non-small cell lung adenocarcinoma or squamous cell carcinoma; breast cancer, for example, triple negative, ER/PR ⁺ Her2 ^- , ER/PR ^- Her2 ⁺ , or triple negative; colorectal cancer, such as adenocarcinoma, mucinous adenocarcinoma or papillary adenocarcinoma; esophageal carcinoma; stomach cancer; kidney cancer, such as clear cell kidney cancer; ovarian cancer, such as ovarian endometrioid carcinoma, ovarian mucinous cystadenocarcinoma or ovarian serous cystadenomarcinoma; melanoma, such as acral melanoma, cutaneous melanoma or mucosal melanoma; cancer of the uterus or cervix; liver cancer, such as hepatocellular carcinoma or bile duct carcinoma; bladder cancer, such as transitional cell or urothelial bladder cancer; or testicular cancer.

[0344] In one aspect, the methods of the invention include administering an antitumor antibody, such as the antibody listed in Table 1, or a variant thereof as described above, as a pharmaceutical composition to a cancer patient in a therapeutically effective amount using a dosage regimen that is suitable for treating cancer . The composition can be formulated for use in various drug delivery systems. One or more physiologically acceptable excipients or carriers may also be included in the compositions for proper formulation. Suitable formulations for use in the present invention are found, for example, in Remington: The Science and Practice of Pharmacy, 21st Edition, Philadelphia, PA. Lippincott Williams & Wilkins, 2005.

[0345] The antitumor antibodies are presented in a solution suitable for administration to a patient, such as a sterile isotonic aqueous injection solution. The antibody is dissolved or suspended at a suitable concentration in a suitable vehicle. In some embodiments, the carrier is an aqueous solution, such as water, saline, phosphate-buffered saline, or the like. The compositions may contain pharmaceutical excipients necessary to provide physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, and the like.

[0346] Pharmaceutical compositions are administered to a patient in an amount sufficient to cure or at least partially relieve the disease or symptoms of the disease and its complications. An amount sufficient to achieve this is defined as a "therapeutically effective dose". The therapeutically effective dose is determined by monitoring the patient's response to therapy. Typical criteria indicating a therapeutically effective dose include a reduction in the intensity of the patient's symptoms of the disease. Amounts effective for this use will depend on the severity of the disease and the general health of the patient, including other factors such as age, weight, sex, route of administration, etc. One or more antibodies may be administered depending on the dosage and frequency according to patient requirements and tolerance. In either case, the methods provide sufficient antitumor antibodies to effectively treat the patient.

[0347] The antitumor antibody can be administered by any suitable routes, including, for example, parenteral, intrapulmonary, and intranasal administration, as well as local administration, such as intratumoral administration. Parenteral infusions include intramuscular, intravenous, intra-arterial, intraperitoneal and subcutaneous administration. In some embodiments, the antibody may be administered by insufflation. In an illustrative embodiment, the antibody can be stored at a concentration of 10 mg/ml in sterile isotonic aqueous saline injection at 4°C and diluted in either 100 ml or 200 ml of 0.9% sodium chloride injection before administration to a patient. In some embodiments, the antibody is administered by intravenous infusion over 1 hour at a dose of 0.01 to 25 mg/kg. In other embodiments, the antibody is administered by intravenous infusion over a period of 15 minutes to 2 hours. In still other embodiments, the administration procedure is carried out via a subcutaneous bolus injection.

[0348] The dose of the antibody is selected to provide effective treatment to the patient and ranges from less than 0.01 mg/kg body weight to about 25 mg/kg body weight or in the range from 1 mg to 2 g per patient. Preferably, the dose is in the range of 0.1-10 mg/kg or approximately 50-1000 mg/patient. The dose may be repeated at an appropriate frequency, which may range from once daily to once every three months or every six months, depending on the pharmacokinetics of the antibody (eg, the half-life of the antibody in the bloodstream) and the pharmacodynamic response (eg, the duration of therapeutic antibody effect). In some embodiments, the in vivo half-life is from about 7 to about 25 days, and antibody dosing is repeated from once a week to once every 3 months or once every 6 months. In other embodiments, the antibody is administered approximately once per month.

[0349] In an illustrative embodiment, the antibody can be stored at a concentration of 10 mg/ml or 20 mg/ml in a sterile isotonic aqueous solution. The solution may contain agents such as buffering agents and stabilizing agents. For example, in some embodiments, a buffering agent, such as histidine, is included to maintain the pH of the formulation at about 5.5. Additional reagents such as sucrose or analogs may be added to prevent aggregation and fragmentation in solution and during freezing and thawing. Agents such as polysorbate 80 or the like may be included to reduce surface tension and stabilize the antibody against excitation-induced denaturation and air-liquid and ice-liquid surface denaturation. In some embodiments, the injection solution is stored at 4°C and diluted with either 100 ml or 200 ml of 0.9% sodium chloride injection before administration to the patient.

[0350] In some embodiments, an intravenous antibody, for example, an antibody having the heavy chain sequence of SEQ ID NO:1723 and the light chain sequence of SEQ ID NO:1724, is formulated at a target concentration of 20 mg/mL in 20 mM histidine buffer, 8 % (w/v) sucrose and 0.02% (w/v) polysorbate 80, pH 5.5.

[0351] An antitumor antibody can be administered with one or more additional therapeutic agents, for example, radiation therapy, chemotherapeutic agents, and/or immunotherapeutic agents.

[0352] In some embodiments, an antitumor antibody may be administered in combination with an agent that targets an immune checkpoint antigen. In one aspect, the agent is a biological therapeutic agent or small molecule. In yet another aspect, the agent is a monoclonal antibody, a humanized antibody, a human antibody, a fusion protein, or a combination thereof. In certain embodiments, the agents inhibit, for example, blocking the binding of a ligand to a receptor, a checkpoint antigen, which may be PD1, PDL1, CTLA-4, ICOS, PDL2, IDO1, IDO2, B7-H3, B7-H4, BTLA, HVEM , TIM3, GAL9, GITR, HAVCR2, LAG3, KIR, LAIR1, LIGHT, MARCO, OX-40, SLAM, , 2B4, CD2, CD27, CD28, CD30, CD40, CD70, CD80, CD86, CD137 (4-1BB) , CD160, CD39, VISTA, TIGIT, SIGLEC, CGEN-15049, 2B4, CHK1, CHK2, A2aR, B-7 family ligands or receptors thereof, or combinations thereof. In some embodiments, the agent targets PD-1, for example, an antibody that blocks PD-L1 binding to PD-1 or otherwise inhibits PD-1. In some embodiments, the agent targets CTLA-4. In some embodiments, the agent targets LAG3. In some embodiments, the agent targets TIM3. In some embodiments, the agents target ICOS.

[0353] In some embodiments, an antitumor antibody may be administered together with a therapeutic antibody, such as an antibody targeting a tumor cell antigen. Examples of therapeutic antibodies include rituximab, trastuzumab, tositumomab, ibritumomab, alemtuzumab, atezolizumab, avelumab, durvalumab, pidilizumab, AMP-224, AMP-514, PDR001, cemiplimab, BMS-936559, CK-301, epratuzumab, bevacizumab, elot uzumab, necitumumab, blinatumomab, brentuximab, cetuximab, daratumumab, denosumab, dinutuximab, gemtuzumab, ibritumomab, ipilimumab, nivolumab, obinutuzumab, ofatumumab, ado-trastuzumab, panitumumab, pembrolizumab, pertuzumab, ramucirumab and ranibizumab.

[0354] In some embodiments, the antitumor antibody is administered with a chemotherapeutic agent. Examples of anticancer chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide; alkylsulfonates such as busulfan, improsulfan and piposulfan; azaridines such as benzodopa, carboquone, meturedopa and uredopa; ethyleneimines and methylmelamines, including altretamine, triethylenemelamine, triethylenethiophosphoramide and trimethylolomelamine; nitrogen mustards such as chlorambucil, chlornaphasine, chlorphosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembiquine, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorosotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomycin, actinomycin, outramycin, azaserin, bleomycin, cactinomycin, calicheamicin, carabicin, carminomycin, carcinophilin, chromomycin, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, ezorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rhodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, cinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil; folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogues such as fludarabine, 6-mercaptopurine, thiamiprin, thioguanine; pyrimidine analogues such as ancytabine, azacitidine, 6-azauridine, carmofour, cytarabine, dideoxyuridine, doxifluridine, enocytabine, floxuridine, androgens such as calusterone, dromostanolone propionate, epithiostanol, mepithiostane, testolactone; drugs that suppress adrenal function, such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as folinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisanthrene; edatraxate; defofamine; demecolcine; diaziquon; elfornitine; elliptinium acetate; ethoglucide; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidanmol; nitracrine; pentostatin; phenomet; pirarubicin; podophyllic acid; 2-ethylhydrazide; procarbazine; razoxane; sisofuran; spirogermanium; tenuazonic acid; triaziquon; 2,2',2''-trichlorotriethylamine; urethane; vindesine; dacarbazine; mannomustin; mitobronitol; mitolactol; pipobromance; gacytosine; arabinoside; cyclophosphamide; thiotepa; taxoids, for example, paclitaxel and docetaxel; chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum-based analogs such as cisplatin and carboplatin; vinblastine; doxetaxel, platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; Novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-1 1; topoisomerase inhibitor RFS 2000; difluoromethylomithine (DMFO); retinoic acid derivatives such as bexarotene, alitretinoin; denileukin diftitox; esperamycins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the foregoing. Also included in this definition are antihormonal agents that act to regulate or inhibit the action of hormones on a tumor, for example, antiestrogens, including, for example, tamoxifen, raloxifene, mifepristone, aromatase inhibitory 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone and toremifene (Fareston); and antiandrogens such as flutamide, nilutamide, bicalutamide, leuprolide and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Other anticancer therapeutic agents include sorafenib and other protein kinase inhibitors such as afatinib, axitinib, crizotinib, dasatinib, erlotinib, fostamatinib, gefitinib, imatinib, lapatinib, lenvatinib, mubritinib, nilotinib, pazopanib, pegaptanib, ruxolitinib, vandetanib, vemura fenib and sunitinib; sirolimus (rapamycin), everolimus and other mTOR inhibitors. Examples of additional chemotherapeutic agents include topoisomerase I inhibitors (eg, irinotecan, topotecan, camptothecin and their analogs or metabolites and doxorubicin); topoisomerase II inhibitors (eg etoposide, teniposide and daunorubicin); alkylating agents (eg, melphalan, chlorambucil, busulfan, thiotepa, ifosfamide, carmustine, lomustine, semustine, streptozocin, decarbazine, methotrexate, mitomycin C and cyclophosphamide); DNA intercalators (eg, cisplatin, oxaliplatin and carboplatin); DNA intercalators and free radical generators such as bleomycin; and nucleoside mimetics (eg, 5-fluorouracil, capecitibine, gemcitabine, fludarabine, cytarabine, mercaptopurine, thioguanine, pentostatin, and hydroxyurea). Exemplary chemotherapeutic agents further include paclitaxel, docetaxel, and related analogs; vincristine, vinblastine and related analogues; thalidomide, lenalidomide and related analogues (eg, CC-5013 and CC-4047); protein tyrosine kinase inhibitors (eg, imatinib mesylate and gefitinib); proteasome inhibitors (eg bortezomib); NF-κΒ inhibitors, including IκΒ-kinase inhibitors and other inhibitors of proteins or enzymes known to be upregulated, overexpressed or activated in malignancies, the inhibition of which suppresses cell replication. Additional agents include asparaginase and Bacillus Calmette-Guerin preparation.

[0355] In some embodiments, an antitumor antibody, as described herein, is administered after or simultaneously with a therapeutic agent, for example, a chemotherapeutic agent, such as doxorubicin, that induces stress granules (“SG-inducing agent”). Increasing the number of stress granules in cancer cells may facilitate the targeting of antitumor antibodies to tumor cells. Other exemplary therapeutic agents that can induce stress granules include pyrimidine analogs (eg, 5-FU, under the trade names ^Adrucil® , ^Carac® , ^Efudex® , ^Efudix® ); protease inhibitors (eg, bortezomib, under the trade name Velcade ^® ); kinase inhibitors (eg, brand and imatinib under the trade names Nexavar ^® and Gleevec ^® , respectively); arsenic compounds (eg arsenic trioxide, under the trade name Trisenox ^® ); platinum-based compounds that cause DNA damage (eg, cisplatin and ^{oxaliplatin®} , under the trade names ^Platinol® and ^Eloxatin® , respectively); microtubule disrupting agents (eg, vinblastine, under the trade name Velban ^® or alkabban-AQ ^® ; vincristine, under the trade name Vincasar ^® , Marqibo ^® , or Oncovin ^® ; Vinorelbin, under the trade name Navelbin ^® ); topoisomerase II inhibitor (eg, etoposide under the trade name Etopophos, ^Toposar® , ^VePesid® ); and agents that cause DNA damage, such as radiation. A number of exemplary therapeutic agents that can induce the formation of stress granules are disclosed in Mahboubi et al., Biochimica et Biophysica Acta 1863 (2017) 884-895.

[0356] Various combinations with an antitumor antibody and an SG-inducing agent (or a combination of such agents) that are described herein can be used to treat a cancer patient. By “combination therapy” or “in combination with” it is not meant that the therapeutic agents must be administered simultaneously and/or formulated for co-delivery, although these modes of delivery are within the scope described herein. The antitumor antibody and the SG-inducing agent can be administered according to the same or different dosage regimens. In some embodiments, the antitumor antibody and the SG-inducing agent are administered sequentially in any order throughout the entire treatment period or portions thereof. In some embodiments, the antitumor antibody and the SG-inducing agent are administered simultaneously or approximately simultaneously (eg, within approximately 1, 5, 10, 15, 20, or 30 minutes of each other). In still other embodiments, the SG-inducing agent can be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more days before the administration of the antitumor antibody. In some embodiments, the SG-inducing agent is administered 1 to 4 weeks or longer before administration of the antitumor antibody.

[0357] An antitumor antibody can also be administered to a cancer patient in combination with a cellular therapy, such as natural killer (NK) cell therapy or a cancer vaccine. In some cases, the cancer vaccine is a peptide vaccine, a nucleic acid vaccine, a cell-based vaccine, a virus or viral fragment vaccine, or an antigen presenting cell (APC) vaccine (eg, a dendritic cell vaccine). Cancer vaccines include Gardasil®, Cervarix®, sipuleucel-T (Provenge®), NeuVax™, HER-2 ICD peptide vaccine, HER-2/neu peptide vaccine, AdHER2/neu dendritic cell vaccine, based on HER-2 stimulated DC1, Ad-sig-hMUC-l/ecdCD40L fusion protein vaccine, MVX-ONCO-1, hTERT/survivin/CMV multipeptide vaccine, E39, J65, P10s-PADRE, rV-CEA-Tricom , GVAX®, Lucanix®, HER2 VRP, AVX901, ONT-10, ISAlOl, ADXSl 1-001, VGX-3100, INO-9012, GSK1437173A, BPX-501, AGS-003, IDC-G305, HyperAcute®-Renal immunotherapy (HAR), Prevenarl3, MAGER-3.A1, NA17.A2, DCVax-Direct, latent membrane protein-2 (LMP2) loaded dendritic cell vaccine (NCT02115126), HS410-101 (NCT02010203, Heat Biologies), EAU RF 2010-01 (NCT01435356, GSK), 140036 (NCT02015104, Rutgers University of New Jersey), 130016 (NCTO 1730118, National Cancer Institute), MVX-201101 (NCT02193503, Maxivax SA), ITL-007-ATCR-MBC ( NCT01741038, Immunovative Therapies, Limited), CDR0000644921 (NCT00923143, Abramson Cancer Center, University of Pennsylvania), SuMo-Sec-01 (NCT00108875, Julius Maximilian University Hospital), or MCC-15651 (NCT01176474, Medarex, Inc, BMS).

[0358] In some embodiments, the antitumor antibody of the present invention can be administered with an agent, such as a corticosteroid, that mitigates the side effects resulting from stimulation of the immune system.

[0359] In the context of the present invention, the therapeutic agent that is administered together with the antitumor antibody of the present invention can be administered before the administration of the antitumor antibody or after the administration of the antitumor antibody. In some embodiments, the antitumor antibody may be administered concomitantly with an additional therapeutic agent.

[0360] The following examples are offered for illustrative purposes and are not intended to limit the invention. Those skilled in the art will readily recognize many non-critical parameters that can be changed or modified to obtain substantially the same results.

EXAMPLES

Example 1. Identification of antibody variants with antitumor effects.

[0361] The seed sequence of the promising antibody, designated AIP-192482, was obtained by sequencing a plasmablast from a patient who had non-small cell lung cancer that was identified by screening an in vivo tumor model in combination with anti-PD1 antibody therapy.

[0362] Initially, the EMT6 ectopic tumor model was used. Balb/c mice were injected subcutaneously along the right flank with 10 ⁶ EMT6 cells. The antitumor activity of the parent antibody from this line was further assessed in the syngeneic EMT6 ectopic breast cancer model in Balb/c mice. Mice were randomized to treatment groups based on tumor volume (TV) once tumors reached an average of 75-120 mm ³ . Treatment with test antibodies and/or checkpoint inhibitor therapy was started on the day of randomization. Unless otherwise stated, test antibodies were administered twice weekly for 3.5 weeks (TWx3.5 weeks) by intraperitoneal (IP) injection. Pools of four antibodies were tested at dose levels of 5 mg/kg (dose in mg/kg body weight) each (20 mg/kg total antibody) by intravenous injection twice weekly for 3.5 weeks (7 doses). Animals were treated in combination with intraperitoneal injection of anti-mouse PD1 antibodies at a dose of 10 mg/kg, twice a week for two weeks. The original promising antibody was also tested alone (out of pool) at 20 mg/kg in combination with an anti-PD1 antibody. An antibody pool containing the promising antibody exhibited antitumor activity (Figure 1).

[0363] Variants of the original promising antibody were created and tested in the EMT6 tumor model (subcutaneous injection of tumor cells). Options were tested as monotherapy and administered in doses of 10 mg/kg twice weekly for 3.5 weeks as above. Variants with antitumor activity were identified (Fig. 2A and 2B).

[0364] Survival probability data for the original antibody candidate and variants are shown in FIG. 3A and 3B. P-values were calculated using the log-rank test. The original promising antibodies demonstrated significant effects on survival at both 5 mg/kg and 10 mg/kg dose levels. The AIP-106042 and AIP-100196 variants (Fig. 3A) showed significant effects, as did the AIP-122563, AIP-165430, AIP-157397, and AIP-171142 variants (Fig. 3B). Other variants also showed increased likelihood of survival, although at lower levels (Figures 3A and 3B). For example, antibody AIP-148327 increased the probability of survival at day 40 compared with controls (Fig. 3B).

[0365] The effects of administration of variants on tumor volume are shown in FIG. 4A and 4B. Data are expressed as normalized area over curve (NAAC). The NAAC value is calculated for each individual antibody based on its tumor volume curves. The NAAC value is between 0 and 1. The closer the value is to 1, the smaller the tumor volume over time, i.e. the more effective the treatment. Variants were identified that had a significant effect on tumor volume, such as AIP-106042 and AIP-100196 (Fig. 4A) and AIP-171142, AIP-157397, AIP-165430, and AIP-122563 (Fig. 4B). Treatment with other antibody variants also resulted in at least some reduction in tumor volume.

[0366] Variants of antibodies identified in the screening of first-generation variants as having antitumor activity have also been generated. These options were also evaluated as monotherapy in the EMT6 tumor model as described above. Options administered the doses shown in FIG. 5A-5D twice a week for 3.5 weeks. Variants with antitumor effects were identified (Fig. 5A-5D).

[0367] Survival data for antibodies treated with second generation variants is shown in FIG. 6A and 6B. P-values were calculated using the log-rank test. Variants were identified that showed a marked increase in the likelihood of survival (eg , AIP-155066, AIP-166120, AIP-142079, AIP-104188 (Fig. 6A) and AIP-158623, AIP-133645, AIP-136538, AIP-187893, and AIP -160470 (Figure 6B).

[0368] The effects of administration of second generation variants on tumor volume in the EMT6 tumor model are shown in FIG. 7A and 7B. Variants AIP-155066, AIP-166120, AIP-142079, and AIP-104188 showed NAAC values significantly higher than control values when administered at 5 mg/kg, where the majority also showed NAAC values significantly higher than control values at 2 .5 mg/kg. Variants AIP-158623, AIP-136538, AIP-133645, and AIP-187893 showed significant NAAC values at all concentrations tested; with some variants exhibiting NAAC values significantly higher than the control.

[0369] Treatment with two variants (AIP-133645 and AIP-160470) identified in the previous analysis were evaluated when administered in combination with an anti-PD1 antibody. The EMT6 tumor model was again used. The original promising antibodies were administered at doses of 5 and 10 mg/kg. The variants were administered at doses of 2.5 and 5 mg/kg. Anti-PD1 antibody was administered at a dose of 10 mg/kg. The study design is shown in Fig. 8. Antibodies were administered by intravenous injection in the indicated doses and frequencies. Survival analysis of the original promising antibody and the two variants when administered as monotherapy is shown in FIG. 9. Both AIP-160470 and AIP-133645 were able to improve survival compared to the original promising antibody. The effects on tumor growth, survival probability, and tumor volume for the promising antibody and the two options when administered as monotherapy are shown in FIG. 10, Fig. 11 and Fig. 12, respectively. The effects on tumor growth, survival probability, and tumor volume when administered in combination with anti-PD1 antibody are shown in FIG. 13, Fig. 14 and fig. 15, respectively.

[0370] The antitumor effects of the original promising antibody and variants AIP-160470 and AIP-133645 were also evaluated as monotherapy in the CT-26 syngeneic ectopic tumor mouse model. Animals were injected subcutaneously with 10 ⁶ CT26 tumor cells along the right flank. Antibodies were administered at a dose of 20 mg/kg by intravenous injection 2 times a week for 3.5 weeks. The effect on tumor growth, survival probability, and tumor volume is shown in FIG. 16, Fig. 17 and Fig. 18, respectively. All three antibodies showed a pronounced therapeutic effect in terms of reducing tumor growth, increasing the likelihood of survival, and reducing tumor volume.

Example 2 Histological Antibody Binding Analysis

[0371] Binding to mouse and human tumor cells and adjacent tissues was also analyzed. The original promising antibody and a subset of variants were tested for binding to human estrogen receptor (ER) positive breast carcinoma (stage II) and adjacent breast tissue. Frozen samples were frozen sectioned, placed on glass slides, and lightly fixed with 4% PFA. Slides were incubated with 10, 1, and 0.3 μg/mL primary antibodies and an IgG control (no signal detected), followed by Cy5-conjugated anti-mouse secondary antibodies counterstained with Hoechst and mounted in aqueous mounting medium. Microscopic specimens of adjacent tissues were stained with hematoxylin and eosin (H&E). In FIG. 19 compares the binding of the original promising antibody to tumor and TAT with the binding of variants AIP-157397 and AIP-165430. The AIP-157397 variant showed a marked increase in tumor binding signal. The signal for binding to TAT was also increased compared to the original promising antibody, but binding could be titrated so that no signal was observed in TAT. The AIP-165430 variant demonstrated increased tumor binding compared to the promising antibody with minimal increase in TAT binding. Isotype controls showed no signal (data not shown).

[0372] Binding of the AIP-106042 and AIP-100196 variants to ER positive human breast cancer tissue and TAT was also assessed using slides prepared as described and stained using 30, 10 and 3 μg/ml primary antibody and control IgG. Sections of tissue adjacent to the tumor were stained with H&E. Both AIP-106042 and AIP-100196 bound to tumor tissue, but at lower levels compared to the promising antibody (Figures 20 and 21). Little to no binding to TAT was observed even at the highest concentrations tested (data not shown).

[0373] Binding variants AIP-160470, AIP-133645, AIP-158623, AIP-155066, AIP-136538, AIP-166120, AIP-187893, AIP-142079, AIP-184490, and AIP-104188 were also evaluated for ER- positive breast tumor tissue and TAT compared to the binding exhibited by the original promising antibody. ER-positive breast tumor sections and TAT sections were subjected to H&E staining and immunostaining with promising antibody, variant, or isotype control (IgG) at concentrations of 1, 3, and 10 μg/ml. Immunoreactivity was assessed by fluorescence microscopy, and images were captured as a function of concentration. Positive immunoreactivity (i.e. signal above the IgG control) was found for the promising antibody and all variants (AIP-160470, AIP-133645, AIP-158623, AIP-155066, AIP-136538, AIP-166120, AIP-187893, AIP -142079, AIP-184490, and AIP-104188) with the exception of AIP-136538 (Fig. 22). Images were compared for similar fluorescence intensity in ER-positive breast cancer nuclei, regardless of antibody concentration. With the exception of AIP-136538 and AIP-104188, all variants tested demonstrated fluorescence intensities in the breast tumor similar to those observed for the original promising antibody, but at concentrations of the primary antibody 3- to 10-fold lower. Tumor labeling selectivity and TAT binding were also assessed. The ratio of tumor signal to adjacent tissue signal was markedly increased compared to the promising antibody with a subset of variants, including AIP-160470 and AIP-133645.

[0374] Antibody binding to EMT-6 tumors was also assessed. Tumor samples were collected from animals approximately 7 days after inoculation with 10 ⁶ EMT-6 cells. EMT-6 binding activity was assessed for variants AIP-157397, AIP-165430, AIP-160470, AIP-133645, AIP-158623, AIP-155066, AIP-136538, AIP-166120, AIP-187893, AIP-142079, AIP- 184490, and AIP-104188 (data not shown). Background immunoreactivity was slightly higher in mouse tissue, likely due to interactions with endogenous Fc receptors. While all variants exhibited binding to EMT-6 tumor cells, differences in signal intensity were apparent between variants.

[0375] The original promising antibody (Figure 23A) and variants AIP-133645 (Figure 23B) and AIP-160470 (Figure 23C) were also evaluated for binding to tumors arising in mice inoculated with human cancer cell lines (xenografts) or mouse cancer cell lines (syngeneic). Frozen tumors were cut into frozen sections and placed on glass slides. Antibodies and isotype control (IgG) were conjugated to AF647, and slides were incubated with the conjugates and then counterstained with Hoechst. A section of tissue adjacent to the tumor was also stained with H&E. Tumor sections stained with the variant antibodies showed increased signal compared with the promising antibody for all tumors, including tumors arising from human lung A549 cells, human pancreatic BXPC3 cells, human colon cancer Colo-205 cells, or prostate cancer cells human PC3, as well as tumors arising from mouse colon, breast, lung, or kidney cancer cell lines.

Example 3. Combination therapy - histological analysis

[0376] The original promising antibody was evaluated in vivo in the EMT-6 tumor model as monotherapy and in combination with an anti-PD-1 antibody using a dosing regimen as described in Example 1. EMT-6 tumors from cohorts treated with PBS, anti-PD1 antibody , a promising antibody or combination therapy, was collected two and three weeks after inoculation and evaluated histologically. Tumor sections were stained with H&E and Mason's trichrome (Trichrome). Immune cell phenotypes and activation status were assessed in tumor sections using immunofluorescence for CD4 (CD4+ T cells), CD8 (CD8+ T cells), CD335 (NK cells), CD68 (macrophages), and iNOS (inducible nitric oxide synthase). Immune cell infiltration increased in tumors following checkpoint inhibitor treatment at both two (data not shown) and three weeks (Figure 24) post-inoculation. In addition, strong infiltration was observed at both two (data not shown) and three weeks (Figure 24) in tumors from mice treated with the promising antibody or a combination of the promising antibody and checkpoint inhibitor. Increased iNOS immunoreactivity indicated an active proinflammatory response in tumors from cohorts treated with the promising antibody and combination therapy.

Example 4 Binding Assay ex vivo correlates with antitumor activity in vivo

[0377] The original candidate antibody and variant antibodies were analyzed in an ex vivo binding assay to determine correlation with in vivo antitumor activity. The ex vivo assay design is shown in Fig. 25. Mice were injected with tumor cells and the tumors were allowed to grow to a size of about 500-600 mm ³ . Tumors were harvested, digested, and antibody binding to the surface of live tumor cells was analyzed by flow cytometry. Binding was correlated with NAAC values representing tumor volume after antibody treatment in vivo as described in Example 1. The results demonstrated that antibody binding to EMT6 cells ex vivo was significantly correlated with the in vivo result (Figure 26 and Figure 27). Thus, ex vivo flow cytometry analysis provides a screening assay that is highly correlated with in vivo function, which can be used to identify antibodies that may cause antitumor effects.

Example 5 Antibody Target Binding Assay

[0378] To determine the target on tumor cells to which AIP-192482 binds, immunoprecipitation (IP) was performed on whole cell extracts. A549 cells were incubated overnight in methionine-cysteine-free medium supplemented with ³⁵ S-labeled methionine and cysteine (37°C, 5% CO ₂ ). Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer (25 mM Tris•HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) followed by 5 washes with buffer (1x phosphate-buffered saline solution with the addition of 450 mM NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol). IP reactions using AIP-192482 or control antibody were performed overnight using antibodies coupled to Dynabeads™ M-280 tosyl-activated paramagnetic beads. The beads were then collected on magnets and washed with 450 mM NaCl-containing buffer and eluted with 50 mM Tris, pH 8.0, 1 mM EDTA, and 1% sodium deoxycholate. The radiolabeled antigen bound to the antibodies was eluted with 2× SDS-PAGE sample buffer under reducing conditions and dissolved in 4-20% SDS-PAGE gels under denaturing conditions. The separated proteins were visualized using autoradiography by imaging on a fluorescent phosphor coating. For mass spectrometry (MS) analysis, lysates were prepared using A549 cells that were not metabolically labeled and the PI responses were proportionally enhanced. The eluates were then assessed using nanoLC-MS/MS analysis (performed by Alphalyse and MS Bioworks).

[0379] SDS-PAGE analysis (Figure 28) identified a large number of unique proteins ranging in size from 15.8 to 152.8 kDa. Numerous RNA-binding proteins were among the proteins identified by MS analysis. Large numbers of these identified proteins have been shown to be present in stress granules, see Markmiller et al., Cell , 172, 590-604, January 25, 2018; and Youn et al., Molecular Cell , 69, 517-532 (2018) and Jain et al., Cell 164, 487-498

January 28, 2016. Table 3 lists exemplary proteins identified in the immunoprecipitation complex precipitated by AIP-192482. These identified proteins are classified based on whether they are also known to be found in stress granules, according to assays that have been published previously: i) biochemical release assay on US-02 cells as described in Jain et al. (2016), ii) APEX (proximal labeling) assay performed on HEK293 cells as described by Markmiller et al. (2018), iii) APEX (proximal labeling) assay performed on neural progenitor cells as described in Markmiller et al. (2018), and iv) BioID (proximal labeling) assay on HEK293 cells as described in Youn et al. (2018). Group 1 proteins (12 proteins) are among the list of proteins (20 proteins) previously detected in stress granules by all four published assays. Group 2 proteins (12 proteins) are among that list of proteins (38 proteins) previously detected in stress granules by three of the four published analyses. Group 3 proteins (20 proteins) are among the proteins previously detected in stress granules by two of the four published analyses. Group 4 proteins (63 proteins) are among the list of proteins (139) previously found in stress granules by Jain and colleagues .

Table 3. Illustrative proteins in the immunoprecipitating complex identified by MS

Group 1 Group 2 Group 3 Group 4 Total number=12/20 (60%) Total number=12/38 (32%) Total number=20/61 (33%) Total number=63/139 (45%) ATXN2 DHX36 CASC3 ACIN1 FAM120A ELAVL1 CELF1 ADAR FUBP3 FMR1 DDX6 ATXN2 FXR1 FXR2 EDC4 BAG2 IGF2BP1 HNRNPA1 FUS DDX17 IGF2BP2 HNRNPAB GRSF1 DDX21 IGF2BP3 PABPC1 HNRNPA3 DDX5 PABPC4 PCBP2 HNRNPDL DHX15 STAU2 PRRC2C HNRNPH1 DHX30 SYNCRIP PUM1 HNRNPUL1 DHX9 UPF1 RBMX MOV10 EDC4 YBX3 ZC3HAV1 PTBP1 EFTUD2 PTBP3 EIF4A3 RBM4 ELAVL1 SND1 FAM120A SRSF9 FBL TNRC6A FTSJ3 TRIM25 FUBP3 TRIM56 FUS YBX1 FXR1 HNRNPA0 HNRNPA1 HNRNPA3 HNRNPC HNRNPD HNRNPH1 HNRNPH3 HNRNPL HNRNPR HNRNPUL1 IGF2BP1 IGF2BP2 IGF2BP3 ILF2 ILF3 MATR3 MOV10 NOP56 PABPC1 PABPC4 PCBP2 PLEC PRPF8 PTBP1 RALY RBM14 RBMX RPL14 RPL4 RPS8 RRBP1 SF3B3 SNRNP200 SRRM2 SRSF10 STAU2 SYNCRIP TARDBP TRIM25 TRIM56 UPF1 YBX3 ZC3H7A

[0380] As shown in Table 3 above, there was significant overlap between the list of proteins identified in the immunoprecipitates using AIP-192482 and the proteins known to be present in stress granules according to the published literature. Additionally, contrary to the prevailing belief that such a small amount of PABPC1 is partitioned into stress granules in stressed cells (6% according to Wheeler et al., Methods 126: 12-17 (2017), to allow immunoprecipitation of stress granules from crude lysates by antibody, binding PABPC1, as shown above, immunoprecipitated AIP-192482 complexes successfully containing PABPC1 directly from whole cell lysates.

[0381] Additional proteins identified by MS that were present in AIP-192482 immunoprecipitates at levels 2-fold or greater, or with a score of 2-fold or greater, compared to control immunoprecipitates are:

ABCF1, ACIN1, ACLY, ADAR, AGO1, AGO2, AGO3, AHNAK, ATP2A2, ATXN2, BAG2, BOP1, BUB3, CAD, CASC3, CDC5L, CELF1, CLTA, CNBP, COPA, CRNKL1, DARS, DDX17, DDX18, DDX21, DDX5, DDX54, DDX6, DHX15, DHX30, DHX36, DHX57, DHX9, DICER1, DKC1, DNTTIP2, EDC4, EEF1D, EEF2, EFTUD2, EIF2AK2, EIF2S1, EIF3D, EIF3E, EIF3I, EIF4A3, EIF4G1, EIF6 ,ELAVL1,EPRS, FAM120A, FBL, FMR1, FTSJ3, FUBP3, FUS, FXR1, FXR2, GAR1, GEMIN4, GNL3, GRSF1, GTPBP4, HEATR1, HIST1H1B, HIST1H1C, HIST1H3A, HNRNPA0, HNRNPA1, HNRNPA2B1, HNRNPA3, HNRNPAB, HNRNPC, HNRNPD, HNRNPDL, HNRNPF, HNRNPH1, HNRNPH3, HNRNPK, HNRNPL, HNRNPM, HNRNPR, HNRNPUL1, HNRNPUL2, IGF2BP1, IGF2BP2, IGF2BP3, ILF2, ILF3, KARS, KHDRBS1, L1RE1, LARP1, MAGOHB, MAK16, MAP1B, MATR3, MBNL1, MOV10 MRTO4 MVP, MYBBP1A, MYO1B, NAT10, NCL, NHP2, NIFK, NKRF, NOL11, NOL6, NOP2, NOP56, NOP58, PABPC1, PABPC4, PCBP2, PDCD11, PES1, PGD, PLEC, PPP1CB, PRKDC, PRKRA, PRPF19, PRPF4B, PRPF8, PRRC2C, PTBP1, PTBP3, PUM1, PURA, PURB, PWP1, PWP2, RAB14, RAB2A, RACK1, RALY, RAN, RBM14, RBM34, RBM4, RBM45, RBM8A, RBMX, RCC2, RPL10A, RPL11, RPL12, RPL13A, RPL14, RPL15, RPL17, RPL18, RPL18A, RPL19, RPL21, RPL22, RPL23, RPL23A, RPL24, RPL26, RPL27, RPL29, RPL3, RPL30, RPL32, RPL34, RPL35A, RPL36, RPL4, RPL5, RPL6, RPL7, RPL7A , RPL8, RPLP0, RPLP1, RPLP2, RPS11, RPS13, RPS17, RPS23, RPS24, RPS26, RPS27A, RPS3, RPS3A, RPS5, RPS6, RPS8, RPS9, RPSA, RRBP1, RRP1, RRP9, RRS1, RSL1D1, RTCB, RUVBL2, RYDEN, SART3, SF3B3, SKIV2L2, SLC3A2, SND1, SNRNP200, SNRNP70, SNRPB, SNRPD1, SNRPD2, SNRPD3, SON, SRP68, SRP72, SRPK1, SRPK2, SRRM2, SRSF1, SRSF10, SRSF2, SRSF3, SRSF6, SRSF7 ,SRSF9, SSB, STAU1, STAU2, STRAP, SYNCRIP, TARBP2, TARDBP, TCOF1, TCP1, THOC2, THOC6, TNRC6A, TOP1, TRA2A, TRA2B, TRIM25, TRIM56, TTN, U2AF2, UGDH, UPF1, UTP15, UTP18, UTP4, UTP6, WDR12, WDR36, WDR43, WDR46, WDR74, WDR75, XAB2, XRCC5, XRN2, YBX1, YBX3, YTHDC2, ZC3H7A, ZC3HAV1, ZCCHC3 and ZNF326.

[0382] To test whether RNA is part of the complex to which AIP-192482 binds, lysates were prepared from radiolabeled A549 cells and then treated with increasing amounts of RNase A (0.001 to 10 μg/ml) or DNase I (20 μg /ml). Treated lysates were used in IP using AIP-192482. Bound proteins were analyzed by SDS-PAGE followed by autoradiography. The results showed that treatment with RNase, but not DNase, eliminated proteins immunoprecipitated by AIP-192482 in an RNase dose-dependent manner (Figure 29). This effect was specific for the AIP-192482 antigen, as no such effect was observed for EGFR binding to the control anti-EGFR antibody (data not shown). This result demonstrated that the RNA promotes the binding of AIP-192482 to its target (see Figures 38A and 38B).

[0383] Additional MS analysis was performed to determine the composition of the target. In one such assay, a RIPA lysate prepared from unlabeled A549 cells was incubated with AIP-192482-conjugated M-280 beads and then cross-linked using DTSSP (ThermoFisher). After quenching, lysates were treated with RNase (100 ng/ml). The beads were washed in high salt buffer and the antigen was eluted using 0.5N. ammonium hydroxide before nanoLC-MS/MS (MS Bioworks). Proteins were digested and analyzed in the gel. One RNA-binding protein, PABPC1, was abundant across all MS runs and was enriched after RNase treatment (Figure 30).

[0384] PABPC1 was expressed as a C-terminal FLAG fusion protein in 293T cells transiently transfected with a human PABPC1-FLAG expression plasmid and purified by anti-FLAG antibody chromatography. Purified PABPC1 was incubated with purified poly(A)-RNA (56-mer) generated by in vitro transcription of a linearized plasmid template driven by the T7 promoter. The PABPC1-RNA complex was then incubated with monovalent Fab AIP-192482, and the resulting complexes were separated on a Superose 6 gel filtration column (GE Lifesciences) at a final ratio of 15:15:1 PABPC1:AIP-192482 Fab:RNA by weight. Absorbance at A ₂₈₀ of the eluate from the column and analysis of column fractions using SDS-PAGE electrophoresis (Fig. 31) showed that Fab AIP-192482, PABPC1 and poly(A)-RNA form a high-molecular complex that elutes from the column noticeably earlier than individual components. RNase A was also included in the AIP-192482 incubation step prior to column chromatography. No high molecular weight complex was observed for this sample.

[0385] As explained above, MS results for cross-linked, RNase-treated immunoprecipitate from A549 cells prepared using AIP-192482 showed the presence of PABPC1 in the immunoprecipitate. PABPC3/4, MOV10, UPF1 and other proteins were also identified as components present in the immunoprecipitate.

Example 6: Confocal Imaging Showing Localization and Components of Complexes Targeted by Antibodies

[0386] Immunofluorescence microscopy was performed on EMT6 tumor tissues stained with antibodies. AIP-192482 has been shown to colocalize with a subpopulation of G3BP-positive structures in EMT6 tumors. See FIG. 32A-D. The images showed significant overlap between the signal of AIP-192482 and the signal for G3BP, another marker of stress granules. The results show the presence of smaller G3BP puncta that are not positive for AIP-192482. Although a subset of these G3BP-positive structures, that is, very small dots, are not positive for AIP-192482 immunoreactivity, larger aggregates that are more heterogeneous in structure show co-reactivity. This suggests that AIP-192482 associates with RNP complexes.

[0387] Using confocal microscopy, the antibodies described herein have been shown to target protein complexes located outside the cell. As shown in FIG. 33A-D, AIP-160470 reacted, where CD9 reactivity was also detected. Confocal imaging demonstrates that AIP-160470 reactivity is clearly extracellular in nature, confirming the flow cytometry data as described below. Similar confocal microscopy experiments were performed with human breast carcinoma tissue, which also demonstrated that AIP-160470 colocalized with numerous CD9-positive vesicles, approximately 1 μm in diameter, that appeared extracellular.

[0388] Additional confocal microscopy imaging demonstrated that AIP-160470 signal colocalized with RNA-binding proteins, including PABPC1 and MOV10, and labeling corresponded to extracellular puncta and the plasma membrane in human ovarian cancer tissue.

Example 7 Flow Cytometry Demonstrating Surface Localization of Antibody Targeted Complexes

[0389] EMT6 cells were treated with the chemotherapeutic agent, doxorubicin (“DOX”) or cisplatin (“CDDP”) for 16 hours. Both DOX and CDDP are known inducers of stress granules, Vilas-Boas, et al., J Neurooncol 127:253-260 (2016); and Morita et al., Biochemical and Biophysical Research Communications 417: 399–403 (2012). Treated cells were plated in a 96-well plate and stained with AIP-192482, AIP-160470, or AIP-195694 (negative control). The cells were then stained with a secondary antibody that was conjugated to Alexa 647 and analyzed on a flow cytometer. The geometric mean fluorescence intensity corresponding to antibody binding to EMT6 cells was plotted against the concentrations of chemotherapeutic agents used to treat the cells, see FIG. 35A-B and FIG. 36. These data demonstrate that these antibodies were bound to the cell surface, which complements the confocal data in FIG. 33, which demonstrates EMT6 cell growth in vivo , also induces such surface reactivity. This extracellular surface localization is also confirmed by ex vivo flow cytometry analysis from Example 4.

Example 8: Retrieving AIP-160470 variants

[0390] Antibody variants to AIP-192482 were evaluated in the examples described above. Numerous additional antibody variants were created by introducing various substitutions into the CDR using AIP-160470 as the reference sequence. Variants were tested in an in vitro Fc receptor interaction assay. Variants included individual substitutions introduced in each CDR, as well as variants in which up to four substitutions were introduced in HCDR1, up to five substitutions were introduced in HCDR2, up to thirteen substitutions were introduced in HCDR3, up to six substitutions were introduced in LCDR1, and in LCDR2 up to three substitutions were introduced, and up to six substitutions were introduced in LCDR3. Combinations of variant sequences CDR1, CDR2 and CDR3 were also tested. Variants were tested for in vitro activity, and a subset was tested for in vivo antitumor activity, as described below. The CDR sequences of the active variants are presented in Table 1B and Table 2B.

In vitro activity

[0391] In vitro antibody activity was determined using an FcR interaction assay. Variants were tested in FcγRIIa-H ADCP Reporter Bioassay (Promega). This assay is used to measure the activity and stability of antibodies that specifically bind and activate FcγRIIa. Jurkat cells stably expressing human FcγRIIa-H (H131 high-affinity variant) and NFAT-induced luciferase were used in the assay. Upon interaction of FcγRs in Jurkat effector cells with the Fc region of a test antibody binding to a target cell, intracellular signals are generated in Jurkat cells that lead to NFAT-RE-mediated luciferase activity that can be quantified. The analysis used to analyze the options is detailed in the Detailed Methodology section below.

[0392] The activity of variants active in the in vitro assay is shown in FIG. 39. Variants are considered active if they showed an EC _{of 50,500} nM or less; or if they have a delta activity value relative to AIP-160470 of at least 0.5, as shown in FIG. 39. An antibody whose delta value relative to AIP-160470 is zero is considered inactive. The activity assessment is described below in the “Detailed Methodology” section.

Activity of variants in vivo

[0393] A subset of variants that were active in vitro were selected to evaluate antitumor activity in vivo using the EMT6 mouse model. Two rounds of in vivo studies were conducted. Round 1 included AIP-192482, AIP-160470 and 16 other variants. Round 2 included AIP-192482, AIP-160470, a duplicate variant from Round 1 (AIP-101235), and 16 additional variants generated as described herein. Thus, the in vivo studies described in this application included 34 unique antibodies, where 3 of the 34 antibodies were tested in both rounds. The variants tested in vivo in Rounds 1 and 2 are described in FIG. 40 and 41, respectively, which include EC ₅₀ values and Δ activity rank scores. In vivo antitumor activity was assessed using survival, normalized area over curve (NAAC) and normalized growth rate (NGRM), where NAAC and NGRM were developed at Atreca. These analyzes are described below in the “Detailed Methodology” section. As explained in the Methodology section, “active in vivo ” based on in vivo activity was assessed by a p value ≤ 0.05 in at least one of the survival analyses, NAAC and NGRM, i.e. if the antibody exhibits a p-value that is less than or equal to 0.05 for survival, NAAC, and/or NGRM (either one is sufficient), the antibody is considered “active in vivo .” The design of this study is presented in Fig. 42. In FIG. 43 shows data showing tumor volume by cohort at round 2 randomization. FIG. Figure 44 shows the antitumor effects of the options in round 2, ranked by median survival. In FIG. 45 shows the antibodies that showed the most effective responses in round 2 according to NAAC effect size. In FIG. Figure 46 shows the antibodies that showed the most effective responses in round 2, ranked by NGRM effect size. In FIG. Figure 47 shows the antibodies that produced the most complete responses in round 2. “Complete response (CR) is when three consecutive tumor volume measurements (TVM) are recorded as 0 mm ³ (day 40 assay).” The antibodies that produced the most complete responses are those that produced a complete response in the majority of animals in a group, for example, if there were 6 mice in a group and 3 of the 6 mice had a CR, then that antibody caused 3 CRs, and the figure shows antibodies with the highest CR value. Data for antibodies that exhibited the most robust responses in round 2 are presented in FIG. 48. "Sustained Response" (SR) as defined in FIG. 48 represents the window of ongoing tumor regression after dosing (Day 40 analysis). A summary of the in vivo activity of the subset of variant antibodies with antitumor effects that are presented in FIG. 49.

[0394] The relationship between activity in the in vitro FcγRIIa assay, in vivo activity, and in vivo antitumor activity was examined to determine whether the in vitro assay is predictive of in vivo activity. To model the relationship between in vitro Fc gamma receptor assay results and in vivo activity, a multiple logistic regression model with linear terms was built using R, version 3.4.3 (The R Foundation). The model was trained on a subset of data including AIP-192482, AIP-186435, AIP-172643, AIP-172872 and AIP-114111, yielding only one false positive (AIP-163039) of all antibodies for which no activity was observed in vivo . For each antibody, both EC ₅₀ (nM) and delta activity were averaged across multiple runs, delta activity was normalized to AIP-160470, and in vivo activity was assessed by p -value ≤ 0.05 in at least one of survival analyses, NAAC and NGRM. The results are shown in Fig. 50A and 50V. The analysis demonstrates that an antibody with an in vitro EC ₅₀ and normalized delta activity above the threshold line shown in the two figures is generally predictive of in vivo antitumor activity.

Engineered FR

[0395] The V _H and V _L sequences of AIP-160470 were also designed to contain framework regions from another IGHV or IGLV gene. Framework regions are regions between certain CDR residues. The FR V _H AIP 160470 regions most closely match IGHV3-15, IMGT ID X92216, and the FR V _L AIP 160470 regions most closely match IGLV1-47, IMGT ID Z73663.

[0396] AIP-127782 has CDR AIP-160470 and was designed to have FR V _H IGHV3-72 (IMGT ID X92206) and FR V _L IGLV1-51 (IMGT ID Z73661). AIP-127782 was active in an in vitro interaction assay. Antitumor activity was also assessed in vivo (below). This antibody also exhibited antitumor activity in an EMT6 mouse model.

[0397] Three additional antibodies were produced. AIP-180422 has the CDR of AIP-160470, the FR V _H of IGHV3-72 (IMGT ID X92206), and the FR V _L of native IGLV1-47 (IMGT ID Z73663). AIP-166722 has CDR AIP-160470, FR V _H IGHV3-72 (IMGT ID X92206) and FR V _L IGLV1-40 (IMGT ID M94116). AIP-193490 has CDR AIP-160470, FR V _H IGHV3-49 (IMGT ID M99401); and FR V _L IGLV1-40 (IMGT ID M94116). All of these antibodies were active in an in vitro interaction assay. These antibodies have not been tested in vivo .

Detailed methodology

Syngeneic mouse tumor model EMT6, assessment of antitumor activity in vivo

[0398] The syngeneic EMT6 mouse tumor model was used as described above to evaluate the antitumor efficacy of chimeric ATRC-101 mIgG2a variants. The procedure used is that modified from DeFalco et al., Clin. Immunol. 187:37-45, 2018. EMT6 murine tumor cells were expanded in culture by passaging the cells every 2-3 days (1:10 subcultures). On the day of inoculation, cells were collected, counted and diluted to 5x10 ⁶ cells/ml in Waymouth medium without additives. Cell viability was checked immediately before and after inoculation. Each 4-6 week old female BALB/c mouse was inoculated into the right posterior flank by subcutaneous injection of 1 x 10 ⁶ EMT6 cells in 0.2 ml of Waymouth medium without supplements. The day of cell inoculation was designated Study Day 0. On average, >30% were included to ensure that the study groups achieved constant and uniform tumor volumes. The mouse tumors consistently became visible and palpable approximately three days after cell inoculation. Before randomization, tumor volume was measured 2-3 times. Mice were randomized on study day 7 using the “paired allocation” randomization function of StudyLog laboratory animal software (version 3.1.399.23) to ensure homogeneous tumor volumes. Mice with pre-ulcerated tumors, irregularly shaped tumors, or multiple tumors were excluded from randomization. Test drugs and vehicle controls were prepared in formulation buffer (Dulbecco's PBS, DPBS). Reconstituted antibodies were placed in sterile, pre-sealed, disposable borosilicate glass vials and stored at 4ºC until dosing. Starting on the day of randomization, test samples were administered at a dose of 10 ml/kg based on mouse body weight via intraperitoneal injection twice a week for a total of 7 doses. All mice were dosed as scheduled or until they were excluded from the study based on defined euthanasia criteria and endpoints in accordance with animal use protocol EB17-010-104 at Explora BioLabs. Tumor volumes were measured twice weekly after randomization using electronic calipers connected to StudyLog laboratory animal software (version 3.1.399.23). Tumor volumes were calculated automatically using the following equation:

Tumor volume (mm ³ ) = length (mm) × width ² (mm) × 0.5

After administration of the study drug, mice with a tumor volume of 0 mm ³ for three consecutive measurements were considered to have demonstrated a complete response (CR). Mice with persistent tumor regression that continued beyond the closure of the dosing window were considered to have exhibited sustained response (SR).

[0399] Mice were euthanized when any of the following IACUC protocol-endorsed endpoints were observed:

The tumor volume exceeds ≥2000 mm ³ , the tumor interferes with the animal's normal functioning (posture, gait, ability to eat or drink, breathing, etc.) or extensive ulceration of the tumor (> 50% of the tumor area; or if ulcerated tumors are proven to cause chronic pain)

[0400] Statistical analysis of tumor volumes was performed using normalized area over curve (NAAC) and normalized growth rate metric (NGRM) developed by Atreca, Inc.

[0401] To determine the NAAC, the area between the tumor volume curve and the tumor volume endpoint of 2000 mm ³ was divided by the total area possible on study day 35 after tumor inoculation. The total possible area is determined between the first time point at which all animals have measurable tumor volume and study day 35 for tumor volumes from 0 mm ³ to 2000 mm ³ . NAAC values are between 0 and 1. Individuals with a small area between the curve and the tumor volume endpoint have NAAC values closer to 0, and individuals with a larger area between the curve and the tumor volume endpoint have NAAC values closer to 1.

[0402] To determine the NGRM, the slope was first calculated for log-transformed tumor volumes as a function of time and then scaled to 20 days after tumor inoculation. These slopes were then normalized to values between 0 and 1. Individuals with increasing tumor volume over time had NGRM values closer to 0, and individuals with stable or decreasing tumor volume over time had NGRM values closer to 1.

[0403] Statistically significant differences between the distributions for the treatment and control groups were assessed for NAAC and NGRM using a one-sided Wilcoxon rank sum test yielding a p -value using R version 3.4.3 (The R Foundation). Animals with final tumor volumes that did not reach 1800 mm ³ and did not survive 80% of the analysis duration were excluded from the NAAC and NGRM analyses.

[0404] A survival analysis was performed using study endpoint data. Survival curves for each group were estimated using the Kaplan-Meier method. Statistical analysis was performed using a one-sided log-rank test to evaluate the survival advantage of the test group compared with PBS controls using R version 3.4.3 (The R Foundation). The model predicted that the antibody referred to herein as AIP-192482, AIP-171142, AIP-165430, AIP-189526, AIP-122563, AIP-158623, AIP-155066, AIP-166120, AIP-133645, AIP-187893 , AIP-142079, AIP-160470, AIP-102396, AIP-150055, AIP-167084, AIP-185304, AIP-134770, AIP-141887, AIP-196203, AIP-128195, AIP-116579, AIP-192329, AIP -197809, AIP-142489, AIP-167726, AIP-199834, AIP-143179, AIP-195587, AIP-153462, AIP-115363, AIP-151090, AIP-168083, AIP-161082, AIP-114196, AIP-1 89338 , AIP-183190, AIP-110143, AIP-147176, AIP-134312, AIP-128243, AIP-156172, AIP-147389, AIP-124314, AIP-185291, AIP-135247, AIP-113513, AIP-102299, AIP -179097, AIP-109343, AIP-119622, AIP-191735, AIP-157078, AIP-153475, AIP-133650, AIP-190915, AIP-167400, AIP-109729, AIP-151709, AIP-136628, AIP-1 01601 , AIP-146871, AIP-170053, AIP-199483, AIP-162041, AIP-180675, AIP-183133, AIP-191470, AIP-151167, AIP-106633, AIP-102624, AIP-109484, AIP-126080, AIP -161571, AIP-163039, AIP-101235, AIP-182061, AIP-181246, AIP-192216, AIP-171912, AIP-172872, AIP-167833, AIP-190051, AIP-145518, AIP-167533, AIP-1 12580 , AIP-143155, AIP-119664, AIP-190526, AIP-114403, AIP-156760, AIP-103803, AIP-195588, AIP-145722, AIP-178251, AIP-116142, AIP-183350, AIP-127108, AIP -128147, AIP-109510, AIP-104086, AIP-143132, AIP-170105, AIP-169636, AIP-152243, AIP-138776, AIP-103817, AIP-130491, AIP-188155, AIP-167246, AIP-1 06139 , AIP-198351, AIP-159326, AIP-192275, AIP-190761, AIP-166832, AIP-148062, AIP-129145, AIP-111240, AIP-153888, AIP-130915, AIP-109048, AIP-170569, AIP -154873, AIP-159037, AIP-186826, AIP-156514, AIP-157122, AIP-173276, AIP-150485, AIP-166847, AIP-124013, AIP-126285, AIP-168605, AIP-190274, AIP-1 36060 , AIP-180422, AIP-166722, AIP-127782, AIP-189473, AIP-192571, AIP-112328, AIP-125258, AIP-150199, AIP-125062, AIP-177193, AIP-115388, AIP-107759, AIP -170221, AIP-143369, AIP-189475, AIP-102833, AIP-157045, AIP-175775, AIP-154181, AIP-125984, AIP-160829, AIP-184744, AIP-128136, AIP-181273, AIP-1 53125 , or AIP-131972 will have antitumor activity.

Analysis of interaction with Fc γ RIIa using EMT6 tumor cells

[0405] Antitumor antibody targets, as described herein, are expressed by tumor cells when they grow in vivo , but are not expressed by tumor cells grown under standard in vitro culture conditions. The assay is performed on ex vivo cells, that is, on tumor cells that have been grown as a tumor graft in a syngeneic (immune system-similar) mouse in vivo , then collected and processed within 24-48 hours.

[0406] The assay consists of four parts: A. In vitro generation of parental EMT6 mouse mammary cancer cells; Inoculation and growth of EMT6 tumors in Balb/c mice in vivo ; C. Collection of EMT6 tumor cells and ex vivo cell bank preparation; Use of EMT6 cells ex vivo to analyze interaction with FcγR2a. The protocol for each stage is presented below.

A. In vitro generation of EMT6 mouse mammary cancer cells

1. Remove the vial containing EMT6 cells from the liquid nitrogen.

2. Thaw in a 37°C water bath until almost completely thawed (a small piece of ice should remain) 3. Add the thawed cell suspension (1 ml) to 9 ml of EMT6 cell culture medium in a 50 ml tube

4. Centrifuge, 300xg, room temperature, 5 min.

5. Aspirate the supernatant and resuspend the cells in 15 ml EMT6 medium

6. Add the cell suspension to the TC-treated T75 cell culture flask

7. Grow cells in a humidified incubator at 37°C with 5% CO2

8. Add Fresh Wednesdays on Monday, Wednesday and Friday

9. Proliferate cells when they reach 80% confluency

a. Aspirate cell culture medium from the flask

b. Rinse once with 10 ml PBS without Ca ²⁺ Mg ²⁺

c. Add 2 ml TrypLE (No. 12604021, Invitrogen)

d. Incubate for 5 minutes at 37°C

e. Gently tap the flask to separate the cells (check under a microscope)

f. Add 7 ml NGM to the Petri dish, mix gently by pipetting to resuspend

g. Divide 1:10 in a new flask

h. Add environments. Mix gently by pipetting to obtain a homogeneous suspension.

i. Grow cells in a humidified incubator at 37°C with 5% CO ₂

10. Once cells reach 80% confluence, collect frozen aliquots:

11. Separate the cells as described above and place in a 50 ml tube

12. Take 10 µl of cell suspension and add 10 µl trypan blue

13. Mix well and count the cells using a Countess II Cytometer (# AMQAX1000, Fisher Scientific).

Calculate cell viability

14. Centrifuge, 300xg, room temperature, 5 min.

15. Resuspend in pure FBS at 4 x 10 ⁶ cells/ml

16. Add an equal amount of FBS containing 20% pre-prepared DMSO. (Do not add 100% DMSO directly to cells)

17. Mix well by gently pipetting

18. Add 1 ml (2 x 10 ⁶ cells) cell suspension into cryovials and freeze in Mr Frosty (51000001, ThermoFisher) at -80 °C

19. Transfer to long-term storage in liquid N ₂ the next day

B. Inoculation and growth of EMT6 tumors in Balb/c mice in vivo

Thawing EMT6 cells from a mother bank

1. Thaw 1 vial of EMT6 cells from section A in a 37°C water bath. Transfer cells to a 15 ml conical tube. Add 10 ml of normal culture medium. Centrifuge at 300xg, room temperature, 5 minutes. Aspirate the supernatant. Resuspend the cell pellet in 15 ml NGM and inoculate into a T75 flask

2. On day 2, passage cells from T75 to T225 using the cell passaging method described above

3. On the 4th day, pass the cells 1:10 (1:12 if on weekends)

4. On the 6th or 7th day, pass the cells 1:10 (1:12 if on weekends/if more is required

number of cells, multiply at this stage)

5. On the 8th or 9th day, multiply the cells into 10 vials

6. On day 10 or 11, collect cells for in vivo injection:

EMT6 tumor inoculation

A. Aspirate the cell culture medium from the flask.

B. Rinse once with 10 ml PBS without Ca ²⁺ Mg ²⁺ (20 ml for T225)

C. Add 2 ml TrypLE (No. 12604021, Invitrogen) (5 ml for T225)

D. Incubate for 5 minutes at 37°C

E. Gently tap the flask to separate the cells (check under a microscope)

F. Rinse the cells from the flask with 7 ml (15 ml for T225) EMT6 medium

G. Count cells and determine viability using trypan blue

a. Do not continue if viability is below 85%

H. Centrifuge, 300xg, RT, 5 min.

I. Aspirate the supernatant

J. Resuspend cells in Waymouth medium without FBS to achieve a concentration of 5 x 10 ⁶ cells/ml

a. 1 T225 cell culture flask will yield approximately 18-24×10 ⁶ viable cells

K. Keep cells on ice from now on.

L. Anesthetize 8-week-old female BALB/c mice using isoflurane inhalation.

M. Shave the left side of the BALB/c mice

N. Use a 1 ml syringe with a 25G needle to subcutaneously inject 200 µl of cell suspension (total 1x10 ⁶ cells)

a. Make sure you don't see cells flowing back into the syringe

b. Ensure that the cell suspension does not leak from the injection site

A. Check cell count and viability after inoculation.

a. Should be in the 10% window

P. Monitor tumor growth using calipers

C. Collect EMT6 tumors and prepare ex vivo cell bank

1. Collect tumors as soon as they reach 500-800 mm ³ when measured with a caliper

2. Remove all surrounding skin and muscle

3. Transfer tumors to RPMI on ice containing 1/500 dilution of primocin (100 μg/ml) 4. (Tumors can be pooled and volumes increased proportionally)

5. Prepare a mixture for breaking down tumors (for 1 tumor)

A. 3.3 ml HBSS with Ca ²⁺ Mg ²⁺

b. 33 µl collagenase A (final concentration: 0.2 mg/ml)

c. 33 µl dispase II (final concentration: 0.8 mg/ml)

d. 17 µl DNase (final concentration: 0.02 mg/ml)

e. 6.6 µl primocin

f. Mix and filter through a 0.22 micron cellulose acetate filter for sterilization

6. Remove tumors from RPMI. Cut tumors into small pieces and add 1 ml of tumor digestion mixture 7. Incubate in a capped flow cytometry tube, 15 or 50 ml screw cap tube at 37°C, rotating continuously for 15 min

8. Allow the cells to settle for 30 seconds

9. Carefully remove the supernatant with a 1 ml pipette and add to 3 ml of pure FBS on ice containing

Primocin at a concentration of 100 μg/ml

10. Add another 1 ml of splitting mixture and repeat 2 times, 3 times in total

11. (you can cut off the top of the 1 ml pipette tip and use it for mechanical dissociation between

stages of cleavage)

12. After the last digestion, the cell suspension should pass through the 1 ml micropipette tip

13. Filter the collected cells in FBS through a 100 micron cell filter into a new 50 ml tube

14. Centrifuge, 300xg, 4 °C, 10 min.

15. Discard the supernatant and resuspend the cells in 1 ml of neat FBS (with 100 µg/ml primocine)

16. Count and adjust cell count to ^6x106 cells/mL using FBS (with 100 µg/mL primocine)

a. Due to debris, cell counts using the Countess II or hemocytometer may be inaccurate i. Staining of nucleated cells Draq5 1:1000 (initial concentration 5 mM) and

Counting on a flow cytometer in the APC channel is recommended

ii. Addition of DAPI at a ratio of 1:1000 allows gating of a population of nucleated cells over living cells

(Violet laser required)

1. Prepare a staining solution by adding 1 µL Draq5 (5 mM stock solution) and 1 µL

DAPI in 1 ml PBS

2. Add 40 µl of staining solution to a 96-well round bottom plate. 3. Add 10 µl of cell suspension and mix well

4. Incubate for 5 minutes at room temperature in the dark

5. Analyze the sample using flow cytometry

a. First gate Draq5 positive cells (APC channel)

b. Identify DAPI negative cells (channel BV421) within

Draq5 positive population

6.If the flow cytometer can measure the number of events/µL, you can calculate the number

cells directly (Cytflex can do this)

7. If the flow cytometer cannot measure events/µL (like most BD instruments),

you will need to add counting balls to determine the number of squares

b. Viability should be above 75%

17. Resuspend the cells at a concentration of 4x10 ⁶ cells/ml with FBS (with primocine at a concentration of 100 μg/ml)

18. Add an equal amount of FBS containing 20% DMSO and 100 µg/ml primocin

19. Mix well by pipetting

20. Add 1 ml (2 x 10 ⁶ cells) cell suspension to cryovials and freeze in Mr Frosty at -80 °C

a. Expected number of cells ~ 10x10^6 cells/tumor

21. Transfer to long-term storage in liquid nitrogen the next day

a. Take 1 sample vial and thaw according to Ex Vivo Cell Thawing protocol b. Control cell counting

D. Use of ex vivo EMT6 cells for interaction analysis

Ex vivo cell thawing

1. Thaw the bottle in a water bath at 37 °C

2. Transfer the contents of the vial into a 50 ml conical tube

3. Add 19 ml RPMI + 2% FBS to the cells drop by drop, mixing the suspension

4. Centrifuge, 300xg, 4 °C, 5 min

5. Resuspend in 1 ml PBS+2% FBS+2 mM EDTA

6. Centrifuge, 300xg, 4 °C, 5 min

7. Resuspend in 2 ml assay buffer (RPMI1640+4% low IgG serum)

8. Resuspend in 1 ml assay buffer.

9. Count and adjust cell count to 0.5 x 10 ⁶ cells/ml in assay buffer

a. Perform cell counts as described in section C; 16a

FcγRIIa Interaction Assay (Promega, Kit #G9991)

1. Prepare serial dilutions of antibodies in assay buffer at 1.5-fold excess.

A. Total analysis volume 75 µl

b. Initial concentration 10 ^-6 M

c. logarithmic dilutions on a 6-point dose-response curve in triplicate

2. Add 25 µl of antibody dilution to a white 96-well flat bottom plate.

A. use only the inner 60 wells

b. Fill unused wells with 75 µl assay buffer

3. Add 25 µl ex vivo cells to each well containing the antibody dilution

a. Gently tap the plate to mix the cells with the antibody

4. Incubate for 15 minutes at 37°C, 5% CO2.

5. Thaw a vial of FcγRIIa-H effector cells (0.62 ml) (Promega, kit 3G991) in a water bath at 37 °C

a. Remove the bottle from 37°C as soon as it is thawed

6. Transfer the contents of the vial to a conical tube containing 5.3 ml of assay buffer

7. Mix by inverting the test tube 4-5 times

8. Count and adjust the number of cells to 0.5x10 ⁶ cells/ml

a. Cell counting can be done using a conventional cytometer or hemocytometer 9. Add 25 µl of FcγRIIa-H effector cells to the opsonized target cells

a. E:T ratio 1:1

10. Gently shake the plates to mix the contents (total volume 75 µl)

11. Incubate 5 hours at 37°C, 5% CO2

12. After 5 hours, prepare Bio-Glo Luciferase Solution by adding a whole vial of Bio-Glo™

Bio-Glo Luciferase Assay Substrate Assay Buffer (10 mL total per kit).

13. Remove the plate from the incubator

14. Add 75 µl of Bio-Glo™ mixture to each reaction well

15. Incubate at room temperature in the dark for 15 minutes

16. Measure luminescence using a suitable tablet reader

17. Plot curves and calculate EC50 values

Reagents and buffers

Complete environment for EMT6 (Normal Growth Media, NGM)

Waymouth MB 752/1 + 2 mM L-glutamine + 15% fetal bovine serum (FBS) + 1% penicillin-streptomycin

Analysis buffer

RPMI1640+4% low IgG fetal bovine serum (FBS)

Collagenase A (Sigma-Aldrich, No. 10103586001)

1. Add HBSS with Ca ²⁺ Mg ²⁺ to obtain a stock solution with a concentration of 50 mg/ml

2. Invert the test tube several times

3. Incubate for 5 minutes at room temperature

4. Add to a 1.5 ml snap cap tube

5. Store at -20°C for up to a month

6. Avoid repeating freeze/thaw cycles

Dispase II (Sigma-Aldrich, No. D4693-1G)

1. Dilute 1 g dispase II in 10 ml water, molecular biology grade, with 10 mM

Sodium acetate (pH 7.5) and 5 mM calcium acetate

2. Invert the test tube several times

3. Incubate 60 minutes at room temperature

4. Add to a 1.5 ml snap cap tube

5. Store at 4°C for up to a month

DNase (Sigma-Aldrich, no. 4536282001)

1. Add HBSS with Ca ²⁺ Mg ²⁺ to obtain a stock solution with a concentration of 2 mg/ml

2. Invert the test tube several times

3. Incubate for 5 minutes at room temperature

4. Add to a 1.5 ml snap cap tube

5. Store at -20°C for up to 7 days

6. Avoid repeating freeze/thaw cycles

Example 9: Evaluation of Antibodies for Cancer Treatment - Review

[0407] Antibody for use in the treatment of cancer was further evaluated in the following examples. The antibody is designated ATRC-101 in this example. It is a fully human immunoglobulin G subclass 1 (IgG1)/lambda antibody that contains the V _H and V _L regions of AIP-160470. The amino acid sequences of the heavy and light chains are shown in SEQ ID NO:1723 and 1724, respectively. ATRC-101 is a variant antibody sequence found in an antibody repertoire generated using Immune Repertoire Capture® (IRC™) technology from plasmablastic B cells isolated from a patient with non-small cell lung cancer (NSCLC) adenocarcinoma. At the time of sample collection, the patient was receiving treatment, which in part included a monoclonal antibody against programmed death receptor 1 (PD-1).

[0408] The safety profile of ATRC-101 was established in a series of in vitro cytokine release and tissue cross-reactivity assays, as well as in a repeat dose safety study in a syngeneic disease model (female BALB/c mice inoculated with EMT6 tumor cells). To assess the potential off-target toxicity of ATRC-101, a non-Good Laboratory Practice (GLP) 4-week repeat dose toxicity study was also conducted in cynomolgus monkeys.

[0409] The design of the preclinical safety study package for ATRC-101 reflects the characteristics of the antibody target and the proposed mechanism of action. The ATRC-101 target is a tumor-associated extracellular complex containing RNA-binding protein and (poly(A)-RNA). Although poly(A)-RNA and RNA-binding proteins, such as members of the polyadenylate-binding protein family, are widely expressed in normal tissues of humans, rhesus monkeys, and mice, ATRC-101 binds preferentially to tumor cells. Tumor-selective binding of ATRC-101 was observed in various types of human tumors, including NSCLC, breast cancer, CRC, ovarian cancer and melanoma, where tumor cells were positive but adjacent tissues were not. Binding to EMT6 mouse tumor cells isolated from tumor tissues is lost over time when these cells are cultured in vitro . In addition, ATRC-101 binding to human tumor tissues has been shown to be dependent on the ribonuclease-sensitive component of the complex. ATRC-101 does not bind to tumor-adjacent normal cells, normal cynomolgus macaque tissues, or most normal mouse tissues. Together, these data demonstrate that the ATRC-101 target is tumor associated and that cell surface localization depends on tumor growth conditions in vivo . Tumor association may be based on misfolding, mislocalization, post-translational modification, and/or as yet unidentified factors. Therefore, the mouse and cynomolgus macaque are not suitable species for toxicological testing due to the absence or very low expression of the ATRC-101 target in normal animal tissues.

[0410] Pharmacological evaluations in preclinical models demonstrate that once ATRC-101 binds to a target expressed on tumor cells, Fc-dependent interaction with innate immune cells alters the composition of lymphoid and myeloid cell populations present in the tumor microenvironment from phenotypes predominantly associated predominantly with protumorigenic and immunosuppressive activities, in relation to phenotypes associated with antitumor and more proinflammatory activities. ATRC-101 does not appear to mediate antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) in vitro . All available data demonstrate that binding of ATRC-101 to its target does not trigger or abolish any signal transduction pathways.

[0411] ATRC-101 does not bind to normal human peripheral blood mononuclear cells (PBMCs). In addition, ATRC-101 does not induce cytokine release in vitro in either PBMC-based or whole blood-based assays. Therefore, ATRC-101 is considered to pose a low risk of triggering cytokine release in humans.

[0412] To support preclinical efficacy and safety studies in mice and pharmacokinetic/toxicokinetic studies in cynomolgus monkeys, sensitive and specific liquid chromatography-tandem mass spectrometry (LC-MS/MS) and enzyme-linked immunosorbent assay (ELISA) methods have been developed for the detection of ATRC- 101 in mouse and monkey serum, respectively.

[0413] The pharmacokinetic profile of ATRC-101 was characterized in a single-dose study and a repeated-dose study in cynomolgus monkeys. Following a single intravenous (IV) bolus administration to cynomolgus monkeys at dose levels of 1, 10 and 30 mg/kg, the time of maximum serum concentration (T _max ) was generally observed between 0.083 and 1 hour after dosing. The half-life (T _1/2 ) ranged from 177 to 225 hours. The apparent clearance rate (CL) and apparent volume of distribution (Vd) ranged from 0.15 to 0.436 ml/hour/kg and 51.4 and 117 ml/kg, respectively. Systemic exposure to ATRC-101 increased with dose in the range tested, and this increase was approximately proportional to dose. In a 4-week intravenous repeat dose toxicity and toxicokinetics study in cynomolgus monkeys where animals received 4 weekly doses of ATRC-101 by intravenous administration on days 1, 8, 15, and 22, _Tmax was typically observed at 0.75 hours after start of infusion (SOI). The terminal elimination phase has not been characterized for any animals due to the relatively steady-state concentrations observed after _Tmax . Systemic exposure increased with dose over the tested range, and the increase was approximately proportional to dose. There were no significant sex-related differences in exposure. After repeated administration, systemic exposure on day 22 was generally higher than on day 1, with individual accumulation factors ranging from 1.64 to 2.17.

[0414] The safety of ATRC-101 and the chimera MFC-042 (containing the identical human Fv region of ATRC-101 but expressed with the Fc region of mouse IgG2a; also referred to as AIP-160470-mIgG2a) was assessed in the syngeneic EMT6-BALB breast cancer model. c. This study assessed the following safety parameters: mortality/mortality, clinical manifestations, body weight, clinical pathology (hematology and clinical chemistry), serum cytokine assessment, serum concentrations of study samples, major abnormalities detected on necropsy, organ weights, and histopathological studies. (9 organs plus tumor tissue in animals with tumors). Repeated intraperitoneal (IP) administration of MFC-042 at dose levels of 0, 0.1, 0.3, 1, 3, 10 and 30 mg/kg or ATRC-101 at dose levels of 0, 1, 10 and 30 mg/kg kg naïve female BALB/c mice with EMT6 syngeneic breast cancer was well tolerated and no toxicologically significant effects were noted for any of the parameters assessed. Based on these safety results, the no apparent adverse effect dose (NOAEL) was 30 mg/kg for MFC-042 and ATRC-101 in naïve female BALB/c mice and female BALB/c mice bearing syngeneic breast cancer EMT6.

[0415] A 4-week non-GLP toxicity study in cynomolgus monkeys was conducted to evaluate the potential off-target toxicity of ATRC-101. The following parameters were assessed in this study: mortality/mortality, clinical manifestations, quality indicators of feed intake, body weight, clinical pathology (hematology, clinical chemistry and urinalysis), cytokines, toxicokinetic parameters, organ weights, macroscopic and microscopic examinations (20 organs). /tissues including brain, heart, lungs, liver, kidneys and pancreas). Administration of ATRC-101 by intravenous (IV) infusion once weekly for 4 weeks was well tolerated in cynomolgus monkeys at all dose levels administered: 10, 30, and 100 mg/kg/week. The NOAEL was 100 mg/kg/week with corresponding maximum observed concentration ( _Cmax ) values of 2410 μg/ml for males and 2690 μg/ml for females, and the area under the concentration-time curve from zero to the time of last measurement (AUC _{0- t)} 185,000 μg•h/ml for males and 186,000 μg•h/ml for females on the 22nd day (528 days).

[0416] ATRC-101 and chimeric variants of ATRC-101 demonstrate antitumor activity in several syngeneic mouse tumor models. The antitumor activity of ATRC-101 is enhanced in combination with a PD-1 inhibitor.

[0417] There was no clinical evidence of irritation or local tolerance problems at ATRC-101 injection sites following repeated administration (once weekly, 4 doses total) at doses up to 100 mg/kg (concentration: 20 mg/mL) in cynomolgus monkeys .

[0418] In a GLP tissue cross-reactivity study on normal human tissues, ATRC-101 staining was observed in some human tissues. However, virtually all staining was cytoplasmic in nature and is therefore not considered a toxicological concern since ATRC-101 is unlikely to cross cell membranes or directly interact with cytoplasmic components.

[0419] Pharmacological evaluation of ATRC-101 was performed using the ATRC-101 clinical candidate as well as ATRC-101 sequence variants expressed with human or mouse Fc regions based on study objectives and available animal models/assays. An overview of the relationship between ATRC-101 and sequence variants is shown in FIG. 51.

[0420] The following examples provide additional information about the studies summarized above

Example 10 Expression of ATRC-101 Target in Tumor Tissues and Cell Lines

[0421] Chromogenic IHC, immunofluorescence microscopy, and flow cytometry were used to evaluate expression of the ATRC-101 target (as defined herein by binding antibody reactivity) in (i) multiple human tumor tissues, (ii) mouse tumor tissues, and (iii) cell lines human and mouse tumor cells.

[0422] In an assay of various human tumors, AIP-160470-mIgG2a bound very selectively to CRC, TNBC and melanoma tumor tissues, but not to adjacent tissues according to FIG. 52.

[0423] The percentage of target binding was assessed on a set of human tumor nuclei. Samples were scored as nonreactive if staining was negative or weak, and reactive if staining was moderate, positive, or persistent. Binding to the AIP-160470-mIgG2a target was present in more than 50% of tumor cores tested for NSCLC (65%), breast cancer (65%), CRC (57%), and ovarian cancer (58%). Melanoma showed 43% reactivity. Liver cancer showed 19% reactivity. Cancer subtype-specific differences in the proportion of reactive nuclei were observed.

[0424] These studies showed that the target ATRC-101 is expressed at high levels in several human tumor tissues, including NSCLC, CRC, TNBC, melanoma and ovarian cancer. These studies demonstrate that the ATRC-101 target is tumor associated and that cell surface localization depends on tumor growth conditions.

[0425] Immunofluorescence was used to evaluate whether RNA nuclease digestion affects the binding of the chimeric antibody AIP-160470-mIgG2a to human estrogen receptor positive (ER+) breast cancer. Pretreatment of fresh frozen tissue sections with RNase A and RNase H abolished binding of the chimeric antibody AIP-160470-mIgG2a to human estrogen receptor positive breast cancer in a concentration-dependent manner as shown in FIG. 53 In contrast, pretreatment with deoxyribonuclease (DNase) I did not abolish binding. These data demonstrate that ATRC-101 target expression assessed by immunofluorescence is dependent on the RNase-sensitive component of the target.

[0426] Expression of the ATRC-101 target was assessed in EMT6 mouse tumor cells grown in syngeneic BALB/c mice. The chimeric antibody AIP-160470-mIgG2a binds to the cores of the EMT6-BALB/c syngeneic tumor, but not to adjacent tissues.

[0427] Surface expression of the ATRC-101 target was also assessed by flow cytometry in mouse and human tumor cell lines. The chimeric antibody AIP-160470-mIgG2a bound to syngeneic EMT6-BALB/c mouse tumor cells ex vivo , dissociated, and immediately stained. No binding was detected when ex vivo mouse EMT6 cells were subsequently cultured in vitro for two or more days before staining. When murine EMT6 cell lines were grown only in vitro before staining and not grown as subcutaneous grafts in BALB/c mice, no binding was observed. Surface binding to Renca, CT26 and LLC1 tumor cells was also observed ex vivo , which were grown as subcutaneous grafts in mice before staining. No surface binding was observed for 21 human tumor cell lines grown in vitro .

[0428] Taken together, observations from IHC, immunofluorescence, and flow cytometry demonstrate that the target of ATRC-101 is a tumor-associated RNA-containing complex, and that the expression of this complex and its surface localization depend on how the tumor cells were cultured .

Example 11 Expression of the ATRC-101 target in normal human, cynomolgus and mouse tissues and normal human blood cells

[0429] Chromogenic IHC and immunofluorescence were used to assess ATRC-101 target expression (defined herein as binding antibody reactivity) in (i) normal human tissues, (ii) normal cynomolgus monkey tissues, and (iii) normal mouse tissues.

[0430] Specific binding of AIP-160470-mIgG2a was assessed by immunofluorescence in two formalin-fixed paraffin-embedded (FFPE) tissue microarrays representing 30 normal human tissue types (FDA808J-1 and FDA808J-2). The chimeric antibody AIP-160470-mIgG2a was used to minimize nonspecific interactions. Tumor-selective binding was observed in human adenocarcinoma, which was included as a positive control (Figure 54A).

[0431] AIP-160470-mIgG2a immunoreactivity was observed in normal tissues of 90 nuclei. Only the stomach and cerebellum showed diffuse indeterminate signal compared with isotype controls, each in one of the three nuclei with evidence of autolysis. A weak heterogeneous signal was detected in the serous acinar glandular epithelium of the tongue (the salivary glands of the head and neck), which are secretory in nature, increasing the possibility of nonspecific binding. In contrast to AIP-160470-mIgG2a, a commercial polyclonal antibody generated in response to PABPC-1 showed immunoreactivity against both tumor tissues and normal tissues (FIGS. 54A and 54B). In a separate analysis, tumor-selective binding was also observed using IHC assessment of colorectal cancer and normal human liver, kidney, stomach, heart, pancreas, and lung tissues.

[0432] Potential cross-species cross-reactivity of ATRC-101 was assessed in normal cynomolgus monkey and mouse tissues in a non-GLP study. The concentration of ATRC-101 antibody used for this assessment was shown to preferentially and distinctively label viable malignant cells in the positive control EMT6 mouse tumor rather than labeling adjacent skin or stroma. Fresh frozen normal cynomolgus macaque tissues representing 15 organ types showed no consistent staining under these conditions compared with isotype controls. In fresh-frozen normal mouse tissues representing 30 different organ types, most did not show specific reactivity. Weak to minimal staining was observed in the oral cavity, stomach, small intestine, and spleen of mice.

[0433] No binding of the chimeric parent antibody AIP-192482-mIgG2a and the chimeric antibody AIP-160470-mIgG2a to normal human PBMC preparations was observed by flow cytometry at concentrations at which binding to ex vivo EMT6-BALB/c syngeneic tumor cells was observed .

Example 12 ATRC-101 and ATRC-101 Variants Binding Affinity and Activity in vitro

[0434] As explained above, the in vitro activity of ATRC-101 was assessed in a dual target-effector interaction assay. This assay uses engineered Jurkat cells harboring a luciferase reporter and ex vivo EMT6 tumor cells (from frozen material) to detect dual interactions with Fv and Fc. The FcγRIIa-H reporter gene is activated in the presence of EMT6 cells ex vivo and ATRC-101 protein, resulting in luciferase expression. Reporter gene activity is determined using the Bio-Glo™ Luciferase Assay System.

[0435] In this assay, ATRC-101 induced luciferase expression with a half-maximal effective concentration (EC50) of 67.8 ± 37 nM. When the assay was performed using cultured EMT6 cells that do not express detectable levels of the target ATRC-101, no luciferase signal was detected. Similarly, the aglycosylated Fc variant ATRC-101, which carries the N297A mutation and therefore lacks Fc effector function, did not induce a luciferase signal in this assay. These data demonstrate that both target binding to the Fv region and interaction with FcγR2a of the Fc region are required for ATRC-101 activity in a dual target-effector interaction assay.

[0436] In vitro activity in a dual target-effector interaction assay was greatest for ATRC-101 (AIP-160470-hIgG1), followed by the sequence optimized variant AIP-133645-hIgG1, and then the parent antibody AIP-192482-hIgG1 . Similarly, in vivo activity in the syngeneic EMT6-BALB/c mouse tumor model was greatest for the chimeric variant ATRC-101 (AIP-160470-mIgG2a), followed by the chimeric variant AIP-133645-mIgG2a with the chimeric variant of the parent antibody AIP-192482 -mIgG2a demonstrates the least antitumor effect.

[0437] In vitro ADCC and CZC assays were performed to evaluate whether ADCC or CZC contribute to the mechanism of action of ATRC-101. The ADCC assay used the CD16-transfected NK92 cell line as effector cells and, as target cells, either ex vivo tumor-derived EMT6 cells that express the target or cultured EMT6 cells that do not express the target. The chimeric antibody AIP-160470-mIgG2a demonstrated no activity in mouse ex vivo EMT6, ex vivo Renca, or ex vivo LLC1 cells in this assay, while the positive control antibody AIP-171125-mIgG2a demonstrated killing of various target cells.

[0438] Similarly, AIP-192482-mIgG2a did not exhibit CDC activity in a CDC assay using rabbit serum as a complement source and ex vivo tumor-derived EMT6 cells as target cells. These data indicate that ATRC-101 does not act through ADCC or CDZ mechanisms.

Evaluation of ATRC-101-induced cytokine release in human peripheral blood mononuclear cell and whole blood in vitro assays

[0439] Systemic activation of immune cells by monoclonal antibodies can lead to cytokine release syndrome. An in vitro cytokine release assay (CRA) using immobilized antibodies and human PBMCs has been shown to predict cytokine release syndrome in patients. The ability of ATRC-101 to induce cytokine release in vitro was assessed using human PBMCs and whole blood versions of the CRA at Charles River Laboratories (Portishead, UK).

[0440] In the PBMC version of the CRA, the ability of ATRC-101 to induce cytokine release was assessed in PBMCs obtained from multiple healthy human donors. This assay format uses test and control samples immobilized at a concentration of 1 μg/well and is believed to be capable of predicting cytokine storm responses similar to those observed during a phase I clinical study of the therapeutic monoclonal antibody TGN1412. Anti-CD28 clone 28.1 (Ancell Corp., Bayport, MN, USA) and anti-CD3 muromonab (Orthoclone OKT3) were used as positive controls in the CRA for PBMCs. Human IgG1 isotype (hIgG1) antibody (targeting β-galactosidase), formulation buffer, and Dulbecco's phosphate-buffered saline (DPBS) were included as negative controls.

[0441] In the whole blood version of the CRA, the ability of ATRC-101 to induce cytokine release was assessed in whole blood from multiple healthy human donors. This assay format uses test drugs in a 1.1 nM solution. Anti-CD28 and alemtuzumab (anti-CD52) were used as positive controls, and hIgG1 isotype antibody, formulation buffer, and DPBS were included as negative controls in this assay format.

[0442] In both PBMC and whole blood CRA variants, the cytokine release observed with ATRC-101 was comparable to the cytokine release observed for the hIgG1 isotype control. ATRC-101-associated cytokine release was generally significantly lower than that observed in response to stimulation with the corresponding positive control antibodies. Based on these data, ATRC-101 poses a low risk of triggering cytokine release in humans.

Example 13. Pharmacology in vivo

[0443] ATRC-101 has been shown to bind to in vitro reconstituted complexes containing in vitro transcribed RNA and (i) recombinant human/non-human primate PABPC-1 or (ii) recombinant murine PABPC-1 with comparable affinity and binds with tumor cores from both humans and mice. Therefore, in vivo pharmacological evaluation of ATRC-101 in syngeneic mouse models was performed using the clinical candidate ATRC-101 as well as ATRC-101 sequence variants expressed with human or mouse Fc regions. Chimeric mouse variants are expected to have greater antitumor efficacy in syngeneic mouse models than hIgG1 because hIgG1 has reduced affinity for mouse Fc-gamma receptors.

Preclinical evaluation of the efficacy and safety of MFC-042 and ATRC-101 in the syngeneic EMT6 breast cancer model (studies ATRC-101.PD.18.01 and ATRC-101.PD.18.02)

[0444] The purpose of this study was to evaluate the preclinical efficacy and safety endpoints of MFC-042 (containing identical human Fv region ATRC-101 but expressed with the Fc region of mouse IgG2a; also referred to as AIP-160470-mIgG2a) and ATRC-101, which administered to naïve female BALB/c mice and female BALB/c mice with syngeneic breast cancer EMT6. This study consisted of two parts that were conducted simultaneously: the evaluation of MFC-042 (Part A; ATRC-101.PD.18.01) and ATRC-101 (Part B; ATRC-101.PD.18.02).

[0445] In Part A of the study, seven groups of female BALB/c mice (15 animals/group) with developed subcutaneous EMT6 tumors (group mean tumor volume (MTV)=112-113 mm3) were administered by intraperitoneal (IP) injection (vehicle), 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, or 30 mg/kg MFC-042 at 1, 4, 8, 11, and 15 days. Two groups of tumor-free (naïve) mice (15 animals/group) received vehicle or 30 mg/kg MFC-042 using the same dosing schedule. On day 16, animals were sacrificed for necropsy.

[0446] In Part B of the study, four groups of female BALB/c mice (15 animals/group) that had developed subcutaneous EMT6 tumors (group MTV=108 mm3) were given an IP injection of 0 mg/kg (vehicle), 3 mg/kg, 10 mg/kg or 30 mg/kg ATRC-101 on days 1, 4, 8, 11, and 15. Two groups of naïve mice (15 animals/group) received vehicle or 30 mg/kg ATRC-101 using the same dosing regimen. On day 16, animals were sacrificed for necropsy.

[0447] The following parameters and endpoints were evaluated in this study: mortality/mortality, clinical manifestations, body weight, global efficacy assessment, clinical pathology parameters (hematology and clinical chemistry), serum cytokine assessment, serum concentrations of study drug, severe abnormalities revealed by necropsy, organ mass, and microscopic examination (9 organs plus tumor tissue in animals with tumors). Overall efficacy was determined based on tumor growth inhibition (TGI), defined as the percentage difference between the MTV of the treated and control groups, and assessed at day 15 (Part A) or day 14 (Part B).

[0448] Repeated intraperitoneal administration of MFC-042 and ATRC-101 to naïve female BALB/c mice and female BALB/c mice bearing EMT6 mammary tumors was well tolerated at doses up to 30 mg/kg.

[0449] In Part A (Figure 55A), Group 1 MTV (vehicle control) reached 787 mm3 on day 15, with individual tumor volumes ranging from 288 to 1352 mm3. In comparison, the lower dose MFC-042 treatment groups (groups 2-4) were not statistically different from the vehicle control group or from each other ( p > 0.05 using Mann-Whitney U test) with MTV 719 , 847 and 726 mm3, equivalent to 9, -8 and 8% TGI for the treatment groups that received 0.1, 0.3 and 1 mg/kg MFC-042, respectively. Higher doses of MFC-042 (3, 10, and 30 mg/kg) reduced MTV to 221 (72% TGI), 92 (88% TGI), and 196 mm3 (75% TGI), respectively, and were significantly different from group 1 ( p <0.01 for 3 mg/kg and p <0.001 for 10 and 30 mg/kg). Notably, all three high doses achieved TGI values that were well above the 60% threshold that the contract research organization considered to be indicative of potential therapeutic activity. Minimal antitumor activity was observed at 3 mg/kg with serum concentrations ranging from 16.6 to 20.3 μg/ml. Maximum antitumor activity was observed at 10 mg/kg with measured serum concentrations ranging from 21.9 to 87.5 μg/mL 6 hours after dosing on day 1. Microscopically, tumors in mice treated with ≥ 3 mg/kg MFC-042 had smaller areas of necrosis, sometimes lacked central areas of necrosis, and were often accompanied by mixed-cell inflammation (≥ 10 mg/kg). Tumor emboli were not observed in the lungs of mice administered MFC-042 at a dose of ≥ 10 mg/kg.

[0450] In Part B (Figure 55B), Group 1 MTV (vehicle control) reached 486 mm3 on day 14, with individual tumor volumes ranging from 221 to 936 mm3. In comparison, treatment with 1 mg/kg ATRC-101 (group 2) was not statistically different from the vehicle control ( p >0.05) with an MTV of 550 mm3, equivalent to -13% TGI. In contrast, higher doses of ATRC-101 (10 and 30 mg/kg) reduced MTV to 256 mm3 (47% TGI) and 75 mm3 (85% TGI), respectively, and were significantly different from group 1 ( p < 0.01 for 10 mg/kg and p < 0.001 for 30 mg/kg). Notably, 30 mg/kg ATRC-101, where the highest serum concentration measured was 295 μg/mL, exceeded the 60% TGI threshold, indicating potential therapeutic activity. Lower potency of ATRC-101 compared to MFC-042 is expected given that ATRC-101 is a fully human antibody with reduced affinity for mouse Fc-gamma receptors. Under the microscope, tumors from mice treated with 30 mg/kg ATRC-101 had smaller areas of necrosis, sometimes lacked a central area of necrosis, and had a lower mitotic rate. In addition, tumor emboli were not observed in the lungs of ATRC-101-treated mice.

[0451] In summary, administration of MFC-042 (3 mg/kg, 10 mg/kg, and 30 mg/kg) or ATRC-101 (10 mg/kg and 30 mg/kg) significantly inhibited the growth of syngeneic EMT6 breast carcinoma tumors in female BALB/c mice. All treatments were well tolerated.

Efficacy of ATRC-101 variants in syngeneic mouse tumor models

[0452] The antitumor efficacy of chimeric variants of ATRC-101 was assessed in syngeneic tumor models EMT6, CT26, and E0711, selected based on their demonstrated sensitivity to checkpoint inhibitor therapy. These studies were performed using mouse chimeric variants containing the human Fv region expressed with the mouse Fc region to ensure optimal interactions with mouse Fc gamma receptors in vivo .

Efficacy of ATRC-101 variants alone or in combination with PD-1 blockade in a syngeneic mouse tumor model EMT6

[0453] Four studies were conducted to evaluate the antitumor efficacy of chimeric ATRC-101 mIgG2a variants in the EMT6 syngeneic mouse model of breast cancer. In all three studies, BALB/c mice were inoculated subcutaneously with 1 x 106 EMT6 mouse mammary carcinoma cells on day 0, and study drug administration was initiated when tumors formed. Statistical comparisons between tumor volumes from different treatment groups were performed using the Wilcoxon NAAC rank sum test and the normalized growth rate metric (NGRM) developed at Atreca, Inc.

[0454] In one study (Study EFF-010), a syngeneic EMT6-BALB/c mouse tumor model was used to evaluate the effect of Fc effector function on antitumor efficacy following administration of the AIP-192482 isotype variant. The parent antibody AIP-192482 was expressed as Fc effector competent mIgG2a (AIP-192482-mIgG2a), Fc effector mutant non-N-glycosylated mIgG2a (AIP-192482-mIgG2a-N297A), or mouse immunoglobulin G subclass 1 (mIgG1 ; AIP-192482-mIgG1) or mouse immunoglobulin G, subclass 3 (mIgG3; AIP-192482-mIgG3) with weak Fc effector function compared to mIgG2a.

[0455] In this study, administration of 10 mg/kg AIP-192482-mIgG2a resulted in significant antitumor efficacy compared to vehicle control ( p < 0.0001 based on one-sided Wilcoxon rank sum test NAAC or NGRM) with complete tumor regression (CR) observed in 15 of 20 mice (Fig. 56). No significant antitumor efficacy was observed following administration of the AIP-192482-mIgG2a-N297A variant, while AIP-192482-mIgG1 and AIP-192482-mIgG3 exhibited some antitumor activity ( p < 0.001 and p = 0.01, respectively, based on Wilcoxon rank sum test NAAC). These results demonstrate that Fc effector function is associated with and required for the antitumor activity of the chimeric parent AIP-192482 in the syngeneic EMT6-BALB/c mouse model.

[0456] In another study (Study EFF-016), seven groups of mice with established subcutaneous EMT6 tumors (mean tumor volume per group 156 mm3) were randomized into treatment groups of 20 mice per group on day 6 of the study. Mice were administered i.p. (i) 10 mg/kg AIP-192482-mIgG2a, (ii) 5 mg/kg AIP-192482-mIgG2a, (iii) 5 mg/kg AIP-133645-mIgG2a, (iv) 2.5 mg/kg AIP-133645-mIgG2a, (v) 5 mg/kg AIP-160470 mIgG2a or (vi) 2.5 mg/kg AIP-160470-mIgG2a on days 7, 10, 14, 17, 21, 24 and 27 . Animals receiving vehicle control were dosed with Dulbecco's PBS (DPBS).

[0457] Administration of AIP-192482-mIgG2a, AIP-133645-mIgG2a, or AIP-160470-mIgG2a resulted in a significant reduction in tumor volume at each dose level tested compared to the vehicle control group in NAAC and NGRM analyzes (Fig. 57). At 5 mg/kg dose levels, both AIP-133645-mIgG2a and AIP-160470-mIgG2a had significantly greater antitumor efficacy than AIP-192482-mIgG2a ( p < 0.05 by NAAC and NGRM analysis for both comparisons). At 5 mg/kg, the largest effect size compared to vehicle control (demonstrating an antitumor effect) was observed for AIP-160470-mIgG2a. [

[0458] Administration of AIP-192482 mIgG2a, AIP-133645-mIgG2a, or AIP-160470-mIgG2a at each dose level resulted in a significant increase in survival compared with vehicle administration ( p < 0.001 for all study drugs and dose levels), with a mean survival was prolonged compared with the vehicle control group.

[0459] All chimeric variants of mIgG2a ATRC-101 showed antitumor efficacy in this study, with the largest effect size observed for AIP-160470-mIgG2a, a chimeric version of ATRC-101.

[0460] In Study EFF-004, the syngeneic mouse tumor model EMT6-BALB/c was used to evaluate the effect of 20 mg/kg AIP-192482-mIgG2a on tumor volume and survival when administered alone or in combination with 10 mg/kg anti-PD monoclonal antibody -1 mouse (clone RMP1-14, BioXCell). In this study, AIP-192482-mIgG2a at a dose of 20 mg/kg demonstrated significant antitumor activity when administered alone or in combination with a mouse anti-PD-1 monoclonal antibody, while a mouse anti-PD-1 monoclonal antibody did not exhibit antitumor efficacy when administered as monotherapy.

[0461] In this study, administration of AIP-192482-mIgG2a alone and AIP-192482-mIgG2a in combination with a mouse PD-1 monoclonal antibody resulted in CR in 11 of 16 and 13 of 15 mice, respectively. Animals with PR were reinfected on day 51, 24 days after the last treatment. Of the 24 mice that had CR after administration of AIP-192482-mIgG2a alone or in combination with a mouse anti-PD-1 monoclonal antibody, the remaining 20 mice were tumor-free after reinfection, indicating that AIP-192482-mIgG2a may cause immunological memory.

[0462] The effect of co-administration with a mouse anti-PD-1 monoclonal antibody was further studied in study EFF-020. Female BALB/c mice that developed subcutaneous EMT6 tumors were randomized into treatment groups of 20 mice per group on study day 7, with a mean tumor volume per group of approximately 104 mm3. Mice were intraperitoneally treated with vehicle (DPBS) or 2 dose levels of each of AIP-192482-mIgG2a or AIP-160470-mIgG2a on days 7, 11, 14, 18, 21, 25, 28. Mice were also dosed intraperitoneally with 10 mg/kg anti-mouse PD-1 monoclonal antibody (clone RMP1-14, BioXCell) or vehicle (DPBS) on days 7, 11, 14, 18.

[0463] In this study, the monotherapy groups showed a significant reduction in tumor growth compared to the vehicle control group ( p < 0.01 for NAAC and NGRM analyzes for each comparison. Administration of 5 mg/kg or 10 mg/kg mIgG2a AIP -192482 in combination with a mouse PD-1 monoclonal antibody resulted in a significant reduction in tumor volumes compared with the vehicle control group, the mouse PD-1 monotherapy group, and the corresponding AIP-192482-mIgG2a monotherapy group ( p < 0. 05 by analysis of NAAC and NGRM scores for each comparison;(Figure 58A) The number of CRs increased from 0 in the AIP-192482-mIgG2a monotherapy groups to 6 CR and 4 CR, respectively, at 5 mg/kg or 10 mg/kg AIP-192482-mIgG2a in combination with a monoclonal antibody to mouse PD-1.

[0464] In this study, administration of 2.5 mg/kg or 5 mg/kg AIP-160470-mIgG2a in combination with a mouse anti-PD-1 monoclonal antibody resulted in a significant reduction in tumor volumes compared to the vehicle control group and the anti-mouse PD-1 monotherapy ( p < 0.001 by analysis of NAAC and NGRM scores for each comparison; FIG. 58B). Tumor volumes were not significantly different when AIP-160470-mIgG2a was administered in combination with an anti-mouse PD-1 monoclonal antibody and when AIP-160470-mIgG2a was administered as monotherapy at any dose level. However, the effect size and number of PRs increased

Efficacy of ATRC-101 variants in the CT26-BALB/c syngeneic tumor model of mice

[0465] Two studies, EFF-031 and EFF-039, were conducted to evaluate the antitumor efficacy of chimeric ATRC-101 mIgG2a variants in a syngeneic mouse tumor model, CT26-BALB/c. In both studies, BALB/c mice were inoculated subcutaneously with the mouse colon carcinoma cell line at 1 x 106 CT26 and study drug administration was initiated when tumors formed. Statistical comparisons between tumor volumes from different treatment groups were performed using the Wilcoxon rank sum test of NAAC and NGRM parameters developed at Atreca, Inc.

[0466] In the EFF-031 study, the syngeneic CT26-BALB/c tumor mouse model was used to evaluate the effects of (i) AIP-192482-mIgG2a, (ii) AIP-133645-mIg2a, or (iii) AIP-160470-mIgG2a administered into /b at a dose of 20 mg/kg three times a week for 3 weeks, depending on tumor volume and survival. In this study, all three study drugs showed significant antitumor efficacy and survival compared with the vehicle control group dosed with DPBS.

[0467] In the EFF-039 study, mice that developed subcutaneous CT26 tumors (mean tumor volume per group of approximately 145 mm3) were randomized to treatment groups on day 9 of the study. Mice were intraperitoneally dosed with 20 mg/kg AIP-192482-mIgG2a (40 mice) or vehicle (DPBS; 20 mice) on days 9, 11, 13, 15, 18, 20, 22, 25, 27, and 29. Tumors in the vehicle control group showed rapid growth in tumor volumes according to FIG. 59A). The antitumor activity of AIP-192482-mIgG2a was significantly higher than that of the vehicle control group ( p =1.21×10-10 for NAAC and p =1.63×10-11 for NGRM). A significant improvement in survival was observed in the AIP-192482-mIgG2a group compared with vehicle control.

[0468] Animals dosed with AIP-192482-mIgG2a were observed until day 97 to assess duration of response. By day 97, the AIP-192482-mIgG2a group showed CR in 21 of 40 mice (Figure 59B).

[0469] CR animals were inoculated with 1 x 106 CT26 cells in the contralateral flank on study day 99, 70 days after the last dose of AIP-192482-mIgG2a. In parallel, 20 age-matched, antibody-naïve BALB/c mice were inoculated with 1 x 106 CT26 cells on day 99 of the study as a control. In case of re-infection, no doses of the study drug were administered. Naive control BALB/c mice inoculated with CT26 cells showed rapid tumor growth. In contrast, all 21 mice that had a CR to previous AIP-192482-mIgG2a administration remained tumor-free after reinfection, indicating that AIP-192482-mIgG2a administration can induce a durable antitumor response and immunological memory in a syngeneic mouse tumor model CT26 after any dose level of AIP-160470-mIgG2a in combination with mouse anti-PD-1 monoclonal antibody compared with corresponding AIP-160470-mIgG2a monotherapy, 4 CR to 10 CR at 2.5 mg/kg and 4 to 8 CR at 5 mg/kg AIP-160470-mIgG2a.

[0470] Taken together, the data demonstrate that administration of ATRC-101 variants has antitumor activity in the syngeneic CT26-BALB/c mouse tumor model and that activity is enhanced in combination with PD-1 blockade.

Efficacy of ATRC-101 variants in the syngeneic CT26-BALBc mouse model

[0471] Two studies, EFF-031 and EFF-039, were conducted to evaluate the antitumor efficacy of chimeric ATRC-101 mIgG2a variants in a syngeneic mouse tumor model, CT26-BALB/c. In both studies, BALB/c mice were inoculated subcutaneously with the mouse colon carcinoma cell line at 1 x 106 CT26 and study drug administration was initiated when tumors formed. Statistical comparisons between tumor volumes from different treatment groups were performed using the Wilcoxon rank sum test of NAAC and NGRM parameters developed at Atreca, Inc.

[0472] In the EFF-031 study, the syngeneic CT26-BALB/c tumor mouse model was used to evaluate the effects of (i) AIP-192482-mIgG2a, (ii) AIP-133645-mIg2a, or (iii) AIP-160470-mIgG2a administered into /b at a dose of 20 mg/kg three times a week for 3 weeks, depending on tumor volume and survival. In this study, all three study drugs showed significant antitumor efficacy and survival compared with the vehicle control group dosed with DPBS.

[0473] In the EFF-039 study, BALB/c mice that developed subcutaneous CT26 tumors (mean tumor volume per group of approximately 145 mm3) were randomized to treatment groups on day 9 of the study. Mice were intraperitoneally dosed with 20 mg/kg AIP-192482-mIgG2a (40 mice) or vehicle (DPBS; 20 mice) on days 9, 11, 13, 15, 18, 20, 22, 25, 27, and 29. Tumors in the vehicle control group showed rapid growth in tumor volumes (FIG. 59A). The antitumor activity of AIP-192482-mIgG2a was significantly higher than that of the vehicle control group ( p =1.21×10-10 for NAAC and p =1.63×10-11 for NGRM). A significant improvement in survival was observed in the AIP-192482-mIgG2a group compared with vehicle control.

[0474] Animals dosed with AIP-192482-mIgG2a were observed until day 97 to assess duration of response. By day 97, the AIP-192482-mIgG2a group showed CR in 21 of 40 mice (Figure 59B).

[0475] CR animals were inoculated with 1 x 106 CT26 cells in the contralateral flank on study day 99, 70 days after the last dose of AIP-192482-mIgG2a. In parallel, 20 age-matched, antibody-naïve BALB/c mice were inoculated with 1 x 106 CT26 cells on day 99 of the study as a control. In case of re-infection, no doses of the study drug were administered. Naive control BALB/c mice inoculated with CT26 cells showed rapid tumor growth. In contrast, all 21 mice that had a CR to previous AIP-192482-mIgG2a administration remained tumor-free after reinfection, indicating that AIP-192482-mIgG2a administration can induce a durable antitumor response and immunological memory in a syngeneic mouse tumor model CT26-BALB/c.

Efficacy of ATRC-101 variant AIP-192482-mIgG2a alone and in combination with PD-1 blockade in syngeneic mouse models of E0771 tumor

[0476] The syngeneic mouse tumor model E0771-C57BL/6 was used to evaluate the effect of AIP-192482-mIgG2a administration on tumor volumes when administered alone or in combination with a mouse monoclonal antibody to PD-1 (clone RMP1-14, BioXCell), in study EFF-006. C57BL/6 mice were inoculated subcutaneously with 1 × 106 cells of the mouse mammary medullary adenocarcinoma line E0771. Four groups of female mice that developed subcutaneous E0771 tumors were randomized into treatment groups of 20 mice per group on study day 8, with a mean tumor volume of approximately 104 mm3 in each group. Mice were intraperitoneally injected with 20 mg/kg AIP-192482-mIgG2a or vehicle (DPBS) on days 9, 13, 16, 20, 23, 27, and 30. Mice were also dosed intraperitoneally with 2.5 mg/kg anti-mouse PD-1 monoclonal antibody or vehicle (DPBS) on days 9, 13, 16, and 20. Statistical comparisons between tumor volumes from different treatment groups were performed using the Wilcoxon rank sum test of NAAC and NGRM parameters developed at Atreca, Inc.

[0477] In this study, administration of AIP-192482-mIgG2a or mouse anti-PD-1 monoclonal antibody alone resulted in delayed growth of tumor volumes in some animals, but did not result in a significant reduction in tumor volume compared to vehicle control (FIG. 60). Administration of AIP-192482-mIgG2a in combination with a mouse monoclonal antibody to PD-1 resulted in a significant reduction in tumor volumes compared with vehicle ( p=0.0176 for NAAC and p=0.0007 for NGRM), administration of anti-PD antibody alone -1 mice (p=0.0455 for NAAC and p=0.00194 for NGRM) and administration of AIP-192482-mIgG2a alone (p=0.0262 for NGRM).

[0478] These results demonstrate that administration of the ATRC-101 variant in combination with a mouse anti-PD-1 monoclonal antibody enhances antitumor efficacy compared to the corresponding monotherapies in a syngeneic mouse tumor model E0771-C57BL/6.

Impact of Host T Cells on the Antitumor Efficacy of AIP-192482-mIgG2a in the EMT6-BALB/c Syngeneic Mouse Tumor Model

[0479] Syngeneic EMT6-BALB/c mouse tumor models were used to evaluate the potential contribution of T cells to the antitumor efficacy of the parent antibody AIP-192482-mIgG2a, which has antitumor activity in the syngeneic EMT6-BALB/c mouse tumor model.

[0480] In the TMD04 study, the antitumor efficacy of AIP-192482-mIgG2a was assessed in the presence or absence of an anti-mouse CD8α antibody that depletes mouse CD8+ T cells. To evaluate antitumor efficacy, BALB/c mice were inoculated subcutaneously with EMT6 cells. Once tumors had formed, mice were dosed twice weekly with (i) T cell-depleting anti-mouse CD8α antibody or vehicle (DPBS) and (ii) AIP-192482-mIgG2a or vehicle control (DPBS). In this study, administration of AIP-192482-mIgG2a resulted in a significant reduction in tumor growth in the absence of mouse CD8α depleting antibody ( p < 0.0001 for both NAAC and NGRM comparisons; FIG. 61). When anti-mouse CD8α antibody was administered, the antitumor efficacy of AIP-192482-mIgG2 was neutralized.

[0481] In the EMT6-ATRC-e002 study, the antitumor efficacy of AIP-192482-mIgG2a was assessed in nude BALB/c mice bearing an EMT6 tumor (BALB/cnu/nu (CAnN.Cg- Foxn1nu /Crl)), which lack T cells. Nude BALB/c mice were inoculated subcutaneously with EMT6 cells. 7 days after tumor inoculation (mean tumor volume in the group between 80 mm3 and 150 mm3), mice were treated three times a week with (i) 10 mg/kg AIP-192482-mIgG2a, (ii) 20 mg/kg AIP-192482-mIgG2a , or (iii) control media (DPBS). Animals in all three treatment groups demonstrated a rapid increase in tumor volumes throughout day 25 of the study, with no effect of AIP-192482-mIgG2a administration on tumor volumes.

[0482] Taken together, data from both experiments demonstrate that T cells, most likely CD8+ T cells, are required for the antitumor activity of AIP-192482-mIgG2a in mouse models.

Effect of AIP-192482-mIgG2a on the tumor microenvironment in the syngeneic mouse tumor model EMT6-BALB/c

[0483] The effect of administration of the parent antibody AIP-192482-mIgG2a on the TME was assessed in the syngeneic mouse model EMT6-BALB/c, in which AIP-192482-mIgG2a has antitumor activity.

[0484] In the EFF-004 study, TME was assessed by immunofluorescence in tumors collected from mice treated with an IP dose of 20 mg/kg AIP-192482-mIgG2a or vehicle (DPBS) on days 7, 10, 14, 18, and 21 . At day 15 after 3 doses of AIP-192482-mIgG2a or vehicle, the proportion of CD8+ T cells in tumors from AIP-192482-mIgG2a-dosed mice was significantly higher than in tumors from vehicle-treated mice (p < 0 .05 by Fisher's least significant difference (Figure 62).Similarly, the proportion of iNOS (inducible nitric oxide synthase), pro-inflammatory M1-polarized macrophages in tumors from mice dosed with AIP-192482-mIgG2a was significantly higher by 15- day than in tumors from vehicle-treated mice (p < 0.01 by unpaired t test (Figure 62).

[0485] At day 22 after administration of 5 doses of AIP-192482-mIgG2a or vehicle, the proportion of CD4+FoxP3+ regulatory T cells (Treg) in tumors from mice dosed with AIP-192482-mIgG2a was significantly lower than in tumors obtained from mice that received vehicle.

[0486] In one study (Study TMD04), BALB/c mice that developed EMT6 tumors were dosed intraperitoneally with 10 mg/kg AIP-192482-mIgG2a or vehicle twice weekly. In this study, the majority of mice dosed with AIP-192482-mIgG2a were sacrificed at the end of the study on day 26, and the majority of vehicle-treated mice were sacrificed when they reached a tumor volume of ≥2000 mm3 between days 25 and 27. Tumors were collected after euthanasia and dissociated, and the resulting cell preparations were stained to assess the presence of lymphoid and myeloid subsets in the tumor using flow cytometry.

[0487] There was a significant increase in the proportion of CD8+ T cells, CD4+ T cells, natural killer (NK) cells, dendritic cells, Tregs, and monocytic myeloid suppressor cells (M-MDSC) between tumors from mice dosed with AIP-192482-mIgG2a , compared to tumors from vehicle-injected mice. In contrast, F4/80+ macrophage and granulocytic myeloid suppressor cell (G-MDSC) populations were reduced, each showing a greater than 10-fold reduction in tumors from AIP-192482-mIgG2a-dosed mice compared with tumors from mice treated with AIP-192482-mIgG2a. receiving a dose of vehicle.

[0488] Taken together, the cell types identified by immunofluorescence on tissue samples and by flow cytometry of cell suspensions demonstrate that binding of the ATRC-101 target results in a change in the proportion and nature of lymphoid and myeloid cell populations in the TME compared to populations predominantly associated with protumorigenic and immunosuppressive properties, versus those more closely associated with antitumorigenic, proinflammatory properties.

Secondary pharmacodynamics

[0489] The specificity and selectivity of ATRC-101 was assessed using a cell expression screening chip system (Retrogenix, Whaley Bridge, High Peak, UK). Cell expression screening chip systems were used to assess specificity and identify targets. The parent antibody AIP-192482, expressed as human IgG1 (AIP-192482-hIgG1), evaluated in this study did not show background binding to the HEK293 cells used.

[0490] AIP-192482-hIgG1 was screened at a concentration of 2 μg/ml on chip-fixed HEK293 cells, each of which expressed one of 3559 full-length human plasma membrane proteins. Duplicate chips were examined in the primary screen as well as in the confirmation/specificity screen. No specific binding of AIP-192482-hIgG1 was observed to any of the expressed proteins. The results demonstrate that ATRC-101 does not bind specifically or selectively to any of the 3,559 human plasma membrane proteins that comprise the library tested.

Pharmacological safety

[0491] ATRC-101 is a selective monoclonal antibody intended for the treatment of cancer patients and is not a class of drugs or chemicals expected to cause cardiovascular reactions. As detailed in ICH Guidelines S6 (R1), S7A and S9, specific pharmacological safety studies are not required for biotechnology-derived products that target specific receptors, such as monoclonal antibodies for anti-cancer pharmaceuticals.

[0492] In addition, mice and cynomolgus macaques are not suitable species for pharmacological safety or toxicological studies due to the absence or very low expression of the ATRC-101 target in normal tissues. However, a 4-week intravenous toxicity investigational study was conducted in cynomolgus monkeys and no off-target effects were observed (as assessed by routine clinical observations, clinical pathology, cytokines, macroscopic and microscopic assessments) at ATRC-101 dose levels ≤ 100 mg/kg (AUC range 185,000 to 186,000 h•µg/ml). Also, no target-related adverse effects (as assessed by routine clinical observations, clinical pathology, cytokines, macroscopic and microscopic assessments) were observed in the EMT6-BALB/c syngeneic tumor model at ATRC-101 and MFC-042 dose levels ≤ 30 mg/kg (highest serum concentrations of 295 μg/ml and 290 μg/ml in tumor-bearing mice, respectively).

[0493] Based on immunoprecipitation and mass spectroscopy data, ATRC-101 recognizes a target that is a complex containing member(s) of the human polyadenylate binding protein family and poly(A) RNA. ATRC-101 binds with nanomolar affinity to in vitro reconstituted complexes containing in vitro transcribed poly(A)-RNA and (i) recombinant human/non-human primate PABPC-1, or (ii) recombinant murine PABPC-1.

[0494] Although PABPC-1 and poly(A)-RNA are widely present in normal cells, the target ATRC-101 appears to be tumor associated. Tumor-selective binding to the ATRC-101 target was observed in various human tumor types, including NSCLC, breast cancer, CRC, ovarian cancer, and melanoma, where tumor cores were positive but adjacent tissues were not. Similarly, the target ATRC-101 is found in EMT6 mouse tumor cores but not in adjacent tissues. Binding to EMT6 mouse tumor cells extracted from tumor nuclei is lost over time when these cells are cultured in vitro . In addition, target binding of ATRC-101 in human tumor nuclei has been shown to be dependent on a component of the RNase-sensitive complex.

[0495] In normal human tissues, normal cynomolgus monkey tissues, and most normal mouse tissues, pharmacological evaluations did not reveal unambiguous binding to the target of ATRC-101. In a GLP tissue cross-reactivity study in normal human tissues, ATRC-101 staining was observed in some human tissues. However, virtually all staining detected was cytoplasmic in nature, with the exception of rare and sparse staining noted in epithelial cells of the distal tubules of the human kidney. These results are not considered toxicologically significant.

[0496] Overall, pharmacological and toxicological evaluations demonstrate that the target of ATRC-101 is tumor associated and that cell surface localization depends on tumor growth conditions in vivo . The basis for the tumor association of the ATRC-101 target and the selectivity of ATRC-101 remain under investigation.

[0497] ATRC-101 and chimeric variants of ATRC-101 exhibit antitumor activity in syngeneic mouse models EMT6, CT26 and E0771 without evidence of toxicity. ATRC-101 variants demonstrate enhanced antitumor activity when combined with PD-1 blockade. The antitumor activity of ATRC-101 variants is dependent on Fc effector function and the presence of host T cells and is associated with antitumor, proinflammatory changes in the TME. ATRC-101 does not appear to act through ADCC or CCZ mechanisms. ATRC-101 does not bind to human PBMCs in vitro and does not appear to induce cytokine release in in vitro assays of PBMCs and whole blood.

[0498] Based on these in vivo and in vitro observations, the clinical candidate ATRC-101 is predicted to induce tumor growth inhibition and regression, in part, by (a) altering the composition of the tumor microenvironment to be more antitumorigenic and proinflammatory. and (b) inducing an adaptive immune response that recruits effector CD8+ T cells to attack tumors.

[0499] Based on tumor-selective binding in human carcinomas and melanomas and antitumor activity in mouse models, ATRC-101 is selected for administration to patients for the treatment of advanced solid tumors.

Example 14: Toxicology

[0500] Preclinical safety studies of ATRC-101 consisted of in vitro evaluations of ATRC-101 using human cells and tissues and in vivo animal studies in a murine disease model to assess potential target-related toxicity and in cynomolgus monkeys to address potential toxicity target-related and non-target toxicity, respectively. This preclinical safety strategy is consistent with the recommendations detailed in ICH S6 (R1) as well as ICH S9 and is considered appropriate for assessing the safety profile of ATRC-101. The scope of the toxicological evaluation was consistent with its intended clinical use for cancer treatment.

[0501] The scope of toxicology evaluation of ATRC-101 demonstrated an acceptable safety profile and supports first human dose administration in cancer patients. The proposed starting human dose is 0.3 mg/kg, which is 8 times lower than the NOAEL (30 mg/kg; human equivalent dose (HED)=2.4 mg/kg) in the EMT6 syngeneic breast cancer study. and is expected to provide an adequate safety profile for the initial clinical dose.

[0502] The human tissue cross-reactivity study was conducted in accordance with GLP regulations. Non-GLP studies were performed in accordance with International Conference on Harmonization (ICH) guidelines using good scientific practice and in accordance with the applicable standard operating procedures (SOPs) of the testing laboratory and relevant centers.

Toxicity after a single dose

[0503] No single-dose toxicity study was performed. However, a pharmacokinetics (PK) and tolerability study of a single IV bolus dose with a 4-week follow-up period was conducted in cynomolgus monkeys. In this study, ATRC-101 administration was well tolerated in cynomolgus monkeys at doses up to 30 mg/kg.

Repeated dose toxicity

[0504] Given that the ATRC-101 target is tumor associated with no or very low expression in normal animal tissues, the potential target-related toxicity of ATRC-101 was assessed in the syngeneic EMT6-BALB/c breast cancer model upon repeated administration. In addition, a non-GLP repeated dose toxicity study was conducted in cynomolgus monkeys to evaluate the potential off-target toxicity of ATRC-101.

Preclinical evaluation of the efficacy and safety of ATRC-101 and MFC-042 in the syngeneic EMT6 breast cancer model (studies ATRC-101.PD.18.01 and ATRC-101.PD.18.02)

[0505] Safety parameters were included in this preclinical efficacy and safety study in the syngeneic EMT6-BALB/c mouse model of breast cancer to evaluate the potential target-related toxicity of ATRC-101 and MFC-042 (containing an identical human Fv region in ATRC- 101, but expressed with the Fc region of mouse IgG2a). This study consisted of two parts that were conducted simultaneously: the evaluation of MFC-042 (Part A; ATRC-101.PD.18.01) and ATRC-101 (Part B; ATRC-101.PD.18.02).

[0506] In Part A of the study, seven groups of female BALB/c mice (15 animals/group) developing subcutaneous EMT6 tumors (group mean tumor volumes (MTV)=112-113 mm ³ ) were administered by intraperitoneal injection of 0 (vehicle), 0 ,1, 0.3, 1, 3, 10, or 30 mg/kg MFC-042 on days 1, 4, 8, 11, and 15. Two groups of tumor-free (naïve) mice (15 animals/group) received vehicle or 30 mg/kg MFC-042 using the same dosing schedule. On day 16, animals were sacrificed for necropsy.

[0507] In Part B of the study, four groups of female BALB/c mice (15 animals/group) that had developed subcutaneous EMT6 tumors (group MTV=108 mm ³ ) were given an IP injection of 0 (vehicle), 3, 10 or 30 mg/ kg ATRC-101 on days 1, 4, 8, 11 and 15. Two groups of naïve mice (15 animals/group) received vehicle or 30 mg/kg ATRC-101 using the same dosing schedule. On day 16, animals were sacrificed for necropsy.

[0508] Parameters assessed in this study included mortality/mortality, clinical manifestations, body weight, global efficacy assessment, clinical pathology (hematology and clinical chemistry), serum concentration of study drug, serum cytokine analysis, major abnormalities detected during necropsy, organ masses and microscopic examinations (brain, heart, lungs, liver, kidneys, pancreas, spleen, stomach and lymph nodes, as well as tumor tissue in animals with tumors).

[0509] Repeated doses of ATRC-101 ≥ 10 mg/kg or MFC-042 at ≥ 3 mg/kg in tumor-bearing mice significantly suppressed the growth of EMT6-BALB/c syngeneic mammary tumors. In these groups, tumor growth inhibition, often with evidence of tumor regression, reached or exceeded the threshold for potential therapeutic activity.

[0510] There were no deaths associated with ATRC-101 or MFC-042 in the study. There were no adverse clinical observations or effects on body weight associated with ATRC-101 or MFC-042. No toxicologically significant effects were noted in hematological and clinical biochemical parameters. There were no obvious pathologies or noticeable changes in organ weights in mice sacrificed on day 16.

[0511] The cytokine levels and trends observed following administration of ATRC-101 and MFC-042 were within the expected biological response from administration of human proteins in a mouse tumor model and/or were associated with the antitumor activity of the study drugs and therefore were not considered adverse. .

[0512] Under the microscope, tumor masses collected at necropsy consisted of neoplastic cells located in fluids and nodes. Overall, tumor masses were observed in all mice inoculated with EMT6 tumor cells. There were no adverse microscopic findings associated with ATRC-101 or MFC-042 at terminal euthanasia.

[0513] Repeated intraperitoneal administration of ATRC-101 at dose levels of 0, 1, 10 and 30 mg/kg or MFC-042 at dose levels of 0, 0.1, 0.3, 1, 3, 10 and 30 mg/kg, naïve female BALB/c mice and female BALB/c mice with syngeneic EMT6 breast cancer were well tolerated and no toxicologically significant effects were noted. Based on these safety results, the NOAEL was 30 mg/kg for ATRC-101 and MFC-042 in naïve female BALB/c mice and female BALB/c mice with syngeneic EMT6 breast cancer. At this dose level, the highest serum ATRC-101 concentrations were 295 μg/mL and 281 μg/mL in tumor-bearing and naïve mice, respectively; the highest serum concentrations of MFC-042 were 367 μg/mL and 533 μg/mL in tumor-bearing and naïve mice, respectively.

4-Week Dose Range Toxicology Study Using ATRC-101 in Cynomolgus Macaques (ATRC-101.TX.18.01)

[0514] The purpose of this study was to determine the potential off-target toxicity and toxicokinetics (TK) of ATRC-101 when administered intravenously (duration 30 minutes) once weekly for 4 weeks (days 1, 8, 15, and 22) in cynomolgus monkeys. In the study, 8 naïve monkeys were randomly divided into 4 groups (1 animal/sex/group). Animals were dosed once weekly with 0 (vehicle), 10, 30, or 100 mg/kg ATRC-101 via a 30-minute intravenous infusion for 4 weeks (4 doses). The dose volume was 5 ml/kg.

[0515] The following parameters were assessed in this study: mortality/mortality, clinical manifestations, qualitative indicators of feed intake, body weight, clinical pathology (hematology, clinical chemistry and urinalysis), cytokines, toxicokinetic parameters, organ weights, macroscopic and microscopic examinations (20 organs/tissues including brain, heart, lungs, liver, kidneys and pancreas).

[0516] When assessing TK, C _max was typically observed at 0.75 hours (T _max ) after the start of the infusion (0.25 hours after the end of the infusion). The terminal elimination phase has not been characterized for any animals due to the relatively steady-state concentrations observed after _Tmax . Systemic exposure increased with dose in the study range. Although there was 1 animal/sex/group, the increase appeared to be approximately proportional to dose. There were no sex-related differences in exposure. After repeated administration, systemic exposure on day 22 was generally higher than on day 1, with individual accumulation factors ranging from 1.64 to 2.17.

[0517] Once-weekly intravenous administration of ATRC-101 to cynomolgus monkeys for 4 weeks at doses of 0, 10, 30, or 100 mg/kg/week was well tolerated. All animals survived until terminal necropsy (day 29). There were no ATRC-101-related changes in clinical manifestations, quality of feed intake, body weight, clinical pathology parameters, or most cytokines. There was no gross pathology associated with ATRC-101, definitive organ weights, or microscopic findings.

[0518] Administration of ATRC-101 by intravenous infusion once weekly for 4 weeks was well tolerated in cynomolgus monkeys at all dose levels administered: 10, 30, and 100 mg/kg/week. The NOAEL was considered to be 100 mg/kg/week, with associated _Cmax values of 2410 μg/ml for males and 2690 μg/ml for females, and AUC _0-t values of 185,000 μg•h/ml for males and 186,000 μg• h/ml for females on day 22.

Local tolerance

[0519] Local tolerance of ATRC-101 was assessed in a non-GLP 4-week repeat dose toxicity study in cynomolgus monkeys (ATRC-101.TX.18.01). There was no clinical evidence of irritation or local tolerance issues at ATRC-101 injection sites following repeated administration (IV, once weekly, 4 doses total) at doses up to 100 mg/kg with ATRC-101 concentrations of 20 mg/mL.

Other toxicity studies

Tissue cross-reactivity study of ATRC-101 in normal human tissues (ATRC-101.TX.19.01)

[0520] A GLP tissue cross-reactivity study in normal human tissues was conducted to evaluate the potential cross-reactivity of ATRC-101 (2 and 10 μg/mL) with frozen sections from a comprehensive panel of 34 normal human tissues (3 donors per tissue).

[0521] ATRC-101 caused weak to strong staining of the cytoplasm and cytoplasmic granules of rare positive control neoplastic cells in human breast tumor 016327T2 at both concentrations. ATRC-101 did not react specifically with negative control stromal fibroblasts in human breast tumor 016327T2 at any staining concentration. The control, human IgG1, did not react specifically with either the positive or negative tissue controls. There was also no staining of control micropreparations for analysis. The specific reactions of ATRC-101 in all staining experiments with positive control material and the lack of specific reactivity with negative control material, as well as the lack of reactivity of the control drug, showed that the assay was sensitive, specific and reproducible.

[0522] Membrane and cytoplasmic staining with ATRC-101 was observed in tubular epithelium (weak-strong, rare) in the kidney. Cytoplastic staining was noted in the epithelium (weak-strong, variable) in the fallopian tubes (mucosa), pancreas (ducts, acini), salivary gland (acini), thyroid gland (follicles, parafollicular cells) and uterus (endometrium); mononuclear cells (weak-moderate, rare) in the small intestine; myoepithelium (weak-moderate, rarely-episodic) in the mammary gland; islet cells (weak to moderate, very rare) in the pancreas; neurons (weak-intense, rare-random) of the brain (cerebellum, cerebrum) and spinal cord; retinal cells (weak-strong, single) in the outer plexiform layer of the eye; cells/processes associated with peripheral nerves (weak-strong, very rare-occasional) in bladder, chest, eyes, gastrointestinal tract (esophagus, small intestine [ganglion cells]), skin, spinal cord (spinal nerve roots) , striated muscles (skeletal); pituicytitis (mild-moderate, common) in the posterior lobe of the pituitary gland. Subcellular localization of neuropil staining (weak-moderate, common) in the human brain (cerebellum, cerebrum) cannot be identified at light microscopic resolution.

[0523] Thus, ATRC-101 staining has been observed in some human tissues. However, virtually all ATRC-101 staining was cytoplasmic in nature, and binding of monoclonal antibodies to cytoplasmic regions in tissue cross-reactivity studies is generally considered to be negligible or of no toxicological significance due to the limited ability of antibody drugs to penetrate cytoplasmic compartments in vivo (Hall et al. al, 2008; Leach et al, 2010). Membrane staining with ATRC-101 was limited to rare (1-5% of cells) tubular epithelial cells in human kidneys. Therefore, this staining is not expected to be toxicologically significant. The subcellular localization of neuropil staining in the human brain could not be identified at light microscopic resolution; however, this staining is not expected to be toxicologically significant because this tissue element is protected by the blood-brain barrier.

Results of preclinical toxicological studies

[0524] ATRC-101 binds to a tumor-associated version of a complex containing a member of the polyadenylate binding protein family and poly(A) RNA. This antibody is considered to pose a low risk of triggering cytokine release in humans based on results from an in vitro human PBMC binding and cytokine release study. A comprehensive series of preclinical toxicity studies were conducted to establish the toxicological profile of ATRC-101.

[0525] The potential target-related toxicity of ATRC-101 was assessed in a preclinical efficacy and safety study in the EMT6-BALB/c syngeneic breast cancer mouse model. In this study, administration of ATRC-101 at doses of 0, 1, 10 and 30 mg/kg or MFC-042 (identical to the human Fv region of ATRC-101 on the Fc region of mouse IgG2a) at dose levels of 0, 0.1 0.3, 1 , 3, 10, and 30 mg/kg in naïve and EMT6-BALB/c syngeneic breast cancer mice were well tolerated and no toxicologically significant effects were noted. The NOAEL was considered to be 30 mg/kg for ATRC-101 and MFC-042 in naïve and tumor-bearing female BALB/c mice. At this dose level, the highest serum ATRC-101 concentrations were 295 μg/mL and 281 μg/mL in tumor-bearing and naïve mice, respectively; the highest serum concentrations of MFC-042 were 367 μg/mL and 533 μg/mL in tumor-bearing and naïve mice, respectively.

[0526] The potential off-target toxicity of ATRC-101 was assessed in a 4-week repeat dose toxicity study in cynomolgus monkeys. Administration of ATRC-101 by intravenous infusion once weekly for 4 weeks was well tolerated in cynomolgus monkeys at all dose levels administered: 10, 30, and 100 mg/kg/week. The NOAEL was considered to be 100 mg/kg/week, with C _max values of 2410 µg/ml for males and 2690 µg/ml for females, and AUC _0-t values of 185,000 µg•h/ml/ml for males and 186,000 µg •h/ml for females on day 22.

[0527] In a GLP tissue cross-reactivity study on normal human tissues, ATRC-101 staining was observed in some human tissues. However, virtually all staining was cytoplasmic in nature and is not a toxicological concern since ATRC-101 is unlikely to cross cell membranes or directly interact with cytoplasmic components. Membrane-associated staining with ATRC-101 was limited to rare (1-5% of cells) tubular epithelial cells in human kidneys. Given the rarity of the staining, this staining is not expected to be toxicologically significant. In addition, ATRC-101 (i) does not appear to mediate either ADCC or CDC, (ii) binding of ATRC-101 to its target has not been found to trigger or abolish any signal transduction pathways, (iii) and any potential renal toxicity will be monitored using urinalysis and clinical chemistry in the proposed clinical trial. Taken together, the membrane staining noted on rare tubular epithelial cells in an in vitro tissue cross-reactivity study is considered a low risk for patient safety.

[0528] Taken together, the results of the preclinical toxicology studies demonstrate an acceptable safety profile and support the advancement of ATRC-101 into clinical trials in cancer patients.

Justification of the dose permissible for the human body

[0529] The scientific rationale for selecting a starting human dose of 0.3 mg/kg is based on a comprehensive assessment of all available ATRC-101 preclinical pharmacology, PK and toxicology data, as well as the available literature. At a proposed starting human dose of 0.3 mg/kg, C _max is expected to be approximately 7.81 μg/mL and AUC _0-672h is expected to be 53.1 day•μg/mL based on human dose modeling of ATRC-101.

[0530] The proposed initial dose of 0.3 mg/kg provides a significant safety profile compared to the NOAEL dose of 30 mg/kg determined in a preclinical repeat dose efficacy and safety study in female BALB/c mice bearing EMT6 mammary tumors. A starting human dose of 0.3 mg/kg is 1/8 of the NOAEL (30 mg/kg for mice=2.44 mg/kg equivalent human dose). This provides a safety profile approximately 47 times the expected C _max (7.81 μg/mL) in humans at the proposed starting dose of 0.3 mg/kg.

Example 15 Pharmacokinetics

[0531] In a single-dose PK study, 6 naïve cynomolgus monkeys (3 males and 3 females) were randomized into 3 dose groups and administered ATRC-101 at a dose of 1, 10, or 30 mg/kg via intravenous (i.v.) c) bolus injection. Animals were observed for 28 days after ATRC-101 administration. Serum samples were collected at different time points and analyzed by enzyme-linked immunosorbent assay (ELISA) to determine the concentration of ATRC-101.

[0532] Following a single intravenous dose, maximum serum concentrations (C _max ) were observed between 0.083 and 1 hour post-dose, except in females at the 1 mg/kg dose level, where it was observed 8 hours post-dose. The half-life (T _1/2 ) ranged from 177 to 225 hours. The rate of apparent clearance (CL) and apparent volume of distribution (Vd) ranged from 0.159 to 0.436 ml/hour/kg, and 51.4 and 117 ml/kg, respectively. Systemic exposure increased with dose in the study range. The increase was approximately dose proportional, except in females for the 1 to 10 mg/kg dose range, where the increase was less than dose proportional. There were no significant sex-related differences in exposure except at the 1 mg/kg dose, where exposure in females was 2-fold higher than exposure in males.

[0533] The toxicokinetic (TK) profile of ATRC-101 was evaluated in a 4-week repeated IV toxicity study in cynomolgus monkeys. Eight (8) naïve animals (4 males and 4 females) received a once-weekly intravenous infusion (30 minutes) of ATRC-101 at a dose of 0, 10, 30, or 100 mg/kg, for a total of 4 doses. Serum samples were collected at different time points and analyzed by ELISA. Maximum serum concentrations were generally observed at 0.75 hours after the start of infusion (SOI). The terminal phase of elimination has not been characterized for any animals due to the relatively steady-state concentrations observed after the _Cmax ( _Tmax ) time. Systemic exposure increased with dose over the tested range, and the increase was approximately proportional to dose. There were no significant sex-related differences in exposure. After repeated administration, systemic exposure on day 22 was generally higher than on day 1, with individual accumulation factors ranging from 1.64 to 2.17.

LC-MS/MS method for measuring ATRC-101 concentration in serum of BALB/c mice (ATRC-101.PD.18.02)

[0534] The concentration of ATRC-101 in the serum of BALB/c mice was determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). In this method, PEP-1, a signature peptide cleaved from ATRC-101, was measured to determine the concentration of ATRC-101 (the concentration of PEP-1 is equivalent to the concentration of ATRC-101). In this assay, each 10 μL aliquot of standard, quality control (QC), or test sample was mixed with 25 μL of internal standard working solution (25 μg/mL in water), 15 μL of water, and 150 μL of SMART Digest buffer (Thermo Fisher Scientific , Waltham, Massachusetts, USA). Samples were briefly centrifuged and a 200 μL aliquot of the resulting supernatant was transferred into SMART Digest microtubes. Samples were vortexed and incubated at 65°C with shaking for 2 hours. A 200 μL aliquot of the reaction mixture was mixed with 5 μL of 20% sodium bisulfite. The reaction was quenched with 5 μl of pure formic acid. Samples were vortexed and centrifuged. A 150 μL aliquot of the resulting supernatant was transferred to a clean, low-binding 96-well plate. An aliquot was injected into the LC-MS/MS system for analysis. The liquid chromatography system used a Phenomenex XB-C18, 1.0 x 50 mm (2.7 µm particle size) column with a gradient flow of water/formic acid (100/0.5, v/v) and acetonitrile /formic acid (100/0.5, v/v) at a flow rate of 0.600 ml/min. The signature peptide and internal standard were detected using a Waters Xevo TQ-S triple quadrupole LC-MS/MS system equipped with an ESI ionization source (TurboIonSpray ^® ) operating in positive ion mode. This method was useful for quantification over nominal concentration ranges of 2 to 250 μg/mL for ATRC-101 from a 10 μL aliquot of BALB/c mouse serum.

ELISA method for measuring the concentration of ATRC-101 in cynomolgus monkey serum (ATRC-101.PK.18.01)

[0535] The concentration of ATRC-101 in cynomolgus monkey serum was determined by ELISA. This analysis used a quantitative immunoassay method. Briefly, microtiter plates were coated with sheep anti-human IgG to capture ATRC-101. The assay was calibrated using a standard curve constructed from eleven standards within the range obtained using the human antibody, ATRC-101 at concentrations of 800, 400, 300, 200, 150, 100, 75, 50, 30, 20, 10 ng/ml , including fixation points at 10 and 800 ng/ml, in pure cynomolgus monkey serum. QC samples were prepared with serum concentrations of 250, 175, and 40 ng/mL ATRC-101 in pure cynomolgus serum. Regression of microplate reader data was performed using Watson LIMS version 7.3.0.01. A 4-parameter model with the weighting equation 1/y ² was used to fit the sigmoid calibration curve. Standards, quality control samples, and test samples were analyzed at the minimum required 5-fold dilution, and sample concentrations in pure monkey serum were determined (μg/mL). One set of quality control samples was prepared before and after the preparation of standards, test samples, and blanks. Detection of ATRC-101 was performed using goat anti-human IgG (heavy and light chains) conjugated to horseradish peroxidase. Tetramethylbenzidine was used as a chromogenic substrate. The quantitation range for the method was 20–400 ng/mL.

[0536] The absorption of ATRC-101 was characterized in a single-dose IV bolus pharmacokinetics study and a repeated IV infusion toxicity study in cynomolgus monkeys. The concentration of ATRC-101 in monkey serum was determined by ELISA.

[0537] In a single-dose pharmacokinetic study, 6 naive cynomolgus monkeys (3 males and 3 females) were randomized into 3 dose groups and administered ATRC-101 at a dose of 1, 10, or 30 mg/kg via IV bolus injection . _Tmax was generally observed between 0.083 and 1 hour after dosing. T _1/2 varied from 177 to 225 hours. CL and Vd ranged from 0.15 to 0.436 ml/hour/kg and from 51.4 to 117 ml/kg, respectively. Systemic exposure to ATRC-101 increased with dose in the study range, and this increase was approximately proportional to dose.

[0538] In a 4-week repeated intravenous dose toxicokinetic study in cynomolgus monkeys, 8 animals (4 males and 4 females) were randomly assigned to 4 groups to receive a once-weekly intravenous infusion (30 minutes) of ATRC-101 at 0 , 10, 30 or 100 mg/kg, 4 doses in total. _Tmax was typically observed 0.75 hours after SOI. The terminal elimination phase has not been characterized for any animals due to the relatively steady-state concentrations observed after _Tmax . Systemic exposure increased with dose over the tested range, and the increase was approximately proportional to dose. There were no significant sex-related differences in exposure. After repeated administration, systemic exposure on day 22 was generally higher than on day 1, with individual accumulation factors ranging from 1.64 to 2.17.

Single dose bolus pharmacokinetic study of ATRC-101 in cynomolgus monkeys with a 4-week follow-up period (ATRC-101.PK.18.01)

[0539] The purpose of this study was to evaluate the PK of ATRC-101 in cynomolgus monkeys following a single intravenous bolus dose.

[0540] In this study, 6 naïve animals (1 animal/sex/group) were randomly divided into 3 groups and administered ATRC-101 at a dose of 1, 10, or 30 mg/kg as a single dose via intravenous bolus injection. ATRC-101 was formulated with 20 mM histidine, 8% sucrose, 0.02% polysorbate 80 at pH 6.0 and further diluted to the target concentration for dosing. The dose volume was 3.0 ml/kg. Pharmacokinetic samples were collected 1 day predose, 5 minutes, 1, 4, 8, 12, 24, 48, 96, 168, 240, 336, 504, and 672 hours postdose. Serum ATRC-101 concentrations were determined by ELISA.

[0541] Parameters in this study included survival, clinical follow-up, body weight, body temperature, clinical pathology (hematology and serum chemistry), and PK analysis. All animals survived until the end of the study. No clinical manifestations associated with ATRC-101 were observed. There were no ATRC-101-related data on body weight, body temperature, or clinical pathology. Serum concentrations of ATRC-101 were below the lower limit of quantitation (LOQ=20 ng/mL) in all samples collected at the predose time point for the treatment groups. Following administration of ATRC-101 on day 1, ATRC-101 could be measured over a 672-hour sampling period for the dose levels assessed. Fig. 63. Concentrations in females receiving 1 mg/kg 8 hours post-dose were higher compared with 10 mg/kg (241 µg/ml and 129 µg/ml, respectively).

[0542] Following administration of ATRC-101, T _max was observed between 0.083 and 1 hour post-dose, except in females at the 1 mg/kg dose level, where the maximum concentration was observed at 8 hours post-dose. Maximum serum concentrations were followed by a decrease in ATRC-101 with T _1/2 ranging from 177 to 225 hours. CL and Vd ranged from 0.159 to 0.436 ml/hour/kg and from 51.4 to 117 ml/kg, respectively.

[0543] Systemic exposure to ATRC-101, as measured by _Cmax and area under the curve from time 0 to analysis (AUC _0-t ), increased with dose within the test range. The increase appeared to be approximately dose proportional for the dose levels assessed, except in females for the dose range of 1 to 10 mg/kg, where the increase was less than dose proportional. There were no significant sex-related differences in exposure except at the 1 mg/kg dose level, where exposure in females was 2-fold higher than in males.

4-Week Dose Range Toxicology Study Using ATRC-101 in Cynomolgus Macaques (ATRC-101.TX.18.01)

[0544] The purpose of this study was to evaluate the potential off-target toxicity and TK of ATRC-101 when intravenously infused once weekly for 4 weeks in cynomolgus monkeys.

[0545] In the study, 8 naïve monkeys were randomly divided into 4 groups (1 animal/sex/group). Animals were dosed once weekly with 0 (vehicle), 10, 30, or 100 mg/kg ATRC-101 via a 30-minute intravenous infusion for 4 weeks (4 doses). The dose volume was 5 ml/kg. Toxicokinetic samples were collected at different time points on days 1 and 22. Serum ATRC-101 concentrations were determined by ELISA.

[0546] Serum concentrations of ATRC-101 were below the LLOQ (20 ng/mL) in all pre-dose samples collected on day 7, in all control group samples collected on days 1 and 22 , and in all samples at the predose time point for treatment groups on day 1. Following administration of ATRC-101 on days 1 and 22, ATRC-101 was quantifiable over the 168-hour sampling period for all dose levels. Serum concentrations of ATRC-101 in ATRC-101 treatment groups are shown in Fig. 64.

[0547] Following administration of ATRC-101, _Tmax was observed between 0.75 and 4.5 hours SOI, corresponding to 0.25 and 4 hours after the end of infusion (EOI), with most cases falling at 0.75 hours after SOI (0.25 hours after EOI). The terminal elimination phase has not been characterized for any animals due to the relatively steady-state concentrations observed after _Tmax .

[0548] Systemic exposure of ATRC-101, as determined by C _max and AUC _0-t , increased with dose within the tested range. Given that there was 1 animal/sex/group, the increase appeared to be approximately proportional to dose. There were no sex-related differences in exposure. After repeated administration, systemic exposure on day 22 was generally higher than on day 1, with individual accumulation factors ranging from 1.64 to 2.17.

[0549] A PK modeling approach was used to predict the PK parameters of ATRC-101 in humans. Observed systemic ATRC-101 concentrations over time in study ATRC-101.PK.18.01 were modeled using a standard 2-component PK model and allometrically scaled to humans based on body weight. Modeling was performed to obtain predicted temporal changes in human serum following doses of 0.1, 0.3, 1, 3, 10 and 30 mg/kg administered once every three weeks for 6 weeks. Human exposure rates were predicted after a single intravenous dose. At a concentration of 0.3 mg/kg, _Cmax in humans is estimated to reach 7.81 µg/ml, and AUC _0-672h is 53.1 day⋅µg/ml.

[0550] Predicted human PK parameters were correlated with corresponding concentrations from in vitro pharmacological activity studies in a dual target-effector interaction assay. In a dual target-effector interaction assay, the half-maximal effective concentration (EC ₅₀ ) of ATRC-101 was shown to be 68 nM. The ATRC-101 dose-response curves in this analysis were fitted to a four-parameter logistic regression model to estimate effective concentrations (EC ₂₀ , EC ₅₀ , and EC ₈₀ ). The 0.3 mg/kg dose level in humans was estimated to result in a _Cmax (7.81 μg/mL) below the EC ₅₀ and reaching 20% of the maximum effective concentration (EC ₂₀ ) over approximately 6 days (~33% interval dosing; based on dual target and effector interaction analysis.

[0551] Following single intravenous bolus administration to cynomolgus monkeys at doses of 1, 10 and 30 mg/kg, T _max was observed between 0.083 and 1 hour post-dose, except in females at the 1 mg/kg dose level, where it was observed at 8 hours after dosing. T _1/2 varied from 177 to 225 hours. CL and Vd ranged from 0.15 to 0.436 ml/hour/kg and from 51.4 to 117 ml/kg, respectively. Systemic exposure to ATRC-101 increased with dose over the study range, and the increase appeared to be approximately dose proportional, except in females for dose levels of 1 to 10 mg/kg, where the increase was less than dose proportional. There were no significant sex-related differences in exposure except at the 1 mg/kg dose level, where exposure in females was 2-fold higher than in males.

[0552] In a 4-week repeat dose toxicity and TK study, _Tmax was typically observed at 0.75 hours post-SOI after once weekly dosing via a 30-minute intravenous infusion at doses of 10, 30, and 100 mg/kg/day. a week. The terminal elimination phase has not been characterized for any animals due to the relatively steady-state concentrations observed after _Tmax . Systemic exposure increased with dose over the tested range, and this increase appeared to be approximately proportional to dose. There were no significant sex-related differences in exposure. After repeated administration, systemic exposure on day 22 was generally higher than on day 1, with individual accumulation factors ranging from 1.64 to 2.17.

[0553] Taken together, these data demonstrate that the PK profile of ATRC-101 is typical of a human IgG1 monoclonal antibody. Data from a single-dose pharmacokinetic study in cynomolgus monkeys were used to predict the pharmacokinetic parameters of ATRC-101 in humans. At a dose of 0.3 mg/kg, ATRC-101 _Cmax in humans is estimated to be 7.81 μg/ml and AUC _0-672h is 53.1 day•μg/ml.

[0554] In accordance with regulatory requirements, no animal studies of the metabolism, tissue distribution, or excretion of ATRC-101 were performed. ATRC-101, like a typical monoclonal antibody, is expected to be degraded into small peptides and amino acids through biochemical pathways that are independent of drug-metabolizing enzymes such as cytochrome P450 enzymes, so no drug-drug interactions are expected.

[0555] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to those skilled in the art and should be included within the spirit and scope of this application and scope the attached claims. All publications, patents, accession numbers, and patent applications cited herein are incorporated herein by reference for the purposes in which they are cited.

TABLE 1A

AIP number Sequence V _H Sequence V _L 1 AIP-101235 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRSGSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:77) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:123) 2 AIP-127782 EVQLVESGGGLVQPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTEYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:78) QSVLTQPPSVSAAPGQKVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:124) 3 AIP-189473 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTTSFCCRGASCPSSDTSYCAGSYKSYYFVNIWGKGTTVTVSS (SEQ ID NO:79) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:125) 4 AIP-192571 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGNQCPSSDTSYCGGQYPSYYYMDPWGKGTTVTVSS (SEQ ID NO:80) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:126) 5 AIP-125258 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGKQCPSSDTSYCNGYYADYYFMDVWGKGTTVTVSS (SEQ ID NO:81) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:127) 6 AIP-150199 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGKQCPSSDTSYCGGQFKSYYFMDVWGKGTTVTVSS (SEQ ID NO:82) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:128) 7 AIP-115388 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCHSNNCPSSDTSYCNGYYKQYYFMDVWGKGTTVTVSS (SEQ ID NO:83) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:129) 8 AIP-143369 EVQLVESGGALVKPGGSLRLSCAASGFTYSAAWMSWVRQAPGKGLEWVGRIKAVHDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:84) QSVLTQPPSASGTPGQRVTISCSGSSTNIGSSSVTWYQQLPGTAPKLLIYKDNQRPLGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:130) 9 AIP-157045 EVQLVESGGALVKPGGSLRLSCAASGFTFSMAWMSWVRQAPGKGLEWVGRIKSNTDAETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:85) QSVLTQPPSASGTPGQRVTISCSGSKSNIGSSYVSWYQQLPGTAPKLLIYMNNQRPYGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDDQLSVRVFGGGTKLTVL (SEQ ID NO:131) 10 AIP-175775 EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGNSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:86) QSVLTQPPSASGTPGQRVTISCSGSKSNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDNSLSIRVFGGGTKLTVL (SEQ ID NO:132) eleven AIP-154181 EVQLVESGGALVKPGGSLRLSCAASGFTYSKAWMSWVRQAPGKGLEWVGRIKSVQDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSFYYMDVWGKGTTVTVSS (SEQ ID NO:87) QSVLTQPPSASGTPGQRVTISCSGASSNIGSSSVSWYQQLPGTAPKLLIYKNTQRASGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSNSVRIFGGGTKLTVL (SEQ ID NO:133) 12 AIP-125984 EVQLVESGGALVKPGGSLRLSCAASGFTFAKAWMSWVRQAPGKGLEWVGRIKSVTDGHTTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:88) QSVLTQPPSASGTPGQRVTISCSGSSTNIGSSTVSWYQQLPGTAPKLLIYKNNARPYGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDDSLTVRIFGGGTKLTVL (SEQ ID NO:134) 13 AIP-160829 EVQLVESGGALVKPGGSLRLSCAASGFVFSKAWMSWVRQAPGKGLEWVGRIKSVTDGGITDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGNSCPSSDTSYCNGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:89) QSVLTQPPSASGTPGQRVTISCSGASSNIGSSSVSWYQQLPGTAPKLLIYKNTQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDDQLSVRVFGGGTKLTVL (SEQ ID NO:135) 14 AIP-184744 EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSSTSDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGGSCPSRDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:90) QSVLTQPPSASGTPGQRVTISCSGSSTNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSNSVRIFGGGTKLTVL (SEQ ID NO:136) 15 AIP-128136 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVQDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSSDTSYCGGYYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:91) QSVLTQPPSASGTPGQRVTISCSGSKSNIGSSSVYWYQQLPGTAPKLLIYKNNQRPYGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDALSVRVFGGGTKLTVL (SEQ ID NO:137) 16 AIP-181273 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSSDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:92) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDALSVRVFGGGTKLTVL (SEQ ID NO:138) 17 AIP-153125 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVQDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGYYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:93) QSVLTQPPSASGTPGQRVTISCSGSKSNIGSSYVSWYQQLPGTAPKLLIYKNNQRPYGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:139) 18 AIP-160470 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:94) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140) 19 AIP-192482 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSVLYLQMSSLKTEDTAVYFCTSSFCCRGGSCPSHDTSFCGGQDKRYYYMDVWGKGTTVTVSS (SEQ ID NO:95) QSVLTQAPSASETPGQRVIISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:141) 20 AIP-171142 EVQLVESGGGLVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTSFCCRGGSCPSHDTSFCGGQDKRYYYMDVWGQGTTVTVSS (SEQ ID NO:96) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:142) 21 AIP-157397 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSVLYLQMSSLKTEDTAVYFCTSSFCCRGGSCPSHDTSFCGGQYNRYYYMDVWGKGTTVTVSS (SEQ ID NO:97) QSVLTQAPSASETPGQRVIISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:143) 22 AIP-165430 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSVLYLQMSSLKTEDTAVYFCTSSFCCRGGSCPSHDTSFCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:98) QSVLTQAPSASETPGQRVIISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:144) 23 AIP-189526 EVQLVESGGGLVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSTSDGGITDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTSFCCRGGRCPSRDTSFCGGQYNSYYMDVWGQGTTVTVSS (SEQ ID NO:99) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:145) 24 AIP-122563 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSFCGGQDKRYYYMDVWGKGTTVTVSS (SEQ ID NO:100) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:146) 25 AIP-158623 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSFCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:101) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:147) 26 AIP-155066 EVQLVESGGGLVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTSFCCRGGSCPSHDTSFCGGQYKSYYYMDVWGQGTTVTVSS (SEQ ID NO:102) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:148) 27 AIP-136538 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSFCGGQDSRYYYMDVWGKGTTVTVSS (SEQ ID NO:103) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:149) 28 AIP-166120 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:104) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:150) 29 AIP-133645 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSFCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:105) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDESLSVRVFGGGTKLTVL (SEQ ID NO:151) thirty AIP-187893 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSFCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:106) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:152) 31 AIP-142079 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSFCGGSYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:107) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:153) 32 AIP-104188 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQDSRYYYMDVWGKGTTVTVSS (SEQ ID NO:108) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDESLSVRVFGGGTKLTVL (SEQ ID NO:154) 33 AIP-106042 EVQLVESGGGLVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTEGETTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTSFCCRGGSCPSHDTSFCGGQYKSYYYMDVWGQGTTVTVSS (SEQ ID NO:109) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDESLSVRVFGGGTKLTVL (SEQ ID NO:155) 34 AIP-100196 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTEGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSFCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:110) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDESLSVRVFGGGTKLTVL (SEQ ID NO:156) 35 AIP-180675 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:111) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:157) 36 AIP-170105 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:112) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:158) 37 AIP-126080 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQNKQYYYMDVWGKGTTVTVSS (SEQ ID NO:113) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:159) 38 AIP-161571 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGNCPSHETSYCGNQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:114) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:160) 39 AIP-181246 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYVNIWGKGTTVTVSS (SEQ ID NO:115) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:161) 40 AIP-192216 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTTSFCCRGASCPSHDTSYCAGSYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:116) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:162) 41 AIP-168605 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:117) QSVLTQPPSASGTPGQRVTISCSGSSSDIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWNDALSVRVFGGGTKLTVL (SEQ ID NO:163) 42 AIP-172872 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGEQTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:118) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNTQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLNVRVFGGGTKLTVL (SEQ ID NO:164) 43 AIP-190051 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:119) QSVLTQPPSASGTPGQRVTISCSGSPSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDALSVRVFGGGTKLTVL (SEQ ID NO:165) 44 AIP-167533 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKAADDGKQTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:120) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:166) 45 AIP-112580 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGNSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:121) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:167) 46 AIP-136060 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:122) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNSLRPQGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:168)

Table 1B

AIP number HCDR1 HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 1 AIP-101235 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRSGSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:20) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 2 AIP-127782 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTEYAASVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 3 AIP-189473 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TTSFCCRGASCPSSDTSYCAGSYKSYYFVNI (SEQ ID NO:22) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 4 AIP-192571 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGNQCPSSDTSYCGGQYPSYYYMDP (SEQ ID NO:23) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 5 AIP-125258 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) ISSFCCRGKQCPSSDTSYCNGYYADYYFMDV (SEQ ID NO:24) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 6 AIP-150199 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) ISSFCCRGKQCPSSDTSYCGGQFKSYYFMDV (SEQ ID NO:25) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 7 AIP-115388 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) ISSFCCHSNNCPSSDTSYCNGYYKQYYFMDV (SEQ ID NO:26) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 8 AIP-143369 GFTYSAAWMS (SEQ ID NO:2) RIKAVHDGETTDYAAPVKG (SEQ ID NO:10) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21) SGSSTNIGSSSVT (SEQ ID NO:49) KDNQRPL (SEQ ID NO:60) STWDDSLSVRV (SEQ ID NO:68) 9 AIP-157045 GFTFSMAWMS (SEQ ID NO:3) RIKSNTDAETTDYAAPVKG (SEQ ID NO:11) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21) SGSKSNIGSSYVS (SEQ ID NO:50) MNNQRPY (SEQ ID NO:61) ATWDDQLSVRV (SEQ ID NO:69) 10 AIP-175775 GFTFSAAWMS (SEQ ID NO:4) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) ISSFCCRGNSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:27) SGSKSNIGSSSVS (SEQ ID NO:51) KDNQRPS (SEQ ID NO:62) ATWDNSLSIRV (SEQ ID NO:70) eleven AIP-154181 GFTYSKAWMS (SEQ ID NO:5) RIKSVQDGETTDYAAPVKG (SEQ ID NO:12) TSSFCCRGGSCPSHDTSYCGGQYKSFYYMDV (SEQ ID NO:28) SGASSNIGSSSSVS (SEQ ID NO:52) KNTQRAS (SEQ ID NO:63) SSWDDSNSVRI (SEQ ID NO:71) 12 AIP-125984 GFTFAKAWMS (SEQ ID NO:6) RIKSVTDGHTTDYAAPVKG (SEQ ID NO:13) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21) SGSSTNIGSSTVS (SEQ ID NO:53) KNNARPY (SEQ ID NO:64) ATWDDSLTVRI (SEQ ID NO:76) 13 AIP-160829 GFVFSKAWMS (SEQ ID NO:7) RIKSVTDGGITDYAAPVKG
(SEQ ID NO:14) ISSFCCRGNSCPSSDTSYCNGQYKSYYFMDV (SEQ ID NO:29) SGASSNIGSSSSVS (SEQ ID NO:52) KNTQRPS (SEQ ID NO:65) ATWDDQLSVRV (SEQ ID NO:69) 14 AIP-184744 GFTFSAAWMS (SEQ ID NO:4) RIKSTSDGETTDYAAPVKG (SEQ ID NO:15) ISSFCCRGGSCPSRDTSYCGGQYKSYYFMDV (SEQ ID NO:30) SGSSTNIGSSSSVS (SEQ ID NO:54) KDNQRPS (SEQ ID NO:62) SSWDDSNSVRI (SEQ ID NO:71) 15 AIP-128136 GFTFSKAWMS (SEQ ID NO:1) RIKSVQDGETTDYAAPVKG (SEQ ID NO:12) TSSFCCRGGSCPSSDTSYCGGYYKSYYFMDV (SEQ ID NO:31) SGSKSNIGSSSVY (SEQ ID NO:55) KNNQRPY (SEQ ID NO:66) STWDDALSVRV (SEQ ID NO:72) 16 AIP-181273 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSSDTSYCGGQYKSYYFMDV (SEQ ID NO:32) SGSSSNIGSSSVY (SEQ ID NO:56) KNNQRPS (SEQ ID NO:59) STWDDALSVRV (SEQ ID NO:72) 17 AIP-153125 GFTFSKAWMS (SEQ ID NO:1) RIKSVQDGETTDYAAPVKG (SEQ ID NO:12) TSSFCCRGGSCPSHDTSYCGGYYKSYYYMDV (SEQ ID NO:33) SGSKSNIGSSYVS (SEQ ID NO:50) KNNQRPY (SEQ ID NO:66) STWDDSLSVRV (SEQ ID NO:68) 18 AIP-160470 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 19 AIP-192482 GFTFSKAWMT (SEQ ID NO:8) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:34) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 20 AIP-171142 GFTFSKAWMT (SEQ ID NO:8) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TTSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:35) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 21 AIP-157397 GFTFSKAWMT (SEQ ID NO:8) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSFCGGQYNRYYYMDV (SEQ ID NO:36) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 22 AIP-165430 GFTFSKAWMT (SEQ ID NO:8) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSFCGGQYKSYYYMDV (SEQ ID NO:37) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 23 AIP-189526 GFTFSKAWMT (SEQ ID NO:8) RIKSTSDGGITDYAAPVKG
(SEQ ID NO:16) TTSFCCRGGRCPSRDTSFCGGQYNSYYYMDV (SEQ ID NO:38) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 24 AIP-122563 GFTFSKAWMT (SEQ ID NO:8) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:34) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 25 AIP-158623 GFTFSKAWMT (SEQ ID NO:8) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSFCGGQYKSYYYMDV (SEQ ID NO:37) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 26 AIP-155066 GFTFSKAWMT (SEQ ID NO:8) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TTSFCCRGGSCPSHDTSFCGGQYKSYYYMDV (SEQ ID NO:39) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 27 AIP-136538 GFTFSKAWMT (SEQ ID NO:8) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSFCGGQDSRYYYMDV (SEQ ID NO:40) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 28 AIP-166120 GFTFSKAWMT (SEQ ID NO:8) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 29 AIP-133645 GFTFSKAWMT (SEQ ID NO:8) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSFCGGQYKSYYYMDV (SEQ ID NO:37) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDESLSVRV (SEQ ID NO:73) thirty AIP-187893 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSFCGGQYKSYYYMDV (SEQ ID NO:37) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 31 AIP-142079 GFTFSKAWMT (SEQ ID NO:8) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSFCGGSYKSYYYMDV (SEQ ID NO:41) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 32 AIP-104188 GFTFSKAWMT (SEQ ID NO:8) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSYCGGQDSRYYYMDV (SEQ ID NO:42) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDESLSVRV (SEQ ID NO:73) 33 AIP-106042 GFTFSKAWMT (SEQ ID NO:8) RIKSVTEGETTDYAAPVKG (SEQ ID NO:17) TTSFCCRGGSCPSHDTSFCGGQYKSYYYMDV (SEQ ID NO:39) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDESLSVRV (SEQ ID NO:73) 34 AIP-100196 GFTFSKAWMT (SEQ ID NO:8) RIKSVTEGETTDYAAPVKG (SEQ ID NO:17) TSSFCCRGGSCPSHDTSFCGGQYKSYYYMDV (SEQ ID NO:37) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDESLSVRV (SEQ ID NO:73) 35 AIP-180675 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSYCGGQYKSYYFMDV (SEQ ID NO:43) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 36 AIP-170105 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21) SGSSSNIGSSSVY (SEQ ID NO:56) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 37 AIP-126080 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSYCGGQNKQYYYMDV (SEQ ID NO:44) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 38 AIP-161571 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGNCPSHETSYCGNQYKSYYYMDV (SEQ ID NO:45) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 39 AIP-181246 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSYCGGQYKSYYYVNI (SEQ ID NO:46) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 40 AIP-192216 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TTSFCCRGASCPSHDTSYCAGSYKSYYYMDV (SEQ ID NO:47) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 41 AIP-168605 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21) SGSSSDIGSSSVS (SEQ ID NO:57) KNNQRPS (SEQ ID NO:59) STWNDALSVRV (SEQ ID NO:74) 42 AIP-172872 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGEQTDYAAPVKG
(SEQ ID NO:18) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21) SGSSSNIGSSSVS (SEQ ID NO:48) KNTQRPS (SEQ ID NO:65) STWDDSLNVRV (SEQ ID NO:75) 43 AIP-190051 GFTFSKAWMT (SEQ ID NO:8) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21) SGSPSNIGSSSVS (SEQ ID NO:58) KNNQRPS (SEQ ID NO:59) STWDDALSVRV (SEQ ID NO:72) 44 AIP-167533 GFTFSKAWMS (SEQ ID NO:1) RIKAADGKQTDYAAPVKG
(SEQ ID NO:19) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 45 AIP-112580 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) ISSFCCRGNSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:27) SGSSSNIGSSSVS (SEQ ID NO:48) KNNQRPS (SEQ ID NO:59) STWDDSLSVRV (SEQ ID NO:68) 46 AIP-136060 GFTFSKAWMS (SEQ ID NO:1) RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21) SGSSSNIGSSSVS (SEQ ID NO:48) KNSLRPQ (SEQ ID NO:67) STWDDSLSVRV (SEQ ID NO:68)

TABLE 2A

AIP number Sequence V _H Sequence V _L 1 AIP-148327 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTEGETTDYAAPVKGRFTISRDDSKSVLYLQMSSLKTEDTAVYFCTSSFCCRGGSCPSHDTSFCGGQDKRYYYMDVWGKGTTVTVSS (SEQ ID NO:1333) QSVLTQAPSASETPGQRVIISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDESLSVRVFGGGTKLTVL (SEQ ID NO:1527) 2 AIP-198092 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTEGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSFCGGQDKRYYYMDVWGKGTTVTVSS (SEQ ID NO:1334) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDESLSVRVFGGGTKLTVL (SEQ ID NO:1528) 3 AIP-184490 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSFCGGSYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1335) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDESLSVRVFGGGTKLTVL (SEQ ID NO:1529) 4 AIP-102396 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1336) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDESLSVRVFGGGTKLTVL (SEQ ID NO:1530) 5 AIP-150055 EVQLVESGGALVKPGGSLRLSCAASGYTFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1337) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1531) 6 AIP-167084 EVQLVESGGALVKPGGSLRLSCAASGFDFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1338) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1532) 7 AIP-185304 EVQLVESGGALVKPGGSLRLSCAASGFVFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1339) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1533) 8 AIP-134770 EVQLVESGGALVKPGGSLRLSCAASGFTYSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1340) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1534) 9 AIP-141887 EVQLVESGGALVKPGGSLRLSCAASGFTFAKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1341) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1535) 10 AIP-196203 EVQLVESGGALVKPGGSLRLSCAASGFTFSNAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1342) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1536) eleven AIP-184151 EVQLVESGGALVKPGGSLRLSCAASGFTFSRAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1343) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1537) 12 AIP-128195 EVQLVESGGALVKPGGSLRLSCAASGFTFSMAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1344) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1538) 13 AIP-116579 EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1345) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1539) 14 AIP-192329 EVQLVESGGALVKPGGSLRLSCAASGFTFSHAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1346) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1540) 15 AIP-192329 EVQLVESGGALVKPGGSLRLSCAASGFTFSHAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1347) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1541) 16 AIP-197809 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAYMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1348) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1542) 17 AIP-142489 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWFSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1349) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1543) 18 AIP-148102 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIQSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1350) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1544) 19 AIP-167726 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKAVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1351) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1545) 20 AIP-199834 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSATDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1352) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1546) 21 AIP-143179 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSNTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1353) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1547) 22 AIP-195587 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVHDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1354) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1548) 23 AIP-153462 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVDDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1355) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1549) 24 AIP-115363 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVQDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1356) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1550) 25 AIP-151090 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTNGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1357) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1551) 26 AIP-168083 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDAETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1358) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1552) 27 AIP-161082 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGQTTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1359) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1553) 28 AIP-114196 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGHTTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1360) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1554) 29 AIP-189338 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGEQTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1361) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1555) thirty AIP-183190 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGEATDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1362) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1556) 31 AIP-110143 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYASPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1363) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1557) 32 AIP-147176 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVQGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1364) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1558) 33 AIP-134312 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1365) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1559) 34 AIP-128243 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTTSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS(SEQ ID NO:1366) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1560) 35 AIP-156172 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSPFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1367) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1561) 36 AIP-147389 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSAFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1368) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1562) 37 AIP-124314 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSYCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1369) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1563) 38 AIP-185291 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCLGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1370) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1564) 39 AIP-135247 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCHGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1371) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1565) 40 AIP-113513 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCQGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1372) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1566) 41 AIP-102299 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRSGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1373) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1567) 42 AIP-179097 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGASCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1374) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1568) 43 AIP-109343 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGKSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1375) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1569) 44 AIP-119622 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGNSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1376) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1570) 45 AIP-191735 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGNCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1377) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1571) 46 AIP-157078 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGQCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1378) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1572) 47 AIP-153475 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGACPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1379) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1573) 48 AIP-133650 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCASHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1380) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1574) 49 AIP-190915 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCLSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1381) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1575) 50 AIP-105241 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPAHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1382) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1576) 51 AIP-167400 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPNHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1383) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1577) 52 AIP-109729 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSSDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1384) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1578) 53 AIP-151709 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSQDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1385) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1579) 54 AIP-137169 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHETSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1386) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1580) 55 AIP-199616 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDQSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1387) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1581) 56 AIP-189296 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSMCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1388) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1582) 57 AIP-152283 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCAGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1389) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1583) 58 AIP-136628 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1390) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1584) 59 AIP-100340 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGNQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1391) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1585) 60 AIP-166959 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGAQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1392) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1586) 61 AIP-190362 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGSYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1393) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1587) 62 AIP-101601 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGYYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1394) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1588) 63 AIP-159023 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQFKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1395) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1589) 64 AIP-146871 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYPSYYYMDVWGKGTTVTVSS (SEQ ID NO:1396) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1590) 65 AIP-170053 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYASYYYMDVWGKGTTVTVSS (SEQ ID NO:1397) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1591) 66 AIP-199483 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYQSYYYMDVWGKGTTVTVSS (SEQ ID NO:1398) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1592) 67 AIP-161048 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKDYYYMDVWGKGTTVTVSS (SEQ ID NO:1399) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1593) 68 AIP-162041 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSFYYMDVWGKGTTVTVSS (SEQ ID NO:1400) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1594) 69 AIP-197886 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYFYMDVWGKGTTVTVSS (SEQ ID NO:1401) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1595) 70 AIP-183133 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYWMDVWGKGTTVTVSS (SEQ ID NO:1402) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1596) 71 AIP-191470 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYLMDVWGKGTTVTVSS (SEQ ID NO:1403) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1597) 72 AIP-151167 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYVDVWGKGTTVTVSS (SEQ ID NO:1404) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1598) 73 AIP-106633 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYFDVWGKGTTVTVSS (SEQ ID NO:1405) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1599) 74 AIP-102624 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMNVWGKGTTVTVSS (SEQ ID NO:1406) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1600) 75 AIP-109484 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDIWGKGTTVTVSS (SEQ ID NO:1407) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1601) 76 AIP-164754 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDPWGKGTTVTVSS (SEQ ID NO:1408) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1602) 77 AIP-169676 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQFKDYYYMDVWGKGTTVTVSS (SEQ ID NO:1409) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1603) 78 AIP-177584 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQSKQYYYMDVWGKGTTVTVSS (SEQ ID NO:1410) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1604) 79 AIP-174676 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQSKKYYYMDVWGKGTTVTVSS (SEQ ID NO:1411) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1605) 80 AIP-120546 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFSCRGGSCPSHDTSYSGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1412) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1606) 81 AIP-186435 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFACRGGSCPSHDTSYVGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1413) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1607) 82 AIP-171074 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGNSCPAHDTSYCGGQYPSYYYMDVWGKGTTVTVSS (SEQ ID NO:1414) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1608) 83 AIP-163039 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSYCCLGGSCPSHDTSYCGGSYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1415) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1609) 84 AIP-147652 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGKSCPSHDNSYCGGQYASYYYMDVWGKGTTVTVSS (SEQ ID NO:1416) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1610) 85 AIP-182061 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSYCCRGGSCPSHDTSYCGGQFKSYYYMDPWGKGTTVTVSS (SEQ ID NO:1417) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1611) 86 AIP-172643 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSTFCCRGGSCLSHDTSYCGGQYKSYYWMDVWGKGTTVTVSS (SEQ ID NO:1418) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1612) 87 AIP-171912 EVQLVESGGALVKPGGSLRLSCAASGFDFSKAWMSWVRQAPGKGLEWVGRIKSVTDGQTTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1419) QSVLTQPPSASGTPGQRVTISCTGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1613) 88 AIP-167833 EVQLVESGGALVKPGGSLRLSCAASGFTFAKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1420) QSVLTQPPSASGTPGQRVTISCSGSSTNIGSSSVSWYQQLPGTAPKLLIYKNNYRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1614) 89 AIP-145518 EVQLVESGGALVKPGGSLRLSCAASGFDASKAWFTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1421) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1615) 90 AIP-143155 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1422) QSVLTQPPSASGTPGQRVTISCTGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1616) 91 AIP-119664 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1423) QSVLTQPPSASGTPGQRVTISCSGASSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1617) 92 AIP-190526 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1424) QSVLTQPPSASGTPGQRVTISCSGSSPNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1618) 93 AIP-114403 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1425) QSVLTQPPSASGTPGQRVTISCSGSKSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1619) 94 AIP-156760 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1426) QSVLTQPPSASGTPGQRVTISCSGSSTNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1620) 95 AIP-103803 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1427) QSVLTQPPSASGTPGQRVTISCSGSSSDIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1621) 96 AIP-182722 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1428) QSVLTQPPSASGTPGQRVTISCSGSSSNIQSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1622) 97 AIP-195588 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1429) QSVLTQPPSASGTPGQRVTISCSGSSSNIGHSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1623) 98 AIP-145722 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1430) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSTSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1624) 99 AIP-178251 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1431) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSNSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1625) 100 AIP-116142 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1432) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSASVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1626) 101 AIP-183350 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1433) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSTVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1627) 102 AIP-127108 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1434) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSAVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1628) 103 AIP-128147 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1435) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSYVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1629) 104 AIP-109510 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1436) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSSTSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1630) 105 AIP-104086 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1437) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVAWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1631) 106 AIP-143132 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1438) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVTWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1632) 107 AIP-169636 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1439) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYRNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1633) 108 AIP-152243 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1440) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYNNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1634) 109 AIP-138776 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1441) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYMNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1635) 110 AIP-103817 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1442) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYANNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1636) 111 AIP-130491 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1443) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYHNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1637) 112 AIP-188155 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1444) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1638) 113 AIP-167246 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1445) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNTQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1639) 114 AIP-106139 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1446) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNYRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1640) 115 AIP-198351 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1447) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNARPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1641) 116 AIP-159326 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1448) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNLRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1642) 117 AIP-192275 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1449) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQQPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1643) 118 AIP-190761 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1450) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRASGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1644) 119 AIP-166832 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1451) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPYGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1645) 120 AIP-148062 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1452) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPLGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1646) 121 AIP-129145 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1453) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1647) 122 AIP-111240 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1454) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1648) 123 AIP-190749 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1455) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTDFDLSVRVFGGGTKLTVL (SEQ ID NO:1649) 124 AIP-153888 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1456) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDNSLSVRVFGGGTKLTVL (SEQ ID NO:1650) 125 AIP-130915 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1457) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDQLSVRVFGGGTKLTVL (SEQ ID NO:1651) 126 AIP-109048 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1458) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDALSVRVFGGGTKLTVL (SEQ ID NO:1652) 127 AIP-170569 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1459) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWWDDDLSVRVFGGGTKLTVL (SEQ ID NO:1653) 128 AIP-154873 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1460) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSNSVRVFGGGTKLTVL (SEQ ID NO:1654) 129 AIP-159037 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1461) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSSSVRVFGGGTKLTVL (SEQ ID NO:1655) 130 AIP-186826 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1462) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLNVRVFGGGTKLTVL (SEQ ID NO:1656) 131 AIP-156514 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1463) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLLVRVFGGGTKLTVL (SEQ ID NO:1657) 132 AIP-157122 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1464) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLTVRVFGGGTKLTVL (SEQ ID NO:1658) 133 AIP-173276 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1465) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSIRVFGGGTKLTVL (SEQ ID NO:1659) 134 AIP-150485 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1466) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVKVFGGGTKLTVL (SEQ ID NO:1660) 135 AIP-135679 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1467) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVWVFGGGTKLTVL (SEQ ID NO:1661) 136 AIP-166847 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1468) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVHVFGGGTKLTVL (SEQ ID NO:1662) 137 AIP-124013 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1469) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVQVFGGGTKLTVL (SEQ ID NO:1663) 138 AIP-126285 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1470) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRIFGGGTKLTVL (SEQ ID NO:1664) 139 AIP-190274 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1471) QSVLTQPPSASGTPGQRVTISCSGSSSDIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWNDQLSVRVFGGGTKLTVL (SEQ ID NO:1665) 140 AIP-150277 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1472) QSVLTQPPSASGTPGQRVTISCHGSESDIGSHDVLWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1666) 141 AIP-104364 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWYSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1473) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1667) 142 AIP-180422 EVQLVESGGGLVQPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTEYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1474) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1668) 143 AIP-166722 EVQLVESGGGLVQPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTEYAASVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1475) QSVLTQPPSVSGAPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1669) 144 AIP-193490 EVQLVESGGGLVQPGPSLRLSCTASGTFFSKAWMSWVRQAPGKGLEWVGFIKSVTDGETTEYAASVKGRFTISRDDSKSIAYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1476) QSVLTQPPSVSGAPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1670) 145 AIP-129967 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSYCCRSGSCPSSDTSYCNGQFKSYYYMDPWGKGTTVTVSS (SEQ ID NO:1477) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1671) 146 AIP-126175 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRSGSCPSSDTSYCNGQYKSYYYVNIWGKGTTVTVSS (SEQ ID NO:1478) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1672) 147 AIP-180905 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTTSFCCRGASCPSHDTSYCAGSYKSYYYVNIWGKGTTVTVSS (SEQ ID NO:1479) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1673) 148 AIP-141706 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSAFCCRGKSCPSSDTSYCGGQYPSYYYVNIWGKGTTVTVSS (SEQ ID NO:1480) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1674) 149 AIP-105092 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSAFCCRGKSCPSHDTSFCGGQDKRYYYVNIWGKGTTVTVSS (SEQ ID NO:1481) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1675) 150 AIP-152031 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSAFCCRGGNCPSHETSYCNGQNKQYYYMDVWGKGTTVTVSS (SEQ ID NO:1482) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1676) 151 AIP-163319 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGNQCPSSDTSFCGGQDKRYYYMDPWGKGTTVTVSS (SEQ ID NO:1483) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1677) 152 AIP-160621 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTTSFCCRGNQCPSHETSYCGGYYKSYFYMDVWGKGTTVTVSS (SEQ ID NO:1484) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1678) 153 AIP-145212 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSYCCRGKQCPSHDTSYCAGQYADYYYMDVWGKGTTVTVSS (SEQ ID NO:1485) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1679) 154 AIP-112328 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGKQCPSSDTSYCNGQYADYYYMDVWGKGTTVTVSS (SEQ ID NO:1486) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1680) 155 AIP-193106 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGKQCPSSDTSYCNGQYADYYYVNIWGKGTTVTVSS (SEQ ID NO:1487) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1681) 156 AIP-125062 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGKQCPSSDTSFCGGQDKRYYFMDVWGKGTTVTVSS (SEQ ID NO:1488) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1682) 157 AIP-124301 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSAFCCRGKQCPSSDTSYCGGQYASFYYMDVWGKGTTVTVSS (SEQ ID NO:1489) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1683) 158 AIP-124068 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCQGNNCPSSDTSYCGGYYKDYYYMDVWGKGTTVTVSS (SEQ ID NO:1490) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1684) 159 AIP-144568 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCQGNNCPSHDTSYCGGQYKSYYYVNIWGKGTTVTVSS (SEQ ID NO:1491) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1685) 160 AIP-139782 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCQGKNCPSHETSYCGGQYADYYYMDVWGKGTTVTVSS (SEQ ID NO:1492) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1686) 161 AIP-171543 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTTSFCCHGNSCPSSDTSYCGGQNKQYYYMDVWGKGTTVTVSS (SEQ ID NO:1493) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1687) 162 AIP-140148 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCHGNSCPSHDTSYCNGQNKQYYYMDVWGKGTTVTVSS (SEQ ID NO:1494) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1688) 163 AIP-177193 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCHSNNCPSSDTSYCNGQYKQYYYMDVWGKGTTVTVSS (SEQ ID NO:1495) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1689) 164 AIP-171348 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCHSNNCPSHDTSYCGGQYKSYYYVNIWGKGTTVTVSS (SEQ ID NO:1496) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1690) 165 AIP-193088 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFACHSNNCPSSDTSYVNGYYKQYYFMDVWGKGTTVTVSS (SEQ ID NO:1497) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1691) 166 AIP-182087 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCHSNNCPSSDTSYCNGQYKQYYYVNIWGKGTTVTVSS (SEQ ID NO:1498) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1692) 167 AIP-151388 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCLGKACLSHDTSYCGGQYASYYYVNIWGKGTTVTVSS (SEQ ID NO:1499) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1693) 168 AIP-149787 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCLGKACLSSDTSYCGGYYASYYFVNIWGKGTTVTVSS (SEQ ID NO:1500) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1694) 169 AIP-126097 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFACLGKACLSSDTSYVGGYYASYYFVNIWGKGTTVTVSS (SEQ ID NO:1501) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1695) 170 AIP-107759 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSYCCLGNSCPSSDTSYCGGQFKSYYYMDPWGKGTTVTVSS (SEQ ID NO:1502) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1696) 171 AIP-148484 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSYCCLGNSCPSSDTSFCGGQDKRYYYMDPWGKGTTVTVSS (SEQ ID NO:1503) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1697) 172 AIP-186403 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCLGGNCPSSETSYCGNQYPSYYYMDVWGKGTTVTVSS (SEQ ID NO:1504) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1698) 173 AIP-166629 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCLGGNCPSSETSYCGNYYPSYFYMDVWGKGTTVTVSS (SEQ ID NO:1505) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1699) 174 AIP-165276 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCLGGNCPSSETSYCGNQYPSYYYVNIWGKGTTVTVSS (SEQ ID NO:1506) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1700) 175 AIP-188293 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTTSFACRGNQCPSHETSYVGGYYKSYFYMDVWGKGTTVTVSS (SEQ ID NO:1507) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1701) 176 AIP-109364 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTTSFACRGNQCPSSETSYVGGYYKSYFFMDVWGKGTTVTVSS (SEQ ID NO:1508) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1702) 177 AIP-191805 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFACRGKQCPSSDTSYVGGQFKSYYFMDVWGKGTTVTVSS (SEQ ID NO:1509) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1703) 178 AIP-181592 EVQLVESGGALVKPGGSLRLSCAASGFTFAKAWMSWVRQAPGKGLEWVGRIKAADDGKQTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCLSHDTSYCGGQYKSYYWMDVWGKGTTVTVSS (SEQ ID NO:1510) QSVLTQPPSASGTPGQRVTISCSGSSTNIGSSSVYWYQQLPGTAPKLLIYKNNYRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1704) 179 AIP-155587 EVQLVESGGALVKPGGSLRLSCAASGFTYAKAWMSWVRQAPGKGLEWVGRIKSVQDGEQTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSYCCLGGSCPSHDTSYCGGSYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1511) QSVLTQPPSASGTPGQRVTISCSGSSTNIGSSSVYWYQQLPGTAPKLLIYKNNYRASGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1705) 180 AIP-147945 EVQLVESGGALVKPGGSLRLSCAASGFDASKAWFTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQNKQYYYMDVWGKGTTVTVSS (SEQ ID NO:1512) QSVLTQPPSASGTPGQRVTISCTGSSSNIGSSYVSWYQQLPGTAPKLLIYKNSLRPQGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1706) 181 AIP-199264 EVQLVESGGALVKPGGSLRLSCAASGFDASKAWFTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFACRGGSCPSHDTSYVGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1513) QSVLTQPPSASGTPGQRVTISCTGSSSNIGSSYVSWYQQLPGTAPKLLIYKNSLRPQGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1707) 182 AIP-123438 EVQLVESGGALVKPGGSLRLSCAASGFDASKAWFTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSYCCLGGSCPSHDTSYCGGSYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1514) QSVLTQPPSASGTPGQRVTISCTGSSSNIGSSYVSWYQQLPGTAPKLLIYKNSLRPQGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1708) 183 AIP-151315 EVQLVESGGALVKPGGSLRLSCAASGFDASKAWFTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGKSCPSHDTSYCGGQYASYYYMDVWGKGTTVTVSS (SEQ ID NO:1515) QSVLTQPPSASGTPGQRVTISCTGSSSNIGSSYVSWYQQLPGTAPKLLIYKNSLRPQGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1709) 184 AIP-197785 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKAADDGKQTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGNCPSHETSYCGNQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1516) QSVLTQPPSASGTPGQRVTISCSGSPSNIGSASTSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1710) 185 AIP-115782 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKAADDGKQTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRSGSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1517) QSVLTQPPSASGTPGQRVTISCSGSPSNIGSASTSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1711) 186 AIP-138130 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKAADDGKQTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYVNIWGKGTTVTVSS (SEQ ID NO:1518) QSVLTQPPSASGTPGQRVTISCSGSPSNIGSASTSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1712) 187 AIP-170221 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKAADDGKQTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTTSFCCRGASCPSHDTSYCAGSYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1519) QSVLTQPPSASGTPGQRVTISCSGSPSNIGSASTSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1713) 188 AIP-167482 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKAADDGKQTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGNSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1520) QSVLTQPPSASGTPGQRVTISCSGSPSNIGSASTSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1714) 189 AIP-189475 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKAVTDGHTTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1521) QSVLTQPPSASGTPGQRVTISCSGASSNIGHSSVYWYQQLPGTAPKLLIYRNNQQPLGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDALSIRVFGGGTKLTVL (SEQ ID NO:1715) 190 AIP-102833 EVQLVESGGALVKPGGSLRLSCAASGFVYSKAWMSWVRQAPGKGLEWVGRIKSVTDGQATDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1522) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNTQRASGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDALNVRVFGGGTKLTVL (SEQ ID NO:1716) 191 AIP-173396 EVQLVESGGALVKPGGSLRLSCAASGFVFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGKSCPSHDTSYCGGQYASYYYMDVWGKGTTVTVSS (SEQ ID NO:1523) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYRNNQQPLGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSSLVRVFGGGTKLTVL (SEQ ID NO:1717) 192 AIP-132355 EVQLVESGGALVKPGGSLRLSCAASGFTFAKAWMSWVRQAPGKGLEWVGRIKSVTDAETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRSGSCPSSDTSYCNGQYKSYYWMDVWGKGTTVTVSS (SEQ ID NO:1524) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVTWYQQLPGTAPKLLIYKNNARPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDNSLSIRVFGGGTKLTVL (SEQ ID NO:1718) 193 AIP-118505 EVQLVESGGALVKPGGSLRLSCAASGFTYAKAWFTWVRQAPGKGLEWVGRIKSTSDGGITDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSFCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:1525) QSVLTQPPSASGTPGQRVTISCSGSKSNIGSSYVSWYQQLPGTAPKLLIYKDNQRASGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDALSVRVFGGGTKLTVL (SEQ ID NO:1719) 194 AIP-131972 EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVSDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSRDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:1526) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1720) 195 AIP-189526 EVQLVESGGGLVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSTSDGGITDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTSFCCRGGRCPSRDTSFCGGQYNSYYMDVWGQGTTVTVSS (SEQ ID NO:1725) QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:1726

TABLE 2B

AIP number HCDR1 HCDR2 HCDR3 LCDR1 LCDR2 LCDR3 196 AIP-148327 GFTFSKAWMT (SEQ ID NO:169) RIKSVTEGETTDYAAPVKG (SEQ ID NO:363) TSSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:557) SGSSSNIGSSSVS (SEQ ID NO:751) KNNQRPS (SEQ ID NO:945) STWDESLSVRV (SEQ ID NO:1139) 197 AIP-198092 GFTFSKAWMT (SEQ ID NO:170) RIKSVTEGETTDYAAPVKG (SEQ ID NO:364) TSSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:558) SGSSSNIGSSSVS (SEQ ID NO:752) KNNQRPS (SEQ ID NO:946) STWDESLSVRV (SEQ ID NO:1140) 198 AIP-184490 GFTFSKAWMT (SEQ ID NO:171) RIKSVTDGETTDYAAPVKG (SEQ ID NO:365) TSSFCCRGGSCPSHDTSFCGGSYKSYYYMDV (SEQ ID NO:559) SGSSSNIGSSSVS (SEQ ID NO:753) KNNQRPS (SEQ ID NO:947) STWDESLSVRV (SEQ ID NO:1141) 199 AIP-102396 GFTFSKAWMS (SEQ ID NO:172) RIKSVTDGETTDYAAPVKG (SEQ ID NO:366) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:560) SGSSSNIGSSSVS (SEQ ID NO:754) KNNQRPS (SEQ ID NO:948) STWDESLSVRV (SEQ ID NO:1142) 200 AIP-150055 GYTFSKAWMS (SEQ ID NO:173) RIKSVTDGETTDYAAPVKG (SEQ ID NO:367) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:561) SGSSSNIGSSSVS (SEQ ID NO:755) KNNQRPS (SEQ ID NO:949) STWDDSLSVRV (SEQ ID NO:1143) 201 AIP-167084 GFDFSKAWMS (SEQ ID NO:174) RIKSVTDGETTDYAAPVKG (SEQ ID NO:368) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:562) SGSSSNIGSSSVS (SEQ ID NO:756) KNNQRPS (SEQ ID NO:950) STWDDSLSVRV (SEQ ID NO:1144) 202 AIP-185304 GFVFSKAWMS (SEQ ID NO:175) RIKSVTDGETTDYAAPVKG (SEQ ID NO:369) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:563) SGSSSNIGSSSVS (SEQ ID NO:757) KNNQRPS (SEQ ID NO:951) STWDDSLSVRV (SEQ ID NO:1145) 203 AIP-134770 GFTYSKAWMS (SEQ ID NO:176) RIKSVTDGETTDYAAPVKG (SEQ ID NO:370) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:564) SGSSSNIGSSSVS (SEQ ID NO:758) KNNQRPS (SEQ ID NO:952) STWDDSLSVRV (SEQ ID NO:1146) 204 AIP-141887 GFTFAKAWMS (SEQ ID NO:177) RIKSVTDGETTDYAAPVKG (SEQ ID NO:371) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:565) SGSSSNIGSSSVS (SEQ ID NO:759) KNNQRPS (SEQ ID NO:953) STWDDSLSVRV (SEQ ID NO:1147) 205 AIP-196203 GFTFSNAWMS (SEQ ID NO:178) RIKSVTDGETTDYAAPVKG (SEQ ID NO:372) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:566) SGSSSNIGSSSVS (SEQ ID NO:760) KNNQRPS (SEQ ID NO:954) STWDDSLSVRV (SEQ ID NO:1148) 206 AIP-184151 GFTFSRAWMS (SEQ ID NO:179) RIKSVTDGETTDYAAPVKG (SEQ ID NO:373) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:567) SGSSSNIGSSSVS (SEQ ID NO:761) KNNQRPS (SEQ ID NO:955) STWDDSLSVRV (SEQ ID NO:1149) 207 AIP-128195 GFTFSMAWMS (SEQ ID NO:180) RIKSVTDGETTDYAAPVKG (SEQ ID NO:374) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:568) SGSSSNIGSSSVS (SEQ ID NO:762) KNNQRPS (SEQ ID NO:956) STWDDSLSVRV (SEQ ID NO:1150) 208 AIP-116579 GFTFSAAWMS (SEQ ID NO:181) RIKSVTDGETTDYAAPVKG (SEQ ID NO:375) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:569) SGSSSNIGSSSVS (SEQ ID NO:763) KNNQRPS (SEQ ID NO:957) STWDDSLSVRV (SEQ ID NO:1151) 209 AIP-192329 GFTFSHAWMS (SEQ ID NO:182) RIKSVTDGETTDYAAPVKG (SEQ ID NO:376) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:570) SGSSSNIGSSSVS (SEQ ID NO:764) KNNQRPS (SEQ ID NO:958) STWDDSLSVRV (SEQ ID NO:1152) 210 AIP-192329 GFTFSHAWMS (SEQ ID NO:183) RIKSVTDGETTDYAAPVKG (SEQ ID NO:377) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:571) SGSSSNIGSSSVS (SEQ ID NO:765) KNNQRPS (SEQ ID NO:959) STWDDSLSVRV (SEQ ID NO:1153) 211 AIP-197809 GFTFSKAYMS (SEQ ID NO:184) RIKSVTDGETTDYAAPVKG (SEQ ID NO:378) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:572) SGSSSNIGSSSVS (SEQ ID NO:766) KNNQRPS (SEQ ID NO:960) STWDDSLSVRV (SEQ ID NO:1154) 212 AIP-142489 GFTFSKAWFS (SEQ ID NO:185) RIKSVTDGETTDYAAPVKG (SEQ ID NO:379) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:573) SGSSSNIGSSSVS (SEQ ID NO:767) KNNQRPS (SEQ ID NO:961) STWDDSLSVRV (SEQ ID NO:1155) 213 AIP-148102 GFTFSKAWMS (SEQ ID NO:186) RIQSVTDGETTDYAAPVKG (SEQ ID NO:380) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:574) SGSSSNIGSSSVS (SEQ ID NO:768) KNNQRPS (SEQ ID NO:962) STWDDSLSVRV (SEQ ID NO:1156) 214 AIP-167726 GFTFSKAWMS (SEQ ID NO:187) RIKAVTDGETTDYAAPVKG (SEQ ID NO:381) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:575) SGSSSNIGSSSVS (SEQ ID NO:769) KNNQRPS (SEQ ID NO:963) STWDDSLSVRV (SEQ ID NO:1157) 215 AIP-199834 GFTFSKAWMS (SEQ ID NO:188) RIKSATDGETTDYAAPVKG (SEQ ID NO:382) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:576) SGSSSNIGSSSVS (SEQ ID NO:770) KNNQRPS (SEQ ID NO:964) STWDDSLSVRV (SEQ ID NO:1158) 216 AIP-143179 GFTFSKAWMS (SEQ ID NO:189) RIKSNTDGETTDYAAPVKG (SEQ ID NO:383) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:577) SGSSSNIGSSSVS (SEQ ID NO:771) KNNQRPS (SEQ ID NO:965) STWDDSLSVRV (SEQ ID NO:1159) 217 AIP-195587 GFTFSKAWMS (SEQ ID NO:190) RIKSVHDGETTDYAAPVKG (SEQ ID NO:384) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:578) SGSSSNIGSSSVS (SEQ ID NO:772) KNNQRPS (SEQ ID NO:966) STWDDSLSVRV (SEQ ID NO:1160) 218 AIP-153462 GFTFSKAWMS (SEQ ID NO:191) RIKSVDDGETTDYAAPVKG (SEQ ID NO:385) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:579) SGSSSNIGSSSVS (SEQ ID NO:773) KNNQRPS (SEQ ID NO:967) STWDDSLSVRV (SEQ ID NO:1161) 219 AIP-115363 GFTFSKAWMS (SEQ ID NO:192) RIKSVQDGETTDYAAPVKG (SEQ ID NO:386) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:580) SGSSSNIGSSSVS (SEQ ID NO:774) KNNQRPS (SEQ ID NO:968) STWDDSLSVRV (SEQ ID NO:1162) 220 AIP-151090 GFTFSKAWMS (SEQ ID NO:193) RIKSVTNGETTDYAAPVKG (SEQ ID NO:387) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:581) SGSSSNIGSSSVS (SEQ ID NO:775) KNNQRPS (SEQ ID NO:969) STWDDSLSVRV (SEQ ID NO:1163) 221 AIP-168083 GFTFSKAWMS (SEQ ID NO:194) RIKSVTDAETTDYAAPVKG (SEQ ID NO:388) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:582) SGSSSNIGSSSVS (SEQ ID NO:776) KNNQRPS (SEQ ID NO:970) STWDDSLSVRV (SEQ ID NO:1164) 222 AIP-161082 GFTFSKAWMS (SEQ ID NO:195) RIKSVTDGQTTDYAAPVKG (SEQ ID NO:389) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:583) SGSSSNIGSSSVS (SEQ ID NO:777) KNNQRPS (SEQ ID NO:971) STWDDSLSVRV (SEQ ID NO:1165) 223 AIP-114196 GFTFSKAWMS (SEQ ID NO:196) RIKSVTDGHTTDYAAPVKG (SEQ ID NO:390) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:584) SGSSSNIGSSSVS (SEQ ID NO:778) KNNQRPS (SEQ ID NO:972) STWDDSLSVRV (SEQ ID NO:1166) 224 AIP-189338 GFTFSKAWMS (SEQ ID NO:197) RIKSVTDGEQTDYAAPVKG (SEQ ID NO:391) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:585) SGSSSNIGSSSVS (SEQ ID NO:779) KNNQRPS (SEQ ID NO:973) STWDDSLSVRV (SEQ ID NO:1167) 225 AIP-183190 GFTFSKAWMS (SEQ ID NO:198) RIKSVTDGEATDYAAPVKG (SEQ ID NO:392) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:586) SGSSSNIGSSSVS (SEQ ID NO:780) KNNQRPS (SEQ ID NO:974) STWDDSLSVRV (SEQ ID NO:1168) 226 AIP-110143 GFTFSKAWMS (SEQ ID NO:199) RIKSVTDGETTDYASPVKG (SEQ ID NO:393) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:587) SGSSSNIGSSSVS (SEQ ID NO:781) KNNQRPS (SEQ ID NO:975) STWDDSLSVRV (SEQ ID NO:1169) 227 AIP-147176 GFTFSKAWMS (SEQ ID NO:200) RIKSVTDGETTDYAAPVQG (SEQ ID NO:394) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:588) SGSSSNIGSSSVS (SEQ ID NO:782) KNNQRPS (SEQ ID NO:976) STWDDSLSVRV (SEQ ID NO:1170) 228 AIP-134312 GFTFSKAWMS (SEQ ID NO:201) RIKSVTDGETTDYAAPVKG (SEQ ID NO:395) ISSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:589) SGSSSNIGSSSVS (SEQ ID NO:783) KNNQRPS (SEQ ID NO:977) STWDDSLSVRV (SEQ ID NO:1171) 229 AIP-128243 GFTFSKAWMS (SEQ ID NO:202) RIKSVTDGETTDYAAPVKG (SEQ ID NO:396) TTSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:590) SGSSSNIGSSSVS (SEQ ID NO:784) KNNQRPS (SEQ ID NO:978) STWDDSLSVRV (SEQ ID NO:1172) 230 AIP-156172 GFTFSKAWMS (SEQ ID NO:203) RIKSVTDGETTDYAAPVKG (SEQ ID NO:397) TSPFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:591) SGSSSNIGSSSVS (SEQ ID NO:785) KNNQRPS (SEQ ID NO:979) STWDDSLSVRV (SEQ ID NO:1173) 231 AIP-147389 GFTFSKAWMS (SEQ ID NO:204) RIKSVTDGETTDYAAPVKG (SEQ ID NO:398) TSAFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:592) SGSSSNIGSSSVS (SEQ ID NO:786) KNNQRPS (SEQ ID NO:980) STWDDSLSVRV (SEQ ID NO:1174) 232 AIP-124314 GFTFSKAWMS (SEQ ID NO:205) RIKSVTDGETTDYAAPVKG (SEQ ID NO:399) TSSYCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:593) SGSSSNIGSSSVS (SEQ ID NO:787) KNNQRPS (SEQ ID NO:981) STWDDSLSVRV (SEQ ID NO:1175) 233 AIP-185291 GFTFSKAWMS (SEQ ID NO:206) RIKSVTDGETTDYAAPVKG (SEQ ID NO:400) TSSFCCLGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:594) SGSSSNIGSSSVS (SEQ ID NO:788) KNNQRPS (SEQ ID NO:982) STWDDSLSVRV (SEQ ID NO:1176) 234 AIP-135247 GFTFSKAWMS (SEQ ID NO:207) RIKSVTDGETTDYAAPVKG (SEQ ID NO:401) TSSFCCHGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:595) SGSSSNIGSSSVS (SEQ ID NO:789) KNNQRPS (SEQ ID NO:983) STWDDSLSVRV (SEQ ID NO:1177) 235 AIP-113513 GFTFSKAWMS (SEQ ID NO:208) RIKSVTDGETTDYAAPVKG (SEQ ID NO:402) TSSFCCQGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:596) SGSSSNIGSSSVS (SEQ ID NO:790) KNNQRPS (SEQ ID NO:984) STWDDSLSVRV (SEQ ID NO:1178) 236 AIP-102299 GFTFSKAWMS (SEQ ID NO:209) RIKSVTDGETTDYAAPVKG (SEQ ID NO:403) TSSFCCRSGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:597) SGSSSNIGSSSVS (SEQ ID NO:791) KNNQRPS (SEQ ID NO:985) STWDDSLSVRV (SEQ ID NO:1179) 237 AIP-179097 GFTFSKAWMS (SEQ ID NO:210) RIKSVTDGETTDYAAPVKG (SEQ ID NO:404) TSSFCCRGASCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:598) SGSSSNIGSSSVS (SEQ ID NO:792) KNNQRPS (SEQ ID NO:986) STWDDSLSVRV (SEQ ID NO:1180) 238 AIP-109343 GFTFSKAWMS (SEQ ID NO:211) RIKSVTDGETTDYAAPVKG (SEQ ID NO:405) TSSFCCRGKSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:599) SGSSSNIGSSSVS (SEQ ID NO:793) KNNQRPS (SEQ ID NO:987) STWDDSLSVRV (SEQ ID NO:1181) 239 AIP-119622 GFTFSKAWMS (SEQ ID NO:212) RIKSVTDGETTDYAAPVKG (SEQ ID NO:406) TSSFCCRGNSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:600) SGSSSNIGSSSVS (SEQ ID NO:794) KNNQRPS (SEQ ID NO:988) STWDDSLSVRV (SEQ ID NO:1182) 240 AIP-191735 GFTFSKAWMS (SEQ ID NO:213) RIKSVTDGETTDYAAPVKG (SEQ ID NO:407) TSSFCCRGGNCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:601) SGSSSNIGSSSVS (SEQ ID NO:795) KNNQRPS (SEQ ID NO:989) STWDDSLSVRV (SEQ ID NO:1183) 241 AIP-157078 GFTFSKAWMS (SEQ ID NO:214) RIKSVTDGETTDYAAPVKG (SEQ ID NO:408) TSSFCCRGGQCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:602) SGSSSNIGSSSVS (SEQ ID NO:796) KNNQRPS (SEQ ID NO:990) STWDDSLSVRV (SEQ ID NO:1184) 242 AIP-153475 GFTFSKAWMS (SEQ ID NO:215) RIKSVTDGETTDYAAPVKG (SEQ ID NO:409) TSSFCCRGGACPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:603) SGSSSNIGSSSVS (SEQ ID NO:797) KNNQRPS (SEQ ID NO:991) STWDDSLSVRV (SEQ ID NO:1185) 243 AIP-133650 GFTFSKAWMS (SEQ ID NO:216) RIKSVTDGETTDYAAPVKG (SEQ ID NO:410) TSSFCCRGGSCASHDTSYCGGQYKSYYYMDV (SEQ ID NO:604) SGSSSNIGSSSVS (SEQ ID NO:798) KNNQRPS (SEQ ID NO:992) STWDDSLSVRV (SEQ ID NO:1186) 244 AIP-190915 GFTFSKAWMS (SEQ ID NO:217) RIKSVTDGETTDYAAPVKG (SEQ ID NO:411) TSSFCCRGGSCLSHDTSYCGGQYKSYYYMDV (SEQ ID NO:605) SGSSSNIGSSSVS (SEQ ID NO:799) KNNQRPS (SEQ ID NO:993) STWDDSLSVRV (SEQ ID NO:1187) 245 AIP-105241 GFTFSKAWMS (SEQ ID NO:218) RIKSVTDGETTDYAAPVKG (SEQ ID NO:412) TSSFCCRGGSCPAHDTSYCGGQYKSYYYMDV (SEQ ID NO:606) SGSSSNIGSSSVS (SEQ ID NO:800) KNNQRPS (SEQ ID NO:994) STWDDSLSVRV (SEQ ID NO:1188) 246 AIP-167400 GFTFSKAWMS (SEQ ID NO:219) RIKSVTDGETTDYAAPVKG (SEQ ID NO:413) TSSFCCRGGSCPNHDTSYCGGQYKSYYYMDV (SEQ ID NO:607) SGSSSNIGSSSVS (SEQ ID NO:801) KNNQRPS (SEQ ID NO:995) STWDDSLSVRV (SEQ ID NO:1189) 247 AIP-109729 GFTFSKAWMS (SEQ ID NO:220) RIKSVTDGETTDYAAPVKG (SEQ ID NO:414) TSSFCCRGGSCPSSDTSYCGGQYKSYYYMDV (SEQ ID NO:608) SGSSSNIGSSSVS (SEQ ID NO:802) KNNQRPS (SEQ ID NO:996) STWDDSLSVRV (SEQ ID NO:1190) 248 AIP-151709 GFTFSKAWMS (SEQ ID NO:221) RIKSVTDGETTDYAAPVKG (SEQ ID NO:415) TSSFCCRGGSCPSQDTSYCGGQYKSYYYMDV (SEQ ID NO:609) SGSSSNIGSSSVS (SEQ ID NO:803) KNNQRPS (SEQ ID NO:997) STWDDSLSVRV (SEQ ID NO:1191) 249 AIP-137169 GFTFSKAWMS (SEQ ID NO:222) RIKSVTDGETTDYAAPVKG (SEQ ID NO:416) TSSFCCRGGSCPSHETSYCGGQYKSYYYMDV (SEQ ID NO:610) SGSSSNIGSSSVS (SEQ ID NO:804) KNNQRPS (SEQ ID NO:998) STWDDSLSVRV (SEQ ID NO:1192) 250 AIP-199616 GFTFSKAWMS (SEQ ID NO:223) RIKSVTDGETTDYAAPVKG (SEQ ID NO:417) TSSFCCRGGSCPSHDQSYCGGQYKSYYYMDV (SEQ ID NO:611) SGSSSNIGSSSVS (SEQ ID NO:805) KNNQRPS (SEQ ID NO:999) STWDDSLSVRV (SEQ ID NO:1193) 251 AIP-189296 GFTFSKAWMS (SEQ ID NO:224) RIKSVTDGETTDYAAPVKG (SEQ ID NO:418) TSSFCCRGGSCPSHDTSMCGGQYKSYYYMDV (SEQ ID NO:612) SGSSSNIGSSSVS (SEQ ID NO:806) KNNQRPS (SEQ ID NO:1000) STWDDSLSVRV (SEQ ID NO:1194) 252 AIP-152283 GFTFSKAWMS (SEQ ID NO:225) RIKSVTDGETTDYAAPVKG (SEQ ID NO:419) TSSFCCRGGSCPSHDTSYCAGQYKSYYYMDV (SEQ ID NO:613) SGSSSNIGSSSVS (SEQ ID NO:807) KNNQRPS (SEQ ID NO:1001) STWDDSLSVRV (SEQ ID NO:1195) 253 AIP-136628 GFTFSKAWMS (SEQ ID NO:226) RIKSVTDGETTDYAAPVKG (SEQ ID NO:420) TSSFCCRGGSCPSHDTSYCNGQYKSYYYMDV (SEQ ID NO:614) SGSSSNIGSSSVS (SEQ ID NO:808) KNNQRPS (SEQ ID NO:1002) STWDDSLSVRV (SEQ ID NO:1196) 254 AIP-100340 GFTFSKAWMS (SEQ ID NO:227) RIKSVTDGETTDYAAPVKG (SEQ ID NO:421) TSSFCCRGGSCPSHDTSYCGNQYKSYYYMDV (SEQ ID NO:615) SGSSSNIGSSSVS (SEQ ID NO:809) KNNQRPS (SEQ ID NO:1003) STWDDSLSVRV (SEQ ID NO:1197) 255 AIP-166959 GFTFSKAWMS (SEQ ID NO:228) RIKSVTDGETTDYAAPVKG (SEQ ID NO:422) TSSFCCRGGSCPSHDTSYCGAQYKSYYYMDV (SEQ ID NO:616) SGSSSNIGSSSVS (SEQ ID NO:810) KNNQRPS (SEQ ID NO:1004) STWDDSLSVRV (SEQ ID NO:1198) 256 AIP-190362 GFTFSKAWMS (SEQ ID NO:229) RIKSVTDGETTDYAAPVKG (SEQ ID NO:423) TSSFCCRGGSCPSHDTSYCGGSYKSYYYMDV (SEQ ID NO:617) SGSSSNIGSSSVS (SEQ ID NO:811) KNNQRPS (SEQ ID NO:1005) STWDDSLSVRV (SEQ ID NO:1199) 257 AIP-101601 GFTFSKAWMS (SEQ ID NO:230) RIKSVTDGETTDYAAPVKG (SEQ ID NO:424) TSSFCCRGGSCPSHDTSYCGGYYKSYYYMDV (SEQ ID NO:618) SGSSSNIGSSSVS (SEQ ID NO:812) KNNQRPS (SEQ ID NO:1006) STWDDSLSVRV (SEQ ID NO:1200) 258 AIP-159023 GFTFSKAWMS (SEQ ID NO:231) RIKSVTDGETTDYAAPVKG (SEQ ID NO:425) TSSFCCRGGSCPSHDTSYCGGQFKSYYYMDV (SEQ ID NO:619) SGSSSNIGSSSVS (SEQ ID NO:813) KNNQRPS (SEQ ID NO:1007) STWDDSLSVRV (SEQ ID NO:1201) 259 AIP-146871 GFTFSKAWMS (SEQ ID NO:232) RIKSVTDGETTDYAAPVKG (SEQ ID NO:426) TSSFCCRGGSCPSHDTSYCGGQYPSYYYMDV (SEQ ID NO:620) SGSSSNIGSSSVS (SEQ ID NO:814) KNNQRPS (SEQ ID NO:1008) STWDDSLSVRV (SEQ ID NO:1202) 260 AIP-170053 GFTFSKAWMS (SEQ ID NO:233) RIKSVTDGETTDYAAPVKG (SEQ ID NO:427) TSSFCCRGGSCPSHDTSYCGGQYASYYYMDV (SEQ ID NO:621) SGSSSNIGSSSVS (SEQ ID NO:815) KNNQRPS (SEQ ID NO:1009) STWDDSLSVRV (SEQ ID NO:1203) 261 AIP-199483 GFTFSKAWMS (SEQ ID NO:234) RIKSVTDGETTDYAAPVKG (SEQ ID NO:428) TSSFCCRGGSCPSHDTSYCGGQYQSYYYMDV (SEQ ID NO:622) SGSSSNIGSSSVS (SEQ ID NO:816) KNNQRPS (SEQ ID NO:1010) STWDDSLSVRV (SEQ ID NO:1204) 262 AIP-161048 GFTFSKAWMS (SEQ ID NO:235) RIKSVTDGETTDYAAPVKG (SEQ ID NO:429) TSSFCCRGGSCPSHDTSYCGGQYKDYYYMDV (SEQ ID NO:623) SGSSSNIGSSSVS (SEQ ID NO:817) KNNQRPS (SEQ ID NO:1011) STWDDSLSVRV (SEQ ID NO:1205) 263 AIP-162041 GFTFSKAWMS (SEQ ID NO:236) RIKSVTDGETTDYAAPVKG (SEQ ID NO:430) TSSFCCRGGSCPSHDTSYCGGQYKSFYYMDV (SEQ ID NO:624) SGSSSNIGSSSVS (SEQ ID NO:818) KNNQRPS (SEQ ID NO:1012) STWDDSLSVRV (SEQ ID NO:1206) 264 AIP-197886 GFTFSKAWMS (SEQ ID NO:237) RIKSVTDGETTDYAAPVKG (SEQ ID NO:431) TSSFCCRGGSCPSHDTSYCGGQYKSYFYMDV (SEQ ID NO:625) SGSSSNIGSSSVS (SEQ ID NO:819) KNNQRPS (SEQ ID NO:1013) STWDDSLSVRV (SEQ ID NO:1207) 265 AIP-183133 GFTFSKAWMS (SEQ ID NO:238) RIKSVTDGETTDYAAPVKG (SEQ ID NO:432) TSSFCCRGGSCPSHDTSYCGGQYKSYYWMDV (SEQ ID NO:626) SGSSSNIGSSSVS (SEQ ID NO:820) KNNQRPS (SEQ ID NO:1014) STWDDSLSVRV (SEQ ID NO:1208) 266 AIP-191470 GFTFSKAWMS (SEQ ID NO:239) RIKSVTDGETTDYAAPVKG (SEQ ID NO:433) TSSFCCRGGSCPSHDTSYCGGQYKSYYLMDV (SEQ ID NO:627) SGSSSNIGSSSVS (SEQ ID NO:821) KNNQRPS (SEQ ID NO:1015) STWDDSLSVRV (SEQ ID NO:1209) 267 AIP-151167 GFTFSKAWMS (SEQ ID NO:240) RIKSVTDGETTDYAAPVKG (SEQ ID NO:434) TSSFCCRGGSCPSHDTSYCGGQYKSYYYVDV (SEQ ID NO:628) SGSSSNIGSSSVS (SEQ ID NO:822) KNNQRPS (SEQ ID NO:1016) STWDDSLSVRV (SEQ ID NO:1210) 268 AIP-106633 GFTFSKAWMS (SEQ ID NO:241) RIKSVTDGETTDYAAPVKG (SEQ ID NO:435) TSSFCCRGGSCPSHDTSYCGGQYKSYYYFDV (SEQ ID NO:629) SGSSSNIGSSSVS (SEQ ID NO:823) KNNQRPS (SEQ ID NO:1017) STWDDSLSVRV (SEQ ID NO:1211) 269 AIP-102624 GFTFSKAWMS (SEQ ID NO:242) RIKSVTDGETTDYAAPVKG (SEQ ID NO:436) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMNV (SEQ ID NO:630) SGSSSNIGSSSVS (SEQ ID NO:824) KNNQRPS (SEQ ID NO:1018) STWDDSLSVRV (SEQ ID NO:1212) 270 AIP-109484 GFTFSKAWMS (SEQ ID NO:243) RIKSVTDGETTDYAAPVKG (SEQ ID NO:437) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDI (SEQ ID NO:631) SGSSSNIGSSSVS (SEQ ID NO:825) KNNQRPS (SEQ ID NO:1019) STWDDSLSVRV (SEQ ID NO:1213) 271 AIP-164754 GFTFSKAWMS (SEQ ID NO:244) RIKSVTDGETTDYAAPVKG (SEQ ID NO:438) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDP (SEQ ID NO:632) SGSSSNIGSSSVS (SEQ ID NO:826) KNNQRPS (SEQ ID NO:1020) STWDDSLSVRV (SEQ ID NO:1214) 272 AIP-169676 GFTFSKAWMS (SEQ ID NO:245) RIKSVTDGETTDYAAPVKG (SEQ ID NO:439) TSSFCCRGGSCPSHDTSYCGGQFKDYYYMDV (SEQ ID NO:633) SGSSSNIGSSSVS (SEQ ID NO:827) KNNQRPS (SEQ ID NO:1021) STWDDSLSVRV (SEQ ID NO:1215) 273 AIP-177584 GFTFSKAWMS (SEQ ID NO:246) RIKSVTDGETTDYAAPVKG (SEQ ID NO:440) TSSFCCRGGSCPSHDTSYCGGQSKQYYYMDV (SEQ ID NO:634) SGSSSNIGSSSVS (SEQ ID NO:828) KNNQRPS (SEQ ID NO:1022) STWDDSLSVRV (SEQ ID NO:1216) 274 AIP-174676 GFTFSKAWMS (SEQ ID NO:247) RIKSVTDGETTDYAAPVKG (SEQ ID NO:441) TSSFCCRGGSCPSHDTSYCGGQSKKYYYMDV (SEQ ID NO:635) SGSSSNIGSSSVS (SEQ ID NO:829) KNNQRPS (SEQ ID NO:1023) STWDDSLSVRV (SEQ ID NO:1217) 275 AIP-120546 GFTFSKAWMS (SEQ ID NO:248) RIKSVTDGETTDYAAPVKG (SEQ ID NO:442) TSSFSCRGGSCPSHDTSYSGGQYKSYYYMDV (SEQ ID NO:636) SGSSSNIGSSSVS (SEQ ID NO:830) KNNQRPS (SEQ ID NO:1024) STWDDSLSVRV (SEQ ID NO:1218) 276 AIP-186435 GFTFSKAWMS (SEQ ID NO:249) RIKSVTDGETTDYAAPVKG (SEQ ID NO:443) TSSFACRGGSCPSHDTSYVGGQYKSYYYMDV (SEQ ID NO:637) SGSSSNIGSSSVS (SEQ ID NO:831) KNNQRPS (SEQ ID NO:1025) STWDDSLSVRV (SEQ ID NO:1219) 277 AIP-171074 GFTFSKAWMS (SEQ ID NO:250) RIKSVTDGETTDYAAPVKG (SEQ ID NO:444) TSSFCCRGNSCPAHDTSYCGGQYPSYYYMDV (SEQ ID NO:638) SGSSSNIGSSSVS (SEQ ID NO:832) KNNQRPS (SEQ ID NO:1026) STWDDSLSVRV (SEQ ID NO:1220) 278 AIP-163039 GFTFSKAWMS (SEQ ID NO:251) RIKSVTDGETTDYAAPVKG (SEQ ID NO:445) TSSYCCLGGSCPSHDTSYCGGSYKSYYYMDV (SEQ ID NO:639) SGSSSNIGSSSVS (SEQ ID NO:833) KNNQRPS (SEQ ID NO:1027) STWDDSLSVRV (SEQ ID NO:1221) 279 AIP-147652 GFTFSKAWMS (SEQ ID NO:252) RIKSVTDGETTDYAAPVKG (SEQ ID NO:446) TSSFCCRGKSCPSHDNSYCGGQYASYYYMDV (SEQ ID NO:640) SGSSSNIGSSSVS (SEQ ID NO:834) KNNQRPS (SEQ ID NO:1028) STWDDSLSVRV (SEQ ID NO:1222) 280 AIP-182061 GFTFSKAWMS (SEQ ID NO:253) RIKSVTDGETTDYAAPVKG (SEQ ID NO:447) TSSYCCRGGSCPSHDTSYCGGQFKSYYYMDP (SEQ ID NO:641) SGSSSNIGSSSVS (SEQ ID NO:835) KNNQRPS (SEQ ID NO:1029) STWDDSLSVRV (SEQ ID NO:1223) 281 AIP-172643 GFTFSKAWMS (SEQ ID NO:254) RIKSVTDGETTDYAAPVKG (SEQ ID NO:448) TSTFCCRGGSCLSHDTSYCGGQYKSYYWMDV (SEQ ID NO:642) SGSSSNIGSSSVS (SEQ ID NO:836) KNNQRPS (SEQ ID NO:1030) STWDDSLSVRV (SEQ ID NO:1224) 282 AIP-171912 GFDFSKAWMS (SEQ ID NO:255) RIKSVTDGQTTDYAAPVKG (SEQ ID NO:449) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:643) TGSSSNIGSSSVS (SEQ ID NO:837) KNNQRPS (SEQ ID NO:1031) STWDDSLSVRV (SEQ ID NO:1225) 283 AIP-167833 GFTFAKAWMS (SEQ ID NO:256) RIKSVTDGETTDYAAPVKG (SEQ ID NO:450) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:644) SGSSTNIGSSSSVS (SEQ ID NO:838) KNNYRPS (SEQ ID NO:1032) STWDDSLSVRV (SEQ ID NO:1226) 284 AIP-145518 GFDASKAWFT (SEQ ID NO:257) RIKSVTDGETTDYAAPVKG (SEQ ID NO:451) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:645) SGSSSNIGSSSVS (SEQ ID NO:839) KNNQRPS (SEQ ID NO:1033) STWDDSLSVRV (SEQ ID NO:1227) 285 AIP-143155 GFTFSKAWMS (SEQ ID NO:258) RIKSVTDGETTDYAAPVKG (SEQ ID NO:452) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:646) TGSSSNIGSSSVS (SEQ ID NO:840) KNNQRPS (SEQ ID NO:1034) STWDDSLSVRV (SEQ ID NO:1228) 286 AIP-119664 GFTFSKAWMS (SEQ ID NO:259) RIKSVTDGETTDYAAPVKG (SEQ ID NO:453) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:647) SGASSNIGSSSSVS (SEQ ID NO:841) KNNQRPS (SEQ ID NO:1035) STWDDSLSVRV (SEQ ID NO:1229) 287 AIP-190526 GFTFSKAWMS (SEQ ID NO:260) RIKSVTDGETTDYAAPVKG (SEQ ID NO:454) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:648) SGSPSNIGSSSVS (SEQ ID NO:842) KNNQRPS (SEQ ID NO:1036) STWDDSLSVRV (SEQ ID NO:1230) 288 AIP-114403 GFTFSKAWMS (SEQ ID NO:261) RIKSVTDGETTDYAAPVKG (SEQ ID NO:455) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:649) SGSKSNIGSSSVS (SEQ ID NO:843) KNNQRPS (SEQ ID NO:1037) STWDDSLSVRV (SEQ ID NO:1231) 289 AIP-156760 GFTFSKAWMS (SEQ ID NO:262) RIKSVTDGETTDYAAPVKG (SEQ ID NO:456) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:650) SGSSTNIGSSSSVS (SEQ ID NO:844) KNNQRPS (SEQ ID NO:1038) STWDDSLSVRV (SEQ ID NO:1232) 290 AIP-103803 GFTFSKAWMS (SEQ ID NO:263) RIKSVTDGETTDYAAPVKG (SEQ ID NO:457) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:651) SGSSSDIGSSSVS (SEQ ID NO:845) KNNQRPS (SEQ ID NO:1039) STWDDSLSVRV (SEQ ID NO:1233) 291 AIP-182722 GFTFSKAWMS (SEQ ID NO:264) RIKSVTDGETTDYAAPVKG (SEQ ID NO:458) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:652) SGSSSNIQSSSVS (SEQ ID NO:846) KNNQRPS (SEQ ID NO:1040) STWDDSLSVRV (SEQ ID NO:1234) 292 AIP-195588 GFTFSKAWMS (SEQ ID NO:265) RIKSVTDGETTDYAAPVKG (SEQ ID NO:459) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:653) SGSSSNIGHSSVS (SEQ ID NO:847) KNNQRPS (SEQ ID NO:1041) STWDDSLSVRV (SEQ ID NO:1235) 293 AIP-145722 GFTFSKAWMS (SEQ ID NO:266) RIKSVTDGETTDYAAPVKG (SEQ ID NO:460) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:654) SGSSSNIGSTSVS (SEQ ID NO:848) KNNQRPS (SEQ ID NO:1042) STWDDSLSVRV (SEQ ID NO:1236) 294 AIP-178251 GFTFSKAWMS (SEQ ID NO:267) RIKSVTDGETTDYAAPVKG (SEQ ID NO:461) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:655) SGSSSNIGSNSVS (SEQ ID NO:849) KNNQRPS (SEQ ID NO:1043) STWDDSLSVRV (SEQ ID NO:1237) 295 AIP-116142 GFTFSKAWMS (SEQ ID NO:268) RIKSVTDGETTDYAAPVKG (SEQ ID NO:462) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:656) SGSSSNIGSASVS (SEQ ID NO:850) KNNQRPS (SEQ ID NO:1044) STWDDSLSVRV (SEQ ID NO:1238) 296 AIP-183350 GFTFSKAWMS (SEQ ID NO:269) RIKSVTDGETTDYAAPVKG (SEQ ID NO:463) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:657) SGSSSNIGSSTVS (SEQ ID NO:851) KNNQRPS (SEQ ID NO:1045) STWDDSLSVRV (SEQ ID NO:1239) 297 AIP-127108 GFTFSKAWMS (SEQ ID NO:270) RIKSVTDGETTDYAAPVKG (SEQ ID NO:464) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:658) SGSSSNIGSSAVS (SEQ ID NO:852) KNNQRPS (SEQ ID NO:1046) STWDDSLSVRV (SEQ ID NO:1240) 298 AIP-128147 GFTFSKAWMS (SEQ ID NO:271) RIKSVTDGETTDYAAPVKG (SEQ ID NO:465) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:659) SGSSSNIGSSYVS (SEQ ID NO:853) KNNQRPS (SEQ ID NO:1047) STWDDSLSVRV (SEQ ID NO:1241) 299 AIP-109510 GFTFSKAWMS (SEQ ID NO:272) RIKSVTDGETTDYAAPVKG (SEQ ID NO:466) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:660) SGSSSNIGSSSTS (SEQ ID NO:854) KNNQRPS (SEQ ID NO:1048) STWDDSLSVRV (SEQ ID NO:1242) 300 AIP-104086 GFTFSKAWMS (SEQ ID NO:273) RIKSVTDGETTDYAAPVKG (SEQ ID NO:467) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:661) SGSSSNIGSSSVA (SEQ ID NO:855) KNNQRPS (SEQ ID NO:1049) STWDDSLSVRV (SEQ ID NO:1243) 301 AIP-143132 GFTFSKAWMS (SEQ ID NO:274) RIKSVTDGETTDYAAPVKG (SEQ ID NO:468) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:662) SGSSSNIGSSSVT (SEQ ID NO:856) KNNQRPS (SEQ ID NO:1050) STWDDSLSVRV (SEQ ID NO:1244) 302 AIP-169636 GFTFSKAWMS (SEQ ID NO:275) RIKSVTDGETTDYAAPVKG (SEQ ID NO:469) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:663) SGSSSNIGSSSVS (SEQ ID NO:857) RNNQRPS (SEQ ID NO:1051) STWDDSLSVRV (SEQ ID NO:1245) 303 AIP-152243 GFTFSKAWMS (SEQ ID NO:276) RIKSVTDGETTDYAAPVKG (SEQ ID NO:470) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:664) SGSSSNIGSSSVS (SEQ ID NO:858) NNNQRPS (SEQ ID NO:1052) STWDDSLSVRV (SEQ ID NO:1246) 304 AIP-138776 GFTFSKAWMS (SEQ ID NO:277) RIKSVTDGETTDYAAPVKG (SEQ ID NO:471) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:665) SGSSSNIGSSSVS (SEQ ID NO:859) MNNQRPS (SEQ ID NO:1053) STWDDSLSVRV (SEQ ID NO:1247) 305 AIP-103817 GFTFSKAWMS (SEQ ID NO:278) RIKSVTDGETTDYAAPVKG (SEQ ID NO:472) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:666) SGSSSNIGSSSVS (SEQ ID NO:860) ANNQRPS (SEQ ID NO:1054) STWDDSLSVRV (SEQ ID NO:1248) 306 AIP-130491 GFTFSKAWMS (SEQ ID NO:279) RIKSVTDGETTDYAAPVKG (SEQ ID NO:473) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:667) SGSSSNIGSSSVS (SEQ ID NO:861) HNNQRPS (SEQ ID NO:1055) STWDDSLSVRV (SEQ ID NO:1249) 307 AIP-188155 GFTFSKAWMS (SEQ ID NO:280) RIKSVTDGETTDYAAPVKG (SEQ ID NO:474) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:668) SGSSSNIGSSSVS (SEQ ID NO:862) KDNQRPS (SEQ ID NO:1056) STWDDSLSVRV (SEQ ID NO:1250) 308 AIP-167246 GFTFSKAWMS (SEQ ID NO:281) RIKSVTDGETTDYAAPVKG (SEQ ID NO:475) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:669) SGSSSNIGSSSVS (SEQ ID NO:863) KNTQRPS (SEQ ID NO:1057) STWDDSLSVRV (SEQ ID NO:1251) 309 AIP-106139 GFTFSKAWMS (SEQ ID NO:282) RIKSVTDGETTDYAAPVKG (SEQ ID NO:476) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:670) SGSSSNIGSSSVS (SEQ ID NO:864) KNNYRPS (SEQ ID NO:1058) STWDDSLSVRV (SEQ ID NO:1252) 310 AIP-198351 GFTFSKAWMS (SEQ ID NO:283) RIKSVTDGETTDYAAPVKG (SEQ ID NO:477) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:671) SGSSSNIGSSSVS (SEQ ID NO:865) KNNARPS (SEQ ID NO:1059) STWDDSLSVRV (SEQ ID NO:1253) 311 AIP-159326 GFTFSKAWMS (SEQ ID NO:284) RIKSVTDGETTDYAAPVKG (SEQ ID NO:478) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:672) SGSSSNIGSSSVS (SEQ ID NO:866) KNNLRPS (SEQ ID NO:1060) STWDDSLSVRV (SEQ ID NO:1254) 312 AIP-192275 GFTFSKAWMS (SEQ ID NO:285) RIKSVTDGETTDYAAPVKG (SEQ ID NO:479) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:673) SGSSSNIGSSSVS (SEQ ID NO:867) KNNQQPS (SEQ ID NO:1061) STWDDSLSVRV (SEQ ID NO:1255) 313 AIP-190761 GFTFSKAWMS (SEQ ID NO:286) RIKSVTDGETTDYAAPVKG (SEQ ID NO:480) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:674) SGSSSNIGSSSVS (SEQ ID NO:868) KNNQRAS (SEQ ID NO:1062) STWDDSLSVRV (SEQ ID NO:1256) 314 AIP-166832 GFTFSKAWMS (SEQ ID NO:287) RIKSVTDGETTDYAAPVKG (SEQ ID NO:481) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:675) SGSSSNIGSSSVS (SEQ ID NO:869) KNNQRPY (SEQ ID NO:1063) STWDDSLSVRV (SEQ ID NO:1257) 315 AIP-148062 GFTFSKAWMS (SEQ ID NO:288) RIKSVTDGETTDYAAPVKG (SEQ ID NO:482) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:676) SGSSSNIGSSSVS (SEQ ID NO:870) KNNQRPL (SEQ ID NO:1064) STWDDSLSVRV (SEQ ID NO:1258) 316 AIP-129145 GFTFSKAWMS (SEQ ID NO:289) RIKSVTDGETTDYAAPVKG (SEQ ID NO:483) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:677) SGSSSNIGSSSVS (SEQ ID NO:871) KNNQRPS (SEQ ID NO:1065) ATWDDSLSVRV (SEQ ID NO:1259) 317 AIP-111240 GFTFSKAWMS (SEQ ID NO:290) RIKSVTDGETTDYAAPVKG (SEQ ID NO:484) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:678) SGSSSNIGSSSVS (SEQ ID NO:872) KNNQRPS (SEQ ID NO:1066) SSWDDSLSVRV (SEQ ID NO:1260) 318 AIP-190749 GFTFSKAWMS (SEQ ID NO:291) RIKSVTDGETTDYAAPVKG (SEQ ID NO:485) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:679) SGSSSNIGSSSVS (SEQ ID NO:873) KNNQRPS (SEQ ID NO:1067) STFDDSLSVRV (SEQ ID NO:1261) 319 AIP-153888 GFTFSKAWMS (SEQ ID NO:292) RIKSVTDGETTDYAAPVKG (SEQ ID NO:486) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:680) SGSSSNIGSSSVS (SEQ ID NO:874) KNNQRPS (SEQ ID NO:1068) STWDNSLSVRV (SEQ ID NO:1262) 320 AIP-130915 GFTFSKAWMS (SEQ ID NO:293) RIKSVTDGETTDYAAPVKG (SEQ ID NO:487) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:681) SGSSSNIGSSSVS (SEQ ID NO:875) KNNQRPS (SEQ ID NO:1069) STWDDQLSVRV (SEQ ID NO:1263) 321 AIP-109048 GFTFSKAWMS (SEQ ID NO:294) RIKSVTDGETTDYAAPVKG (SEQ ID NO:488) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:682) SGSSSNIGSSSVS (SEQ ID NO:876) KNNQRPS (SEQ ID NO:1070) STWDDALSVRV (SEQ ID NO:1264) 322 AIP-170569 GFTFSKAWMS (SEQ ID NO:295) RIKSVTDGETTDYAAPVKG (SEQ ID NO:489) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:683) SGSSSNIGSSSVS (SEQ ID NO:877) KNNQRPS (SEQ ID NO:1071) STWDDDLSVRV (SEQ ID NO:1265) 323 AIP-154873 GFTFSKAWMS (SEQ ID NO:296) RIKSVTDGETTDYAAPVKG (SEQ ID NO:490) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:684) SGSSSNIGSSSVS (SEQ ID NO:878) KNNQRPS (SEQ ID NO:1072) STWDDSNSVRV (SEQ ID NO:1266) 324 AIP-159037 GFTFSKAWMS (SEQ ID NO:297) RIKSVTDGETTDYAAPVKG (SEQ ID NO:491) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:685) SGSSSNIGSSSVS (SEQ ID NO:879) KNNQRPS (SEQ ID NO:1073) STWDDSSSVRV (SEQ ID NO:1267) 325 AIP-186826 GFTFSKAWMS (SEQ ID NO:298) RIKSVTDGETTDYAAPVKG (SEQ ID NO:492) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:686) SGSSSNIGSSSVS (SEQ ID NO:880) KNNQRPS (SEQ ID NO:1074) STWDDSLNVRV (SEQ ID NO:1268) 326 AIP-156514 GFTFSKAWMS (SEQ ID NO:299) RIKSVTDGETTDYAAPVKG (SEQ ID NO:493) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:687) SGSSSNIGSSSVS (SEQ ID NO:881) KNNQRPS (SEQ ID NO:1075) STWDDSLLVRV (SEQ ID NO:1269) 327 AIP-157122 GFTFSKAWMS (SEQ ID NO:300) RIKSVTDGETTDYAAPVKG (SEQ ID NO:494) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:688) SGSSSNIGSSSVS (SEQ ID NO:882) KNNQRPS (SEQ ID NO:1076) STWDDSLTVRV (SEQ ID NO:1270) 328 AIP-173276 GFTFSKAWMS (SEQ ID NO:301) RIKSVTDGETTDYAAPVKG (SEQ ID NO:495) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:689) SGSSSNIGSSSVS (SEQ ID NO:883) KNNQRPS (SEQ ID NO:1077) STWDDSLSIRV (SEQ ID NO:1271) 329 AIP-150485 GFTFSKAWMS (SEQ ID NO:302) RIKSVTDGETTDYAAPVKG (SEQ ID NO:496) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:690) SGSSSNIGSSSVS (SEQ ID NO:884) KNNQRPS (SEQ ID NO:1078) STWDDSLSVKV (SEQ ID NO:1272) 330 AIP-135679 GFTFSKAWMS (SEQ ID NO:303) RIKSVTDGETTDYAAPVKG (SEQ ID NO:497) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:691) SGSSSNIGSSSVS (SEQ ID NO:885) KNNQRPS (SEQ ID NO:1079) STWDDSLSVWV (SEQ ID NO:1273) 331 AIP-166847 GFTFSKAWMS (SEQ ID NO:304) RIKSVTDGETTDYAAPVKG (SEQ ID NO:498) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:692) SGSSSNIGSSSVS (SEQ ID NO:886) KNNQRPS (SEQ ID NO:1080) STWDDSLSVHV (SEQ ID NO:1274) 332 AIP-124013 GFTFSKAWMS (SEQ ID NO:305) RIKSVTDGETTDYAAPVKG (SEQ ID NO:499) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:693) SGSSSNIGSSSVS (SEQ ID NO:887) KNNQRPS (SEQ ID NO:1081) STWDDSLSVQV (SEQ ID NO:1275) 333 AIP-126285 GFTFSKAWMS (SEQ ID NO:306) RIKSVTDGETTDYAAPVKG (SEQ ID NO:500) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:694) SGSSSNIGSSSVS (SEQ ID NO:888) KNNQRPS (SEQ ID NO:1082) STWDDSLSVRI (SEQ ID NO:1276) 334 AIP-190274 GFTFSKAWMS (SEQ ID NO:307) RIKSVTDGETTDYAAPVKG (SEQ ID NO:501) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:695) SGSSSDIGSSSVS (SEQ ID NO:889) KNNQRPS (SEQ ID NO:1083) STWNDQLSVRV (SEQ ID NO:1277) 335 AIP-150277 GFTFSKAWMS (SEQ ID NO:308) RIKSVTDGETTDYAAPVKG (SEQ ID NO:502) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:696) HGSESDIGSHDVL (SEQ ID NO:890) KNNQRPS (SEQ ID NO:1084) STWDDSLSVRV (SEQ ID NO:1278) 336 AIP-104364 GFTFSKAWYS (SEQ ID NO:309) RIKSVTDGETTDYAAPVKG (SEQ ID NO:503) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:697) SGSSSNIGSSSVS (SEQ ID NO:891) KNNQRPS (SEQ ID NO:1085) STWDDSLSVRV (SEQ ID NO:1279) 337 AIP-180422 GFTFSKAWMS (SEQ ID NO:310) RIKSVTDGETTEYAASVKG (SEQ ID NO:504) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:698) SGSSSNIGSSSVS (SEQ ID NO:892) KNNQRPS (SEQ ID NO:1086) STWDDSLSVRV (SEQ ID NO:1280) 338 AIP-166722 GFTFSKAWMS (SEQ ID NO:311) RIKSVTDGETTEYAASVKG (SEQ ID NO:505) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:699) SGSSSNIGSSSVS (SEQ ID NO:893) KNNQRPS (SEQ ID NO:1087) STWDDSLSVRV (SEQ ID NO:1281) 339 AIP-193490 GFTFSKAWMS (SEQ ID NO:312) FIKSVTDGETTEYAASVKG (SEQ ID NO:506) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:700) SGSSSNIGSSSVS (SEQ ID NO:894) KNNQRPS (SEQ ID NO:1088) STWDDSLSVRV (SEQ ID NO:1282) 340 AIP-129967 GFTFSKAWMS (SEQ ID NO:313) RIKSVTDGETTDYAAPVKG (SEQ ID NO:507) TSSYCCRSGSCPSSDTSYCNGQFKSYYYMDP (SEQ ID NO:701) SGSSSNIGSSSVS (SEQ ID NO:895) KNNQRPS (SEQ ID NO:1089) STWDDSLSVRV (SEQ ID NO:1283) 341 AIP-126175 GFTFSKAWMS (SEQ ID NO:314) RIKSVTDGETTDYAAPVKG (SEQ ID NO:508) TSSFCCRSGSCPSSDTSYCNGQYKSYYYVNI (SEQ ID NO:702) SGSSSNIGSSSVS (SEQ ID NO:896) KNNQRPS (SEQ ID NO:1090) STWDDSLSVRV (SEQ ID NO:1284) 342 AIP-180905 GFTFSKAWMS (SEQ ID NO:315) RIKSVTDGETTDYAAPVKG (SEQ ID NO:509) TTSFCCRGASCPSHDTSYCAGSYKSYYYVNI (SEQ ID NO:703) SGSSSNIGSSSVS (SEQ ID NO:897) KNNQRPS (SEQ ID NO:1091) STWDDSLSVRV (SEQ ID NO:1285) 343 AIP-141706 GFTFSKAWMS (SEQ ID NO:316) RIKSVTDGETTDYAAPVKG (SEQ ID NO:510) TSAFCCRGKSCPSSDTSYCGGQYPSYYYVNI (SEQ ID NO:704) SGSSSNIGSSSVS (SEQ ID NO:898) KNNQRPS (SEQ ID NO:1092) STWDDSLSVRV (SEQ ID NO:1286) 344 AIP-105092 GFTFSKAWMS (SEQ ID NO:317) RIKSVTDGETTDYAAPVKG (SEQ ID NO:511) TSAFCCRGKSCPSHDTSFCGGQDKRYYYVNI (SEQ ID NO:705) SGSSSNIGSSSVS (SEQ ID NO:899) KNNQRPS (SEQ ID NO:1093) STWDDSLSVRV (SEQ ID NO:1287) 345 AIP-152031 GFTFSKAWMS (SEQ ID NO:318) RIKSVTDGETTDYAAPVKG (SEQ ID NO:512) TSAFCCRGGNCPSHETSYCNGQNKQYYYMDV (SEQ ID NO:706) SGSSSNIGSSSVS (SEQ ID NO:900) KNNQRPS (SEQ ID NO:1094) STWDDSLSVRV (SEQ ID NO:1288) 346 AIP-163319 GFTFSKAWMS (SEQ ID NO:319) RIKSVTDGETTDYAAPVKG (SEQ ID NO:513) TSSFCCRGNQCPSSDTSFCGGQDKRYYYMDP (SEQ ID NO:707) SGSSSNIGSSSVS (SEQ ID NO:901) KNNQRPS (SEQ ID NO:1095) STWDDSLSVRV (SEQ ID NO:1289) 347 AIP-160621 GFTFSKAWMS (SEQ ID NO:320) RIKSVTDGETTDYAAPVKG (SEQ ID NO:514) TTSFCCRGNQCPSHETSYCGGYYKSYFYMDV (SEQ ID NO:708) SGSSSNIGSSSVS (SEQ ID NO:902) KNNQRPS (SEQ ID NO:1096) STWDDSLSVRV (SEQ ID NO:1290) 348 AIP-145212 GFTFSKAWMS (SEQ ID NO:321) RIKSVTDGETTDYAAPVKG (SEQ ID NO:515) TSSYCCRGKQCPSHDTSYCAGQYADYYYMDV (SEQ ID NO:709) SGSSSNIGSSSVS (SEQ ID NO:903) KNNQRPS (SEQ ID NO:1097) STWDDSLSVRV (SEQ ID NO:1291) 349 AIP-112328 GFTFSKAWMS (SEQ ID NO:322) RIKSVTDGETTDYAAPVKG (SEQ ID NO:516) ISSFCCRGKQCPSSDTSYCNGQYADYYYMDV (SEQ ID NO:710) SGSSSNIGSSSVS (SEQ ID NO:904) KNNQRPS (SEQ ID NO:1098) STWDDSLSVRV (SEQ ID NO:1292) 350 AIP-193106 GFTFSKAWMS (SEQ ID NO:323) RIKSVTDGETTDYAAPVKG (SEQ ID NO:517) TSSFCCRGKQCPSSDTSYCNGQYADYYYVNI (SEQ ID NO:711) SGSSSNIGSSSVS (SEQ ID NO:905) KNNQRPS (SEQ ID NO:1099) STWDDSLSVRV (SEQ ID NO:1293) 351 AIP-125062 GFTFSKAWMS (SEQ ID NO:324) RIKSVTDGETTDYAAPVKG (SEQ ID NO:518) ISSFCCRGKQCPSSDTSFCGGQDKRYYFMDV (SEQ ID NO:712) SGSSSNIGSSSVS (SEQ ID NO:906) KNNQRPS (SEQ ID NO:1100) STWDDSLSVRV (SEQ ID NO:1294) 352 AIP-124301 GFTFSKAWMS (SEQ ID NO:325) RIKSVTDGETTDYAAPVKG (SEQ ID NO:519) TSAFCCRGKQCPSSDTSYCGGQYASFYYMDV (SEQ ID NO:713) SGSSSNIGSSSVS (SEQ ID NO:907) KNNQRPS (SEQ ID NO:1101) STWDDSLSVRV (SEQ ID NO:1295) 353 AIP-124068 GFTFSKAWMS (SEQ ID NO:326) RIKSVTDGETTDYAAPVKG (SEQ ID NO:520) TSSFCCQGNNCPSSDTSYCGGYYKDYYYMDV (SEQ ID NO:714) SGSSSNIGSSSVS (SEQ ID NO:908) KNNQRPS (SEQ ID NO:1102) STWDDSLSVRV (SEQ ID NO:1296) 354 AIP-144568 GFTFSKAWMS (SEQ ID NO:327) RIKSVTDGETTDYAAPVKG (SEQ ID NO:521) TSSFCCQGNNCPSHDTSYCGGQYKSYYYVNI (SEQ ID NO:715) SGSSSNIGSSSVS (SEQ ID NO:909) KNNQRPS (SEQ ID NO:1103) STWDDSLSVRV (SEQ ID NO:1297) 355 AIP-139782 GFTFSKAWMS (SEQ ID NO:328) RIKSVTDGETTDYAAPVKG (SEQ ID NO:522) TSSFCCQGKNCPSHETSYCGGQYADYYYMDV (SEQ ID NO:716) SGSSSNIGSSSVS (SEQ ID NO:910) KNNQRPS (SEQ ID NO:1104) STWDDSLSVRV (SEQ ID NO:1298) 356 AIP-171543 GFTFSKAWMS (SEQ ID NO:329) RIKSVTDGETTDYAAPVKG (SEQ ID NO:523) TTSFCCHGNSCPSSDTSYCGGQNKQYYYMDV (SEQ ID NO:717) SGSSSNIGSSSVS (SEQ ID NO:911) KNNQRPS (SEQ ID NO:1105) STWDDSLSVRV (SEQ ID NO:1299) 357 AIP-140148 GFTFSKAWMS (SEQ ID NO:330) RIKSVTDGETTDYAAPVKG (SEQ ID NO:524) ISSFCCHGNSCPSHDTSYCNGQNKQYYYMDV (SEQ ID NO:718) SGSSSNIGSSSVS (SEQ ID NO:912) KNNQRPS (SEQ ID NO:1106) STWDDSLSVRV (SEQ ID NO:1300) 358 AIP-177193 GFTFSKAWMS (SEQ ID NO:331) RIKSVTDGETTDYAAPVKG (SEQ ID NO:525) ISSFCCHSNNCPSSDTSYCNGQYKQYYYMDV (SEQ ID NO:719) SGSSSNIGSSSVS (SEQ ID NO:913) KNNQRPS (SEQ ID NO:1107) STWDDSLSVRV (SEQ ID NO:1301) 359 AIP-171348 GFTFSKAWMS (SEQ ID NO:332) RIKSVTDGETTDYAAPVKG (SEQ ID NO:526) TSSFCCHSNNCPSHDTSYCGGQYKSYYYVNI (SEQ ID NO:720) SGSSSNIGSSSVS (SEQ ID NO:914) KNNQRPS (SEQ ID NO:1108) STWDDSLSVRV (SEQ ID NO:1302) 360 AIP-193088 GFTFSKAWMS (SEQ ID NO:333) RIKSVTDGETTDYAAPVKG (SEQ ID NO:527) ISSFACHSNNCPSSDTSYVNGYYKQYYFMDV (SEQ ID NO:721) SGSSSNIGSSSVS (SEQ ID NO:915) KNNQRPS (SEQ ID NO:1109) STWDDSLSVRV (SEQ ID NO:1303) 361 AIP-182087 GFTFSKAWMS (SEQ ID NO:334) RIKSVTDGETTDYAAPVKG (SEQ ID NO:528) TSSFCCHSNNCPSSDTSYCNGQYKQYYYVNI (SEQ ID NO:722) SGSSSNIGSSSVS (SEQ ID NO:916) KNNQRPS (SEQ ID NO:1110) STWDDSLSVRV (SEQ ID NO:1304) 362 AIP-151388 GFTFSKAWMS (SEQ ID NO:335) RIKSVTDGETTDYAAPVKG (SEQ ID NO:529) TSSFCCLGKACLSHDTSYCGGQYASYYYVNI (SEQ ID NO:723) SGSSSNIGSSSVS (SEQ ID NO:917) KNNQRPS (SEQ ID NO:1111) STWDDSLSVRV (SEQ ID NO:1305) 363 AIP-149787 GFTFSKAWMS (SEQ ID NO:336) RIKSVTDGETTDYAAPVKG (SEQ ID NO:530) TSSFCCLGKACLSSDTSYCGGYYASYYFVNI (SEQ ID NO:724) SGSSSNIGSSSVS (SEQ ID NO:918) KNNQRPS (SEQ ID NO:1112) STWDDSLSVRV (SEQ ID NO:1306) 364 AIP-126097 GFTFSKAWMS (SEQ ID NO:337) RIKSVTDGETTDYAAPVKG (SEQ ID NO:531) TSSFACLGKACLSSDTSYVGGYYASYYFVNI (SEQ ID NO:725) SGSSSNIGSSSVS (SEQ ID NO:919) KNNQRPS (SEQ ID NO:1113) STWDDSLSVRV (SEQ ID NO:1307) 365 AIP-107759 GFTFSKAWMS (SEQ ID NO:338) RIKSVTDGETTDYAAPVKG (SEQ ID NO:532) TSSYCCLGNSCPSSDTSYCGGQFKSYYYMDP (SEQ ID NO:726) SGSSSNIGSSSVS (SEQ ID NO:920) KNNQRPS (SEQ ID NO:1114) STWDDSLSVRV (SEQ ID NO:1308) 366 AIP-148484 GFTFSKAWMS (SEQ ID NO:339) RIKSVTDGETTDYAAPVKG (SEQ ID NO:533) TSSYCCLGNSCPSSDTSFCGGQDKRYYYMDP (SEQ ID NO:727) SGSSSNIGSSSVS (SEQ ID NO:921) KNNQRPS (SEQ ID NO:1115) STWDDSLSVRV (SEQ ID NO:1309) 367 AIP-186403 GFTFSKAWMS (SEQ ID NO:340) RIKSVTDGETTDYAAPVKG (SEQ ID NO:534) ISSFCCLGGNCPSSETSYCGNQYPSYYYMDV (SEQ ID NO:728) SGSSSNIGSSSVS (SEQ ID NO:922) KNNQRPS (SEQ ID NO:1116) STWDDSLSVRV (SEQ ID NO:1310) 368 AIP-166629 GFTFSKAWMS (SEQ ID NO:341) RIKSVTDGETTDYAAPVKG (SEQ ID NO:535) ISSFCCLGGNCPSSETSYCGNYYPSYFYMDV (SEQ ID NO:729) SGSSSNIGSSSVS (SEQ ID NO:923) KNNQRPS (SEQ ID NO:1117) STWDDSLSVRV (SEQ ID NO:1311) 369 AIP-165276 GFTFSKAWMS (SEQ ID NO:342) RIKSVTDGETTDYAAPVKG (SEQ ID NO:536) TSSFCCLGGNCPSSETSYCGNQYPSYYYVNI (SEQ ID NO:730) SGSSSNIGSSSVS (SEQ ID NO:924) KNNQRPS (SEQ ID NO:1118) STWDDSLSVRV (SEQ ID NO:1312) 370 AIP-188293 GFTFSKAWMS (SEQ ID NO:343) RIKSVTDGETTDYAAPVKG (SEQ ID NO:537) TTSFACRGNQCPSHETSYVGGYYKSYFYMDV (SEQ ID NO:731) SGSSSNIGSSSVS (SEQ ID NO:925) KNNQRPS (SEQ ID NO:1119) STWDDSLSVRV (SEQ ID NO:1313) 371 AIP-109364 GFTFSKAWMS (SEQ ID NO:344) RIKSVTDGETTDYAAPVKG (SEQ ID NO:538) TTSFACRGNQCPSSETSYVGGYYKSYFFMDV (SEQ ID NO:732) SGSSSNIGSSSVS (SEQ ID NO:926) KNNQRPS (SEQ ID NO:1120) STWDDSLSVRV (SEQ ID NO:1314) 372 AIP-191805 GFTFSKAWMS (SEQ ID NO:345) RIKSVTDGETTDYAAPVKG (SEQ ID NO:539) ISSFACRGKQCPSSDTSYVGGQFKSYYFMDV (SEQ ID NO:733) SGSSSNIGSSSVS (SEQ ID NO:927) KNNQRPS (SEQ ID NO:1121) STWDDSLSVRV (SEQ ID NO:1315) 373 AIP-181592 GFTFAKAWMS (SEQ ID NO:346) RIKAADGKQTDYAAPVKG (SEQ ID NO:540) TSSFCCRGGSCLSHDTSYCGGQYKSYYWMDV (SEQ ID NO:734) SGSSTNIGSSSSVY (SEQ ID NO:928) KNNYRPS (SEQ ID NO:1122) STWDDSLSVRV (SEQ ID NO:1316) 374 AIP-155587 GFTYAKAWMS (SEQ ID NO:347) RIKSVQDGEQTDYAAPVKG (SEQ ID NO:541) TSSYCCLGGSCPSHDTSYCGGSYKSYYYMDV (SEQ ID NO:735) SGSSTNIGSSSSVY (SEQ ID NO:929) KNNYRAS (SEQ ID NO:1123) STWDDSLSVRV (SEQ ID NO:1317) 375 AIP-147945 GFDASKAWFT (SEQ ID NO:348) RIKSVTDGETTDYAAPVKG (SEQ ID NO:542) TSSFCCRGGSCPSHDTSYCGGQNKQYYYMDV (SEQ ID NO:736) TGSSSNIGSSYVS (SEQ ID NO:930) KNSLRPQ (SEQ ID NO:1124) STWDDSLSVRV (SEQ ID NO:1318) 376 AIP-199264 GFDASKAWFT (SEQ ID NO:349) RIKSVTDGETTDYAAPVKG (SEQ ID NO:543) TSSFACRGGSCPSHDTSYVGGQYKSYYYMDV (SEQ ID NO:737) TGSSSNIGSSYVS (SEQ ID NO:931) KNSLRPQ (SEQ ID NO:1125) STWDDSLSVRV (SEQ ID NO:1319) 377 AIP-123438 GFDASKAWFT (SEQ ID NO:350) RIKSVTDGETTDYAAPVKG (SEQ ID NO:544) TSSYCCLGGSCPSHDTSYCGGSYKSYYYMDV (SEQ ID NO:738) TGSSSNIGSSYVS (SEQ ID NO:932) KNSLRPQ (SEQ ID NO:1126) STWDDSLSVRV (SEQ ID NO:1320) 378 AIP-151315 GFDASKAWFT (SEQ ID NO:351) RIKSVTDGETTDYAAPVKG (SEQ ID NO:545) TSSFCCRGKSCPSHDTSYCGGQYASYYYMDV (SEQ ID NO:739) TGSSSNIGSSYVS (SEQ ID NO:933) KNSLRPQ (SEQ ID NO:1127) STWDDSLSVRV (SEQ ID NO:1321) 379 AIP-197785 GFTFSKAWMS (SEQ ID NO:352) RIKAADGKQTDYAAPVKG (SEQ ID NO:546) TSSFCCRGGNCPSHETSYCGNQYKSYYYMDV (SEQ ID NO:740) SGSPSNIGSASTS (SEQ ID NO:934) KNNQRPS (SEQ ID NO:1128) STWDDSLSVRV (SEQ ID NO:1322) 380 AIP-115782 GFTFSKAWMS (SEQ ID NO:353) RIKAADGKQTDYAAPVKG (SEQ ID NO:547) TSSFCCRSGSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:741) SGSPSNIGSASTS (SEQ ID NO:935) KNNQRPS (SEQ ID NO:1129) STWDDSLSVRV (SEQ ID NO:1323) 381 AIP-138130 GFTFSKAWMS (SEQ ID NO:354) RIKAADGKQTDYAAPVKG (SEQ ID NO:548) TSSFCCRGGSCPSHDTSYCGGQYKSYYYVNI (SEQ ID NO:742) SGSPSNIGSASTS (SEQ ID NO:936) KNNQRPS (SEQ ID NO:1130) STWDDSLSVRV (SEQ ID NO:1324) 382 AIP-170221 GFTFSKAWMS (SEQ ID NO:355) RIKAADGKQTDYAAPVKG (SEQ ID NO:549) TTSFCCRGASCPSHDTSYCAGSYKSYYYMDV (SEQ ID NO:743) SGSPSNIGSASTS (SEQ ID NO:937) KNNQRPS (SEQ ID NO:1131) STWDDSLSVRV (SEQ ID NO:1325) 383 AIP-167482 GFTFSKAWMS (SEQ ID NO:356) RIKAADGKQTDYAAPVKG (SEQ ID NO:550) ISSFCCRGNSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:744) SGSPSNIGSASTS (SEQ ID NO:938) KNNQRPS (SEQ ID NO:1132) STWDDSLSVRV (SEQ ID NO:1326) 384 AIP-189475 GFTFSKAWMS (SEQ ID NO:357) RIKAVTDGHTTDYAAPVKG (SEQ ID NO:551) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:745) SGASSNIGHSSVY (SEQ ID NO:939) RNNQQPL (SEQ ID NO:1133) STWDDALSIRV (SEQ ID NO:1327) 385 AIP-102833 GFVYSKAWMS (SEQ ID NO:358) RIKSVTDGQATDYAAPVKG (SEQ ID NO:552) TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:746) SGSSSNIGSSSVS (SEQ ID NO:940) KNTQRAS (SEQ ID NO:1134) STWDDALNVRV (SEQ ID NO:1328) 386 AIP-173396 GFVFSKAWMS (SEQ ID NO:359) RIKSVTDGETTDYAAPVKG (SEQ ID NO:553) TSSFCCRGKSCPSHDTSYCGGQYASYYYMDV (SEQ ID NO:747) SGSSSNIGSSSVS (SEQ ID NO:941) RNNQQPL (SEQ ID NO:1135) SSWDDSSLVRV (SEQ ID NO:1329) 387 AIP-132355 GFTFAKAWMS (SEQ ID NO:360) RIKSVTDAETTDYAAPVKG (SEQ ID NO:554) TSSFCCRSGSCPSSDTSYCNGQYKSYYWMDV (SEQ ID NO:748) SGSSSNIGSSSVT (SEQ ID NO:942) KNNARPS (SEQ ID NO:1136) ATWDNSLSIRV (SEQ ID NO:1330) 388 AIP-118505 GFTYAKAWFT (SEQ ID NO:361) RIKSTSDGGITDYAAPVKG (SEQ ID NO:555) TSSFCCRGGSCPSHDTSFCGGQYKSYYYMDV (SEQ ID NO:749) SGSKSNIGSSYVS (SEQ ID NO:943) KDNQRAS (SEQ ID NO:1137) STWDDALSVRV (SEQ ID NO:1331) 389 AIP-131972 GFTFSKAWMS (SEQ ID NO:362) RIKSVSDGETTDYAAPVKG (SEQ ID NO:556) TSSFCCRGGSCPSRDTSYCGGQYKSYYFMDV (SEQ ID NO:750) SGSSSNIGSSSVY (SEQ ID NO:944) KNNQRPS (SEQ ID NO:1138) STWDDSLSVRV (SEQ ID NO:1332) 390 AIP-189526 GFTFSKAWMT
(SEQ ID NO:171) RIKSTSDGGITDYAAPVKG (SEQ NO:555) TTSFCCRGGRCPSRDTSFCGGQYNSYYYMDV (SEQ ID NO:1727) SGSSSNIGSSSVS
(SEQ ID NO:943) KNNQRPS (SEQ ID NO:1138) STWDDSLSVRV
(SEQ ID NO:1332)

--->

LIST OF SEQUENCES

<110> ATRECA, INC.

< 120> ANTIBODIES THAT BIND TUMOR TISSUE FOR DIAGNOSIS

AND TREATMENTS

<130> 097519-1174263 (1860PCWO)

<140> PCT/US2020/018350

<141> 2020-02-14

<150> 62/927501

<151> 10/29/2019

<150> 62/852830

<151> 05/24/2019

<150> 62/843751

<151> 05/06/2019

<150> 62/843298

<151> 05/03/2019

<150> 62/806285

<151> 02/15/2019

<150> 62/806310

<151> 02/15/2019

<160> 1772

<170> PatentIn version 3.5

<210> 1

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 2

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 2

Gly Phe Thr Tyr Ser Ala Ala Trp Met Ser

1 5 10

<210> 3

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 3

Gly Phe Thr Phe Ser Met Ala Trp Met Ser

1 5 10

<210> 4

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 4

Gly Phe Thr Phe Ser Ala Ala Trp Met Ser

1 5 10

<210> 5

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 5

Gly Phe Thr Tyr Ser Lys Ala Trp Met Ser

1 5 10

<210> 6

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 6

Gly Phe Thr Phe Ala Lys Ala Trp Met Ser

1 5 10

<210> 7

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 7

Gly Phe Val Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 8

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 8

Gly Phe Thr Phe Ser Lys Ala Trp Met Thr

1 5 10

<210> 9

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 9

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 10

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 10

Arg Ile Lys Ala Val His Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 11

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 11

Arg Ile Lys Ser Asn Thr Asp Ala Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 12

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 12

Arg Ile Lys Ser Val Gln Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 13

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 13

Arg Ile Lys Ser Val Thr Asp Gly His Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 14

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 14

Arg Ile Lys Ser Val Thr Asp Gly Gly Ile Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 15

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 15

Arg Ile Lys Ser Thr Ser Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 16

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 16

Arg Ile Lys Ser Thr Ser Asp Gly Gly Ile Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 17

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 17

Arg Ile Lys Ser Val Thr Glu Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 18

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 18

Arg Ile Lys Ser Val Thr Asp Gly Glu Gln Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 19

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 19

Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 20

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 20

Thr Ser Ser Phe Cys Cys Arg Ser Gly Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 21

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 21

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 22

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 22

Thr Thr Ser Phe Cys Cys Arg Gly Ala Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Ala Gly Ser Tyr Lys Ser Tyr Tyr Phe Val Asn Ile

20 25 30

<210> 23

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 23

Thr Ser Ser Phe Cys Cys Arg Gly Asn Gln Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Pro Ser Tyr Tyr Tyr Met Asp Pro

20 25 30

<210> 24

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 24

Ile Ser Ser Phe Cys Cys Arg Gly Lys Gln Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Tyr Tyr Ala Asp Tyr Tyr Phe Met Asp Val

20 25 30

<210> 25

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 25

Ile Ser Ser Phe Cys Cys Arg Gly Lys Gln Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Phe Lys Ser Tyr Tyr Phe Met Asp Val

20 25 30

<210> 26

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 26

Ile Ser Ser Phe Cys Cys His Ser Asn Asn Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Tyr Tyr Lys Gln Tyr Tyr Phe Met Asp Val

20 25 30

<210> 27

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 27

Ile Ser Ser Phe Cys Cys Arg Gly Asn Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 28

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 28

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Phe Tyr Tyr Met Asp Val

20 25 30

<210> 29

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 29

Ile Ser Ser Phe Cys Cys Arg Gly Asn Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Phe Met Asp Val

20 25 30

<210> 30

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 30

Ile Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser Arg Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Phe Met Asp Val

20 25 30

<210> 31

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 31

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Tyr Tyr Lys Ser Tyr Tyr Phe Met Asp Val

20 25 30

<210> 32

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 32

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Phe Met Asp Val

20 25 30

<210> 33

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 33

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Tyr Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 34

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 34

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 35

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 35

Thr Thr Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 36

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 36

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Tyr Asn Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 37

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 37

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 38

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 38

Thr Thr Ser Phe Cys Cys Arg Gly Gly Arg Cys Pro Ser Arg Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Tyr Asn Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 39

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 39

Thr Thr Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 40

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 40

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Asp Ser Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 41

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 41

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 42

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 42

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Asp Ser Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 43

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 43

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Phe Met Asp Val

20 25 30

<210> 44

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 44

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Asn Lys Gln Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 45

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 45

Thr Ser Ser Phe Cys Cys Arg Gly Gly Asn Cys Pro Ser His Glu Thr

1 5 10 15

Ser Tyr Cys Gly Asn Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 46

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 46

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Val Asn Ile

20 25 30

<210> 47

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 47

Thr Thr Ser Phe Cys Cys Arg Gly Ala Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Ala Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 48

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 48

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 49

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 49

Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser Ser Val Thr

1 5 10

<210> 50

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 50

Ser Gly Ser Lys Ser Asn Ile Gly Ser Ser Tyr Val Ser

1 5 10

<210> 51

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 51

Ser Gly Ser Lys Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 52

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 52

Ser Gly Ala Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 53

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 53

Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser Thr Val Ser

1 5 10

<210> 54

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 54

Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 55

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 55

Ser Gly Ser Lys Ser Asn Ile Gly Ser Ser Ser Val Tyr

1 5 10

<210> 56

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 56

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Tyr

1 5 10

<210> 57

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 57

Ser Gly Ser Ser Ser Asp Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 58

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 58

Ser Gly Ser Pro Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 59

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 59

Lys Asn Asn Gln Arg Pro Ser

15

<210> 60

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 60

Lys Asp Asn Gln Arg Pro Leu

15

<210> 61

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 61

Met Asn Asn Gln Arg Pro Tyr

15

<210> 62

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 62

Lys Asp Asn Gln Arg Pro Ser

15

<210> 63

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 63

Lys Asn Thr Gln Arg Ala Ser

15

<210> 64

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 64

Lys Asn Asn Ala Arg Pro Tyr

15

<210> 65

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 65

Lys Asn Thr Gln Arg Pro Ser

15

<210> 66

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 66

Lys Asn Asn Gln Arg Pro Tyr

15

<210> 67

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 67

Lys Asn Ser Leu Arg Pro Gln

15

<210> 68

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 68

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 69

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 69

Ala Thr Trp Asp Asp Gln Leu Ser Val Arg Val

1 5 10

<210> 70

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 70

Ala Thr Trp Asp Asn Ser Leu Ser Ile Arg Val

1 5 10

<210> 71

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 71

Ser Ser Trp Asp Asp Ser Asn Ser Val Arg Ile

1 5 10

<210> 72

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 72

Ser Thr Trp Asp Asp Ala Leu Ser Val Arg Val

1 5 10

<210> 73

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 73

Ser Thr Trp Asp Glu Ser Leu Ser Val Arg Val

1 5 10

<210> 74

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 74

Ser Thr Trp Asn Asp Ala Leu Ser Val Arg Val

1 5 10

<210> 75

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 75

Ser Thr Trp Asp Asp Ser Leu Asn Val Arg Val

1 5 10

<210> 76

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 76

Ala Thr Trp Asp Asp Ser Leu Thr Val Arg Ile

1 5 10

<210> 77

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 77

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Ser Gly Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 78

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 78

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Glu Tyr Ala Ala

50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 79

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 79

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Cys Cys Arg Gly Ala Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Ala Gly Ser Tyr Lys Ser Tyr Tyr Phe Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 80

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 80

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Asn Gln Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Pro Ser Tyr Tyr Tyr Met Asp

115 120 125

Pro Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 81

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 81

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys Arg Gly Lys Gln Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Tyr Tyr Ala Asp Tyr Tyr Phe Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 82

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 82

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys Arg Gly Lys Gln Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Phe Lys Ser Tyr Tyr Phe Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 83

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 83

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys His Ser Asn Asn Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Tyr Tyr Lys Gln Tyr Tyr Phe Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 84

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 84

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Tyr Ser Ala Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ala Val His Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 85

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 85

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Met Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Asn Thr Asp Ala Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 86

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 86

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ala Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys Arg Gly Asn Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 87

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 87

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Tyr Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Gln Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Phe Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 88

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 88

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly His Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 89

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 89

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Val Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Gly Ile Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys Arg Gly Asn Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Phe Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 90

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 90

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ala Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Thr Ser Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser Arg

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Phe Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 91

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 91

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Gln Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Tyr Tyr Lys Ser Tyr Tyr Phe Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 92

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 92

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Phe Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 93

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 93

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Gln Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Tyr Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 94

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 94

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 95

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 95

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Val

65 70 75 80

Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Phe Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 96

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 96

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 97

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 97

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Val

65 70 75 80

Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Phe Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Tyr Asn Arg Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 98

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 98

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Val

65 70 75 80

Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Phe Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 99

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 99

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Thr Ser Asp Gly Gly Ile Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Cys Cys Arg Gly Gly Arg Cys Pro Ser Arg

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Tyr Asn Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 100

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 100

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 101

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 101

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 102

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 102

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 103

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 103

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Asp Ser Arg Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 104

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 104

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 105

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 105

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 106

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 106

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 107

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 107

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 108

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 108

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Asp Ser Arg Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 109

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 109

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Glu Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 110

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 110

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Glu Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 111

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 111

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Phe Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 112

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 112

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 113

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 113

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Asn Lys Gln Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 114

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 114

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Asn Cys Pro Ser His

100 105 110

Glu Thr Ser Tyr Cys Gly Asn Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 115

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 115

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 116

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 116

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Cys Cys Arg Gly Ala Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Ala Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 117

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 117

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 118

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 118

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Gln Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 119

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 119

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 120

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 120

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 121

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 121

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys Arg Gly Asn Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 122

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 122

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 123

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 123

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 124

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 124

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Ala Ala Pro Gly Gln

1 5 10 15

Lys Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Ile Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Thr Leu Gly Ile Thr Gly Leu Gln

65 70 75 80

Thr Gly Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 125

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 125

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 126

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 126

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 127

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 127

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 128

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 128

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 129

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 129

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 130

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 130

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser

20 25 30

Ser Val Thr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asp Asn Gln Arg Pro Leu Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 131

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 131

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Lys Ser Asn Ile Gly Ser Ser

20 25 30

Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Met Asn Asn Gln Arg Pro Tyr Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Gln Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 132

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 132

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Lys Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asn Ser Leu

85 90 95

Ser Ile Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 133

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 133

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ala Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Thr Gln Arg Ala Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Trp Asp Asp Ser Asn

85 90 95

Ser Val Arg Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 134

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 134

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser

20 25 30

Thr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Ala Arg Pro Tyr Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu

85 90 95

Thr Val Arg Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 135

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 135

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ala Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Thr Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Gln Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 136

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 136

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Trp Asp Asp Ser Asn

85 90 95

Ser Val Arg Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 137

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 137

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Lys Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Tyr Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ala Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 138

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 138

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ala Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 139

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 139

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Lys Ser Asn Ile Gly Ser Ser

20 25 30

Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Tyr Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 140

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 140

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 141

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 141

Gln Ser Val Leu Thr Gln Ala Pro Ser Ala Ser Glu Thr Pro Gly Gln

1 5 10 15

Arg Val Ile Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 142

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 142

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 143

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 143

Gln Ser Val Leu Thr Gln Ala Pro Ser Ala Ser Glu Thr Pro Gly Gln

1 5 10 15

Arg Val Ile Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 144

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 144

Gln Ser Val Leu Thr Gln Ala Pro Ser Ala Ser Glu Thr Pro Gly Gln

1 5 10 15

Arg Val Ile Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 145

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 145

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 146

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 146

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 147

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 147

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 148

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 148

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 149

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 149

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 150

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 150

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 151

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 151

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Glu Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 152

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 152

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 153

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 153

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 154

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 154

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Glu Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 155

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 155

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Glu Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 156

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 156

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Glu Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 157

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 157

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 158

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 158

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 159

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 159

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 160

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 160

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 161

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 161

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 162

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 162

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 163

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 163

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asp Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asn Asp Ala Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 164

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 164

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Thr Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Asn Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 165

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 165

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Pro Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ala Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 166

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 166

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 167

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 167

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 168

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 168

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Ser Leu Arg Pro Gln Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 169

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 169

Gly Phe Thr Phe Ser Lys Ala Trp Met Thr

1 5 10

<210> 170

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 170

Gly Phe Thr Phe Ser Lys Ala Trp Met Thr

1 5 10

<210> 171

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 171

Gly Phe Thr Phe Ser Lys Ala Trp Met Thr

1 5 10

<210> 172

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 172

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 173

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 173

Gly Tyr Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 174

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 174

Gly Phe Asp Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 175

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 175

Gly Phe Val Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 176

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 176

Gly Phe Thr Tyr Ser Lys Ala Trp Met Ser

1 5 10

<210> 177

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 177

Gly Phe Thr Phe Ala Lys Ala Trp Met Ser

1 5 10

<210> 178

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 178

Gly Phe Thr Phe Ser Asn Ala Trp Met Ser

1 5 10

<210> 179

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 179

Gly Phe Thr Phe Ser Arg Ala Trp Met Ser

1 5 10

<210> 180

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 180

Gly Phe Thr Phe Ser Met Ala Trp Met Ser

1 5 10

<210> 181

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 181

Gly Phe Thr Phe Ser Ala Ala Trp Met Ser

1 5 10

<210> 182

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 182

Gly Phe Thr Phe Ser His Ala Trp Met Ser

1 5 10

<210> 183

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 183

Gly Phe Thr Phe Ser His Ala Trp Met Ser

1 5 10

<210> 184

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 184

Gly Phe Thr Phe Ser Lys Ala Tyr Met Ser

1 5 10

<210> 185

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 185

Gly Phe Thr Phe Ser Lys Ala Trp Phe Ser

1 5 10

<210> 186

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 186

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 187

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 187

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 188

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 188

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 189

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 189

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 190

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 190

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 191

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 191

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 192

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 192

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 193

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 193

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 194

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 194

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 195

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 195

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 196

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 196

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 197

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 197

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 198

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 198

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 199

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 199

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 200

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 200

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 201

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 201

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 202

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 202

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 203

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 203

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 204

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 204

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 205

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 205

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 206

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 206

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 207

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 207

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 208

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 208

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 209

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 209

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 210

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 210

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 211

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 211

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 212

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 212

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 213

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 213

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 214

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 214

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 215

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 215

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 216

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 216

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 217

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 217

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 218

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 218

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 219

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 219

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 220

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 220

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 221

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 221

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 222

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 222

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 223

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 223

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 224

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 224

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 225

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 225

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 226

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 226

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 227

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 227

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 228

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 228

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 229

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 229

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 230

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 230

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 231

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 231

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 232

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 232

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 233

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 233

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 234

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 234

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 235

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 235

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 236

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 236

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 237

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 237

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 238

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 238

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 239

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 239

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 240

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 240

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 241

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 241

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 242

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 242

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 243

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 243

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 244

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 244

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 245

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 245

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 246

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 246

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 247

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 247

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 248

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 248

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 249

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 249

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 250

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 250

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 251

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 251

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 252

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 252

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 253

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 253

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 254

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 254

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 255

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 255

Gly Phe Asp Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 256

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 256

Gly Phe Thr Phe Ala Lys Ala Trp Met Ser

1 5 10

<210> 257

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 257

Gly Phe Asp Ala Ser Lys Ala Trp Phe Thr

1 5 10

<210> 258

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 258

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 259

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 259

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 260

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 260

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 261

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 261

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 262

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 262

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 263

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 263

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 264

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 264

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 265

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 265

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 266

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 266

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 267

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 267

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 268

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 268

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 269

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 269

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 270

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 270

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 271

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 271

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 272

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 272

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 273

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 273

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 274

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 274

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 275

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 275

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 276

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 276

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 277

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 277

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 278

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 278

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 279

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 279

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 280

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 280

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 281

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 281

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 282

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 282

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 283

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 283

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 284

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 284

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 285

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 285

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 286

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 286

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 287

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 287

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 288

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 288

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 289

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 289

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 290

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 290

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 291

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 291

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 292

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 292

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 293

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 293

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 294

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 294

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 295

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 295

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 296

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 296

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 297

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 297

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 298

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 298

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 299

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 299

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 300

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 300

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 301

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 301

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 302

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 302

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 303

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 303

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 304

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 304

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 305

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 305

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 306

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 306

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 307

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 307

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 308

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 308

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 309

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 309

Gly Phe Thr Phe Ser Lys Ala Trp Tyr Ser

1 5 10

<210> 310

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 310

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 311

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 311

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 312

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 312

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 313

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 313

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 314

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 314

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 315

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 315

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 316

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 316

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 317

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 317

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 318

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 318

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 319

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 319

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 320

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 320

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 321

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 321

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 322

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 322

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 323

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 323

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 324

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 324

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 325

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 325

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 326

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 326

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 327

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 327

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 328

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 328

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 329

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 329

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 330

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 330

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 331

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 331

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 332

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 332

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 333

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 333

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 334

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 334

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 335

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 335

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 336

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 336

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 337

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 337

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 338

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 338

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 339

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 339

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 340

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 340

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 341

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 341

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 342

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 342

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 343

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 343

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 344

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 344

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 345

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 345

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 346

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 346

Gly Phe Thr Phe Ala Lys Ala Trp Met Ser

1 5 10

<210> 347

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 347

Gly Phe Thr Tyr Ala Lys Ala Trp Met Ser

1 5 10

<210> 348

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 348

Gly Phe Asp Ala Ser Lys Ala Trp Phe Thr

1 5 10

<210> 349

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 349

Gly Phe Asp Ala Ser Lys Ala Trp Phe Thr

1 5 10

<210> 350

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 350

Gly Phe Asp Ala Ser Lys Ala Trp Phe Thr

1 5 10

<210> 351

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 351

Gly Phe Asp Ala Ser Lys Ala Trp Phe Thr

1 5 10

<210> 352

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 352

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 353

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 353

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 354

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 354

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 355

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 355

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 356

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 356

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 357

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 357

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 358

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 358

Gly Phe Val Tyr Ser Lys Ala Trp Met Ser

1 5 10

<210> 359

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 359

Gly Phe Val Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 360

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 360

Gly Phe Thr Phe Ala Lys Ala Trp Met Ser

1 5 10

<210> 361

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 361

Gly Phe Thr Tyr Ala Lys Ala Trp Phe Thr

1 5 10

<210> 362

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 362

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 363

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 363

Arg Ile Lys Ser Val Thr Glu Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 364

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 364

Arg Ile Lys Ser Val Thr Glu Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 365

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 365

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 366

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 366

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 367

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 367

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 368

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 368

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 369

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 369

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 370

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 370

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 371

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 371

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 372

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 372

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 373

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 373

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 374

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 374

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 375

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 375

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 376

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 376

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 377

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 377

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 378

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 378

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 379

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 379

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 380

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 380

Arg Ile Gln Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 381

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 381

Arg Ile Lys Ala Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 382

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 382

Arg Ile Lys Ser Ala Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 383

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 383

Arg Ile Lys Ser Asn Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 384

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 384

Arg Ile Lys Ser Val His Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 385

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 385

Arg Ile Lys Ser Val Asp Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 386

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 386

Arg Ile Lys Ser Val Gln Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 387

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 387

Arg Ile Lys Ser Val Thr Asn Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 388

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 388

Arg Ile Lys Ser Val Thr Asp Ala Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 389

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 389

Arg Ile Lys Ser Val Thr Asp Gly Gln Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 390

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 390

Arg Ile Lys Ser Val Thr Asp Gly His Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 391

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 391

Arg Ile Lys Ser Val Thr Asp Gly Glu Gln Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 392

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 392

Arg Ile Lys Ser Val Thr Asp Gly Glu Ala Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 393

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 393

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ser Pro

1 5 10 15

Val Lys Gly

<210> 394

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 394

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Gln Gly

<210> 395

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 395

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 396

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 396

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 397

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 397

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 398

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 398

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 399

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 399

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 400

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 400

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 401

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 401

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 402

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 402

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 403

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 403

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 404

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 404

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 405

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 405

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 406

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 406

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 407

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 407

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 408

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 408

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 409

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 409

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 410

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 410

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 411

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 411

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 412

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 412

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 413

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 413

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 414

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 414

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 415

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 415

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 416

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 416

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 417

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 417

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 418

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 418

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 419

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 419

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 420

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 420

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 421

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 421

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 422

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 422

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 423

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 423

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 424

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 424

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 425

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 425

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 426

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 426

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 427

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 427

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 428

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 428

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 429

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 429

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 430

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 430

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 431

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 431

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 432

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 432

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 433

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 433

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 434

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 434

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 435

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 435

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 436

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 436

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 437

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 437

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 438

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 438

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 439

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 439

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 440

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 440

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 441

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 441

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 442

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 442

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 443

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 443

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 444

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 444

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 445

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 445

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 446

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 446

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 447

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 447

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 448

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 448

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 449

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 449

Arg Ile Lys Ser Val Thr Asp Gly Gln Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 450

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 450

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 451

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 451

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 452

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 452

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 453

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 453

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 454

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 454

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 455

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 455

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 456

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 456

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 457

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 457

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 458

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 458

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 459

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 459

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 460

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 460

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 461

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 461

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 462

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 462

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 463

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 463

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 464

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 464

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 465

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 465

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 466

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 466

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 467

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 467

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 468

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 468

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 469

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 469

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 470

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 470

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 471

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 471

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 472

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 472

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 473

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 473

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 474

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 474

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 475

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 475

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 476

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 476

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 477

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 477

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 478

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 478

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 479

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 479

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 480

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 480

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 481

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 481

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 482

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 482

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 483

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 483

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 484

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 484

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 485

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 485

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 486

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 486

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 487

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 487

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 488

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 488

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 489

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 489

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 490

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 490

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 491

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 491

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 492

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 492

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 493

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 493

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 494

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 494

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 495

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 495

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 496

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 496

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 497

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 497

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 498

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 498

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 499

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 499

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 500

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 500

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 501

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 501

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 502

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 502

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 503

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 503

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 504

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 504

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Glu Tyr Ala Ala Ser

1 5 10 15

Val Lys Gly

<210> 505

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 505

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Glu Tyr Ala Ala Ser

1 5 10 15

Val Lys Gly

<210> 506

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 506

Phe Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Glu Tyr Ala Ala Ser

1 5 10 15

Val Lys Gly

<210> 507

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 507

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 508

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 508

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 509

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 509

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 510

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 510

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 511

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 511

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 512

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 512

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 513

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 513

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 514

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 514

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 515

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 515

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 516

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 516

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 517

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 517

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 518

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 518

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 519

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 519

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 520

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 520

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 521

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 521

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 522

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 522

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 523

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 523

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 524

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 524

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 525

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 525

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 526

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 526

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 527

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 527

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 528

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 528

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 529

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 529

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 530

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 530

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 531

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 531

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 532

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 532

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 533

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 533

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 534

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 534

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 535

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 535

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 536

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 536

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 537

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 537

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 538

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 538

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 539

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 539

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 540

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 540

Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 541

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 541

Arg Ile Lys Ser Val Gln Asp Gly Glu Gln Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 542

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 542

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 543

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 543

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 544

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 544

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 545

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 545

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 546

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 546

Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 547

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 547

Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 548

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 548

Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 549

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 549

Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 550

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 550

Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 551

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 551

Arg Ile Lys Ala Val Thr Asp Gly His Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 552

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 552

Arg Ile Lys Ser Val Thr Asp Gly Gln Ala Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 553

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 553

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 554

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 554

Arg Ile Lys Ser Val Thr Asp Ala Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 555

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 555

Arg Ile Lys Ser Thr Ser Asp Gly Gly Ile Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 556

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 556

Arg Ile Lys Ser Val Ser Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 557

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 557

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 558

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 558

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 559

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 559

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 560

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 560

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 561

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 561

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 562

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 562

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 563

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 563

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 564

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 564

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 565

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 565

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 566

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 566

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 567

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 567

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 568

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 568

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 569

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 569

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 570

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 570

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 571

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 571

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 572

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 572

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 573

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 573

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 574

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 574

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 575

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 575

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 576

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 576

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 577

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 577

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 578

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 578

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 579

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 579

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 580

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 580

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 581

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 581

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 582

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 582

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 583

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 583

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 584

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 584

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 585

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 585

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 586

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 586

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 587

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 587

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 588

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 588

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 589

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 589

Ile Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 590

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 590

Thr Thr Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 591

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 591

Thr Ser Pro Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 592

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 592

Thr Ser Ala Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 593

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 593

Thr Ser Ser Tyr Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 594

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 594

Thr Ser Ser Phe Cys Cys Leu Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 595

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 595

Thr Ser Ser Phe Cys Cys His Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 596

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 596

Thr Ser Ser Phe Cys Cys Gln Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 597

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 597

Thr Ser Ser Phe Cys Cys Arg Ser Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 598

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 598

Thr Ser Ser Phe Cys Cys Arg Gly Ala Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 599

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 599

Thr Ser Ser Phe Cys Cys Arg Gly Lys Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 600

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 600

Thr Ser Ser Phe Cys Cys Arg Gly Asn Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 601

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 601

Thr Ser Ser Phe Cys Cys Arg Gly Gly Asn Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 602

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 602

Thr Ser Ser Phe Cys Cys Arg Gly Gly Gln Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 603

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 603

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ala Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 604

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 604

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Ala Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 605

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 605

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Leu Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 606

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 606

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ala His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 607

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 607

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Asn His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 608

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 608

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 609

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 609

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser Gln Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 610

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 610

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Glu Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 611

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 611

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Gln

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 612

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 612

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Met Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 613

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 613

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Ala Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 614

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 614

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 615

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 615

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Asn Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 616

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 616

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Ala Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 617

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 617

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 618

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 618

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Tyr Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 619

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 619

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Phe Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 620

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 620

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Pro Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 621

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 621

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Ala Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 622

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 622

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Gln Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 623

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 623

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Asp Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 624

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 624

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Phe Tyr Tyr Met Asp Val

20 25 30

<210> 625

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 625

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Phe Tyr Met Asp Val

20 25 30

<210> 626

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 626

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Trp Met Asp Val

20 25 30

<210> 627

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 627

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Leu Met Asp Val

20 25 30

<210> 628

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 628

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Val Asp Val

20 25 30

<210> 629

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 629

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Phe Asp Val

20 25 30

<210> 630

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 630

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asn Val

20 25 30

<210> 631

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 631

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Ile

20 25 30

<210> 632

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 632

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Pro

20 25 30

<210> 633

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 633

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Phe Lys Asp Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 634

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 634

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Ser Lys Gln Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 635

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 635

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Ser Lys Lys Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 636

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 636

Thr Ser Ser Phe Ser Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Ser Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 637

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 637

Thr Ser Ser Phe Ala Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Val Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 638

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 638

Thr Ser Ser Phe Cys Cys Arg Gly Asn Ser Cys Pro Ala His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Pro Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 639

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 639

Thr Ser Ser Tyr Cys Cys Leu Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 640

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 640

Thr Ser Ser Phe Cys Cys Arg Gly Lys Ser Cys Pro Ser His Asp Asn

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Ala Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 641

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 641

Thr Ser Ser Tyr Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Phe Lys Ser Tyr Tyr Tyr Met Asp Pro

20 25 30

<210> 642

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 642

Thr Ser Thr Phe Cys Cys Arg Gly Gly Ser Cys Leu Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Trp Met Asp Val

20 25 30

<210> 643

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 643

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 644

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 644

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 645

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 645

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 646

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 646

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 647

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 647

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 648

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 648

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 649

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 649

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 650

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 650

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 651

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 651

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 652

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 652

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 653

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 653

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 654

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 654

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 655

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 655

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 656

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 656

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 657

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 657

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 658

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 658

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 659

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 659

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 660

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 660

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 661

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 661

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 662

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 662

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 663

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 663

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 664

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 664

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 665

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 665

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 666

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 666

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 667

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 667

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 668

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 668

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 669

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 669

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 670

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 670

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 671

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 671

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 672

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 672

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 673

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 673

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 674

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 674

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 675

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 675

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 676

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 676

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 677

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 677

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 678

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 678

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 679

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 679

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 680

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 680

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 681

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 681

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 682

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 682

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 683

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 683

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 684

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 684

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 685

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 685

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 686

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 686

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 687

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 687

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 688

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 688

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 689

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 689

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 690

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 690

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 691

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 691

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 692

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 692

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 693

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 693

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 694

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 694

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 695

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 695

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 696

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 696

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 697

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 697

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 698

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 698

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 699

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 699

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 700

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 700

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 701

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 701

Thr Ser Ser Tyr Cys Cys Arg Ser Gly Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Phe Lys Ser Tyr Tyr Tyr Met Asp Pro

20 25 30

<210> 702

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 702

Thr Ser Ser Phe Cys Cys Arg Ser Gly Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Tyr Val Asn Ile

20 25 30

<210> 703

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 703

Thr Thr Ser Phe Cys Cys Arg Gly Ala Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Ala Gly Ser Tyr Lys Ser Tyr Tyr Tyr Val Asn Ile

20 25 30

<210> 704

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 704

Thr Ser Ala Phe Cys Cys Arg Gly Lys Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Pro Ser Tyr Tyr Tyr Val Asn Ile

20 25 30

<210> 705

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 705

Thr Ser Ala Phe Cys Cys Arg Gly Lys Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Val Asn Ile

20 25 30

<210> 706

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 706

Thr Ser Ala Phe Cys Cys Arg Gly Gly Asn Cys Pro Ser His Glu Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Asn Lys Gln Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 707

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 707

Thr Ser Ser Phe Cys Cys Arg Gly Asn Gln Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp Pro

20 25 30

<210> 708

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 708

Thr Thr Ser Phe Cys Cys Arg Gly Asn Gln Cys Pro Ser His Glu Thr

1 5 10 15

Ser Tyr Cys Gly Gly Tyr Tyr Lys Ser Tyr Phe Tyr Met Asp Val

20 25 30

<210> 709

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 709

Thr Ser Ser Tyr Cys Cys Arg Gly Lys Gln Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Ala Gly Gln Tyr Ala Asp Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 710

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 710

Ile Ser Ser Phe Cys Cys Arg Gly Lys Gln Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Tyr Ala Asp Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 711

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 711

Thr Ser Ser Phe Cys Cys Arg Gly Lys Gln Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Tyr Ala Asp Tyr Tyr Tyr Val Asn Ile

20 25 30

<210> 712

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 712

Ile Ser Ser Phe Cys Cys Arg Gly Lys Gln Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Phe Met Asp Val

20 25 30

<210> 713

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 713

Thr Ser Ala Phe Cys Cys Arg Gly Lys Gln Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Ala Ser Phe Tyr Tyr Met Asp Val

20 25 30

<210> 714

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 714

Thr Ser Ser Phe Cys Cys Gln Gly Asn Asn Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Tyr Tyr Lys Asp Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 715

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 715

Thr Ser Ser Phe Cys Cys Gln Gly Asn Asn Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Val Asn Ile

20 25 30

<210> 716

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 716

Thr Ser Ser Phe Cys Cys Gln Gly Lys Asn Cys Pro Ser His Glu Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Ala Asp Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 717

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 717

Thr Thr Ser Phe Cys Cys His Gly Asn Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Asn Lys Gln Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 718

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 718

Ile Ser Ser Phe Cys Cys His Gly Asn Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Asn Lys Gln Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 719

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 719

Ile Ser Ser Phe Cys Cys His Ser Asn Asn Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Tyr Lys Gln Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 720

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 720

Thr Ser Ser Phe Cys Cys His Ser Asn Asn Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Val Asn Ile

20 25 30

<210> 721

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 721

Ile Ser Ser Phe Ala Cys His Ser Asn Asn Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Val Asn Gly Tyr Tyr Lys Gln Tyr Tyr Phe Met Asp Val

20 25 30

<210> 722

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 722

Thr Ser Ser Phe Cys Cys His Ser Asn Asn Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Tyr Lys Gln Tyr Tyr Tyr Val Asn Ile

20 25 30

<210> 723

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 723

Thr Ser Ser Phe Cys Cys Leu Gly Lys Ala Cys Leu Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Ala Ser Tyr Tyr Tyr Val Asn Ile

20 25 30

<210> 724

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 724

Thr Ser Ser Phe Cys Cys Leu Gly Lys Ala Cys Leu Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Tyr Tyr Ala Ser Tyr Tyr Phe Val Asn Ile

20 25 30

<210> 725

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 725

Thr Ser Ser Phe Ala Cys Leu Gly Lys Ala Cys Leu Ser Ser Asp Thr

1 5 10 15

Ser Tyr Val Gly Gly Tyr Tyr Ala Ser Tyr Tyr Phe Val Asn Ile

20 25 30

<210> 726

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 726

Thr Ser Ser Tyr Cys Cys Leu Gly Asn Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Phe Lys Ser Tyr Tyr Tyr Met Asp Pro

20 25 30

<210> 727

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 727

Thr Ser Ser Tyr Cys Cys Leu Gly Asn Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp Pro

20 25 30

<210> 728

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 728

Ile Ser Ser Phe Cys Cys Leu Gly Gly Asn Cys Pro Ser Ser Glu Thr

1 5 10 15

Ser Tyr Cys Gly Asn Gln Tyr Pro Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 729

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 729

Ile Ser Ser Phe Cys Cys Leu Gly Gly Asn Cys Pro Ser Ser Glu Thr

1 5 10 15

Ser Tyr Cys Gly Asn Tyr Tyr Pro Ser Tyr Phe Tyr Met Asp Val

20 25 30

<210> 730

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 730

Thr Ser Ser Phe Cys Cys Leu Gly Gly Asn Cys Pro Ser Ser Glu Thr

1 5 10 15

Ser Tyr Cys Gly Asn Gln Tyr Pro Ser Tyr Tyr Tyr Val Asn Ile

20 25 30

<210> 731

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 731

Thr Thr Ser Phe Ala Cys Arg Gly Asn Gln Cys Pro Ser His Glu Thr

1 5 10 15

Ser Tyr Val Gly Gly Tyr Tyr Lys Ser Tyr Phe Tyr Met Asp Val

20 25 30

<210> 732

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 732

Thr Thr Ser Phe Ala Cys Arg Gly Asn Gln Cys Pro Ser Ser Glu Thr

1 5 10 15

Ser Tyr Val Gly Gly Tyr Tyr Lys Ser Tyr Phe Phe Met Asp Val

20 25 30

<210> 733

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 733

Ile Ser Ser Phe Ala Cys Arg Gly Lys Gln Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Val Gly Gly Gln Phe Lys Ser Tyr Tyr Phe Met Asp Val

20 25 30

<210> 734

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 734

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Leu Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Trp Met Asp Val

20 25 30

<210> 735

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 735

Thr Ser Ser Tyr Cys Cys Leu Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 736

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 736

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Asn Lys Gln Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 737

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 737

Thr Ser Ser Phe Ala Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Val Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 738

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 738

Thr Ser Ser Tyr Cys Cys Leu Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 739

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 739

Thr Ser Ser Phe Cys Cys Arg Gly Lys Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Ala Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 740

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 740

Thr Ser Ser Phe Cys Cys Arg Gly Gly Asn Cys Pro Ser His Glu Thr

1 5 10 15

Ser Tyr Cys Gly Asn Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 741

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 741

Thr Ser Ser Phe Cys Cys Arg Ser Gly Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 742

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 742

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Val Asn Ile

20 25 30

<210> 743

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 743

Thr Thr Ser Phe Cys Cys Arg Gly Ala Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Ala Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 744

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 744

Ile Ser Ser Phe Cys Cys Arg Gly Asn Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 745

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 745

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 746

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 746

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 747

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 747

Thr Ser Ser Phe Cys Cys Arg Gly Lys Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Ala Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 748

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 748

Thr Ser Ser Phe Cys Cys Arg Ser Gly Ser Cys Pro Ser Ser Asp Thr

1 5 10 15

Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Trp Met Asp Val

20 25 30

<210> 749

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 749

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 750

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 750

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser Arg Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Phe Met Asp Val

20 25 30

<210> 751

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 751

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 752

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 752

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 753

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 753

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 754

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 754

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 755

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 755

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 756

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 756

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 757

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 757

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 758

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 758

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 759

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 759

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 760

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 760

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 761

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 761

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 762

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 762

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 763

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 763

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 764

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 764

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 765

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 765

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 766

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 766

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 767

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 767

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 768

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 768

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 769

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 769

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 770

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 770

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 771

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 771

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 772

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 772

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 773

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 773

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 774

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 774

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 775

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 775

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 776

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 776

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 777

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 777

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 778

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 778

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 779

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 779

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 780

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 780

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 781

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 781

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 782

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 782

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 783

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 783

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 784

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 784

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 785

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 785

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 786

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 786

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 787

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 787

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 788

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 788

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 789

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 789

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 790

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 790

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 791

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 791

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 792

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 792

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 793

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 793

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 794

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 794

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 795

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 795

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 796

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 796

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 797

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 797

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 798

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 798

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 799

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 799

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 800

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 800

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 801

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 801

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 802

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 802

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 803

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 803

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 804

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 804

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 805

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 805

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 806

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 806

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 807

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 807

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 808

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 808

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 809

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 809

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 810

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 810

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 811

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 811

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 812

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 812

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 813

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 813

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 814

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 814

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 815

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 815

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 816

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 816

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 817

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 817

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 818

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 818

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 819

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 819

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 820

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 820

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 821

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 821

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 822

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 822

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 823

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 823

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 824

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 824

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 825

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 825

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 826

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 826

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 827

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 827

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 828

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 828

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 829

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 829

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 830

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 830

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 831

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 831

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 832

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 832

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 833

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 833

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 834

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 834

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 835

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 835

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 836

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 836

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 837

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 837

Thr Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 838

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 838

Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 839

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 839

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 840

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 840

Thr Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 841

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 841

Ser Gly Ala Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 842

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 842

Ser Gly Ser Pro Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 843

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 843

Ser Gly Ser Lys Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 844

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 844

Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 845

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 845

Ser Gly Ser Ser Ser Asp Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 846

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 846

Ser Gly Ser Ser Ser Asn Ile Gln Ser Ser Ser Val Ser

1 5 10

<210> 847

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 847

Ser Gly Ser Ser Ser Asn Ile Gly His Ser Ser Val Ser

1 5 10

<210> 848

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 848

Ser Gly Ser Ser Ser Asn Ile Gly Ser Thr Ser Val Ser

1 5 10

<210> 849

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 849

Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn Ser Val Ser

1 5 10

<210> 850

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 850

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ala Ser Val Ser

1 5 10

<210> 851

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 851

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Thr Val Ser

1 5 10

<210> 852

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 852

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ala Val Ser

1 5 10

<210> 853

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 853

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Tyr Val Ser

1 5 10

<210> 854

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 854

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Thr Ser

1 5 10

<210> 855

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 855

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ala

1 5 10

<210> 856

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 856

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Thr

1 5 10

<210> 857

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 857

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 858

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 858

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 859

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 859

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 860

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 860

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 861

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 861

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 862

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 862

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 863

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 863

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 864

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 864

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 865

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 865

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 866

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 866

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 867

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 867

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 868

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 868

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 869

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 869

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 870

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 870

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 871

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 871

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 872

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 872

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 873

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 873

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 874

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 874

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 875

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 875

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 876

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 876

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 877

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 877

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 878

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 878

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 879

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 879

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 880

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 880

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 881

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 881

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 882

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 882

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 883

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 883

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 884

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 884

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 885

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 885

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 886

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 886

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 887

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 887

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 888

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 888

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 889

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 889

Ser Gly Ser Ser Ser Asp Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 890

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 890

His Gly Ser Glu Ser Asp Ile Gly Ser His Asp Val Leu

1 5 10

<210> 891

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 891

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 892

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 892

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 893

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 893

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 894

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 894

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 895

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 895

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 896

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 896

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 897

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 897

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 898

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 898

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 899

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 899

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 900

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 900

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 901

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 901

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 902

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 902

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 903

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 903

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 904

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 904

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 905

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 905

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 906

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 906

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 907

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 907

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 908

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 908

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 909

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 909

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 910

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 910

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 911

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 911

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 912

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 912

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 913

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 913

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 914

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 914

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 915

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 915

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 916

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 916

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 917

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 917

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 918

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 918

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 919

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 919

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 920

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 920

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 921

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 921

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 922

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 922

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 923

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 923

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 924

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 924

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 925

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 925

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 926

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 926

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 927

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 927

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 928

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 928

Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser Ser Val Tyr

1 5 10

<210> 929

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 929

Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser Ser Val Tyr

1 5 10

<210> 930

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 930

Thr Gly Ser Ser Ser Asn Ile Gly Ser Ser Tyr Val Ser

1 5 10

<210> 931

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 931

Thr Gly Ser Ser Ser Asn Ile Gly Ser Ser Tyr Val Ser

1 5 10

<210> 932

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 932

Thr Gly Ser Ser Ser Asn Ile Gly Ser Ser Tyr Val Ser

1 5 10

<210> 933

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 933

Thr Gly Ser Ser Ser Asn Ile Gly Ser Ser Tyr Val Ser

1 5 10

<210> 934

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 934

Ser Gly Ser Pro Ser Asn Ile Gly Ser Ala Ser Thr Ser

1 5 10

<210> 935

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 935

Ser Gly Ser Pro Ser Asn Ile Gly Ser Ala Ser Thr Ser

1 5 10

<210> 936

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 936

Ser Gly Ser Pro Ser Asn Ile Gly Ser Ala Ser Thr Ser

1 5 10

<210> 937

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 937

Ser Gly Ser Pro Ser Asn Ile Gly Ser Ala Ser Thr Ser

1 5 10

<210> 938

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 938

Ser Gly Ser Pro Ser Asn Ile Gly Ser Ala Ser Thr Ser

1 5 10

<210> 939

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 939

Ser Gly Ala Ser Ser Asn Ile Gly His Ser Ser Val Tyr

1 5 10

<210> 940

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 940

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 941

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 941

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 942

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 942

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Thr

1 5 10

<210> 943

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 943

Ser Gly Ser Lys Ser Asn Ile Gly Ser Ser Tyr Val Ser

1 5 10

<210> 944

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 944

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Tyr

1 5 10

<210> 945

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 945

Lys Asn Asn Gln Arg Pro Ser

15

<210> 946

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 946

Lys Asn Asn Gln Arg Pro Ser

15

<210> 947

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 947

Lys Asn Asn Gln Arg Pro Ser

15

<210> 948

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 948

Lys Asn Asn Gln Arg Pro Ser

15

<210> 949

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 949

Lys Asn Asn Gln Arg Pro Ser

15

<210> 950

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 950

Lys Asn Asn Gln Arg Pro Ser

15

<210> 951

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 951

Lys Asn Asn Gln Arg Pro Ser

15

<210> 952

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 952

Lys Asn Asn Gln Arg Pro Ser

15

<210> 953

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 953

Lys Asn Asn Gln Arg Pro Ser

15

<210> 954

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 954

Lys Asn Asn Gln Arg Pro Ser

15

<210> 955

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 955

Lys Asn Asn Gln Arg Pro Ser

15

<210> 956

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 956

Lys Asn Asn Gln Arg Pro Ser

15

<210> 957

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 957

Lys Asn Asn Gln Arg Pro Ser

15

<210> 958

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 958

Lys Asn Asn Gln Arg Pro Ser

15

<210> 959

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 959

Lys Asn Asn Gln Arg Pro Ser

15

<210> 960

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 960

Lys Asn Asn Gln Arg Pro Ser

15

<210> 961

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 961

Lys Asn Asn Gln Arg Pro Ser

15

<210> 962

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 962

Lys Asn Asn Gln Arg Pro Ser

15

<210> 963

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 963

Lys Asn Asn Gln Arg Pro Ser

15

<210> 964

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 964

Lys Asn Asn Gln Arg Pro Ser

15

<210> 965

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 965

Lys Asn Asn Gln Arg Pro Ser

15

<210> 966

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 966

Lys Asn Asn Gln Arg Pro Ser

15

<210> 967

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 967

Lys Asn Asn Gln Arg Pro Ser

15

<210> 968

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 968

Lys Asn Asn Gln Arg Pro Ser

15

<210> 969

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 969

Lys Asn Asn Gln Arg Pro Ser

15

<210> 970

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 970

Lys Asn Asn Gln Arg Pro Ser

15

<210> 971

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 971

Lys Asn Asn Gln Arg Pro Ser

15

<210> 972

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 972

Lys Asn Asn Gln Arg Pro Ser

15

<210> 973

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 973

Lys Asn Asn Gln Arg Pro Ser

15

<210> 974

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 974

Lys Asn Asn Gln Arg Pro Ser

15

<210> 975

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 975

Lys Asn Asn Gln Arg Pro Ser

15

<210> 976

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 976

Lys Asn Asn Gln Arg Pro Ser

15

<210> 977

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 977

Lys Asn Asn Gln Arg Pro Ser

15

<210> 978

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 978

Lys Asn Asn Gln Arg Pro Ser

15

<210> 979

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 979

Lys Asn Asn Gln Arg Pro Ser

15

<210> 980

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 980

Lys Asn Asn Gln Arg Pro Ser

15

<210> 981

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 981

Lys Asn Asn Gln Arg Pro Ser

15

<210> 982

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 982

Lys Asn Asn Gln Arg Pro Ser

15

<210> 983

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 983

Lys Asn Asn Gln Arg Pro Ser

15

<210> 984

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 984

Lys Asn Asn Gln Arg Pro Ser

15

<210> 985

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 985

Lys Asn Asn Gln Arg Pro Ser

15

<210> 986

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 986

Lys Asn Asn Gln Arg Pro Ser

15

<210> 987

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 987

Lys Asn Asn Gln Arg Pro Ser

15

<210> 988

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 988

Lys Asn Asn Gln Arg Pro Ser

15

<210> 989

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 989

Lys Asn Asn Gln Arg Pro Ser

15

<210> 990

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 990

Lys Asn Asn Gln Arg Pro Ser

15

<210> 991

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 991

Lys Asn Asn Gln Arg Pro Ser

15

<210> 992

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 992

Lys Asn Asn Gln Arg Pro Ser

15

<210> 993

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 993

Lys Asn Asn Gln Arg Pro Ser

15

<210> 994

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 994

Lys Asn Asn Gln Arg Pro Ser

15

<210> 995

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 995

Lys Asn Asn Gln Arg Pro Ser

15

<210> 996

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 996

Lys Asn Asn Gln Arg Pro Ser

15

<210> 997

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 997

Lys Asn Asn Gln Arg Pro Ser

15

<210> 998

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 998

Lys Asn Asn Gln Arg Pro Ser

15

<210> 999

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 999

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1000

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1000

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1001

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1001

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1002

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1002

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1003

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1003

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1004

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1004

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1005

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1005

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1006

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1006

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1007

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1007

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1008

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1008

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1009

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1009

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1010

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1010

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1011

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1011

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1012

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1012

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1013

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1013

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1014

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1014

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1015

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1015

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1016

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1016

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1017

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1017

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1018

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1018

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1019

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1019

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1020

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1020

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1021

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1021

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1022

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1022

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1023

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1023

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1024

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1024

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1025

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1025

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1026

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1026

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1027

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1027

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1028

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1028

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1029

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1029

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1030

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1030

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1031

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1031

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1032

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1032

Lys Asn Asn Tyr Arg Pro Ser

15

<210> 1033

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1033

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1034

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1034

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1035

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1035

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1036

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1036

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1037

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1037

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1038

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1038

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1039

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1039

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1040

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1040

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1041

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1041

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1042

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1042

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1043

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1043

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1044

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1044

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1045

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1045

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1046

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1046

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1047

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1047

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1048

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1048

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1049

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1049

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1050

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1050

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1051

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1051

Arg Asn Asn Gln Arg Pro Ser

15

<210> 1052

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1052

Asn Asn Asn Gln Arg Pro Ser

15

<210> 1053

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1053

Met Asn Asn Gln Arg Pro Ser

15

<210> 1054

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1054

Ala Asn Asn Gln Arg Pro Ser

15

<210> 1055

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1055

His Asn Asn Gln Arg Pro Ser

15

<210> 1056

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1056

Lys Asp Asn Gln Arg Pro Ser

15

<210> 1057

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1057

Lys Asn Thr Gln Arg Pro Ser

15

<210> 1058

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1058

Lys Asn Asn Tyr Arg Pro Ser

15

<210> 1059

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1059

Lys Asn Asn Ala Arg Pro Ser

15

<210> 1060

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1060

Lys Asn Asn Leu Arg Pro Ser

15

<210> 1061

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1061

Lys Asn Asn Gln Gln Pro Ser

15

<210> 1062

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1062

Lys Asn Asn Gln Arg Ala Ser

15

<210> 1063

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1063

Lys Asn Asn Gln Arg Pro Tyr

15

<210> 1064

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1064

Lys Asn Asn Gln Arg Pro Leu

15

<210> 1065

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1065

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1066

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1066

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1067

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1067

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1068

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1068

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1069

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1069

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1070

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1070

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1071

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1071

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1072

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1072

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1073

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1073

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1074

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1074

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1075

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1075

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1076

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1076

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1077

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1077

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1078

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1078

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1079

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1079

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1080

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1080

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1081

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1081

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1082

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1082

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1083

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1083

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1084

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1084

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1085

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1085

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1086

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1086

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1087

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1087

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1088

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1088

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1089

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1089

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1090

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1090

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1091

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1091

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1092

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1092

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1093

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1093

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1094

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1094

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1095

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1095

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1096

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1096

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1097

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1097

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1098

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1098

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1099

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1099

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1100

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1100

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1101

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1101

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1102

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1102

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1103

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1103

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1104

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1104

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1105

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1105

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1106

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1106

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1107

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1107

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1108

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1108

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1109

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1109

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1110

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1110

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1111

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1111

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1112

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1112

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1113

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1113

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1114

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1114

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1115

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1115

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1116

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1116

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1117

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1117

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1118

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1118

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1119

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1119

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1120

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1120

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1121

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1121

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1122

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1122

Lys Asn Asn Tyr Arg Pro Ser

15

<210> 1123

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1123

Lys Asn Asn Tyr Arg Ala Ser

15

<210> 1124

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1124

Lys Asn Ser Leu Arg Pro Gln

15

<210> 1125

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1125

Lys Asn Ser Leu Arg Pro Gln

15

<210> 1126

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1126

Lys Asn Ser Leu Arg Pro Gln

15

<210> 1127

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1127

Lys Asn Ser Leu Arg Pro Gln

15

<210> 1128

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1128

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1129

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1129

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1130

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1130

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1131

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1131

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1132

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1132

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1133

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1133

Arg Asn Asn Gln Gln Pro Leu

15

<210> 1134

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1134

Lys Asn Thr Gln Arg Ala Ser

15

<210> 1135

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1135

Arg Asn Asn Gln Gln Pro Leu

15

<210> 1136

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1136

Lys Asn Asn Ala Arg Pro Ser

15

<210> 1137

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1137

Lys Asp Asn Gln Arg Ala Ser

15

<210> 1138

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1138

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1139

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1139

Ser Thr Trp Asp Glu Ser Leu Ser Val Arg Val

1 5 10

<210> 1140

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1140

Ser Thr Trp Asp Glu Ser Leu Ser Val Arg Val

1 5 10

<210> 1141

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1141

Ser Thr Trp Asp Glu Ser Leu Ser Val Arg Val

1 5 10

<210> 1142

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1142

Ser Thr Trp Asp Glu Ser Leu Ser Val Arg Val

1 5 10

<210> 1143

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1143

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1144

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1144

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1145

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1145

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1146

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1146

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1147

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1147

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1148

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1148

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1149

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1149

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1150

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1150

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1151

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1151

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1152

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1152

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1153

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1153

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1154

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1154

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1155

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1155

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1156

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1156

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1157

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1157

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1158

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1158

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1159

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1159

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1160

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1160

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1161

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1161

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1162

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1162

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1163

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1163

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1164

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1164

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1165

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1165

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1166

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1166

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1167

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1167

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1168

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1168

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1169

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1169

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1170

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1170

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1171

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1171

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1172

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1172

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1173

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1173

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1174

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1174

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1175

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1175

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1176

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1176

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1177

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1177

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1178

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1178

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1179

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1179

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1180

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1180

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1181

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1181

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1182

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1182

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1183

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1183

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1184

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1184

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1185

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1185

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1186

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1186

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1187

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1187

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1188

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1188

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1189

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1189

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1190

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1190

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1191

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1191

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1192

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1192

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1193

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1193

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1194

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1194

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1195

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1195

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1196

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1196

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1197

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1197

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1198

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1198

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1199

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1199

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1200

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1200

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1201

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1201

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1202

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1202

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1203

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1203

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1204

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1204

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1205

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1205

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1206

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1206

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1207

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1207

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1208

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1208

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1209

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1209

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1210

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1210

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1211

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1211

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1212

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1212

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1213

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1213

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1214

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1214

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1215

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1215

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1216

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1216

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1217

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1217

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1218

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1218

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1219

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1219

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1220

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1220

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1221

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1221

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1222

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1222

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1223

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1223

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1224

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1224

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1225

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1225

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1226

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1226

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1227

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1227

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1228

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1228

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1229

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1229

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1230

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1230

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1231

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1231

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1232

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1232

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1233

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1233

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1234

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1234

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1235

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1235

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1236

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1236

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1237

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1237

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1238

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1238

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1239

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1239

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1240

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1240

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1241

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1241

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1242

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1242

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1243

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1243

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1244

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1244

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1245

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1245

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1246

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1246

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1247

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1247

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1248

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1248

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1249

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1249

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1250

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1250

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1251

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1251

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1252

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1252

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1253

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1253

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1254

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1254

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1255

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1255

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1256

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1256

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1257

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1257

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1258

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1258

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1259

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1259

Ala Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1260

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1260

Ser Ser Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1261

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1261

Ser Thr Phe Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1262

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1262

Ser Thr Trp Asp Asn Ser Leu Ser Val Arg Val

1 5 10

<210> 1263

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1263

Ser Thr Trp Asp Asp Gln Leu Ser Val Arg Val

1 5 10

<210> 1264

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1264

Ser Thr Trp Asp Asp Ala Leu Ser Val Arg Val

1 5 10

<210> 1265

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1265

Ser Thr Trp Asp Asp Asp Leu Ser Val Arg Val

1 5 10

<210> 1266

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1266

Ser Thr Trp Asp Asp Ser Asn Ser Val Arg Val

1 5 10

<210> 1267

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1267

Ser Thr Trp Asp Asp Ser Ser Ser Val Arg Val

1 5 10

<210> 1268

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1268

Ser Thr Trp Asp Asp Ser Leu Asn Val Arg Val

1 5 10

<210> 1269

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1269

Ser Thr Trp Asp Asp Ser Leu Leu Val Arg Val

1 5 10

<210> 1270

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1270

Ser Thr Trp Asp Asp Ser Leu Thr Val Arg Val

1 5 10

<210> 1271

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1271

Ser Thr Trp Asp Asp Ser Leu Ser Ile Arg Val

1 5 10

<210> 1272

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1272

Ser Thr Trp Asp Asp Ser Leu Ser Val Lys Val

1 5 10

<210> 1273

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1273

Ser Thr Trp Asp Asp Ser Leu Ser Val Trp Val

1 5 10

<210> 1274

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1274

Ser Thr Trp Asp Asp Ser Leu Ser Val His Val

1 5 10

<210> 1275

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1275

Ser Thr Trp Asp Asp Ser Leu Ser Val Gln Val

1 5 10

<210> 1276

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1276

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Ile

1 5 10

<210> 1277

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1277

Ser Thr Trp Asn Asp Gln Leu Ser Val Arg Val

1 5 10

<210> 1278

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1278

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1279

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1279

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1280

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1280

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1281

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1281

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1282

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1282

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1283

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1283

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1284

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1284

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1285

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1285

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1286

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1286

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1287

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1287

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1288

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1288

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1289

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1289

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1290

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1290

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1291

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1291

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1292

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1292

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1293

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1293

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1294

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1294

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1295

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1295

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1296

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1296

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1297

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1297

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1298

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1298

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1299

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1299

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1300

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1300

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1301

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1301

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1302

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1302

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1303

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1303

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1304

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1304

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1305

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1305

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1306

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1306

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1307

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1307

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1308

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1308

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1309

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1309

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1310

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1310

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1311

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1311

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1312

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1312

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1313

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1313

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1314

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1314

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1315

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1315

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1316

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1316

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1317

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1317

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1318

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1318

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1319

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1319

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1320

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1320

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1321

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1321

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1322

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1322

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1323

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1323

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1324

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1324

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1325

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1325

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1326

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1326

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1327

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1327

Ser Thr Trp Asp Asp Ala Leu Ser Ile Arg Val

1 5 10

<210> 1328

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1328

Ser Thr Trp Asp Asp Ala Leu Asn Val Arg Val

1 5 10

<210> 1329

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1329

Ser Ser Trp Asp Asp Ser Ser Leu Val Arg Val

1 5 10

<210> 1330

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1330

Ala Thr Trp Asp Asn Ser Leu Ser Ile Arg Val

1 5 10

<210> 1331

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1331

Ser Thr Trp Asp Asp Ala Leu Ser Val Arg Val

1 5 10

<210> 1332

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1332

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1333

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1333

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Glu Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Val

65 70 75 80

Leu Tyr Leu Gln Met Ser Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Phe Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1334

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1334

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Glu Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1335

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1335

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1336

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1336

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1337

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1337

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Tyr Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1338

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1338

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1339

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1339

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Val Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1340

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1340

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Tyr Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1341

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1341

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1342

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1342

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1343

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1343

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Arg Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1344

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1344

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Met Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1345

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1345

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ala Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1346

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1346

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser His Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1347

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1347

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser His Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1348

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1348

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1349

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1349

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Phe Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1350

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1350

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Gln Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1351

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1351

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ala Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1352

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1352

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Ala Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1353

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1353

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Asn Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1354

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1354

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val His Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1355

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1355

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Asp Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1356

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1356

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Gln Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1357

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1357

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asn Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1358

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1358

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Ala Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1359

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1359

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Gln Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1360

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1360

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly His Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1361

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1361

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Gln Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1362

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1362

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Ala Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1363

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1363

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ser

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1364

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1364

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Gln Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1365

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1365

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1366

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1366

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1367

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1367

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Pro Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1368

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1368

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ala Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1369

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1369

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Tyr Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1370

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1370

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Leu Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1371

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1371

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys His Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1372

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1372

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Gln Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1373

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1373

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Ser Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1374

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1374

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Ala Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1375

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1375

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Lys Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1376

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1376

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Asn Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1377

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1377

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Asn Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1378

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1378

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Gln Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1379

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1379

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ala Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1380

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1380

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Ala Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1381

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1381

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Leu Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1382

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1382

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ala His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1383

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1383

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Asn His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1384

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1384

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1385

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1385

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser Gln

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1386

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1386

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Glu Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1387

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1387

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Gln Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1388

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1388

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Met Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1389

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1389

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Ala Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1390

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1390

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1391

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1391

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Asn Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1392

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1392

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Ala Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1393

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1393

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1394

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1394

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Tyr Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1395

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1395

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Phe Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1396

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1396

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Pro Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1397

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1397

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Ala Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1398

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1398

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Gln Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1399

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1399

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Asp Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1400

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1400

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Phe Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1401

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1401

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Phe Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1402

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1402

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Trp Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1403

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1403

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Leu Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1404

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1404

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Val Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1405

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1405

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Phe Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1406

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1406

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asn

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1407

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1407

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1408

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1408

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Pro Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1409

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1409

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Phe Lys Asp Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1410

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1410

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Ser Lys Gln Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1411

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1411

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Ser Lys Lys Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1412

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1412

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Ser Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Ser Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1413

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1413

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Ala Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Val Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1414

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1414

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Asn Ser Cys Pro Ala His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Pro Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1415

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1415

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Tyr Cys Cys Leu Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1416

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1416

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Lys Ser Cys Pro Ser His

100 105 110

Asp Asn Ser Tyr Cys Gly Gly Gln Tyr Ala Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1417

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1417

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Tyr Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Phe Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Pro Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1418

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1418

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Thr Phe Cys Cys Arg Gly Gly Ser Cys Leu Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Trp Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1419

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1419

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Gln Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1420

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1420

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1421

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1421

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Ala Ser Lys Ala

20 25 30

Trp Phe Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1422

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1422

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1423

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1423

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1424

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1424

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1425

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1425

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1426

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1426

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1427

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1427

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1428

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1428

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1429

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1429

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1430

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1430

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1431

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1431

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1432

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1432

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1433

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1433

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1434

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1434

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1435

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1435

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1436

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1436

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1437

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1437

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1438

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1438

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1439

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1439

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1440

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1440

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1441

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1441

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1442

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1442

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1443

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1443

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1444

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1444

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1445

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1445

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1446

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1446

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1447

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1447

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1448

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1448

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1449

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1449

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1450

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1450

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1451

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1451

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1452

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1452

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1453

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1453

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1454

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1454

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1455

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1455

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1456

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1456

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1457

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1457

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1458

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1458

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1459

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1459

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1460

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1460

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1461

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1461

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1462

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1462

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1463

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1463

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1464

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1464

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1465

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1465

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1466

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1466

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1467

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1467

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1468

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1468

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1469

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1469

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1470

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1470

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1471

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1471

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1472

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1472

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1473

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1473

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Tyr Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1474

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1474

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Glu Tyr Ala Ala

50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1475

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1475

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Glu Tyr Ala Ala

50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Ser

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1476

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1476

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Pro

1 5 10 15

Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Phe Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Glu Tyr Ala Ala

50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Ile

65 70 75 80

Ala Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1477

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1477

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Tyr Cys Cys Arg Ser Gly Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Phe Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Pro Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1478

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1478

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Ser Gly Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Tyr Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1479

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1479

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Cys Cys Arg Gly Ala Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Ala Gly Ser Tyr Lys Ser Tyr Tyr Tyr Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1480

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1480

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ala Phe Cys Cys Arg Gly Lys Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Pro Ser Tyr Tyr Tyr Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1481

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1481

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ala Phe Cys Cys Arg Gly Lys Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1482

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1482

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ala Phe Cys Cys Arg Gly Gly Asn Cys Pro Ser His

100 105 110

Glu Thr Ser Tyr Cys Asn Gly Gln Asn Lys Gln Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1483

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1483

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Asn Gln Cys Pro Ser Ser

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp

115 120 125

Pro Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1484

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1484

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Cys Cys Arg Gly Asn Gln Cys Pro Ser His

100 105 110

Glu Thr Ser Tyr Cys Gly Gly Tyr Tyr Lys Ser Tyr Phe Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1485

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1485

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Tyr Cys Cys Arg Gly Lys Gln Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Ala Gly Gln Tyr Ala Asp Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1486

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1486

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys Arg Gly Lys Gln Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Tyr Ala Asp Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1487

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1487

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Lys Gln Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Tyr Ala Asp Tyr Tyr Tyr Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1488

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1488

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys Arg Gly Lys Gln Cys Pro Ser Ser

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Phe Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1489

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1489

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ala Phe Cys Cys Arg Gly Lys Gln Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Ala Ser Phe Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1490

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1490

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Gln Gly Asn Asn Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Tyr Tyr Lys Asp Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1491

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1491

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Gln Gly Asn Asn Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1492

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1492

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Gln Gly Lys Asn Cys Pro Ser His

100 105 110

Glu Thr Ser Tyr Cys Gly Gly Gln Tyr Ala Asp Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1493

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1493

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Cys Cys His Gly Asn Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Asn Lys Gln Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1494

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1494

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys His Gly Asn Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Asn Lys Gln Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1495

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1495

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys His Ser Asn Asn Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Tyr Lys Gln Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1496

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1496

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys His Ser Asn Asn Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1497

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1497

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Ala Cys His Ser Asn Asn Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Val Asn Gly Tyr Tyr Lys Gln Tyr Tyr Phe Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1498

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1498

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys His Ser Asn Asn Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Tyr Lys Gln Tyr Tyr Tyr Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1499

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1499

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Leu Gly Lys Ala Cys Leu Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Ala Ser Tyr Tyr Tyr Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1500

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1500

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Leu Gly Lys Ala Cys Leu Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Tyr Tyr Ala Ser Tyr Tyr Phe Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1501

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1501

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Ala Cys Leu Gly Lys Ala Cys Leu Ser Ser

100 105 110

Asp Thr Ser Tyr Val Gly Gly Tyr Tyr Ala Ser Tyr Tyr Phe Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1502

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1502

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Tyr Cys Cys Leu Gly Asn Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Phe Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Pro Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1503

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1503

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Tyr Cys Cys Leu Gly Asn Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp

115 120 125

Pro Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1504

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1504

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys Leu Gly Gly Asn Cys Pro Ser Ser

100 105 110

Glu Thr Ser Tyr Cys Gly Asn Gln Tyr Pro Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1505

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1505

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys Leu Gly Gly Asn Cys Pro Ser Ser

100 105 110

Glu Thr Ser Tyr Cys Gly Asn Tyr Tyr Pro Ser Tyr Phe Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1506

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1506

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Leu Gly Gly Asn Cys Pro Ser Ser

100 105 110

Glu Thr Ser Tyr Cys Gly Asn Gln Tyr Pro Ser Tyr Tyr Tyr Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1507

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1507

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Ala Cys Arg Gly Asn Gln Cys Pro Ser His

100 105 110

Glu Thr Ser Tyr Val Gly Gly Tyr Tyr Lys Ser Tyr Phe Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1508

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1508

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Ala Cys Arg Gly Asn Gln Cys Pro Ser Ser

100 105 110

Glu Thr Ser Tyr Val Gly Gly Tyr Tyr Lys Ser Tyr Phe Phe Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1509

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1509

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Ala Cys Arg Gly Lys Gln Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Val Gly Gly Gln Phe Lys Ser Tyr Tyr Phe Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1510

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1510

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Leu Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Trp Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1511

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1511

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Tyr Ala Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Gln Asp Gly Glu Gln Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Tyr Cys Cys Leu Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1512

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1512

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Ala Ser Lys Ala

20 25 30

Trp Phe Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Asn Lys Gln Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1513

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1513

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Ala Ser Lys Ala

20 25 30

Trp Phe Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Ala Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Val Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1514

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1514

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Ala Ser Lys Ala

20 25 30

Trp Phe Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Tyr Cys Cys Leu Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1515

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1515

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Ala Ser Lys Ala

20 25 30

Trp Phe Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Lys Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Ala Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1516

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1516

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Asn Cys Pro Ser His

100 105 110

Glu Thr Ser Tyr Cys Gly Asn Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1517

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1517

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Ser Gly Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1518

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1518

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Val Asn

115 120 125

Ile Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1519

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1519

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Cys Cys Arg Gly Ala Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Ala Gly Ser Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1520

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1520

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ala Ala Asp Asp Gly Lys Gln Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Ile Ser Ser Phe Cys Cys Arg Gly Asn Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1521

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1521

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ala Val Thr Asp Gly His Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1522

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1522

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Val Tyr Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Gln Ala Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1523

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1523

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Val Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Lys Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Ala Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1524

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1524

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ala Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Ala Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Ser Gly Ser Cys Pro Ser Ser

100 105 110

Asp Thr Ser Tyr Cys Asn Gly Gln Tyr Lys Ser Tyr Tyr Trp Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1525

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1525

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Tyr Ala Lys Ala

20 25 30

Trp Phe Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Thr Ser Asp Gly Gly Ile Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1526

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1526

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Ser Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser Arg

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Phe Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1527

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1527

Gln Ser Val Leu Thr Gln Ala Pro Ser Ala Ser Glu Thr Pro Gly Gln

1 5 10 15

Arg Val Ile Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Glu Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1528

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1528

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Glu Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1529

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1529

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Glu Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1530

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1530

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Glu Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1531

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1531

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1532

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1532

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1533

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1533

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1534

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1534

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1535

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1535

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1536

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1536

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1537

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1537

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1538

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1538

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1539

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1539

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1540

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1540

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1541

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1541

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1542

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1542

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1543

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1543

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1544

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1544

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1545

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1545

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1546

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1546

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1547

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1547

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1548

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1548

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1549

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1549

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1550

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1550

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1551

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1551

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1552

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1552

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1553

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1553

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1554

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1554

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1555

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1555

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1556

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1556

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1557

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1557

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1558

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1558

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1559

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1559

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1560

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1560

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1561

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1561

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1562

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1562

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1563

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1563

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1564

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1564

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1565

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1565

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1566

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1566

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1567

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1567

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1568

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1568

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1569

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1569

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1570

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1570

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1571

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1571

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1572

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1572

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1573

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1573

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1574

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1574

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1575

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1575

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1576

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1576

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1577

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1577

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1578

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1578

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1579

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1579

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1580

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1580

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1581

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1581

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1582

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1582

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1583

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1583

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1584

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1584

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1585

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1585

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1586

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1586

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1587

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1587

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1588

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1588

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1589

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1589

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1590

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1590

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1591

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1591

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1592

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1592

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1593

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1593

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1594

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1594

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1595

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1595

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1596

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1596

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1597

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1597

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1598

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1598

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1599

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1599

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1600

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1600

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1601

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1601

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1602

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1602

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1603

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1603

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1604

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1604

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1605

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1605

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1606

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1606

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1607

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1607

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1608

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1608

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1609

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1609

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1610

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1610

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1611

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1611

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1612

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1612

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1613

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1613

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1614

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1614

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Tyr Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1615

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1615

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1616

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1616

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1617

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1617

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ala Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1618

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1618

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Pro Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1619

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1619

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Lys Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1620

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1620

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1621

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1621

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asp Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1622

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1622

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gln Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1623

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1623

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly His Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1624

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1624

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Thr

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1625

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1625

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1626

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1626

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ala

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1627

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1627

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Thr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1628

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1628

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ala Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1629

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1629

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1630

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1630

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Thr Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1631

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1631

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ala Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1632

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1632

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Thr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1633

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1633

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Arg Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1634

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1634

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Asn Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1635

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1635

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Met Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1636

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1636

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Ala Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1637

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1637

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr His Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1638

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1638

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asp Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1639

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1639

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Thr Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1640

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1640

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Tyr Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1641

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1641

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Ala Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1642

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1642

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Leu Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1643

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1643

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Gln Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1644

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1644

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Ala Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1645

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1645

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Tyr Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1646

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1646

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Leu Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1647

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1647

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1648

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1648

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1649

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1649

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Phe Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1650

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1650

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asn Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1651

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1651

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Gln Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1652

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1652

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ala Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1653

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1653

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Asp Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1654

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1654

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Asn

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1655

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1655

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Ser

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1656

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1656

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Asn Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1657

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1657

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Leu Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1658

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1658

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Thr Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1659

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1659

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Ile Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1660

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1660

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Lys Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1661

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1661

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Trp Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1662

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1662

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val His Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1663

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1663

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Gln Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1664

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1664

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Ile Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1665

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1665

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asp Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asn Asp Gln Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1666

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1666

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys His Gly Ser Glu Ser Asp Ile Gly Ser His

20 25 30

Asp Val Leu Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1667

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1667

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1668

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1668

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1669

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1669

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln

65 70 75 80

Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1670

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1670

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu Gln

65 70 75 80

Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1671

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1671

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1672

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1672

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1673

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1673

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1674

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1674

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1675

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1675

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1676

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1676

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1677

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1677

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1678

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1678

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1679

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1679

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1680

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1680

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1681

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1681

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1682

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1682

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1683

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1683

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1684

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1684

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1685

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1685

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1686

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1686

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1687

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1687

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1688

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1688

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1689

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1689

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1690

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1690

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1691

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1691

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1692

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1692

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1693

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1693

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1694

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1694

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1695

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1695

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1696

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1696

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1697

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1697

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1698

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1698

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1699

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1699

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1700

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1700

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1701

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1701

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1702

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1702

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1703

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1703

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1704

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1704

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser

20 25 30

Ser Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Tyr Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1705

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1705

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Thr Asn Ile Gly Ser Ser

20 25 30

Ser Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Tyr Arg Ala Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1706

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1706

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Ser Leu Arg Pro Gln Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1707

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1707

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Ser Leu Arg Pro Gln Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1708

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1708

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Ser Leu Arg Pro Gln Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1709

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1709

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Ser Leu Arg Pro Gln Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1710

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1710

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Pro Ser Asn Ile Gly Ser Ala

20 25 30

Ser Thr Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1711

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1711

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Pro Ser Asn Ile Gly Ser Ala

20 25 30

Ser Thr Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1712

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1712

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Pro Ser Asn Ile Gly Ser Ala

20 25 30

Ser Thr Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1713

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1713

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Pro Ser Asn Ile Gly Ser Ala

20 25 30

Ser Thr Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1714

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1714

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Pro Ser Asn Ile Gly Ser Ala

20 25 30

Ser Thr Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1715

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1715

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ala Ser Ser Asn Ile Gly His Ser

20 25 30

Ser Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Arg Asn Asn Gln Gln Pro Leu Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ala Leu

85 90 95

Ser Ile Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1716

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1716

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Thr Gln Arg Ala Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ala Leu

85 90 95

Asn Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1717

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1717

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Arg Asn Asn Gln Gln Pro Leu Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Trp Asp Asp Ser Ser

85 90 95

Leu Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1718

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1718

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Thr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Ala Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Thr Trp Asp Asn Ser Leu

85 90 95

Ser Ile Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1719

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1719

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Lys Ser Asn Ile Gly Ser Ser

20 25 30

Tyr Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asp Asn Gln Arg Ala Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ala Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1720

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1720

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1721

<211> 329

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1721

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys

1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr

20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser

35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser

50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr

65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys

85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys

100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro

115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys

130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp

145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu

165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu

180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn

195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly

210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu

225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr

245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn

260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe

275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn

290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr

305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly

325

<210> 1722

<211> 106

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1722

Gly Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser

1 5 10 15

Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp

20 25 30

Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro

35 40 45

Val Lys Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn

50 55 60

Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys

65 70 75 80

Ser His Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val

85 90 95

Glu Lys Thr Val Ala Pro Ala Glu Cys Ser

100 105

<210> 1723

<211> 469

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1723

Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Ser Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His

100 105 110

Asp Thr Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Lys Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys

130 135 140

Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly

145 150 155 160

Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro

165 170 175

Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr

180 185 190

Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val

195 200 205

Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn

210 215 220

Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro

225 230 235 240

Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu

245 250 255

Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp

260 265 270

Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp

275 280 285

Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly

290 295 300

Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn

305 310 315 320

Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp

325 330 335

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro

340 345 350

Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu

355 360 365

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn

370 375 380

Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile

385 390 395 400

Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr

405 410 415

Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys

420 425 430

Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys

435 440 445

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu

450 455 460

Ser Leu Ser Pro Gly

465

<210> 1724

<211> 216

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1724

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Gln

100 105 110

Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu

115 120 125

Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Val Ser Asp Phe Tyr

130 135 140

Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Gly Ser Pro Val Lys

145 150 155 160

Val Gly Val Glu Thr Thr Lys Pro Ser Lys Gln Ser Asn Asn Lys Tyr

165 170 175

Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His

180 185 190

Arg Ser Tyr Ser Cys Arg Val Thr His Glu Gly Ser Thr Val Glu Lys

195 200 205

Thr Val Ala Pro Ala Glu Cys Ser

210 215

<210> 1725

<211> 140

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1725

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly

1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Lys Ala

20 25 30

Trp Met Thr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val

35 40 45

Gly Arg Ile Lys Ser Thr Ser Asp Gly Gly Ile Thr Asp Tyr Ala Ala

50 55 60

Pro Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr

65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Lys Thr Glu Asp Thr Ala Val Tyr

85 90 95

Tyr Cys Thr Thr Ser Phe Cys Cys Arg Gly Gly Arg Cys Pro Ser Arg

100 105 110

Asp Thr Ser Phe Cys Gly Gly Gln Tyr Asn Ser Tyr Tyr Tyr Met Asp

115 120 125

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser

130 135 140

<210> 1726

<211> 110

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1726

Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln

1 5 10 15

Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser

20 25 30

Ser Val Ser Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu

35 40 45

Ile Tyr Lys Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser

50 55 60

Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg

65 70 75 80

Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Thr Trp Asp Asp Ser Leu

85 90 95

Ser Val Arg Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu

100 105 110

<210> 1727

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1727

Thr Thr Ser Phe Cys Cys Arg Gly Gly Arg Cys Pro Ser Arg Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Tyr Asn Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 1728

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (3)..(3)

<223> /replace="V"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="Y"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="A"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="A" or "M"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="T"

<220>

<221> SITE

<222> (1)..(10)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1728

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 1729

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="A"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="N" or "A" or "T"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="Q" or "S" or "D" or "H"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="E"

<220>

<221> OPTION

<222> (8)..(8)

<223> /replace="A"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="H" or "K" or "G"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="Q" or "I"

<220>

<221> OPTION

<222> (12)..(12)

<223> /replace="E"

<220>

<221> OPTION

<222> (16)..(16)

<223> /replace="S"

<220>

<221> SITE

<222> (1)..(19)

<223> /note="The variant residues shown in the sequence are not

preferable to those listed in the footnotes

for variant positions"

<400> 1729

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 1730

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (1)..(1)

<223> /replace="T"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="R"

<220>

<221> OPTION

<222> (8)..(8)

<223> /replace="S"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="G" or "K" or "N"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="Q" or "R," or "S"

<220>

<221> OPTION

<222> (14)..(14)

<223> /replace="R" or "S"

<220>

<221> OPTION

<222> (15)..(15)

<223> /replace="E"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="Y"

<220>

<221> OPTION

<222> (20)..(20)

<223> /replace="G" or "N"

<220>

<221> OPTION

<222> (21)..(21)

<223> /replace="N"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S" or "Y"

<220>

<221> OPTION

<222> (23)..(23)

<223> /replace="F" or "N" or "Y"

<220>

<221> OPTION

<222> (24)..(24)

<223> /replace="K" or "N" or "P" or "S"

<220>

<221> OPTION

<222> (25)..(25)

<223> /replace="Q" or "R" or "S"

<220>

<221> OPTION

<222> (26)..(26)

<223> /replace="Y"

<220>

<221> OPTION

<222> (28)..(28)

<223> /replace="Y"

<220>

<221> OPTION

<222> (29)..(29)

<223> /replace="V"

<220>

<221> OPTION

<222> (30)..(30)

<223> /replace="N"

<220>

<221> OPTION

<222> (31)..(31)

<223> /replace="P" or "V"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

preferable to those listed in the footnotes

for variant positions"

<400> 1730

Ile Ser Ser Phe Cys Cys His Gly Ala Asn Cys Pro Ser His Asp Thr

1 5 10 15

Ser Phe Cys Ala Gly Gln Asp Ala Asp Phe Tyr Phe Met Asp Ile

20 25 30

<210> 1731

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (3)..(3)

<223> /replace="A"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="P" or "K"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="T"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="D"

<220>

<221> OPTION

<222> (11)..(11)

<223> /replace="Y" or "T"

<220>

<221> OPTION

<222> (13)..(13)

<223> /replace="Y" or "T"

<220>

<221> SITE

<222> (1)..(13)

<223> /note="The variant residues shown in the sequence are not

preferable to those listed in the footnotes

for variant positions"

<400> 1731

Ser Gly Ser Ser Ser Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 1732

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (1)..(1)

<223> /replace="M"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="D"

<220>

<221> OPTION

<222> (3)..(3)

<223> /replace="N" or "T"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="Q" or "A"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="A"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="S" or "Y" or "L"

<220>

<221> SITE

<222> (1)..(7)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1732

Lys Asn Ser Leu Arg Pro Gln

15

<210> 1733

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (1)..(1)

<223> /replace="S"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="N"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="D" or "N"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="A" or "Q"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="N"

<220>

<221> OPTION

<222> (8)..(8)

<223> /replace="S" or "T"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="V"

<220>

<221> OPTION

<222> (11)..(11)

<223> /replace="V"

<220>

<221> SITE

<222> (1)..(11)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1733

Ala Ser Trp Asp Glu Ser Leu Asn Ile Arg Ile

1 5 10

<210> 1734

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="Y"

<220>

<221> OPTION

<222> (3)..(3)

<223> /replace="T" or "V"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="F" or "Y"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="S"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="H" or "K" or "M" or "N" or "R"

<220>

<221> OPTION

<222> (8)..(8)

<223> /replace="Y"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="M" or "Y"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="T"

<220>

<221> SITE

<222> (1)..(10)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1734

Gly Phe Asp Ala Ala Ala Ala Trp Phe Ser

1 5 10

<210> 1735

<211> 15

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (1)..(1)

<223> /replace="R"

<220>

<221> OPTION

<222> (3)..(3)

<223> /replace="Q"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="S"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="N" or "T" or "V"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="H" or "Q" or "S" or "T"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="E" or "N"

<220>

<221> OPTION

<222> (8)..(8)

<223> /replace="G"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="G" or "H" or "K" or "Q"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="I" or "Q" or "T"

<220>

<221> OPTION

<222> (12)..(12)

<223> /replace="E"

<220>

<221> OPTION

<222> (13)..(13)

<223> /replace="S"

<220>

<221> OPTION

<222> (14)..(14)

<223> /replace="S"

<220>

<221> OPTION

<222> (15)..(15)

<223> /replace="Q"

<220>

<221> SITE

<222> (1)..(15)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1735

Phe Ile Lys Ala Ala Asp Asp Ala Glu Ala Thr Asp Ala Pro Lys

1 5 10 15

<210> 1736

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (1)..(1)

<223> /replace="T"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (3)..(3)

<223> /replace="P" or "S" or "T"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="Y"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="C" or "S"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="L" or "Q" or "R"

<220>

<221> OPTION

<222> (8)..(8)

<223> /replace="S"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="G" or "K" or "N"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="N" or "Q" or "R" or "S"

<220>

<221> OPTION

<222> (12)..(12)

<223> /replace="L" or "P"

<220>

<221> OPTION

<222> (13)..(13)

<223> /replace="N" or "S"

<220>

<221> OPTION

<222> (14)..(14)

<223> /replace="Q" or "R" or "S"

<220>

<221> OPTION

<222> (15)..(15)

<223> /replace="E"

<220>

<221> OPTION

<222> (16)..(16)

<223> /replace="Q" or "T"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="M" or "Y"

<220>

<221> OPTION

<222> (19)..(19)

<223> /replace="S" or "V"

<220>

<221> OPTION

<222> (20)..(20)

<223> /replace="G" or "N"

<220>

<221> OPTION

<222> (21)..(21)

<223> /replace="G" or "N"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S" or "Y"

<220>

<221> OPTION

<222> (23)..(23)

<223> /replace="F" or "N" or "S" or "Y"

<220>

<221> OPTION

<222> (24)..(24)

<223> /replace="K" or "N" or "P" or "Q" or "S"

<220>

<221> OPTION

<222> (25)..(25)

<223> /replace="K" or "Q" or "R" or "S"

<220>

<221> OPTION

<222> (26)..(26)

<223> /replace="Y"

<220>

<221> OPTION

<222> (27)..(27)

<223> /replace="Y"

<220>

<221> OPTION

<222> (28)..(28)

<223> /replace="L" or "W" or "Y"

<220>

<221> OPTION

<222> (29)..(29)

<223> /replace="M" or "V"

<220>

<221> OPTION

<222> (30)..(30)

<223> /replace="N"

<220>

<221> OPTION

<222> (31)..(31)

<223> /replace="P" or "V"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1736

Ile Ser Ala Phe Ala Cys His Gly Ala Ala Cys Ala Ala His Asp Asn

1 5 10 15

Ser Phe Cys Ala Ala Gln Asp Ala Asp Phe Phe Phe Phe Asp Ile

20 25 30

<210> 1737

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (1)..(1)

<223> /replace="S" or "T"

<220>

<221> OPTION

<222> (3)..(3)

<223> /replace="S"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="K" or "P" or "S"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="T"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="N"

<220>

<221> OPTION

<222> (8)..(8)

<223> /replace="Q"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="S"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="H" or "N" or "S" or "T"

<220>

<221> OPTION

<222> (11)..(11)

<223> /replace="D" or "S" or "T" or "Y"

<220>

<221> OPTION

<222> (12)..(12)

<223> /replace="V"

<220>

<221> OPTION

<222> (13)..(13)

<223> /replace="L" or "S" or "T" or "Y"

<220>

<221> SITE

<222> (1)..(13)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1737

His Gly Ala Glu Ser Asp Ile Gly His Ala Ala Thr Ala

1 5 10

<210> 1738

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (1)..(1)

<223> /replace="H" or "K" or "M" or "N" or "R"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="N"

<220>

<221> OPTION

<222> (3)..(3)

<223> /replace="S" or "T"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="L" or "Q" or "Y"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="R"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="P"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="Q" or "S" or "Y"

<220>

<221> SITE

<222> (1)..(7)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1738

Ala Asp Asn Ala Gln Ala Leu

15

<210> 1739

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (1)..(1)

<223> /replace="S"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (3)..(3)

<223> /replace="W"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="N"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="E" or "N"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="D" or "Q" or "S"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="N" or "S"

<220>

<221> OPTION

<222> (8)..(8)

<223> /replace="N" or "S" or "T"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="V"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="K" or "Q" or "R" or "W"

<220>

<221> OPTION

<222> (11)..(11)

<223> /replace="V"

<220>

<221> SITE

<222> (1)..(11)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1739

Ala Ser Phe Asp Asp Ala Leu Leu Ile His Ile

1 5 10

<210> 1740

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<400> 1740

Thr Ser Ser Phe Cys Cys Arg Gly Gly Arg Cys Pro Ser Arg Asp Thr

1 5 10 15

Ser Phe Cys Gly Gly Gln Tyr Asn Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 1741

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1741

Ser Gly Ser Ser Asp Asn Ile Gly Ser Ser Ser Val Ser

1 5 10

<210> 1742

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="Y"

<220>

<221> OPTION

<222> (3)..(3)

<223> /replace="T" or "V"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="F" or "Y"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="S"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="H" or "K" or "M" or "N"

<220>

<221> OPTION

<222> (8)..(8)

<223> /replace="Y"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="M"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="T"

<220>

<221> SITE

<222> (1)..(10)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1742

Gly Phe Asp Ala Ala Ala Ala Trp Phe Ser

1 5 10

<210> 1743

<211> 14

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="S"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="N" or "T" or "V"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="H" or "Q" or "S" or "T"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="N"

<220>

<221> OPTION

<222> (8)..(8)

<223> /replace="G"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="G" or "H" or "K" or "Q"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="I" or "Q" or "T"

<220>

<221> OPTION

<222> (11)..(11)

<223> /replace="E"

<220>

<221> OPTION

<222> (12)..(12)

<223> /replace="S"

<220>

<221> OPTION

<222> (13)..(13)

<223> /replace="S"

<220>

<221> OPTION

<222> (14)..(14)

<223> /replace="Q"

<220>

<221> SITE

<222> (1)..(14)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1743

Arg Ile Lys Ala Ala Asp Asp Ala Glu Ala Asp Ala Pro Lys

1 5 10

<210> 1744

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (1)..(1)

<223> /replace="T"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (3)..(3)

<223> /replace="P" or "S"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="Y"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="L" or "Q" or "R"

<220>

<221> OPTION

<222> (8)..(8)

<223> /replace="S"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="G" or "K" or "N"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="N" or "Q" or "R" or "S"

<220>

<221> OPTION

<222> (12)..(12)

<223> /replace="L" or "P"

<220>

<221> OPTION

<222> (13)..(13)

<223> /replace="S"

<220>

<221> OPTION

<222> (14)..(14)

<223> /replace="Q" or "R" or "S"

<220>

<221> OPTION

<222> (15)..(15)

<223> /replace="E"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="Y"

<220>

<221> OPTION

<222> (20)..(20)

<223> /replace="G" or "N"

<220>

<221> OPTION

<222> (21)..(21)

<223> /replace="N"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S" or "Y"

<220>

<221> OPTION

<222> (23)..(23)

<223> /replace="F" or "N" or "Y"

<220>

<221> OPTION

<222> (24)..(24)

<223> /replace="K" or "N" or "P" or "Q"

<220>

<221> OPTION

<222> (25)..(25)

<223> /replace="Q" or "R" or "S"

<220>

<221> OPTION

<222> (26)..(26)

<223> /replace="Y"

<220>

<221> OPTION

<222> (28)..(28)

<223> /replace="L" or "W" or "Y"

<220>

<221> OPTION

<222> (29)..(29)

<223> /replace="M" or "V"

<220>

<221> OPTION

<222> (30)..(30)

<223> /replace="N"

<220>

<221> OPTION

<222> (31)..(31)

<223> /replace="P" or "V"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1744

Ile Ser Ala Phe Cys Cys His Gly Ala Ala Cys Ala Asn His Asp Thr

1 5 10 15

Ser Phe Cys Ala Gly Gln Asp Ala Asp Phe Tyr Phe Phe Asp Ile

20 25 30

<210> 1745

<211> 13

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (1)..(1)

<223> /replace="T"

<220>

<221> OPTION

<222> (3)..(3)

<223> /replace="S"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="P" or "S"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="T"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="N"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="S"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="N" or "S" or "T"

<220>

<221> OPTION

<222> (11)..(11)

<223> /replace="S" or "T" or "Y"

<220>

<221> OPTION

<222> (12)..(12)

<223> /replace="V"

<220>

<221> OPTION

<222> (13)..(13)

<223> /replace="S" or "T" or "Y"

<220>

<221> SITE

<222> (1)..(13)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1745

Ser Gly Ala Lys Ser Asp Ile Gly His Ala Ala Thr Ala

1 5 10

<210> 1746

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (1)..(1)

<223> /replace="S"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (4)..(4)

<223> /replace="N"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="E" or "N"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="D" or "Q" or "S"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="N" or "S"

<220>

<221> OPTION

<222> (8)..(8)

<223> /replace="N" or "S" or "T"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="V"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="K" or "Q" or "R"

<220>

<221> OPTION

<222> (11)..(11)

<223> /replace="V"

<220>

<221> SITE

<222> (1)..(11)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1746

Ala Ser Trp Asp Asp Ala Leu Leu Ile His Ile

1 5 10

<210> 1747

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="S"

<220>

<221> OPTION

<222> (14)..(14)

<223> /replace="R"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="F"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S"

<220>

<221> OPTION

<222> (23)..(23)

<223> /replace="D"

<220>

<221> OPTION

<222> (24)..(24)

<223> /replace="N" or "S"

<220>

<221> OPTION

<222> (25)..(25)

<223> /replace="S"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1747

Thr Ser Ser Phe Cys Cys Arg Gly Gly Arg Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 1748

<211> 12

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="E"

<220>

<221> SITE

<222> (1)..(12)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1748

Ser Thr Trp Asp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1749

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="T"

<220>

<221> SITE

<222> (1)..(10)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1749

Gly Phe Thr Phe Ser Lys Ala Trp Met Ser

1 5 10

<210> 1750

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="T"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="S"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="E"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="G"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="T"

<220>

<221> SITE

<222> (1)..(19)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1750

Arg Ile Lys Ser Val Thr Asp Gly Glu Ile Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 1751

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="S"

<220>

<221> OPTION

<222> (14)..(14)

<223> /replace="R"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="F"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1751

Thr Ser Ser Phe Cys Cys Arg Gly Gly Arg Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 1752

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="S"

<220>

<221> OPTION

<222> (14)..(14)

<223> /replace="R"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="F"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1752

Thr Ser Ser Phe Cys Cys Arg Gly Gly Arg Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Asp Ser Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 1753

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="S"

<220>

<221> OPTION

<222> (14)..(14)

<223> /replace="R"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="F"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1753

Thr Ser Ser Phe Cys Cys Arg Gly Gly Arg Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Asn Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 1754

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="S"

<220>

<221> OPTION

<222> (14)..(14)

<223> /replace="R"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="F"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1754

Thr Ser Ser Phe Cys Cys Arg Gly Gly Arg Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Asn Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 1755

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="S"

<220>

<221> OPTION

<222> (14)..(14)

<223> /replace="R"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="F"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1755

Thr Ser Ser Phe Cys Cys Arg Gly Gly Arg Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 1756

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="E"

<220>

<221> SITE

<222> (1)..(19)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1756

Arg Ile Lys Ser Val Thr Asp Gly Glu Thr Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 1757

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="F"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S"

<220>

<221> OPTION

<222> (23)..(23)

<223> /replace="D"

<220>

<221> OPTION

<222> (24)..(24)

<223> /replace="N" or "S"

<220>

<221> OPTION

<222> (25)..(25)

<223> /replace="S"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1757

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 1758

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="F"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1758

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 1759

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="F"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1759

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Asp Ser Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 1760

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="F"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1760

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Tyr Asn Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 1761

<211> 31

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

polypeptide"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="T"

<220>

<221> OPTION

<222> (18)..(18)

<223> /replace="F"

<220>

<221> OPTION

<222> (22)..(22)

<223> /replace="S"

<220>

<221> SITE

<222> (1)..(31)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1761

Thr Ser Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr

1 5 10 15

Ser Tyr Cys Gly Gly Gln Asp Lys Arg Tyr Tyr Tyr Met Asp Val

20 25 30

<210> 1762

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="E"

<220>

<221> SITE

<222> (1)..(11)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1762

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<210> 1763

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1763

Gly Phe Thr Phe Ser Lys Ala Trp

15

<210> 1764

<211> 10

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1764

Ile Lys Ser Val Thr Asp Gly Glu Thr Thr

1 5 10

<210> 1765

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1765

Ser Ser Asn Ile Gly Ser Ser Ser

15

<210> 1766

<211> 5

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1766

Lys Ala Trp Met Ser

15

<210> 1767

<211> 29

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1767

Ser Phe Cys Cys Arg Gly Gly Ser Cys Pro Ser His Asp Thr Ser Tyr

1 5 10 15

Cys Gly Gly Gln Tyr Lys Ser Tyr Tyr Tyr Met Asp Val

20 25

<210> 1768

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1768

Gly Phe Thr Phe Ser Lys Ala

15

<210> 1769

<211> 8

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<400> 1769

Lys Ser Val Thr Asp Gly Glu Thr

15

<210> 1770

<211> 19

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="T"

<220>

<221> OPTION

<222> (6)..(6)

<223> /replace="S"

<220>

<221> OPTION

<222> (7)..(7)

<223> /replace="E"

<220>

<221> OPTION

<222> (9)..(9)

<223> /replace="G"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="T"

<220>

<221> OPTION

<222> (12)..(12)

<223> /replace="E"

<220>

<221> SITE

<222> (1)..(19)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1770

Arg Ile Lys Ser Val Thr Asp Gly Glu Ile Thr Asp Tyr Ala Ala Pro

1 5 10 15

Val Lys Gly

<210> 1771

<211> 7

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (1)..(1)

<223> /replace="R"

<220>

<221> OPTION

<222> (2)..(2)

<223> /replace="D"

<220>

<221> OPTION

<222> (3)..(3)

<223> /replace="D"

<220>

<221> SITE

<222> (1)..(7)

<223> /note="The variant residues shown in the sequence are not

are preferred over those given in the footnotes

for variant positions"

<400> 1771

Lys Asn Asn Gln Arg Pro Ser

15

<210> 1772

<211> 11

<212> Protein

<213> Artificial sequence

<220>

<221> source

<223> /note="Description of artificial sequence: Synthetic

peptide"

<220>

<221> OPTION

<222> (5)..(5)

<223> /replace="E"

<220>

<221> OPTION

<222> (10)..(10)

<223> /replace="W"

<220>

<221> SITE

<222> (1)..(11)

<223> /note="Variant residues given in the sequence

are not preferred over those given in the footnotes

for variant positions"

<400> 1772

Ser Thr Trp Asp Asp Ser Leu Ser Val Arg Val

1 5 10

<---

Claims (466)

1. An antibody that binds to tumor tissue, where the antibody binds to the extracellular RNA-protein complex and, where the antibody contains: heavy chain variable region containing: HCDR1 containing the sequence GFTFSKAWMS (SEQ ID NO:1), or a variant of HCDR1 in which 1 amino acid is substituted relative to the specified sequence; HCDR2 containing the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9), or a variant of HCDR2 in which 1 amino acid is substituted relative to the specified sequence; And HCDR3 containing the sequence TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21), or a variant of HCDR3 in which 1, 2 or 3 amino acids are substituted relative to the specified sequence; light chain variable region containing: LCDR1 containing the sequence SGSSSNIGSSSVS (SEQ ID NO:48), or a variant of LCDR1 in which 1 amino acid is substituted relative to the specified sequence; LCDR2 containing the sequence KNNQRPS (SEQ ID NO:59), or a variant of LCDR2 in which 1 amino acid is substituted relative to the specified sequence; And LCDR3 containing the sequence STWDDSLSVRV (SEQ ID NO:68), or a variant of LCDR3 in which 1 amino acid is substituted relative to the specified sequence. 2. Antibody according to claim 1, where the antibody contains HCDR1 containing the sequence GFTFSKAWMS (SEQ ID NO:1), HCDR2 containing the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9), HCDR3 containing the sequence TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21), LCDR1 containing the sequence SGSSSNIGSSSVS (SEQ ID NO:48), LCDR2 containing the sequence KNNQRPS (SEQ ID NO:59), and LCDR3 containing the sequence STWDDSLSVRV (SEQ ID NO:68). 3. Antibody according to claim 2, where V _H contains an amino acid sequence that is at least 95% identical EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:94); And V _L contains an amino acid sequence that is 95% identical QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140). 4. Antibody according to claim 3, where V _H contains the sequence EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:94); And V _L contains the sequence QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140). 5. Antibody according to claim 1, where the antibody contains heavy chain constant region sequence SEQ ID NO:1721 and light chain constant region sequence SEQ ID NO:1722. 6. Antibody according to claim 5, where the heavy chain contains the sequence SEQ ID NO:1723, and the light chain contains the sequence SEQ ID NO:1724. 7. An antibody that binds to tumor tissue, where the antibody binds to an extracellular RNA-protein complex and where the antibody contains six CDRs containing the sequences HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3, respectively, as follows: SEQ ID NO: 8, 9, 34, 48, 59, 68; SEQ ID NO: 8, 9, 35, 48, 59, 68; SEQ ID NO: 8, 9, 37, 48, 59, 68; SEQ ID NO: 8, 16, 38, 48, 59, 68; SEQ ID NO: 8, 9, 34, 48, 59, 68; SEQ ID NO: 8, 9, 37, 48, 59, 68; SEQ ID NO: 8, 9, 39, 48, 59, 68; SEQ ID NO: 8, 9, 21, 48, 59, 68; SEQ ID NO: 8, 9, 37, 48, 59, 73; SEQ ID NO: 1, 9, 37, 48, 59, 68; SEQ ID NO: 8, 9, 41, 48, 59, 68; SEQ ID NO: 172, 366, 560, 754, 948, 1142; SEQ ID NO: 173, 367, 561, 755, 949, 1143; SEQ ID NO: 174, 368, 562, 756, 950, 1144; SEQ ID NO: 175, 369, 563, 757, 951, 1145; SEQ ID NO: 176, 370, 564, 758, 952, 1146; SEQ ID NO: 177, 371, 565, 759, 953, 1147; SEQ ID NO: 178, 372, 566, 760, 954, 1148; SEQ ID NO: 180, 374, 568, 762, 956, 1150; SEQ ID NO: 181, 375, 569, 763, 957, 1151; SEQ ID NO: 182, 376, 570, 764, 958, 1152; SEQ ID NO: 184, 378, 572, 766, 960, 1154; SEQ ID NO: 185, 379, 573, 767, 961, 1155; SEQ ID NO: 187, 381, 575, 769, 963, 1157; SEQ ID NO: 188, 382, 576, 770, 964, 1158; SEQ ID NO: 189, 383, 577, 771, 965, 1159; SEQ ID NO: 190, 384, 578, 772, 966, 1160; SEQ ID NO: 191, 385, 579, 773, 967, 1161; SEQ ID NO: 192, 386, 580, 774, 968, 1162; SEQ ID NO: 193, 387, 581, 775, 969, 1163; SEQ ID NO: 194, 388, 582, 776, 970, 1164; SEQ ID NO: 195, 389, 583, 777, 971, 1165; SEQ ID NO: 196, 390, 584, 778, 972, 1166; SEQ ID NO: 197, 391, 585, 779, 973, 1167 SEQ ID NO: 198, 392, 586, 780, 974, 1168; SEQ ID NO: 199, 393, 587, 781, 975, 1169; SEQ ID NO: 200, 394, 588, 782, 976, 1170; SEQ ID NO: 201, 395, 589, 783, 977, 1171; SEQ ID NO: 202, 396, 590, 784, 978, 1172; SEQ ID NO: 203, 397, 591, 785, 979, 1173; SEQ ID NO: 204, 398, 592, 786, 980, 1174; SEQ ID NO: 205, 399, 593, 787, 981, 1175; SEQ ID NO: 206, 400, 594, 788, 982, 1176; SEQ ID NO: 207, 401, 595, 789, 983, 1177; SEQ ID NO: 208, 402, 596, 790, 984, 1178; SEQ ID NO: 209, 403, 597, 791, 985, 1179; SEQ ID NO: 210, 404, 598, 792, 986, 1180 SEQ ID NO: 211, 405, 599, 793, 987, 1181; SEQ ID NO: 212, 406, 600, 794, 988, 1182; SEQ ID NO: 213, 407, 601, 795, 989, 1183; SEQ ID NO: 214. 408, 602, 796, 990, 1184; SEQ ID NO: 215, 409, 603, 797, 991, 1185; SEQ ID NO: 216, 410, 604, 798, 992, 1186; SEQ ID NO: 217, 411, 605, 799, 993, 1187; SEQ ID NO: 219, 413, 607, 801, 995, 1189; SEQ ID NO: 220, 414, 608, 802, 996, 1190; SEQ ID NO: 221, 415, 609, 803, 997, 1191; SEQ ID NO: 226, 420, 614, 808, 1002, 1196; SEQ ID NO: 230, 424, 618, 812, 1006, 1200; SEQ ID NO: 232, 426, 620, 814, 1008, 1202; SEQ ID NO: 233, 427, 621, 815, 1009, 1203; SEQ ID NO: 234, 428, 622, 816, 1010, 1204; SEQ ID NO: 236, 430, 624, 818, 1012, 1206; SEQ ID NO: 1, 9, 43, 48, 59, 68; SEQ ID NO: 238, 432, 626, 820, 1014, 1208; SEQ ID NO: 239, 433, 627, 821, 1015, 1209; SEQ ID NO: 240, 434, 628, 822, 1016, 1210; SEQ ID NO: 241, 435, 629, 823, 1017, 1211; SEQ ID NO: 242, 436, 630, 824, 1018, 1212; SEQ ID NO: 243, 437, 631, 825, 1019, 1213; SEQ ID NO: 1, 9, 44, 48, 59, 68; SEQ ID NO: 1, 9, 45, 48, 59, 68; SEQ ID NO: 251, 445, 639, 833, 1027, 1221; SEQ ID NO: 1, 9, 20, 48, 59, 68; SEQ ID NO: 253, 447, 641, 835, 1029, 1223; SEQ ID NO: 1, 9, 46, 48, 59, 68; SEQ ID NO: 1, 9, 47, 48, 59, 68; SEQ ID NO: 255, 449, 643, 837, 1031, 1225; SEQ ID NO: 1, 18, 21, 48, 65, 75; SEQ ID NO: 256, 450, 644, 838, 1032, 1226; SEQ ID NO: 8, 9, 21, 58, 59, 72; SEQ ID NO: 257, 451, 645, 839, 1033, 1227; SEQ ID NO: 1, 19, 21, 48, 59, 68; SEQ ID NO: 1, 9, 27, 48, 59, 68; SEQ ID NO: 258, 452, 646, 840, 1034, 1228; SEQ ID NO: 259, 453, 647, 841, 1035, 1229; SEQ ID NO: 260, 454, 648, 842, 1036, 1230; SEQ ID NO: 261, 455, 649, 843, 1037, 1231; SEQ ID NO: 262, 456, 650, 844, 1038, 1232; SEQ ID NO: 263, 457, 651, 845, 1039, 1233; SEQ ID NO: 265, 459, 653, 847, 1041, 1235; SEQ ID NO: 266, 460, 654, 848, 1042, 1236; SEQ ID NO: 267, 461, 655, 849, 1043, 1237; SEQ ID NO: 268, 462, 656, 850, 1044, 1238; SEQ ID NO: 269, 463, 657, 851, 1045, 1239; SEQ ID NO: 270, 464, 658, 852, 1046, 1240; SEQ ID NO: 271, 465, 659, 853, 1047, 1241; SEQ ID NO: 272, 466, 660, 854, 1048, 1241; SEQ ID NO: 273, 467, 661, 855, 1049, 1243; SEQ ID NO: 274, 468, 662, 856, 1050, 1244; SEQ ID NO: 1, 9, 21, 56, 59, 68; SEQ ID NO: 275; 469, 663, 857, 1051, 1245; SEQ ID NO: 276, 470, 664, 858, 1052, 1246; SEQ ID NO: 277, 471, 665, 859, 1053, 1247; SEQ ID NO: 278, 472, 666, 860, 1054, 1248; SEQ ID NO: 279, 473, 667, 861, 1055, 1249; SEQ ID NO: 280, 474, 668, 862, 1056, 1250; SEQ ID NO: 281, 475, 669, 863, 1057, 1251; SEQ ID NO: 282, 476, 670, 864, 1058, 1252; SEQ ID NO: 283, 477, 671, 865, 1059, 1253; SEQ ID NO: 284, 478, 672, 866, 1060, 1254; SEQ ID NO: 285, 479, 673, 867, 1061, 1255; SEQ ID NO: 286, 480, 674, 868, 1062, 1256; SEQ ID NO: 287, 481, 675, 869, 1063, 1257; SEQ ID NO: 288, 482, 676, 870, 1064, 1258; SEQ ID NO: 289, 483, 677, 871, 1065, 1259; SEQ ID NO: 290, 484, 678, 872, 1066, 1260; SEQ ID NO: 292, 486, 680, 874, 1068, 1262; SEQ ID NO: 293, 487, 681, 875, 1069, 1263; SEQ ID NO: 294, 488, 682, 876, 1070, 1264; SEQ ID NO: 295, 489, 683, 877, 1071, 1265; SEQ ID NO: 296, 490, 684, 878, 1072, 1266; SEQ ID NO: 297, 491, 685, 879, 1073, 1267; SEQ ID NO: 298, 492, 686, 880, 1074, 1268; SEQ ID NO: 299, 493, 687, 881, 1075, 1269; SEQ ID NO: 300, 494, 688, 882, 1076, 1270; SEQ ID NO: 301, 495, 689, 883, 1077, 1271; SEQ ID NO: 302, 496, 690, 884, 1078, 1272; SEQ ID NO: 304, 498, 692, 886, 1080, 1274; SEQ ID NO: 305, 499, 693, 887, 1081, 1275; SEQ ID NO: 306, 500, 694, 888, 1082, 1276 SEQ ID NO: 1, 9, 21, 57, 59, 74; SEQ ID NO: 307, 501, 695, 889, 1083, 1277; SEQ ID NO: 1, 9, 21, 48, 67, 68; SEQ ID NO: 310, 504, 698, 892, 1086, 1280; SEQ ID NO: 311, 505, 699, 893, 1087, 1281; SEQ ID NO: 1, 504, 21, 48, 59, 68; SEQ ID NO: 1, 9, 22, 48, 59, 68; SEQ ID NO: 1, 9, 23, 48, 59, 68; SEQ ID NO: 322, 516, 710, 904, 1098, 1292; SEQ ID NO: 1, 9, 24, 48, 59, 68; SEQ ID NO: 1, 9, 25, 48, 59, 68; SEQ ID NO: 324, 518, 712, 906, 1100, 1294; SEQ ID NO: 331, 525, 719, 913, 1107, 1301; SEQ ID NO: 1, 9, 26, 48, 59, 68; SEQ ID NO: 338, 532, 726, 920, 1114, 1308; SEQ ID NO: 355, 549, 743, 937, 1131, 1325; SEQ ID NO: 2, 10, 21, 49, 60, 68; SEQ ID NO: 357, 551, 745, 939, 1133, 1327; SEQ ID NO: 358, 552, 746, 940, 1134, 1328; SEQ ID NO: 3, 11, 21, 50, 61, 69; SEQ ID NO: 4, 9, 27, 51, 62, 70; SEQ ID NO: 5, 12, 28, 52, 63, 71; SEQ ID NO: 6, 13, 21, 53, 64, 76; SEQ ID NO: 7, 14, 29, 52, 65, 69; SEQ ID NO: 4, 15, 30, 54, 62, 71; SEQ ID NO: 1, 12, 31, 55, 66, 72; SEQ ID NO: 1, 9, 32, 56, 59, 72; SEQ ID NO: 1, 12, 33, 50, 66, 68; or SEQ ID NO: 362, 556, 750, 944, 1138, 1332; or a variant thereof, wherein at least one, two, three, four, five or all six CDR sequences contain 1 or 2 amino acid substitutions. 8. The antibody according to claim 7, where the antibody contains the sequences HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3: SEQ ID NO: 8, 9, 34, 48, 59, 68; SEQ ID NO: 8, 9, 35, 48, 59, 68; SEQ ID NO: 8, 9, 37, 48, 59, 68; SEQ ID NO: 8, 16, 38, 48, 59, 68; SEQ ID NO: 8, 9, 34, 48, 59, 68; SEQ ID NO: 8, 9, 37, 48, 59, 68; SEQ ID NO: 8, 9, 39, 48, 59, 68; SEQ ID NO: 8, 9, 21, 48, 59, 68; SEQ ID NO: 8, 9, 37, 48, 59, 73; SEQ ID NO: 1, 9, 37, 48, 59, 68; SEQ ID NO: 8, 9, 41, 48, 59, 68; SEQ ID NO: 172, 366, 560, 754, 948, 1142; SEQ ID NO: 173, 367, 561, 755, 949, 1143; SEQ ID NO: 174, 368, 562, 756, 950, 1144; SEQ ID NO: 175, 369, 563, 757, 951, 1145; SEQ ID NO: 176, 370, 564, 758, 952, 1146; SEQ ID NO: 177, 371, 565, 759, 953, 1147; SEQ ID NO: 178, 372, 566, 760, 954, 1148; SEQ ID NO: 180, 374, 568, 762, 956, 1150; SEQ ID NO: 181, 375, 569, 763, 957, 1151; SEQ ID NO: 182, 376, 570, 764, 958, 1152 SEQ ID NO: 184, 378, 572, 766, 960, 1154; SEQ ID NO: 185, 379, 573, 767, 961, 1155; SEQ ID NO: 187, 381, 575, 769, 963, 1157; SEQ ID NO: 188, 382, 576, 770, 964, 1158; SEQ ID NO: 189, 383, 577, 771, 965, 1159; SEQ ID NO: 190, 384, 578, 772, 966, 1160; SEQ ID NO: 191, 385, 579, 773, 967, 1161; SEQ ID NO: 192, 386, 580, 774, 968, 1162; SEQ ID NO: 193, 387, 581, 775, 969, 1163; SEQ ID NO: 194, 388, 582, 776, 970, 1164; SEQ ID NO: 195, 389, 583, 777, 971, 1165; SEQ ID NO: 196, 390, 584, 778, 972, 1166; SEQ ID NO: 197, 391, 585, 779, 973, 1167; SEQ ID NO: 198, 392, 586, 780, 974, 1168; SEQ ID NO: 199, 393, 587, 781, 975, 1169; SEQ ID NO: 200, 394, 588, 782, 976, 1170; SEQ ID NO: 201, 395, 589, 783, 977, 1171; SEQ ID NO: 202, 396, 590, 784, 978, 1172; SEQ ID NO: 203, 397, 591, 785, 979, 1173; SEQ ID NO: 204, 398, 592, 786, 980, 1174; SEQ ID NO: 205, 399, 593, 787, 981, 1175; SEQ ID NO: 206, 400, 594, 788, 982, 1176; SEQ ID NO: 207, 401, 595, 789, 983, 1177; SEQ ID NO: 208, 402, 596, 790, 984, 1178; SEQ ID NO: 209, 403, 597, 791, 985, 1179; SEQ ID NO: 210, 404, 598, 792, 986, 1180 SEQ ID NO: 211, 405, 599, 793, 987, 1181; SEQ ID NO: 212, 406, 600, 794, 988, 1182; SEQ ID NO: 213, 407, 601, 795, 989, 1183; SEQ ID NO: 214. 408, 602, 796, 990, 1184; SEQ ID NO: 215, 409, 603, 797, 991, 1185; SEQ ID NO: 216, 410, 604, 798, 992, 1186; SEQ ID NO: 217, 411, 605, 799, 993, 1187; SEQ ID NO: 219, 413, 607, 801, 995, 1189; SEQ ID NO: 220, 414, 608, 802, 996, 1190; SEQ ID NO: 221, 415, 609, 803, 997, 1191; SEQ ID NO: 226, 420, 614, 808, 1002, 1196; SEQ ID NO: 230, 424, 618, 812, 1006, 1200; SEQ ID NO: 232, 426, 620, 814, 1008, 1202; SEQ ID NO: 233, 427, 621, 815, 1009, 1203; SEQ ID NO: 234, 428, 622, 816, 1010, 1204; SEQ ID NO: 236, 430, 624, 818, 1012, 1206; SEQ ID NO: 1, 9, 43, 48, 59, 68; SEQ ID NO: 238, 432, 626, 820, 1014, 1208; SEQ ID NO: 239, 433, 627, 821, 1015, 1209; SEQ ID NO: 240, 434, 628, 822, 1016, 1210; SEQ ID NO: 241, 435, 629, 823, 1017, 1211; SEQ ID NO: 242, 436, 630, 824, 1018, 1212; SEQ ID NO: 243, 437, 631, 825, 1019, 1213; SEQ ID NO: 1, 9, 44, 48, 59, 68; SEQ ID NO: 1, 9, 45, 48, 59, 68; SEQ ID NO: 251, 445, 639, 833, 1027, 1221; SEQ ID NO: 1, 9, 20, 48, 59, 68; SEQ ID NO: 253, 447, 641, 835, 1029, 1223; SEQ ID NO: 1, 9, 46, 48, 59, 68; SEQ ID NO: 1, 9, 47, 48, 59, 68; SEQ ID NO: 255, 449, 643, 837, 1031, 1225; SEQ ID NO: 1, 18, 21, 48, 65, 75; SEQ ID NO: 256, 450, 644, 838, 1032, 1226; SEQ ID NO: 8, 9, 21, 58, 59, 72; SEQ ID NO: 257, 451, 645, 839, 1033, 1227; SEQ ID NO: 1, 19, 21, 48, 59, 68; SEQ ID NO: 1, 9, 27, 48, 59, 68; SEQ ID NO: 258, 452, 646, 840, 1034, 1228; SEQ ID NO: 259, 453, 647, 841, 1035, 1229; SEQ ID NO: 260, 454, 648, 842, 1036, 1230; SEQ ID NO: 261, 455, 649, 843, 1037, 1231; SEQ ID NO: 262, 456, 650, 844, 1038, 1232; SEQ ID NO: 263, 457, 651, 845, 1039, 1233; SEQ ID NO: 265, 459, 653, 847, 1041, 1235; SEQ ID NO: 266, 460, 654, 848, 1042, 1236; SEQ ID NO: 267, 461, 655, 849, 1043, 1237; SEQ ID NO: 268, 462, 656, 850, 1044, 1238; SEQ ID NO: 269, 463, 657, 851, 1045, 1239; SEQ ID NO: 270, 464, 658, 852, 1046, 1240; SEQ ID NO: 271, 465, 659, 853, 1047, 1241; SEQ ID NO: 272, 466, 660, 854, 1048, 1241; SEQ ID NO: 273, 467, 661, 855, 1049, 1243; SEQ ID NO: 274, 468, 662, 856, 1050, 1244; SEQ ID NO: 1, 9, 21, 56, 59, 68; SEQ ID NO: 275; 469, 663, 857, 1051, 1245; SEQ ID NO: 276, 470, 664, 858, 1052, 1246; SEQ ID NO: 277, 471, 665, 859, 1053, 1247; SEQ ID NO: 278, 472, 666, 860, 1054, 1248; SEQ ID NO: 279, 473, 667, 861, 1055, 1249; SEQ ID NO: 280, 474, 668, 862, 1056, 1250; SEQ ID NO: 281, 475, 669, 863, 1057, 1251; SEQ ID NO: 282, 476, 670, 864, 1058, 1252; SEQ ID NO: 283, 477, 671, 865, 1059, 1253; SEQ ID NO: 284, 478, 672, 866, 1060, 1254; SEQ ID NO: 285, 479, 673, 867, 1061, 1255; SEQ ID NO: 286, 480, 674, 868, 1062, 1256; SEQ ID NO: 287, 481, 675, 869, 1063, 1257; SEQ ID NO: 288, 482, 676, 870, 1064, 1258; SEQ ID NO: 289, 483, 677, 871, 1065, 1259; SEQ ID NO: 290, 484, 678, 872, 1066, 1260; SEQ ID NO: 292, 486, 680, 874, 1068, 1262; SEQ ID NO: 293, 487, 681, 875, 1069, 1263; SEQ ID NO: 294, 488, 682, 876, 1070, 1264; SEQ ID NO: 295, 489, 683, 877, 1071, 1265; SEQ ID NO: 296, 490, 684, 878, 1072, 1266; SEQ ID NO: 297, 491, 685, 879, 1073, 1267; SEQ ID NO: 298, 492, 686, 880, 1074, 1268; SEQ ID NO: 299, 493, 687, 881, 1075, 1269; SEQ ID NO: 300, 494, 688, 882, 1076, 1270; SEQ ID NO: 301, 495, 689, 883, 1077, 1271; SEQ ID NO: 302, 496, 690, 884, 1078, 1272; SEQ ID NO: 304, 498, 692, 886, 1080, 1274; SEQ ID NO: 305, 499, 693, 887, 1081, 1275; SEQ ID NO: 306, 500, 694, 888, 1082, 1276 SEQ ID NO: 1, 9, 21, 57, 59, 74; SEQ ID NO: 307, 501, 695, 889, 1083, 1277; SEQ ID NO: 1, 9, 21, 48, 67, 68; SEQ ID NO: 310, 504, 698, 892, 1086, 1280; SEQ ID NO: 311, 505, 699, 893, 1087, 1281; SEQ ID NO: 1, 504, 21, 48, 59, 68; SEQ ID NO: 1, 9, 22, 48, 59, 68; SEQ ID NO: 1, 9, 23, 48, 59, 68; SEQ ID NO: 322, 516, 710, 904, 1098, 1292; SEQ ID NO: 1, 9, 24, 48, 59, 68; SEQ ID NO: 1, 9, 25, 48, 59, 68; SEQ ID NO: 324, 518, 712, 906, 1100, 1294; SEQ ID NO: 331, 525, 719, 913, 1107, 1301; SEQ ID NO: 1, 9, 26, 48, 59, 68; SEQ ID NO: 338, 532, 726, 920, 1114, 1308; SEQ ID NO: 355, 549, 743, 937, 1131, 1325; SEQ ID NO: 2, 10, 21, 49, 60, 68; SEQ ID NO: 357, 551, 745, 939, 1133, 1327; SEQ ID NO: 358, 552, 746, 940, 1134, 1328; SEQ ID NO: 3, 11, 21, 50, 61, 69; SEQ ID NO: 4, 9, 27, 51, 62, 70; SEQ ID NO: 5, 12, 28, 52, 63, 71; SEQ ID NO: 6, 13, 21, 53, 64, 76; SEQ ID NO: 7, 14, 29, 52, 65, 69; SEQ ID NO: 4, 15, 30, 54, 62, 71; SEQ ID NO: 1, 12, 31, 55, 66, 72; SEQ ID NO: 1, 9, 32, 56, 59, 72; SEQ ID NO: 1, 12, 33, 50, 66, 68; or SEQ ID NO: 362, 556, 750, 944, 1138, 1332. 9. An expression vector containing a polynucleotide encoding the V _H region of the antibody according to claim 1. 10. An expression vector containing a polynucleotide encoding the V _L region of the antibody according to claim 1. 11. An expression vector containing a polynucleotide encoding the V _H region and the V _L region of the antibody according to claim 1. 12. A host cell for producing an antibody, wherein the host cell contains a polynucleotide that encodes the V _H region and a polynucleotide that encodes the V _L region of the antibody according to claim 1. 13. A method for producing an antibody, comprising culturing a host cell according to claim 12 under conditions in which a polynucleotide encoding a heavy chain and a polynucleotide encoding a light chain are expressed, thereby obtaining an antibody. 14. An antibody that binds to tumor tissue, where the antibody binds to an extracellular RNA-protein complex and where the antibody contains: (a) a heavy chain variable region containing: (i) HCDR1 with the sequence GF(T/V)(F/Y)(S/A)X ₆ AWM(S/T) (SEQ ID NO:1728), where X ₆ represents K, A, or M; (ii) HCDR2 with sequence RIK(S/A)X ₅ X ₆ (D/E)(G/A)X ₉ X ₁₀ T(D/E)YAA(P/S)VKG (SEQ ID NO:1729) , where X ₅ represents V, N, A, or T; X ₆ represents T, Q, S, D, or H; X ₉ represents E, H, K, or G; and X ₁₀ represents T, Q, or I; And (iii) HCDR3 with sequence (I/T)(S/T)SFCC(H/R)(G/S)X ₉ X ₁₀ CPSX ₁₄ (D/E)TS(F/Y)CX ₂₀ (G/N)X ₂₂ X ₂₃ X ₂₄ X ₂₅ (F/Y)Y(F/Y)(M/V)(D/N)X ₃₁ (SEQ ID NO:1730), where X ₉ represents A, G, K, or N; X ₁₀ represents N, Q, R, or S; X ₁₄ represents H, R, or S; X ₂₀ represents A, G, or N; X ₂₂ represents Q, S, or Y; X ₂₃ represents D, F, N, or Y; X ₂₄ represents A, K, N, P, or S; X ₂₅ represents D, Q, R, or S; and X ₃₁ represents I, P, or V; And (b) a light chain variable region comprising: (i) LCDR1 with sequence SG(S/A)X ₄ (S/T)(N/D)IGSSX ₁₁ VX ₁₃ (SEQ ID NO:1731), where X ₄ represents S, P, or K; X ₁₁ represents S, Y, or T; and X ₁₃ represents S, Y, or T; (ii) LCDR2 with the sequence (K/M)(N/D)X ₃ X ₄ R(P/A)X ₇ (SEQ ID NO:1732), where X ₃ represents S, N or T; X ₄ represents L, Q, or A; X ₇ represents Q, S, Y, or L; And (iii) LCDR3 with sequence (S/A)(T/S)W(D/N)X ₅ X ₆ (L/N)X ₈ (V/I)R(V/I) (SEQ ID NO:1733), where X ₅ represents E, D or N; X ₆ represents S, A, or Q; and X ₈ is N, S or T. 15. Antibody according to claim 14, where: HCDR1 has the sequence GFTFSKAWMS (SEQ ID NO:1), GFTFSAAWMS (SEQ ID NO:4), or GFTFSKAWMT (SEQ ID NO:8); HCDR2 has the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9) or RIKSTSDGETTDYAAPVKG (SEQ ID NO:15); HCDR3 has the sequence TSSFCCRGGSCPSSDTSYCGGQYKSYYFMDV (SEQ ID NO:32), TSSFCCRSGSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:20), TSSFCCRGNQCPSSDTSYCGGQYPSYYYMDP (SEQ ID NO:23), ISSFCCRGGSCPSRDTSYCGGQYKSYYFMDV (SEQ ID NO:30), ISSFCCRGNSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:27), TSSFCCRGGSCPSHDTSYCGGQYKSYYYMDV (SEQ ID NO:21), or TSSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:34); LCDR1 has the sequence SGSSSNIGSSSVY (SEQ ID NO:56), SGSSSNIGSSSVS (SEQ ID NO:48), SGSSTNIGSSSVS (SEQ ID NO:54) or SGSKSNIGSSSVS (SEQ ID NO:51); LCDR2 has the sequence KNNQRPS (SEQ ID NO:59) or KDNQRPS (SEQ ID NO:62); And LCDR3 has the sequence STWDDALSVRV (SEQ ID NO:72), STWDDSLSVRV (SEQ ID NO:68), SSWDDSNSVRI (SEQ ID NO:71) or ATWDNSLSIRV (SEQ ID NO:70). 16. Antibody according to claim 15, where The heavy chain variable region has a sequence that is at least 90% identical to any of the following: EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSSDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:92), EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRSGSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:77), EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGNQCPSSDTSYCGGQYPSYYYMDPWGKGTTVTVSS (SEQ ID NO:80), EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSSTSDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGGSCPSRDTSYCGGQYKSYYFMDVWGKGTTVTVSS (SEQ ID NO:90), EVQLVESGGALVKPGGSLRLSCAASGFTFSAAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCISSFCCRGNSCPSSDTSYCNGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:86), EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMSWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSTLYLQMNSLKTEDTAVYYCTSSFCCRGGSCPSHDTSYCGGQYKSYYYMDVWGKGTTVTVSS (SEQ ID NO:94), and EVQLVESGGALVKPGGSLRLSCAASGTFFSKAWMTWVRQAPGKGLEWVGRIKSVTDGETTDYAAPVKGRFTISRDDSKSVLYLQMSSLKTEDTAVYFCTSSFCCRGGSCPSHDTSFCGGQDKRYYYMDVWGKGTTVTVSS (SEQ ID NO:95). 17. The antibody of claim 15, wherein the light chain variable region has a sequence that is at least 90% identical to any of: QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSVYWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDALSVRVFGGGTKLTVL (SEQ ID NO:138), QSVLTQPPSASGTPGQRVTISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:140), SVLTQPPSASGTPGQRVTISCSGSSTNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSSWDDSNSVRIFGGGTKLTVL (SEQ ID NO:136), QSVLTQPPSASGTPGQRVTISCSGSKSNIGSSSVSWYQQLPGTAPKLLIYKDNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCATWDNSLSIRVFGGGTKLTVL (SEQ ID NO:132), and QSVLTQAPSASETPGQRVIISCSGSSSNIGSSSVSWYQQLPGTAPKLLIYKNNQRPSGVPDRFSGSKSGTSASLAISGLRSEDEADYYCSTWDDSLSVRVFGGGTKLTVL (SEQ ID NO:141). 18. Antibody according to claim 15, where: HCDR1 has the sequence GFTFSKAWMS (SEQ ID NO:1); HCDR2 has the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 has the sequence TSSFCCRGGSCPSSDTSYCGGQYKSYYFMDV (SEQ ID NO:32); LCDR1 has the sequence SGSSSNIGSSSVY (SEQ ID NO:56); LCDR2 has the sequence KNNQRPS (SEQ ID NO:59); And LCDR3 has the sequence STWDDALSVRV (SEQ ID NO:72). 19. Antibody according to claim 15, where: HCDR1 has the sequence GFTFSKAWMS (SEQ ID NO:1); HCDR2 has the sequence RIKSVTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 has the sequence TSSFCCRSGSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:20); LCDR1 has the sequence SGSSSNIGSSSVS (SEQ ID NO:48); LCDR2 has the sequence KNNQRPS (SEQ ID NO:59); And LCDR3 has the sequence STWDDSLSVRV (SEQ ID NO:68). 20. Antibody according to claim 15, where: HCDR1 has the sequence GFTFSKAWMS (SEQ ID NO:1); HCDR2 has the sequence RIKSVTTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 has the sequence TSSFCCRGNQCPSSDTSYCGGQYPSYYYMDP (SEQ ID NO:23); LCDR1 has the sequence SGSSSNIGSSSVS (SEQ ID NO:48); LCDR2 has the sequence KNNQRPS (SEQ ID NO:59); And LCDR3 has the sequence STWDDSLSVRV (SEQ ID NO:68). 21. Antibody according to claim 15, where: HCDR1 has the sequence GFTFSAAWMS (SEQ ID NO:4); HCDR2 has the sequence RIKSTSDGETTDYAAPVKG (SEQ ID NO:15); HCDR3 has the sequence ISSFCCRGGSCPSRDTSYCGGQYKSYYFMDV (SEQ ID NO:30); LCDR1 has the sequence SGSSTNIGSSSSVS (SEQ ID NO:54); LCDR2 has the sequence KDNQRPS (SEQ ID NO:62); And LCDR3 has the sequence SSWDDSNSVRI (SEQ ID NO:71). 22. Antibody according to claim 15, where: HCDR1 has the sequence GFTFSAAWMS (SEQ ID NO:4); HCDR2 has the sequence RIKSVTTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 has the sequence ISSFCCRGNSCPSSDTSYCNGQYKSYYYMDV (SEQ ID NO:27); LCDR1 has the sequence SGSKSNIGSSSVS (SEQ ID NO:51); LCDR2 has the sequence KDNQRPS (SEQ ID NO:62); And LCDR3 has the sequence ATWDNSLSIRV (SEQ ID NO:70). 23. Antibody according to claim 15, where: HCDR1 has the sequence GFTFSKAWMT (SEQ ID NO:8); HCDR2 has the sequence RIKSVTTDGETTDYAAPVKG (SEQ ID NO:9); HCDR3 has the sequence TSSFCCRGGSCPSHDTSFCGGQDKRYYYMDV (SEQ ID NO:34); LCDR1 has the sequence SGSSSNIGSSSVS (SEQ ID NO:48); LCDR2 has the sequence KNNQRPS (SEQ ID NO:59); And LCDR3 has the sequence STWDDSLSVRV (SEQ ID NO:68). 24. An expression vector containing a polynucleotide encoding the V _H region or V _L region of the antibody according to claim 14. 25. An expression vector containing a polynucleotide encoding the V _H region and the V _L region of the antibody according to claim 14. 26. A host cell for producing an antibody, wherein the host cell contains a polynucleotide that encodes the V _H region, and a polynucleotide that encodes the V _L region of the antibody according to claim 16. 27. A method for producing an antibody, comprising culturing a host cell according to claim 26 under conditions in which a polynucleotide encoding a heavy chain and a polynucleotide encoding a light chain are expressed. 28. An expression vector containing a polynucleotide encoding the V _H region or V _L region of an antibody according to claim 7. 29. An expression vector containing a polynucleotide encoding the V _H region and the V _L region of the antibody according to claim 7. 30. A host cell for producing an antibody, wherein the host cell contains a polynucleotide that encodes the VH region and a polynucleotide that encodes the VL region of the antibody according to claim 7. 31. A method for producing an antibody, comprising culturing a host cell according to claim 30 under conditions in which a polynucleotide encoding a heavy chain and a polynucleotide encoding a light chain are expressed, thereby producing an antibody.

Images